id	sid	tid	token	lemma	pos
gsrj-21	1	1	gsr	gsr	PROPN
gsrj-21	1	2	journal	journal	PROPN
gsrj-21	1	3	georgetown	georgetown	PROPN
gsrj-21	1	4	scientific	scientific	PROPN
gsrj-21	1	5	research	research	PROPN
gsrj-21	1	6	journal	journal	PROPN
gsrj-21	1	7	volume	volume	NOUN
gsrj-21	1	8	1	1	NUM
gsrj-21	1	9	|	|	NOUN
gsrj-21	1	10	edition	edition	NOUN
gsrj-21	1	11	2	2	NUM
gsrj-21	1	12	july	july	PROPN
gsrj-21	1	13	31	31	NUM
gsrj-21	1	14	,	,	PUNCT
gsrj-21	1	15	2021	2021	NUM
gsrj-21	1	16	danya	danya	PROPN
gsrj-21	1	17	adams	adams	PROPN
gsrj-21	1	18	issn	issn	PROPN
gsrj-21	1	19	2767	2767	NUM
gsrj-21	1	20	-	-	PUNCT
gsrj-21	1	21	6420	6420	NUM
gsrj-21	1	22	cancer	cancer	NOUN
gsrj-21	1	23	models	model	NOUN
gsrj-21	1	24	to	to	PART
gsrj-21	1	25	defeat	defeat	VERB
gsrj-21	1	26	therapy	therapy	NOUN
gsrj-21	1	27	resistance	resistance	NOUN
gsrj-21	1	28	in	in	ADP
gsrj-21	1	29	pancreatic	pancreatic	ADJ
gsrj-21	1	30	ductal	ductal	ADJ
gsrj-21	1	31	adenocarcinoma	adenocarcinoma	NOUN
gsrj-21	1	32	britney	britney	NOUN
gsrj-21	1	33	he	he	PRON
gsrj-21	1	34	volume	volume	VERB
gsrj-21	1	35	two	two	NUM
gsrj-21	1	36	edition	edition	NOUN
gsrj-21	1	37	one	one	NUM
gsrj-21	1	38	july	july	PROPN
gsrj-21	1	39	2021	2021	NUM
gsrj-21	1	40	georgetown	georgetown	PROPN
gsrj-21	1	41	scientific	scientific	PROPN
gsrj-21	1	42	research	research	PROPN
gsrj-21	1	43	journal	journal	PROPN
gsrj-21	1	44	volume	volume	NOUN
gsrj-21	1	45	one	one	NUM
gsrj-21	1	46	edition	edition	NOUN
gsrj-21	1	47	two	two	NUM
gsrj-21	1	48	spring	spring	NOUN
gsrj-21	1	49	2021	2021	NUM
gsrj-21	1	50	georgetown	georgetown	PROPN
gsrj-21	1	51	scientific	scientific	PROPN
gsrj-21	1	52	research	research	PROPN
gsrj-21	1	53	journal	journal	PROPN
gsrj-21	1	54	43	43	NUM
gsrj-21	1	55	georgetown	georgetown	PROPN
gsrj-21	1	56	scientific	scientific	PROPN
gsrj-21	1	57	research	research	PROPN
gsrj-21	1	58	journal	journal	NOUN
gsrj-21	1	59	cancer	cancer	NOUN
gsrj-21	1	60	models	model	NOUN
gsrj-21	1	61	to	to	PART
gsrj-21	1	62	defeat	defeat	VERB
gsrj-21	1	63	therapy	therapy	NOUN
gsrj-21	1	64	resistance	resistance	NOUN
gsrj-21	1	65	in	in	ADP
gsrj-21	1	66	pancreatic	pancreatic	ADJ
gsrj-21	1	67	ductal	ductal	ADJ
gsrj-21	1	68	adenocarcinoma	adenocarcinoma	NOUN
gsrj-21	1	69	britney	britney	NOUN
gsrj-21	1	70	he	he	PROPN
gsrj-21	1	71	department	department	PROPN
gsrj-21	1	72	of	of	ADP
gsrj-21	1	73	oncology	oncology	PROPN
gsrj-21	1	74	,	,	PUNCT
gsrj-21	1	75	georgetown	georgetown	PROPN
gsrj-21	1	76	university	university	PROPN
gsrj-21	1	77	medical	medical	ADJ
gsrj-21	1	78	center	center	NOUN
gsrj-21	1	79	,	,	PUNCT
gsrj-21	1	80	washington	washington	PROPN
gsrj-21	1	81	d.c	d.c	PROPN
gsrj-21	1	82	.	.	PUNCT
gsrj-21	2	1	e	e	X
gsrj-21	2	2	-	-	NOUN
gsrj-21	2	3	mail	mail	NOUN
gsrj-21	2	4	:	:	PUNCT
gsrj-21	2	5	bkh40@georgetown.edu	bkh40@georgetown.edu	PROPN
gsrj-21	2	6	https://doi.org/10.48091/gsr.v1i2.21	https://doi.org/10.48091/gsr.v1i2.21	PROPN
gsrj-21	2	7	abstract	abstract	ADJ
gsrj-21	2	8	one	one	NUM
gsrj-21	2	9	of	of	ADP
gsrj-21	2	10	the	the	DET
gsrj-21	2	11	largest	large	ADJ
gsrj-21	2	12	hurdles	hurdle	NOUN
gsrj-21	2	13	to	to	ADP
gsrj-21	2	14	the	the	DET
gsrj-21	2	15	efficacy	efficacy	NOUN
gsrj-21	2	16	of	of	ADP
gsrj-21	2	17	cancer	cancer	NOUN
gsrj-21	2	18	therapeutics	therapeutic	NOUN
gsrj-21	2	19	,	,	PUNCT
gsrj-21	2	20	and	and	CCONJ
gsrj-21	2	21	a	a	DET
gsrj-21	2	22	main	main	ADJ
gsrj-21	2	23	cause	cause	NOUN
gsrj-21	2	24	of	of	ADP
gsrj-21	2	25	relapse	relapse	NOUN
gsrj-21	2	26	,	,	PUNCT
gsrj-21	2	27	is	be	AUX
gsrj-21	2	28	therapy	therapy	NOUN
gsrj-21	2	29	resistance	resistance	NOUN
gsrj-21	2	30	.	.	PUNCT
gsrj-21	3	1	in	in	ADP
gsrj-21	3	2	response	response	NOUN
gsrj-21	3	3	,	,	PUNCT
gsrj-21	3	4	researchers	researcher	NOUN
gsrj-21	3	5	have	have	AUX
gsrj-21	3	6	developed	develop	VERB
gsrj-21	3	7	model	model	NOUN
gsrj-21	3	8	systems	system	NOUN
gsrj-21	3	9	to	to	PART
gsrj-21	3	10	better	well	ADV
gsrj-21	3	11	understand	understand	VERB
gsrj-21	3	12	therapy	therapy	NOUN
gsrj-21	3	13	resistance	resistance	NOUN
gsrj-21	3	14	.	.	PUNCT
gsrj-21	4	1	cancer	cancer	NOUN
gsrj-21	4	2	research	research	NOUN
gsrj-21	4	3	employs	employ	VERB
gsrj-21	4	4	several	several	ADJ
gsrj-21	4	5	model	model	NOUN
gsrj-21	4	6	systems	system	NOUN
gsrj-21	4	7	that	that	PRON
gsrj-21	4	8	reflect	reflect	VERB
gsrj-21	4	9	the	the	DET
gsrj-21	4	10	biology	biology	NOUN
gsrj-21	4	11	of	of	ADP
gsrj-21	4	12	actual	actual	ADJ
gsrj-21	4	13	human	human	ADJ
gsrj-21	4	14	tumors	tumor	NOUN
gsrj-21	4	15	:	:	PUNCT
gsrj-21	4	16	in	in	ADP
gsrj-21	4	17	vitro	vitro	X
gsrj-21	4	18	models	model	NOUN
gsrj-21	4	19	(	(	PUNCT
gsrj-21	4	20	2d	2d	NUM
gsrj-21	4	21	,	,	PUNCT
gsrj-21	4	22	3d	3d	NUM
gsrj-21	4	23	cell	cell	NOUN
gsrj-21	4	24	cultures	culture	NOUN
gsrj-21	4	25	)	)	PUNCT
gsrj-21	4	26	,	,	PUNCT
gsrj-21	4	27	in	in	ADP
gsrj-21	4	28	vivo	vivo	NOUN
gsrj-21	4	29	models	model	NOUN
gsrj-21	4	30	(	(	PUNCT
gsrj-21	4	31	pdx	pdx	NOUN
gsrj-21	4	32	,	,	PUNCT
gsrj-21	4	33	gemms	gemms	ADJ
gsrj-21	4	34	,	,	PUNCT
gsrj-21	4	35	transgenic	transgenic	NOUN
gsrj-21	4	36	)	)	PUNCT
gsrj-21	4	37	,	,	PUNCT
gsrj-21	4	38	proteomic	proteomic	NOUN
gsrj-21	4	39	models	model	NOUN
gsrj-21	4	40	,	,	PUNCT
gsrj-21	4	41	and	and	CCONJ
gsrj-21	4	42	computational	computational	ADJ
gsrj-21	4	43	or	or	CCONJ
gsrj-21	4	44	mathematical	mathematical	ADJ
gsrj-21	4	45	models	model	NOUN
gsrj-21	4	46	.	.	PUNCT
gsrj-21	5	1	one	one	NUM
gsrj-21	5	2	cancer	cancer	NOUN
gsrj-21	5	3	that	that	PRON
gsrj-21	5	4	has	have	AUX
gsrj-21	5	5	been	be	AUX
gsrj-21	5	6	extensively	extensively	ADV
gsrj-21	5	7	modeled	model	VERB
gsrj-21	5	8	is	be	AUX
gsrj-21	5	9	pancreatic	pancreatic	ADJ
gsrj-21	5	10	ductal	ductal	ADJ
gsrj-21	5	11	adenocarcinoma	adenocarcinoma	NOUN
gsrj-21	5	12	(	(	PUNCT
gsrj-21	5	13	pdac	pdac	PROPN
gsrj-21	5	14	)	)	PUNCT
gsrj-21	5	15	.	.	PUNCT
gsrj-21	6	1	pdac	pdac	PROPN
gsrj-21	6	2	is	be	AUX
gsrj-21	6	3	the	the	DET
gsrj-21	6	4	third	third	ADJ
gsrj-21	6	5	most	most	ADV
gsrj-21	6	6	common	common	ADJ
gsrj-21	6	7	cause	cause	NOUN
gsrj-21	6	8	of	of	ADP
gsrj-21	6	9	annual	annual	ADJ
gsrj-21	6	10	cancer	cancer	NOUN
gsrj-21	6	11	deaths	death	NOUN
gsrj-21	6	12	in	in	ADP
gsrj-21	6	13	developed	develop	VERB
gsrj-21	6	14	countries	country	NOUN
gsrj-21	6	15	;	;	PUNCT
gsrj-21	6	16	as	as	SCONJ
gsrj-21	6	17	its	its	PRON
gsrj-21	6	18	incidence	incidence	NOUN
gsrj-21	6	19	and	and	CCONJ
gsrj-21	6	20	mortality	mortality	NOUN
gsrj-21	6	21	rates	rate	NOUN
gsrj-21	6	22	continue	continue	VERB
gsrj-21	6	23	to	to	PART
gsrj-21	6	24	increase	increase	VERB
gsrj-21	6	25	,	,	PUNCT
gsrj-21	6	26	pdac	pdac	NOUN
gsrj-21	6	27	is	be	AUX
gsrj-21	6	28	projected	project	VERB
gsrj-21	6	29	to	to	PART
gsrj-21	6	30	be	be	AUX
gsrj-21	6	31	the	the	DET
gsrj-21	6	32	second	second	ADJ
gsrj-21	6	33	leading	leading	ADJ
gsrj-21	6	34	cause	cause	NOUN
gsrj-21	6	35	of	of	ADP
gsrj-21	6	36	cancer	cancer	NOUN
gsrj-21	6	37	deaths	death	NOUN
gsrj-21	6	38	by	by	ADP
gsrj-21	6	39	2030	2030	NUM
gsrj-21	6	40	.	.	PUNCT
gsrj-21	7	1	although	although	SCONJ
gsrj-21	7	2	chemotherapy	chemotherapy	NOUN
gsrj-21	7	3	is	be	AUX
gsrj-21	7	4	a	a	DET
gsrj-21	7	5	pillar	pillar	NOUN
gsrj-21	7	6	of	of	ADP
gsrj-21	7	7	clinical	clinical	ADJ
gsrj-21	7	8	pdac	pdac	NOUN
gsrj-21	7	9	treatment	treatment	NOUN
gsrj-21	7	10	,	,	PUNCT
gsrj-21	7	11	its	its	PRON
gsrj-21	7	12	outcome	outcome	NOUN
gsrj-21	7	13	typically	typically	ADV
gsrj-21	7	14	leads	lead	VERB
gsrj-21	7	15	to	to	ADP
gsrj-21	7	16	multi	multi	ADJ
gsrj-21	7	17	-	-	ADJ
gsrj-21	7	18	drug	drug	ADJ
gsrj-21	7	19	resistance	resistance	NOUN
gsrj-21	7	20	,	,	PUNCT
gsrj-21	7	21	drastically	drastically	ADV
gsrj-21	7	22	restricting	restrict	VERB
gsrj-21	7	23	the	the	DET
gsrj-21	7	24	curative	curative	ADJ
gsrj-21	7	25	effect	effect	NOUN
gsrj-21	7	26	of	of	ADP
gsrj-21	7	27	drugs	drug	NOUN
gsrj-21	7	28	for	for	ADP
gsrj-21	7	29	a	a	DET
gsrj-21	7	30	variety	variety	NOUN
gsrj-21	7	31	of	of	ADP
gsrj-21	7	32	tumors	tumor	NOUN
gsrj-21	7	33	.	.	PUNCT
gsrj-21	8	1	elucidating	elucidate	VERB
gsrj-21	8	2	the	the	DET
gsrj-21	8	3	underlying	underlying	ADJ
gsrj-21	8	4	mechanisms	mechanism	NOUN
gsrj-21	8	5	for	for	ADP
gsrj-21	8	6	resistance	resistance	NOUN
gsrj-21	8	7	through	through	ADP
gsrj-21	8	8	different	different	ADJ
gsrj-21	8	9	models	model	NOUN
gsrj-21	8	10	is	be	AUX
gsrj-21	8	11	essential	essential	ADJ
gsrj-21	8	12	for	for	ADP
gsrj-21	8	13	the	the	DET
gsrj-21	8	14	development	development	NOUN
gsrj-21	8	15	of	of	ADP
gsrj-21	8	16	new	new	ADJ
gsrj-21	8	17	strategies	strategy	NOUN
gsrj-21	8	18	and	and	CCONJ
gsrj-21	8	19	therapies	therapy	NOUN
gsrj-21	8	20	.	.	PUNCT
gsrj-21	9	1	this	this	DET
gsrj-21	9	2	review	review	NOUN
gsrj-21	9	3	provides	provide	VERB
gsrj-21	9	4	insight	insight	NOUN
gsrj-21	9	5	into	into	ADP
gsrj-21	9	6	the	the	DET
gsrj-21	9	7	range	range	NOUN
gsrj-21	9	8	of	of	ADP
gsrj-21	9	9	in	in	ADP
gsrj-21	9	10	vitro	vitro	X
gsrj-21	9	11	and	and	CCONJ
gsrj-21	9	12	in	in	ADP
gsrj-21	9	13	vivo	vivo	NOUN
gsrj-21	9	14	models	model	NOUN
gsrj-21	9	15	of	of	ADP
gsrj-21	9	16	pancreatic	pancreatic	ADJ
gsrj-21	9	17	cancer	cancer	NOUN
gsrj-21	9	18	used	use	VERB
gsrj-21	9	19	in	in	ADP
gsrj-21	9	20	preclinical	preclinical	ADJ
gsrj-21	9	21	research	research	NOUN
gsrj-21	9	22	.	.	PUNCT
gsrj-21	10	1	this	this	DET
gsrj-21	10	2	paper	paper	NOUN
gsrj-21	10	3	provides	provide	VERB
gsrj-21	10	4	an	an	DET
gsrj-21	10	5	overview	overview	NOUN
gsrj-21	10	6	of	of	ADP
gsrj-21	10	7	platforms	platform	NOUN
gsrj-21	10	8	for	for	ADP
gsrj-21	10	9	cancer	cancer	NOUN
gsrj-21	10	10	research	research	NOUN
gsrj-21	10	11	with	with	ADP
gsrj-21	10	12	a	a	DET
gsrj-21	10	13	focus	focus	NOUN
gsrj-21	10	14	on	on	ADP
gsrj-21	10	15	those	those	PRON
gsrj-21	10	16	devoted	devote	VERB
gsrj-21	10	17	to	to	ADP
gsrj-21	10	18	resistance	resistance	NOUN
gsrj-21	10	19	mechanisms	mechanism	NOUN
gsrj-21	10	20	in	in	ADP
gsrj-21	10	21	pdac	pdac	NOUN
gsrj-21	10	22	and	and	CCONJ
gsrj-21	10	23	to	to	ADP
gsrj-21	10	24	the	the	DET
gsrj-21	10	25	primary	primary	ADJ
gsrj-21	10	26	therapeutic	therapeutic	ADJ
gsrj-21	10	27	intervention	intervention	NOUN
gsrj-21	10	28	for	for	ADP
gsrj-21	10	29	pdac	pdac	NOUN
gsrj-21	10	30	,	,	PUNCT
gsrj-21	10	31	gemcitabine	gemcitabine	NOUN
gsrj-21	10	32	(	(	PUNCT
gsrj-21	10	33	gem	gem	NOUN
gsrj-21	10	34	)	)	PUNCT
gsrj-21	10	35	.	.	PUNCT
gsrj-21	11	1	keywords	keyword	NOUN
gsrj-21	11	2	:	:	PUNCT
gsrj-21	11	3	therapy	therapy	NOUN
gsrj-21	11	4	resistance	resistance	NOUN
gsrj-21	11	5	,	,	PUNCT
gsrj-21	11	6	pancreatic	pancreatic	ADJ
gsrj-21	11	7	cancer	cancer	NOUN
gsrj-21	11	8	,	,	PUNCT
gsrj-21	11	9	in	in	ADP
gsrj-21	11	10	vivo	vivo	NOUN
gsrj-21	11	11	models	model	NOUN
gsrj-21	11	12	,	,	PUNCT
gsrj-21	11	13	in	in	ADP
gsrj-21	11	14	vitro	vitro	X
gsrj-21	11	15	models	model	NOUN
gsrj-21	11	16	,	,	PUNCT
gsrj-21	11	17	computational	computational	ADJ
gsrj-21	11	18	,	,	PUNCT
gsrj-21	11	19	proteomic	proteomic	ADJ
gsrj-21	11	20	,	,	PUNCT
gsrj-21	11	21	gemcitabine	gemcitabine	NOUN
gsrj-21	11	22	,	,	PUNCT
gsrj-21	11	23	pdac	pdac	NOUN
gsrj-21	11	24	1	1	NUM
gsrj-21	11	25	.	.	PUNCT
gsrj-21	12	1	introduction	introduction	NOUN
gsrj-21	12	2	one	one	NUM
gsrj-21	12	3	of	of	ADP
gsrj-21	12	4	the	the	DET
gsrj-21	12	5	most	most	ADV
gsrj-21	12	6	studied	study	VERB
gsrj-21	12	7	cancers	cancer	NOUN
gsrj-21	12	8	is	be	AUX
gsrj-21	12	9	pancreatic	pancreatic	ADJ
gsrj-21	12	10	ductal	ductal	ADJ
gsrj-21	12	11	adenocarcinoma	adenocarcinoma	NOUN
gsrj-21	12	12	(	(	PUNCT
gsrj-21	12	13	pdac	pdac	NOUN
gsrj-21	12	14	)	)	PUNCT
gsrj-21	12	15	due	due	ADP
gsrj-21	12	16	to	to	ADP
gsrj-21	12	17	its	its	PRON
gsrj-21	12	18	high	high	ADJ
gsrj-21	12	19	stemness	stemness	NOUN
gsrj-21	12	20	and	and	CCONJ
gsrj-21	12	21	tumorigenicity	tumorigenicity	NOUN
gsrj-21	12	22	,	,	PUNCT
gsrj-21	12	23	making	make	VERB
gsrj-21	12	24	it	it	PRON
gsrj-21	12	25	a	a	DET
gsrj-21	12	26	major	major	ADJ
gsrj-21	12	27	health	health	NOUN
gsrj-21	12	28	concern	concern	NOUN
gsrj-21	12	29	that	that	PRON
gsrj-21	12	30	warrants	warrant	VERB
gsrj-21	12	31	greater	great	ADJ
gsrj-21	12	32	efforts	effort	NOUN
gsrj-21	12	33	towards	towards	ADP
gsrj-21	12	34	earlier	early	ADJ
gsrj-21	12	35	detection	detection	NOUN
gsrj-21	12	36	and	and	CCONJ
gsrj-21	12	37	improved	improved	ADJ
gsrj-21	12	38	treatment	treatment	NOUN
gsrj-21	12	39	.	.	PUNCT
gsrj-21	13	1	there	there	PRON
gsrj-21	13	2	are	be	VERB
gsrj-21	13	3	several	several	ADJ
gsrj-21	13	4	models	model	NOUN
gsrj-21	13	5	for	for	ADP
gsrj-21	13	6	pdac	pdac	NOUN
gsrj-21	13	7	on	on	ADP
gsrj-21	13	8	cancer	cancer	NOUN
gsrj-21	13	9	resistance	resistance	NOUN
gsrj-21	13	10	due	due	ADP
gsrj-21	13	11	to	to	ADP
gsrj-21	13	12	the	the	DET
gsrj-21	13	13	extremely	extremely	ADV
gsrj-21	13	14	deadly	deadly	ADJ
gsrj-21	13	15	nature	nature	NOUN
gsrj-21	13	16	of	of	ADP
gsrj-21	13	17	pdac	pdac	NOUN
gsrj-21	13	18	.	.	PUNCT
gsrj-21	14	1	some	some	PRON
gsrj-21	14	2	of	of	ADP
gsrj-21	14	3	the	the	DET
gsrj-21	14	4	newest	new	ADJ
gsrj-21	14	5	and	and	CCONJ
gsrj-21	14	6	acclaimed	acclaimed	ADJ
gsrj-21	14	7	models	model	NOUN
gsrj-21	14	8	are	be	AUX
gsrj-21	14	9	for	for	ADP
gsrj-21	14	10	pdac	pdac	NOUN
gsrj-21	14	11	cells	cell	NOUN
gsrj-21	14	12	.	.	PUNCT
gsrj-21	15	1	this	this	DET
gsrj-21	15	2	review	review	NOUN
gsrj-21	15	3	will	will	AUX
gsrj-21	15	4	highlight	highlight	VERB
gsrj-21	15	5	the	the	DET
gsrj-21	15	6	models	model	NOUN
gsrj-21	15	7	used	use	VERB
gsrj-21	15	8	for	for	ADP
gsrj-21	15	9	examining	examine	VERB
gsrj-21	15	10	drug	drug	NOUN
gsrj-21	15	11	resistance	resistance	NOUN
gsrj-21	15	12	in	in	ADP
gsrj-21	15	13	pdac	pdac	PROPN
gsrj-21	15	14	.	.	PUNCT
gsrj-21	16	1	pdac	pdac	PROPN
gsrj-21	16	2	is	be	AUX
gsrj-21	16	3	the	the	DET
gsrj-21	16	4	third	third	ADJ
gsrj-21	16	5	most	most	ADV
gsrj-21	16	6	common	common	ADJ
gsrj-21	16	7	cause	cause	NOUN
gsrj-21	16	8	of	of	ADP
gsrj-21	16	9	annual	annual	ADJ
gsrj-21	16	10	cancer	cancer	NOUN
gsrj-21	16	11	deaths	death	NOUN
gsrj-21	16	12	in	in	ADP
gsrj-21	16	13	developed	develop	VERB
gsrj-21	16	14	countries	country	NOUN
gsrj-21	16	15	,	,	PUNCT
gsrj-21	16	16	and	and	CCONJ
gsrj-21	16	17	the	the	DET
gsrj-21	16	18	incidence	incidence	NOUN
gsrj-21	16	19	and	and	CCONJ
gsrj-21	16	20	mortality	mortality	NOUN
gsrj-21	16	21	rates	rate	NOUN
gsrj-21	16	22	of	of	ADP
gsrj-21	16	23	this	this	DET
gsrj-21	16	24	disease	disease	NOUN
gsrj-21	16	25	are	be	AUX
gsrj-21	16	26	climbing	climb	VERB
gsrj-21	16	27	.	.	PUNCT
gsrj-21	17	1	this	this	DET
gsrj-21	17	2	disease	disease	NOUN
gsrj-21	17	3	is	be	AUX
gsrj-21	17	4	projected	project	VERB
gsrj-21	17	5	to	to	PART
gsrj-21	17	6	be	be	AUX
gsrj-21	17	7	the	the	DET
gsrj-21	17	8	second	second	ADJ
gsrj-21	17	9	leading	leading	ADJ
gsrj-21	17	10	cause	cause	NOUN
gsrj-21	17	11	of	of	ADP
gsrj-21	17	12	cancer	cancer	NOUN
gsrj-21	17	13	deaths	death	NOUN
gsrj-21	17	14	by	by	ADP
gsrj-21	17	15	2030.67	2030.67	NUM
gsrj-21	17	16	despite	despite	SCONJ
gsrj-21	17	17	increased	increase	VERB
gsrj-21	17	18	survival	survival	NOUN
gsrj-21	17	19	resulting	result	VERB
gsrj-21	17	20	from	from	ADP
gsrj-21	17	21	various	various	ADJ
gsrj-21	17	22	multidisciplinary	multidisciplinary	ADJ
gsrj-21	17	23	curative	curative	ADJ
gsrj-21	17	24	and	and	CCONJ
gsrj-21	17	25	palliative	palliative	ADJ
gsrj-21	17	26	treatment	treatment	NOUN
gsrj-21	17	27	options	option	NOUN
gsrj-21	17	28	,	,	PUNCT
gsrj-21	17	29	including	include	VERB
gsrj-21	17	30	surgical	surgical	ADJ
gsrj-21	17	31	removal	removal	NOUN
gsrj-21	17	32	,	,	PUNCT
gsrj-21	17	33	stent	stent	NOUN
gsrj-21	17	34	placement	placement	NOUN
gsrj-21	17	35	,	,	PUNCT
gsrj-21	17	36	and	and	CCONJ
gsrj-21	17	37	nonsteroidal	nonsteroidal	ADJ
gsrj-21	17	38	anti	anti	ADJ
gsrj-21	17	39	-	-	ADJ
gsrj-21	17	40	inflammatory	inflammatory	ADJ
gsrj-21	17	41	drugs	drug	NOUN
gsrj-21	17	42	,	,	PUNCT
gsrj-21	17	43	the	the	DET
gsrj-21	17	44	disease	disease	NOUN
gsrj-21	17	45	outcome	outcome	NOUN
gsrj-21	17	46	is	be	AUX
gsrj-21	17	47	most	most	ADV
gsrj-21	17	48	often	often	ADV
gsrj-21	17	49	fatal	fatal	ADJ
gsrj-21	17	50	.	.	PUNCT
gsrj-21	18	1	the	the	DET
gsrj-21	18	2	most	most	ADV
gsrj-21	18	3	recent	recent	ADJ
gsrj-21	18	4	advances	advance	NOUN
gsrj-21	18	5	in	in	ADP
gsrj-21	18	6	chemotherapeutic	chemotherapeutic	ADJ
gsrj-21	18	7	treatment	treatment	NOUN
gsrj-21	18	8	extend	extend	VERB
gsrj-21	18	9	the	the	DET
gsrj-21	18	10	average	average	ADJ
gsrj-21	18	11	survival	survival	NOUN
gsrj-21	18	12	to	to	ADP
gsrj-21	18	13	8.5	8.5	NUM
gsrj-21	18	14	-	-	SYM
gsrj-21	18	15	9.4	9.4	NUM
gsrj-21	18	16	months.68,69	months.68,69	NOUN
gsrj-21	18	17	currently	currently	ADV
gsrj-21	18	18	,	,	PUNCT
gsrj-21	18	19	the	the	DET
gsrj-21	18	20	5	5	NUM
gsrj-21	18	21	-	-	PUNCT
gsrj-21	18	22	year	year	NOUN
gsrj-21	18	23	survival	survival	NOUN
gsrj-21	18	24	rate	rate	NOUN
gsrj-21	18	25	for	for	ADP
gsrj-21	18	26	pdac	pdac	NOUN
gsrj-21	18	27	for	for	ADP
gsrj-21	18	28	all	all	DET
gsrj-21	18	29	stages	stage	NOUN
gsrj-21	18	30	is	be	AUX
gsrj-21	18	31	the	the	DET
gsrj-21	18	32	lowest	low	ADJ
gsrj-21	18	33	among	among	ADP
gsrj-21	18	34	all	all	DET
gsrj-21	18	35	the	the	DET
gsrj-21	18	36	cancers	cancer	NOUN
gsrj-21	18	37	at	at	ADP
gsrj-21	18	38	9	9	NUM
gsrj-21	18	39	%	%	NOUN
gsrj-21	18	40	,	,	PUNCT
gsrj-21	18	41	which	which	PRON
gsrj-21	18	42	drops	drop	VERB
gsrj-21	18	43	to	to	ADP
gsrj-21	18	44	3	3	NUM
gsrj-21	18	45	%	%	NOUN
gsrj-21	18	46	for	for	ADP
gsrj-21	18	47	patients	patient	NOUN
gsrj-21	18	48	diagnosed	diagnose	VERB
gsrj-21	18	49	with	with	ADP
gsrj-21	18	50	distant	distant	ADJ
gsrj-21	18	51	or	or	CCONJ
gsrj-21	18	52	metastatic	metastatic	ADJ
gsrj-21	18	53	pdac.70	pdac.70	NOUN
gsrj-21	18	54	the	the	DET
gsrj-21	18	55	lack	lack	NOUN
gsrj-21	18	56	of	of	ADP
gsrj-21	18	57	effective	effective	ADJ
gsrj-21	18	58	treatment	treatment	NOUN
gsrj-21	18	59	options	option	NOUN
gsrj-21	18	60	for	for	ADP
gsrj-21	18	61	pdac	pdac	NOUN
gsrj-21	18	62	contributes	contribute	VERB
gsrj-21	18	63	to	to	ADP
gsrj-21	18	64	the	the	DET
gsrj-21	18	65	low	low	ADJ
gsrj-21	18	66	survival	survival	NOUN
gsrj-21	18	67	rate	rate	NOUN
gsrj-21	18	68	,	,	PUNCT
gsrj-21	18	69	pointing	point	VERB
gsrj-21	18	70	to	to	ADP
gsrj-21	18	71	the	the	DET
gsrj-21	18	72	44	44	NUM
gsrj-21	18	73	georgetown	georgetown	PROPN
gsrj-21	18	74	scientific	scientific	PROPN
gsrj-21	18	75	research	research	NOUN
gsrj-21	18	76	journal	journal	NOUN
gsrj-21	18	77	need	need	VERB
gsrj-21	18	78	for	for	ADP
gsrj-21	18	79	improved	improved	ADJ
gsrj-21	18	80	treatment	treatment	NOUN
gsrj-21	18	81	and	and	CCONJ
gsrj-21	18	82	earlier	early	ADV
gsrj-21	18	83	detection.67	detection.67	ADP
gsrj-21	18	84	medical	medical	ADJ
gsrj-21	18	85	and	and	CCONJ
gsrj-21	18	86	surgical	surgical	ADJ
gsrj-21	18	87	treatments	treatment	NOUN
gsrj-21	18	88	for	for	ADP
gsrj-21	18	89	this	this	DET
gsrj-21	18	90	highly	highly	ADV
gsrj-21	18	91	lethal	lethal	ADJ
gsrj-21	18	92	disease	disease	NOUN
gsrj-21	18	93	are	be	AUX
gsrj-21	18	94	limited	limited	ADJ
gsrj-21	18	95	and	and	CCONJ
gsrj-21	18	96	often	often	ADV
gsrj-21	18	97	ineffective	ineffective	ADJ
gsrj-21	18	98	.	.	PUNCT
gsrj-21	19	1	for	for	ADP
gsrj-21	19	2	patients	patient	NOUN
gsrj-21	19	3	with	with	ADP
gsrj-21	19	4	unresectable	unresectable	ADJ
gsrj-21	19	5	pdac	pdac	NOUN
gsrj-21	19	6	,	,	PUNCT
gsrj-21	19	7	therapy	therapy	NOUN
gsrj-21	19	8	is	be	AUX
gsrj-21	19	9	restricted	restrict	VERB
gsrj-21	19	10	to	to	ADP
gsrj-21	19	11	chemotherapy	chemotherapy	NOUN
gsrj-21	19	12	,	,	PUNCT
gsrj-21	19	13	for	for	ADP
gsrj-21	19	14	which	which	PRON
gsrj-21	19	15	most	most	ADV
gsrj-21	19	16	eventually	eventually	ADV
gsrj-21	19	17	develop	develop	VERB
gsrj-21	19	18	resistance	resistance	NOUN
gsrj-21	19	19	.	.	PUNCT
gsrj-21	20	1	gemcitabine	gemcitabine	NOUN
gsrj-21	20	2	(	(	PUNCT
gsrj-21	20	3	gem	gem	NOUN
gsrj-21	20	4	)	)	PUNCT
gsrj-21	20	5	emerged	emerge	VERB
gsrj-21	20	6	in	in	ADP
gsrj-21	20	7	1997	1997	NUM
gsrj-21	20	8	as	as	ADP
gsrj-21	20	9	an	an	DET
gsrj-21	20	10	alternative	alternative	NOUN
gsrj-21	20	11	for	for	ADP
gsrj-21	20	12	5fluorouracil	5fluorouracil	NUM
gsrj-21	20	13	and	and	CCONJ
gsrj-21	20	14	ultimately	ultimately	ADV
gsrj-21	20	15	improved	improve	VERB
gsrj-21	20	16	survival	survival	NOUN
gsrj-21	20	17	by	by	ADP
gsrj-21	20	18	a	a	DET
gsrj-21	20	19	few	few	ADJ
gsrj-21	20	20	weeks	week	NOUN
gsrj-21	20	21	.	.	PUNCT
gsrj-21	21	1	the	the	DET
gsrj-21	21	2	introduction	introduction	NOUN
gsrj-21	21	3	of	of	ADP
gsrj-21	21	4	the	the	DET
gsrj-21	21	5	folfirinox	folfirinox	ADJ
gsrj-21	21	6	treatment	treatment	NOUN
gsrj-21	21	7	scheme	scheme	NOUN
gsrj-21	21	8	(	(	PUNCT
gsrj-21	21	9	5	5	NUM
gsrj-21	21	10	-	-	PUNCT
gsrj-21	21	11	fluorouracil	fluorouracil	NOUN
gsrj-21	21	12	,	,	PUNCT
gsrj-21	21	13	leucovorin	leucovorin	NOUN
gsrj-21	21	14	,	,	PUNCT
gsrj-21	21	15	oxaliplatin	oxaliplatin	PROPN
gsrj-21	21	16	,	,	PUNCT
gsrj-21	21	17	and	and	CCONJ
gsrj-21	21	18	irinotecan	irinotecan	NOUN
gsrj-21	21	19	)	)	PUNCT
gsrj-21	21	20	also	also	ADV
gsrj-21	21	21	contributed	contribute	VERB
gsrj-21	21	22	to	to	ADP
gsrj-21	21	23	a	a	DET
gsrj-21	21	24	small	small	ADJ
gsrj-21	21	25	improvement	improvement	NOUN
gsrj-21	21	26	in	in	ADP
gsrj-21	21	27	survival	survival	NOUN
gsrj-21	21	28	for	for	ADP
gsrj-21	21	29	patients	patient	NOUN
gsrj-21	21	30	with	with	ADP
gsrj-21	21	31	an	an	DET
gsrj-21	21	32	advantaged	advantaged	ADJ
gsrj-21	21	33	stage	stage	NOUN
gsrj-21	21	34	of	of	ADP
gsrj-21	21	35	the	the	DET
gsrj-21	21	36	disease.55	disease.55	NOUN
gsrj-21	21	37	currently	currently	ADV
gsrj-21	21	38	,	,	PUNCT
gsrj-21	21	39	the	the	DET
gsrj-21	21	40	most	most	ADV
gsrj-21	21	41	effective	effective	ADJ
gsrj-21	21	42	and	and	CCONJ
gsrj-21	21	43	tolerated	tolerate	VERB
gsrj-21	21	44	drug	drug	NOUN
gsrj-21	21	45	is	be	AUX
gsrj-21	21	46	nab	nab	NOUN
gsrj-21	21	47	-	-	PUNCT
gsrj-21	21	48	paclitaxel	paclitaxel	ADJ
gsrj-21	21	49	(	(	PUNCT
gsrj-21	21	50	n	n	CCONJ
gsrj-21	21	51	-	-	PUNCT
gsrj-21	21	52	ptx	ptx	NOUN
gsrj-21	21	53	)	)	PUNCT
gsrj-21	21	54	and	and	CCONJ
gsrj-21	21	55	,	,	PUNCT
gsrj-21	21	56	when	when	SCONJ
gsrj-21	21	57	used	use	VERB
gsrj-21	21	58	with	with	ADP
gsrj-21	21	59	gem	gem	NOUN
gsrj-21	21	60	,	,	PUNCT
gsrj-21	21	61	has	have	AUX
gsrj-21	21	62	modestly	modestly	ADV
gsrj-21	21	63	prolonged	prolong	VERB
gsrj-21	21	64	median	median	ADJ
gsrj-21	21	65	overall	overall	ADJ
gsrj-21	21	66	survival.54,69	survival.54,69	NOUN
gsrj-21	21	67	the	the	DET
gsrj-21	21	68	poor	poor	ADJ
gsrj-21	21	69	clinical	clinical	ADJ
gsrj-21	21	70	situation	situation	NOUN
gsrj-21	21	71	and	and	CCONJ
gsrj-21	21	72	the	the	DET
gsrj-21	21	73	fact	fact	NOUN
gsrj-21	21	74	that	that	SCONJ
gsrj-21	21	75	only	only	ADV
gsrj-21	21	76	three	three	NUM
gsrj-21	21	77	improvements	improvement	NOUN
gsrj-21	21	78	have	have	AUX
gsrj-21	21	79	been	be	AUX
gsrj-21	21	80	introduced	introduce	VERB
gsrj-21	21	81	over	over	ADP
gsrj-21	21	82	the	the	DET
gsrj-21	21	83	last	last	ADJ
gsrj-21	21	84	20	20	NUM
gsrj-21	21	85	years	year	NOUN
gsrj-21	21	86	underscore	underscore	VERB
gsrj-21	21	87	how	how	SCONJ
gsrj-21	21	88	effective	effective	ADJ
gsrj-21	21	89	therapeutic	therapeutic	ADJ
gsrj-21	21	90	strategies	strategy	NOUN
gsrj-21	21	91	for	for	ADP
gsrj-21	21	92	patients	patient	NOUN
gsrj-21	21	93	with	with	ADP
gsrj-21	21	94	pdac	pdac	NOUN
gsrj-21	21	95	have	have	AUX
gsrj-21	21	96	been	be	AUX
gsrj-21	21	97	difficult	difficult	ADJ
gsrj-21	21	98	to	to	PART
gsrj-21	21	99	identify	identify	VERB
gsrj-21	21	100	.	.	PUNCT
gsrj-21	22	1	despite	despite	SCONJ
gsrj-21	22	2	numerous	numerous	ADJ
gsrj-21	22	3	preclinical	preclinical	ADJ
gsrj-21	22	4	investigations	investigation	NOUN
gsrj-21	22	5	and	and	CCONJ
gsrj-21	22	6	clinical	clinical	ADJ
gsrj-21	22	7	trials	trial	NOUN
gsrj-21	22	8	,	,	PUNCT
gsrj-21	22	9	only	only	ADV
gsrj-21	22	10	moderate	moderate	ADJ
gsrj-21	22	11	progress	progress	NOUN
gsrj-21	22	12	has	have	AUX
gsrj-21	22	13	been	be	AUX
gsrj-21	22	14	made	make	VERB
gsrj-21	22	15	in	in	ADP
gsrj-21	22	16	improving	improve	VERB
gsrj-21	22	17	therapeutic	therapeutic	ADJ
gsrj-21	22	18	strategies.55	strategies.55	NOUN
gsrj-21	22	19	thus	thus	ADV
gsrj-21	22	20	,	,	PUNCT
gsrj-21	22	21	there	there	PRON
gsrj-21	22	22	is	be	VERB
gsrj-21	22	23	a	a	DET
gsrj-21	22	24	desperate	desperate	ADJ
gsrj-21	22	25	need	need	NOUN
gsrj-21	22	26	for	for	ADP
gsrj-21	22	27	novel	novel	ADJ
gsrj-21	22	28	drugs	drug	NOUN
gsrj-21	22	29	,	,	PUNCT
gsrj-21	22	30	improved	improve	VERB
gsrj-21	22	31	radiation	radiation	NOUN
gsrj-21	22	32	protocols	protocol	NOUN
gsrj-21	22	33	,	,	PUNCT
gsrj-21	22	34	and	and	CCONJ
gsrj-21	22	35	increased	increase	VERB
gsrj-21	22	36	avenues	avenue	NOUN
gsrj-21	22	37	for	for	ADP
gsrj-21	22	38	secondand	secondand	NOUN
gsrj-21	22	39	third	third	ADJ
gsrj-21	22	40	-	-	PUNCT
gsrj-21	22	41	line	line	NOUN
gsrj-21	22	42	therapies.55	therapies.55	NOUN
gsrj-21	22	43	although	although	SCONJ
gsrj-21	22	44	chemotherapy	chemotherapy	NOUN
gsrj-21	22	45	is	be	AUX
gsrj-21	22	46	one	one	NUM
gsrj-21	22	47	of	of	ADP
gsrj-21	22	48	the	the	DET
gsrj-21	22	49	pillars	pillar	NOUN
gsrj-21	22	50	of	of	ADP
gsrj-21	22	51	clinical	clinical	ADJ
gsrj-21	22	52	cancer	cancer	NOUN
gsrj-21	22	53	treatment	treatment	NOUN
gsrj-21	22	54	,	,	PUNCT
gsrj-21	22	55	its	its	PRON
gsrj-21	22	56	outcome	outcome	NOUN
gsrj-21	22	57	typically	typically	ADV
gsrj-21	22	58	leads	lead	VERB
gsrj-21	22	59	to	to	PART
gsrj-21	22	60	multidrug	multidrug	VERB
gsrj-21	22	61	resistance	resistance	NOUN
gsrj-21	22	62	,	,	PUNCT
gsrj-21	22	63	drastically	drastically	ADV
gsrj-21	22	64	restricting	restrict	VERB
gsrj-21	22	65	the	the	DET
gsrj-21	22	66	curative	curative	ADJ
gsrj-21	22	67	effect	effect	NOUN
gsrj-21	22	68	of	of	ADP
gsrj-21	22	69	drugs	drug	NOUN
gsrj-21	22	70	for	for	ADP
gsrj-21	22	71	a	a	DET
gsrj-21	22	72	variety	variety	NOUN
gsrj-21	22	73	of	of	ADP
gsrj-21	22	74	tumors	tumor	NOUN
gsrj-21	22	75	,	,	PUNCT
gsrj-21	22	76	such	such	ADJ
gsrj-21	22	77	as	as	ADP
gsrj-21	22	78	in	in	ADP
gsrj-21	22	79	pancreatic	pancreatic	ADJ
gsrj-21	22	80	cancer	cancer	NOUN
gsrj-21	22	81	patients.7,71	patients.7,71	NOUN
gsrj-21	22	82	many	many	ADJ
gsrj-21	22	83	cancer	cancer	NOUN
gsrj-21	22	84	types	type	NOUN
gsrj-21	22	85	that	that	PRON
gsrj-21	22	86	are	be	AUX
gsrj-21	22	87	initially	initially	ADV
gsrj-21	22	88	susceptible	susceptible	ADJ
gsrj-21	22	89	to	to	ADP
gsrj-21	22	90	treatment	treatment	NOUN
gsrj-21	22	91	often	often	ADV
gsrj-21	22	92	develop	develop	VERB
gsrj-21	22	93	therapeutic	therapeutic	ADJ
gsrj-21	22	94	resistance	resistance	NOUN
gsrj-21	22	95	over	over	ADP
gsrj-21	22	96	the	the	DET
gsrj-21	22	97	course	course	NOUN
gsrj-21	22	98	of	of	ADP
gsrj-21	22	99	the	the	DET
gsrj-21	22	100	therapeutic	therapeutic	ADJ
gsrj-21	22	101	regimen	regiman	NOUN
gsrj-21	22	102	.	.	PUNCT
gsrj-21	23	1	resistance	resistance	NOUN
gsrj-21	23	2	is	be	AUX
gsrj-21	23	3	due	due	ADJ
gsrj-21	23	4	to	to	ADP
gsrj-21	23	5	several	several	ADJ
gsrj-21	23	6	intracellular	intracellular	ADJ
gsrj-21	23	7	factors	factor	NOUN
gsrj-21	23	8	,	,	PUNCT
gsrj-21	23	9	including	include	VERB
gsrj-21	23	10	genetic	genetic	ADJ
gsrj-21	23	11	and	and	CCONJ
gsrj-21	23	12	epigenetic	epigenetic	ADJ
gsrj-21	23	13	changes	change	NOUN
gsrj-21	23	14	in	in	ADP
gsrj-21	23	15	signaling	signal	VERB
gsrj-21	23	16	pathways	pathway	NOUN
gsrj-21	23	17	,	,	PUNCT
gsrj-21	23	18	drug	drug	NOUN
gsrj-21	23	19	-	-	PUNCT
gsrj-21	23	20	metabolizing	metabolize	VERB
gsrj-21	23	21	enzymes	enzyme	NOUN
gsrj-21	23	22	,	,	PUNCT
gsrj-21	23	23	and	and	CCONJ
gsrj-21	23	24	drug	drug	NOUN
gsrj-21	23	25	efflux	efflux	NOUN
gsrj-21	23	26	pump	pump	NOUN
gsrj-21	23	27	mechanisms.7,71	mechanisms.7,71	ADJ
gsrj-21	23	28	pancreatic	pancreatic	ADJ
gsrj-21	23	29	tumors	tumor	NOUN
gsrj-21	23	30	are	be	AUX
gsrj-21	23	31	especially	especially	ADV
gsrj-21	23	32	characterized	characterize	VERB
gsrj-21	23	33	by	by	ADP
gsrj-21	23	34	genetic	genetic	ADJ
gsrj-21	23	35	instability	instability	NOUN
gsrj-21	23	36	,	,	PUNCT
gsrj-21	23	37	intra	intra	ADJ
gsrj-21	23	38	-	-	ADJ
gsrj-21	23	39	tumoral	tumoral	ADJ
gsrj-21	23	40	heterogeneity	heterogeneity	NOUN
gsrj-21	23	41	,	,	PUNCT
gsrj-21	23	42	and	and	CCONJ
gsrj-21	23	43	distinct	distinct	ADJ
gsrj-21	23	44	desmoplastic	desmoplastic	ADJ
gsrj-21	23	45	stroma	stroma	NOUN
gsrj-21	23	46	that	that	PRON
gsrj-21	23	47	makes	make	VERB
gsrj-21	23	48	it	it	PRON
gsrj-21	23	49	difficult	difficult	ADJ
gsrj-21	23	50	to	to	PART
gsrj-21	23	51	effectively	effectively	ADV
gsrj-21	23	52	develop	develop	VERB
gsrj-21	23	53	therapeutic	therapeutic	ADJ
gsrj-21	23	54	strategies	strategy	NOUN
gsrj-21	23	55	for	for	ADP
gsrj-21	23	56	pdac	pdac	NOUN
gsrj-21	23	57	.	.	PUNCT
gsrj-21	24	1	the	the	DET
gsrj-21	24	2	lack	lack	NOUN
gsrj-21	24	3	of	of	ADP
gsrj-21	24	4	innovative	innovative	ADJ
gsrj-21	24	5	approaches	approach	NOUN
gsrj-21	24	6	to	to	ADP
gsrj-21	24	7	treating	treat	VERB
gsrj-21	24	8	pdac	pdac	NOUN
gsrj-21	24	9	stems	stem	NOUN
gsrj-21	24	10	from	from	ADP
gsrj-21	24	11	the	the	DET
gsrj-21	24	12	high	high	ADJ
gsrj-21	24	13	degree	degree	NOUN
gsrj-21	24	14	of	of	ADP
gsrj-21	24	15	heterogeneity	heterogeneity	NOUN
gsrj-21	24	16	of	of	ADP
gsrj-21	24	17	this	this	DET
gsrj-21	24	18	tumor	tumor	NOUN
gsrj-21	24	19	with	with	ADP
gsrj-21	24	20	several	several	ADJ
gsrj-21	24	21	different	different	ADJ
gsrj-21	24	22	histopathological	histopathological	ADJ
gsrj-21	24	23	subtypes	subtype	NOUN
gsrj-21	24	24	and	and	CCONJ
gsrj-21	24	25	limited	limited	ADJ
gsrj-21	24	26	knowledge	knowledge	NOUN
gsrj-21	24	27	on	on	ADP
gsrj-21	24	28	the	the	DET
gsrj-21	24	29	molecular	molecular	ADJ
gsrj-21	24	30	mechanisms	mechanism	NOUN
gsrj-21	24	31	behind	behind	ADP
gsrj-21	24	32	tumor	tumor	NOUN
gsrj-21	24	33	development	development	NOUN
gsrj-21	24	34	and	and	CCONJ
gsrj-21	24	35	progression	progression	NOUN
gsrj-21	24	36	.	.	PUNCT
gsrj-21	25	1	the	the	DET
gsrj-21	25	2	development	development	NOUN
gsrj-21	25	3	of	of	ADP
gsrj-21	25	4	chemotherapeutic	chemotherapeutic	ADJ
gsrj-21	25	5	resistance	resistance	NOUN
gsrj-21	25	6	in	in	ADP
gsrj-21	25	7	cancer	cancer	NOUN
gsrj-21	25	8	patients	patient	NOUN
gsrj-21	25	9	poses	pose	VERB
gsrj-21	25	10	a	a	DET
gsrj-21	25	11	major	major	ADJ
gsrj-21	25	12	clinical	clinical	ADJ
gsrj-21	25	13	problem	problem	NOUN
gsrj-21	25	14	for	for	ADP
gsrj-21	25	15	chemotherapeutic	chemotherapeutic	ADJ
gsrj-21	25	16	treatment	treatment	NOUN
gsrj-21	25	17	.	.	PUNCT
gsrj-21	26	1	the	the	DET
gsrj-21	26	2	elucidation	elucidation	NOUN
gsrj-21	26	3	of	of	ADP
gsrj-21	26	4	underlying	underlie	VERB
gsrj-21	26	5	mechanisms	mechanism	NOUN
gsrj-21	26	6	for	for	ADP
gsrj-21	26	7	resistance	resistance	NOUN
gsrj-21	26	8	through	through	ADP
gsrj-21	26	9	different	different	ADJ
gsrj-21	26	10	models	model	NOUN
gsrj-21	26	11	is	be	AUX
gsrj-21	26	12	essential	essential	ADJ
gsrj-21	26	13	for	for	ADP
gsrj-21	26	14	the	the	DET
gsrj-21	26	15	development	development	NOUN
gsrj-21	26	16	of	of	ADP
gsrj-21	26	17	new	new	ADJ
gsrj-21	26	18	strategies	strategy	NOUN
gsrj-21	26	19	and	and	CCONJ
gsrj-21	26	20	therapies.7,71	therapies.7,71	NOUN
gsrj-21	26	21	therapeutic	therapeutic	ADJ
gsrj-21	26	22	resistance	resistance	NOUN
gsrj-21	26	23	in	in	ADP
gsrj-21	26	24	pdac	pdac	NOUN
gsrj-21	26	25	has	have	AUX
gsrj-21	26	26	been	be	AUX
gsrj-21	26	27	explored	explore	VERB
gsrj-21	26	28	through	through	ADP
gsrj-21	26	29	various	various	ADJ
gsrj-21	26	30	cell	cell	NOUN
gsrj-21	26	31	culture	culture	NOUN
gsrj-21	26	32	and	and	CCONJ
gsrj-21	26	33	animal	animal	NOUN
gsrj-21	26	34	model	model	NOUN
gsrj-21	26	35	systems	system	NOUN
gsrj-21	26	36	.	.	PUNCT
gsrj-21	27	1	cell	cell	NOUN
gsrj-21	27	2	cultures	culture	NOUN
gsrj-21	27	3	include	include	VERB
gsrj-21	27	4	twodimensional	twodimensional	ADJ
gsrj-21	27	5	(	(	PUNCT
gsrj-21	27	6	2d	2d	NOUN
gsrj-21	27	7	)	)	PUNCT
gsrj-21	27	8	culture	culture	NOUN
gsrj-21	27	9	conditions	condition	NOUN
gsrj-21	27	10	and	and	CCONJ
gsrj-21	27	11	,	,	PUNCT
gsrj-21	27	12	most	most	ADV
gsrj-21	27	13	notably	notably	ADV
gsrj-21	27	14	,	,	PUNCT
gsrj-21	27	15	three	three	NUM
gsrj-21	27	16	-	-	PUNCT
gsrj-21	27	17	dimensional	dimensional	ADJ
gsrj-21	27	18	(	(	PUNCT
gsrj-21	27	19	3d	3d	NUM
gsrj-21	27	20	)	)	PUNCT
gsrj-21	27	21	culture	culture	NOUN
gsrj-21	27	22	strategies	strategy	NOUN
gsrj-21	27	23	,	,	PUNCT
gsrj-21	27	24	such	such	ADJ
gsrj-21	27	25	as	as	ADP
gsrj-21	27	26	organoids	organoid	NOUN
gsrj-21	27	27	and	and	CCONJ
gsrj-21	27	28	spheroids.36	spheroids.36	NOUN
gsrj-21	27	29	3d	3d	PROPN
gsrj-21	27	30	culture	culture	NOUN
gsrj-21	27	31	models	model	NOUN
gsrj-21	27	32	have	have	AUX
gsrj-21	27	33	incorporated	incorporate	VERB
gsrj-21	27	34	pancreatic	pancreatic	ADJ
gsrj-21	27	35	stellate	stellate	ADJ
gsrj-21	27	36	cells	cell	NOUN
gsrj-21	27	37	(	(	PUNCT
gsrj-21	27	38	psc	psc	PROPN
gsrj-21	27	39	)	)	PUNCT
gsrj-21	27	40	to	to	PART
gsrj-21	27	41	investigate	investigate	VERB
gsrj-21	27	42	the	the	DET
gsrj-21	27	43	prominent	prominent	ADJ
gsrj-21	27	44	desmoplastic	desmoplastic	ADJ
gsrj-21	27	45	/	/	SYM
gsrj-21	27	46	stromal	stromal	ADJ
gsrj-21	27	47	reaction	reaction	NOUN
gsrj-21	27	48	in	in	ADP
gsrj-21	27	49	pdac.62	pdac.62	NOUN
gsrj-21	27	50	moreover	moreover	ADV
gsrj-21	27	51	,	,	PUNCT
gsrj-21	27	52	cells	cell	NOUN
gsrj-21	27	53	grown	grow	VERB
gsrj-21	27	54	in	in	ADP
gsrj-21	27	55	3d	3d	PROPN
gsrj-21	27	56	models	model	NOUN
gsrj-21	27	57	showed	show	VERB
gsrj-21	27	58	resistance	resistance	NOUN
gsrj-21	27	59	to	to	ADP
gsrj-21	27	60	gem	gem	NOUN
gsrj-21	27	61	and	and	CCONJ
gsrj-21	27	62	n	n	CCONJ
gsrj-21	27	63	-	-	PUNCT
gsrj-21	27	64	ptx	ptx	NOUN
gsrj-21	27	65	,	,	PUNCT
gsrj-21	27	66	drugs	drug	NOUN
gsrj-21	27	67	frequently	frequently	ADV
gsrj-21	27	68	used	use	VERB
gsrj-21	27	69	for	for	ADP
gsrj-21	27	70	pdac	pdac	PROPN
gsrj-21	27	71	treatment.36,62	treatment.36,62	PROPN
gsrj-21	27	72	animal	animal	NOUN
gsrj-21	27	73	model	model	NOUN
gsrj-21	27	74	systems	system	NOUN
gsrj-21	27	75	include	include	VERB
gsrj-21	27	76	patient	patient	NOUN
gsrj-21	27	77	-	-	PUNCT
gsrj-21	27	78	derived	derive	VERB
gsrj-21	27	79	xenografts	xenograft	NOUN
gsrj-21	27	80	(	(	PUNCT
gsrj-21	27	81	pdxs	pdxs	PROPN
gsrj-21	27	82	)	)	PUNCT
gsrj-21	27	83	and	and	CCONJ
gsrj-21	27	84	genetically	genetically	ADV
gsrj-21	27	85	engineered	engineer	VERB
gsrj-21	27	86	mouse	mouse	NOUN
gsrj-21	27	87	models	model	NOUN
gsrj-21	27	88	(	(	PUNCT
gsrj-21	27	89	gemms).36	gemms).36	VERB
gsrj-21	27	90	this	this	DET
gsrj-21	27	91	review	review	NOUN
gsrj-21	27	92	provides	provide	VERB
gsrj-21	27	93	an	an	DET
gsrj-21	27	94	overview	overview	NOUN
gsrj-21	27	95	of	of	ADP
gsrj-21	27	96	the	the	DET
gsrj-21	27	97	range	range	NOUN
gsrj-21	27	98	of	of	ADP
gsrj-21	27	99	in	in	ADP
gsrj-21	27	100	vitro	vitro	X
gsrj-21	27	101	and	and	CCONJ
gsrj-21	27	102	in	in	ADP
gsrj-21	27	103	vivo	vivo	NOUN
gsrj-21	27	104	models	model	NOUN
gsrj-21	27	105	of	of	ADP
gsrj-21	27	106	pancreatic	pancreatic	ADJ
gsrj-21	27	107	cancer	cancer	NOUN
gsrj-21	27	108	that	that	PRON
gsrj-21	27	109	are	be	AUX
gsrj-21	27	110	being	be	AUX
gsrj-21	27	111	used	use	VERB
gsrj-21	27	112	in	in	ADP
gsrj-21	27	113	preclinical	preclinical	ADJ
gsrj-21	27	114	research	research	NOUN
gsrj-21	27	115	.	.	PUNCT
gsrj-21	28	1	it	it	PRON
gsrj-21	28	2	considers	consider	VERB
gsrj-21	28	3	an	an	DET
gsrj-21	28	4	overview	overview	NOUN
gsrj-21	28	5	of	of	ADP
gsrj-21	28	6	platforms	platform	NOUN
gsrj-21	28	7	for	for	ADP
gsrj-21	28	8	cancer	cancer	NOUN
gsrj-21	28	9	research	research	NOUN
gsrj-21	28	10	with	with	ADP
gsrj-21	28	11	a	a	DET
gsrj-21	28	12	focus	focus	NOUN
gsrj-21	28	13	on	on	ADP
gsrj-21	28	14	those	those	PRON
gsrj-21	28	15	devoted	devote	VERB
gsrj-21	28	16	to	to	ADP
gsrj-21	28	17	resistance	resistance	NOUN
gsrj-21	28	18	mechanisms	mechanism	NOUN
gsrj-21	28	19	in	in	ADP
gsrj-21	28	20	pdac	pdac	NOUN
gsrj-21	28	21	and	and	CCONJ
gsrj-21	28	22	the	the	DET
gsrj-21	28	23	therapeutic	therapeutic	ADJ
gsrj-21	28	24	intervention	intervention	NOUN
gsrj-21	28	25	gemcitabine	gemcitabine	NOUN
gsrj-21	28	26	.	.	PUNCT
gsrj-21	29	1	the	the	DET
gsrj-21	29	2	goals	goal	NOUN
gsrj-21	29	3	of	of	ADP
gsrj-21	29	4	the	the	DET
gsrj-21	29	5	paper	paper	NOUN
gsrj-21	29	6	are	be	AUX
gsrj-21	29	7	to	to	PART
gsrj-21	29	8	examine	examine	VERB
gsrj-21	29	9	the	the	DET
gsrj-21	29	10	impact	impact	NOUN
gsrj-21	29	11	of	of	ADP
gsrj-21	29	12	each	each	DET
gsrj-21	29	13	tumor	tumor	NOUN
gsrj-21	29	14	resistance	resistance	NOUN
gsrj-21	29	15	model	model	NOUN
gsrj-21	29	16	for	for	ADP
gsrj-21	29	17	pdac	pdac	NOUN
gsrj-21	29	18	.	.	PUNCT
gsrj-21	30	1	2	2	X
gsrj-21	30	2	.	.	X
gsrj-21	30	3	background	background	NOUN
gsrj-21	30	4	therapeutic	therapeutic	ADJ
gsrj-21	30	5	resistance	resistance	NOUN
gsrj-21	30	6	mechanisms	mechanism	NOUN
gsrj-21	30	7	can	can	AUX
gsrj-21	30	8	be	be	AUX
gsrj-21	30	9	tumor	tumor	NOUN
gsrj-21	30	10	cell	cell	NOUN
gsrj-21	30	11	-	-	PUNCT
gsrj-21	30	12	intrinsic	intrinsic	ADJ
gsrj-21	30	13	(	(	PUNCT
gsrj-21	30	14	present	present	ADJ
gsrj-21	30	15	before	before	ADP
gsrj-21	30	16	treatment)1	treatment)1	NOUN
gsrj-21	30	17	,	,	PUNCT
gsrj-21	30	18	acquired	acquire	VERB
gsrj-21	30	19	during	during	ADP
gsrj-21	30	20	treatment	treatment	NOUN
gsrj-21	30	21	by	by	ADP
gsrj-21	30	22	various	various	ADJ
gsrj-21	30	23	therapyinduced	therapyinduce	VERB
gsrj-21	30	24	adaptive	adaptive	ADJ
gsrj-21	30	25	responses,2	responses,2	NOUN
gsrj-21	30	26	or	or	CCONJ
gsrj-21	30	27	mediated	mediate	VERB
gsrj-21	30	28	by	by	ADP
gsrj-21	30	29	the	the	DET
gsrj-21	30	30	tumor	tumor	NOUN
gsrj-21	30	31	microenvironment	microenvironment	NOUN
gsrj-21	30	32	(	(	PUNCT
gsrj-21	30	33	tme).3,4,5,6	tme).3,4,5,6	NUM
gsrj-21	30	34	tumor	tumor	NOUN
gsrj-21	30	35	molecular	molecular	ADJ
gsrj-21	30	36	and	and	CCONJ
gsrj-21	30	37	genetic	genetic	ADJ
gsrj-21	30	38	heterogeneity	heterogeneity	NOUN
gsrj-21	30	39	is	be	AUX
gsrj-21	30	40	the	the	DET
gsrj-21	30	41	main	main	ADJ
gsrj-21	30	42	reason	reason	NOUN
gsrj-21	30	43	for	for	ADP
gsrj-21	30	44	the	the	DET
gsrj-21	30	45	failure	failure	NOUN
gsrj-21	30	46	of	of	ADP
gsrj-21	30	47	conventional	conventional	ADJ
gsrj-21	30	48	cancer	cancer	NOUN
gsrj-21	30	49	therapy	therapy	NOUN
gsrj-21	30	50	as	as	SCONJ
gsrj-21	30	51	resistance	resistance	NOUN
gsrj-21	30	52	can	can	AUX
gsrj-21	30	53	arise	arise	VERB
gsrj-21	30	54	from	from	ADP
gsrj-21	30	55	the	the	DET
gsrj-21	30	56	positive	positive	ADJ
gsrj-21	30	57	selection	selection	NOUN
gsrj-21	30	58	of	of	ADP
gsrj-21	30	59	a	a	DET
gsrj-21	30	60	drug	drug	NOUN
gsrj-21	30	61	-	-	PUNCT
gsrj-21	30	62	resistant	resistant	ADJ
gsrj-21	30	63	tumor	tumor	NOUN
gsrj-21	30	64	subpopulation.5	subpopulation.5	PROPN
gsrj-21	30	65	45	45	NUM
gsrj-21	30	66	georgetown	georgetown	PROPN
gsrj-21	30	67	scientific	scientific	PROPN
gsrj-21	30	68	research	research	PROPN
gsrj-21	30	69	journal	journal	NOUN
gsrj-21	30	70	the	the	DET
gsrj-21	30	71	high	high	ADJ
gsrj-21	30	72	adaptability	adaptability	NOUN
gsrj-21	30	73	of	of	ADP
gsrj-21	30	74	tumors	tumor	NOUN
gsrj-21	30	75	through	through	ADP
gsrj-21	30	76	activation	activation	NOUN
gsrj-21	30	77	of	of	ADP
gsrj-21	30	78	pro	pro	ADJ
gsrj-21	30	79	-	-	ADJ
gsrj-21	30	80	survival	survival	ADJ
gsrj-21	30	81	signaling	signal	VERB
gsrj-21	30	82	pathways	pathway	NOUN
gsrj-21	30	83	and	and	CCONJ
gsrj-21	30	84	the	the	DET
gsrj-21	30	85	inactivation	inactivation	NOUN
gsrj-21	30	86	of	of	ADP
gsrj-21	30	87	downstream	downstream	ADJ
gsrj-21	30	88	death	death	NOUN
gsrj-21	30	89	signaling	signal	VERB
gsrj-21	30	90	pathways	pathway	NOUN
gsrj-21	30	91	can	can	AUX
gsrj-21	30	92	lead	lead	VERB
gsrj-21	30	93	to	to	ADP
gsrj-21	30	94	drug	drug	NOUN
gsrj-21	30	95	resistance.2	resistance.2	PROPN
gsrj-21	30	96	the	the	DET
gsrj-21	30	97	activation	activation	NOUN
gsrj-21	30	98	of	of	ADP
gsrj-21	30	99	epidermal	epidermal	ADJ
gsrj-21	30	100	growth	growth	NOUN
gsrj-21	30	101	factor	factor	NOUN
gsrj-21	30	102	receptor	receptor	NOUN
gsrj-21	30	103	(	(	PUNCT
gsrj-21	30	104	egfr	egfr	X
gsrj-21	30	105	)	)	PUNCT
gsrj-21	30	106	also	also	ADV
gsrj-21	30	107	serves	serve	VERB
gsrj-21	30	108	as	as	ADP
gsrj-21	30	109	a	a	DET
gsrj-21	30	110	resistance	resistance	NOUN
gsrj-21	30	111	mechanism	mechanism	NOUN
gsrj-21	30	112	against	against	ADP
gsrj-21	30	113	chemotherapies	chemotherapy	NOUN
gsrj-21	30	114	,	,	PUNCT
gsrj-21	30	115	including	include	VERB
gsrj-21	30	116	treatments	treatment	NOUN
gsrj-21	30	117	for	for	ADP
gsrj-21	30	118	pancreatic	pancreatic	ADJ
gsrj-21	30	119	cancer	cancer	NOUN
gsrj-21	30	120	,	,	PUNCT
gsrj-21	30	121	such	such	ADJ
gsrj-21	30	122	as	as	ADP
gsrj-21	30	123	5	5	NUM
gsrj-21	30	124	-	-	PUNCT
gsrj-21	30	125	fluorouracil	fluorouracil	NOUN
gsrj-21	30	126	,	,	PUNCT
gsrj-21	30	127	irinotecan	irinotecan	NOUN
gsrj-21	30	128	,	,	PUNCT
gsrj-21	30	129	and	and	CCONJ
gsrj-21	30	130	nanoparticle	nanoparticle	NOUN
gsrj-21	30	131	albumin	albumin	NOUN
gsrj-21	30	132	-	-	PUNCT
gsrj-21	30	133	bound	bind	VERB
gsrj-21	30	134	paclitaxel	paclitaxel	NOUN
gsrj-21	30	135	(	(	PUNCT
gsrj-21	30	136	nab	nab	NOUN
gsrj-21	30	137	-	-	PUNCT
gsrj-21	30	138	paclitaxel).5	paclitaxel).5	NOUN
gsrj-21	30	139	mechanisms	mechanism	NOUN
gsrj-21	30	140	of	of	ADP
gsrj-21	30	141	resistance	resistance	NOUN
gsrj-21	30	142	to	to	ADP
gsrj-21	30	143	cytotoxic	cytotoxic	ADJ
gsrj-21	30	144	and	and	CCONJ
gsrj-21	30	145	targeted	target	VERB
gsrj-21	30	146	chemotherapeutics	chemotherapeutic	NOUN
gsrj-21	30	147	include	include	VERB
gsrj-21	30	148	an	an	DET
gsrj-21	30	149	increased	increase	VERB
gsrj-21	30	150	rate	rate	NOUN
gsrj-21	30	151	of	of	ADP
gsrj-21	30	152	drug	drug	NOUN
gsrj-21	30	153	efflux	efflux	NOUN
gsrj-21	30	154	,	,	PUNCT
gsrj-21	30	155	alterations	alteration	NOUN
gsrj-21	30	156	in	in	ADP
gsrj-21	30	157	the	the	DET
gsrj-21	30	158	drug	drug	NOUN
gsrj-21	30	159	target	target	NOUN
gsrj-21	30	160	,	,	PUNCT
gsrj-21	30	161	activation	activation	NOUN
gsrj-21	30	162	of	of	ADP
gsrj-21	30	163	pro	pro	ADJ
gsrj-21	30	164	-	-	ADJ
gsrj-21	30	165	survival	survival	ADJ
gsrj-21	30	166	compensatory	compensatory	NOUN
gsrj-21	30	167	signaling	signal	VERB
gsrj-21	30	168	pathways	pathway	NOUN
gsrj-21	30	169	,	,	PUNCT
gsrj-21	30	170	and	and	CCONJ
gsrj-21	30	171	ineffective	ineffective	ADJ
gsrj-21	30	172	induction	induction	NOUN
gsrj-21	30	173	of	of	ADP
gsrj-21	30	174	cell	cell	NOUN
gsrj-21	30	175	death.5	death.5	NOUN
gsrj-21	30	176	cell	cell	NOUN
gsrj-21	30	177	plasticity	plasticity	NOUN
gsrj-21	30	178	also	also	ADV
gsrj-21	30	179	facilitates	facilitate	VERB
gsrj-21	30	180	adaptive	adaptive	ADJ
gsrj-21	30	181	cellular	cellular	ADJ
gsrj-21	30	182	reprogramming	reprogramme	VERB
gsrj-21	30	183	to	to	PART
gsrj-21	30	184	drive	drive	VERB
gsrj-21	30	185	acquired	acquire	VERB
gsrj-21	30	186	drug	drug	NOUN
gsrj-21	30	187	resistance.2	resistance.2	PROPN
gsrj-21	30	188	drug	drug	NOUN
gsrj-21	30	189	-	-	PUNCT
gsrj-21	30	190	resistance	resistance	NOUN
gsrj-21	30	191	mechanisms	mechanism	NOUN
gsrj-21	30	192	are	be	AUX
gsrj-21	30	193	regulated	regulate	VERB
gsrj-21	30	194	by	by	ADP
gsrj-21	30	195	the	the	DET
gsrj-21	30	196	tme	tme	PROPN
gsrj-21	30	197	,	,	PUNCT
gsrj-21	30	198	epithelial	epithelial	ADJ
gsrj-21	30	199	-	-	PUNCT
gsrj-21	30	200	mesenchymal	mesenchymal	ADJ
gsrj-21	30	201	transitions	transition	NOUN
gsrj-21	30	202	(	(	PUNCT
gsrj-21	30	203	emts	emts	PROPN
gsrj-21	30	204	)	)	PUNCT
gsrj-21	30	205	,	,	PUNCT
gsrj-21	30	206	and	and	CCONJ
gsrj-21	30	207	microrna.7	microrna.7	PROPN
gsrj-21	30	208	excellent	excellent	ADJ
gsrj-21	30	209	reviews	review	NOUN
gsrj-21	30	210	on	on	ADP
gsrj-21	30	211	the	the	DET
gsrj-21	30	212	contents	content	NOUN
gsrj-21	30	213	of	of	ADP
gsrj-21	30	214	the	the	DET
gsrj-21	30	215	tme	tme	NOUN
gsrj-21	30	216	have	have	AUX
gsrj-21	30	217	been	be	AUX
gsrj-21	30	218	published	publish	VERB
gsrj-21	30	219	previously4,5,10,13,17,20,21	previously4,5,10,13,17,20,21	NOUN
gsrj-21	30	220	and	and	CCONJ
gsrj-21	30	221	from	from	ADP
gsrj-21	30	222	these	these	DET
gsrj-21	30	223	works	work	NOUN
gsrj-21	30	224	,	,	PUNCT
gsrj-21	30	225	it	it	PRON
gsrj-21	30	226	is	be	AUX
gsrj-21	30	227	clear	clear	ADJ
gsrj-21	30	228	that	that	SCONJ
gsrj-21	30	229	the	the	DET
gsrj-21	30	230	tme	tme	NOUN
gsrj-21	30	231	consists	consist	VERB
gsrj-21	30	232	of	of	ADP
gsrj-21	30	233	the	the	DET
gsrj-21	30	234	extracellular	extracellular	ADJ
gsrj-21	30	235	matrix	matrix	NOUN
gsrj-21	30	236	,	,	PUNCT
gsrj-21	30	237	cancer	cancer	NOUN
gsrj-21	30	238	-	-	PUNCT
gsrj-21	30	239	associated	associate	VERB
gsrj-21	30	240	fibroblasts	fibroblast	NOUN
gsrj-21	30	241	,	,	PUNCT
gsrj-21	30	242	immune	immune	ADJ
gsrj-21	30	243	and	and	CCONJ
gsrj-21	30	244	inflammatory	inflammatory	ADJ
gsrj-21	30	245	cells	cell	NOUN
gsrj-21	30	246	,	,	PUNCT
gsrj-21	30	247	tumor	tumor	NOUN
gsrj-21	30	248	-	-	PUNCT
gsrj-21	30	249	associated	associate	VERB
gsrj-21	30	250	macrophages	macrophage	NOUN
gsrj-21	30	251	(	(	PUNCT
gsrj-21	30	252	tam	tam	NOUN
gsrj-21	30	253	)	)	PUNCT
gsrj-21	30	254	,	,	PUNCT
gsrj-21	30	255	and	and	CCONJ
gsrj-21	30	256	blood	blood	NOUN
gsrj-21	30	257	vessels	vessel	NOUN
gsrj-21	30	258	that	that	PRON
gsrj-21	30	259	provide	provide	VERB
gsrj-21	30	260	refuge	refuge	NOUN
gsrj-21	30	261	for	for	ADP
gsrj-21	30	262	cancer	cancer	NOUN
gsrj-21	30	263	cells	cell	NOUN
gsrj-21	30	264	from	from	ADP
gsrj-21	30	265	cytotoxic	cytotoxic	ADJ
gsrj-21	30	266	agents	agent	NOUN
gsrj-21	30	267	.	.	PUNCT
gsrj-21	31	1	additionally	additionally	ADV
gsrj-21	31	2	,	,	PUNCT
gsrj-21	31	3	epithelial	epithelial	ADJ
gsrj-21	31	4	cells	cell	NOUN
gsrj-21	31	5	can	can	AUX
gsrj-21	31	6	undergo	undergo	VERB
gsrj-21	31	7	a	a	DET
gsrj-21	31	8	transition	transition	NOUN
gsrj-21	31	9	to	to	PART
gsrj-21	31	10	become	become	VERB
gsrj-21	31	11	mesenchymal	mesenchymal	ADJ
gsrj-21	31	12	cells	cell	NOUN
gsrj-21	31	13	by	by	ADP
gsrj-21	31	14	losing	lose	VERB
gsrj-21	31	15	their	their	PRON
gsrj-21	31	16	polarized	polarize	VERB
gsrj-21	31	17	organization	organization	NOUN
gsrj-21	31	18	and	and	CCONJ
gsrj-21	31	19	tight	tight	ADJ
gsrj-21	31	20	cell	cell	NOUN
gsrj-21	31	21	-	-	PUNCT
gsrj-21	31	22	cell	cell	NOUN
gsrj-21	31	23	junctions	junction	NOUN
gsrj-21	31	24	to	to	PART
gsrj-21	31	25	change	change	VERB
gsrj-21	31	26	cell	cell	NOUN
gsrj-21	31	27	shape	shape	NOUN
gsrj-21	31	28	and	and	CCONJ
gsrj-21	31	29	develop	develop	VERB
gsrj-21	31	30	a	a	DET
gsrj-21	31	31	fibroblast	fibroblast	ADJ
gsrj-21	31	32	-	-	PUNCT
gsrj-21	31	33	like	like	ADJ
gsrj-21	31	34	morphology.5	morphology.5	PROPN
gsrj-21	31	35	studies	study	NOUN
gsrj-21	31	36	have	have	AUX
gsrj-21	31	37	found	find	VERB
gsrj-21	31	38	a	a	DET
gsrj-21	31	39	correlation	correlation	NOUN
gsrj-21	31	40	between	between	ADP
gsrj-21	31	41	chemotherapeutic	chemotherapeutic	ADJ
gsrj-21	31	42	resistance	resistance	NOUN
gsrj-21	31	43	and	and	CCONJ
gsrj-21	31	44	the	the	DET
gsrj-21	31	45	emt.23,24	emt.23,24	PROPN
gsrj-21	31	46	similarly	similarly	ADV
gsrj-21	31	47	,	,	PUNCT
gsrj-21	31	48	micrornas	microrna	NOUN
gsrj-21	31	49	(	(	PUNCT
gsrj-21	31	50	mirnas	mirna	NOUN
gsrj-21	31	51	)	)	PUNCT
gsrj-21	31	52	,	,	PUNCT
gsrj-21	31	53	a	a	DET
gsrj-21	31	54	class	class	NOUN
gsrj-21	31	55	of	of	ADP
gsrj-21	31	56	small	small	ADJ
gsrj-21	31	57	non	non	ADJ
gsrj-21	31	58	-	-	ADJ
gsrj-21	31	59	coding	coding	ADJ
gsrj-21	31	60	rnas	rna	NOUN
gsrj-21	31	61	that	that	PRON
gsrj-21	31	62	negatively	negatively	ADV
gsrj-21	31	63	regulate	regulate	VERB
gsrj-21	31	64	genes	gene	NOUN
gsrj-21	31	65	at	at	ADP
gsrj-21	31	66	the	the	DET
gsrj-21	31	67	post	post	ADJ
gsrj-21	31	68	-	-	ADJ
gsrj-21	31	69	transcriptional	transcriptional	ADJ
gsrj-21	31	70	level	level	NOUN
gsrj-21	31	71	,	,	PUNCT
gsrj-21	31	72	have	have	AUX
gsrj-21	31	73	also	also	ADV
gsrj-21	31	74	been	be	AUX
gsrj-21	31	75	shown	show	VERB
gsrj-21	31	76	to	to	PART
gsrj-21	31	77	affect	affect	VERB
gsrj-21	31	78	drug	drug	NOUN
gsrj-21	31	79	resistance.7	resistance.7	NOUN
gsrj-21	31	80	recent	recent	ADJ
gsrj-21	31	81	studies	study	NOUN
gsrj-21	31	82	have	have	AUX
gsrj-21	31	83	found	find	VERB
gsrj-21	31	84	a	a	DET
gsrj-21	31	85	correlation	correlation	NOUN
gsrj-21	31	86	between	between	ADP
gsrj-21	31	87	mirna	mirna	NOUN
gsrj-21	31	88	expression	expression	NOUN
gsrj-21	31	89	and	and	CCONJ
gsrj-21	31	90	resistance	resistance	NOUN
gsrj-21	31	91	towards	towards	ADP
gsrj-21	31	92	chemotherapeutic	chemotherapeutic	ADJ
gsrj-21	31	93	targets.7	targets.7	NOUN
gsrj-21	31	94	cancer	cancer	NOUN
gsrj-21	31	95	research	research	NOUN
gsrj-21	31	96	typically	typically	ADV
gsrj-21	31	97	involves	involve	VERB
gsrj-21	31	98	these	these	DET
gsrj-21	31	99	drugresistance	drugresistance	NOUN
gsrj-21	31	100	mechanisms	mechanism	NOUN
gsrj-21	31	101	and	and	CCONJ
gsrj-21	31	102	relies	rely	VERB
gsrj-21	31	103	on	on	ADP
gsrj-21	31	104	model	model	NOUN
gsrj-21	31	105	systems	system	NOUN
gsrj-21	31	106	,	,	PUNCT
gsrj-21	31	107	which	which	PRON
gsrj-21	31	108	reflect	reflect	VERB
gsrj-21	31	109	the	the	DET
gsrj-21	31	110	biology	biology	NOUN
gsrj-21	31	111	of	of	ADP
gsrj-21	31	112	human	human	ADJ
gsrj-21	31	113	tumors	tumor	NOUN
gsrj-21	31	114	to	to	ADP
gsrj-21	31	115	a	a	DET
gsrj-21	31	116	certain	certain	ADJ
gsrj-21	31	117	extent.25	extent.25	NOUN
gsrj-21	31	118	models	model	NOUN
gsrj-21	31	119	throughout	throughout	ADP
gsrj-21	31	120	cancer	cancer	NOUN
gsrj-21	31	121	research	research	NOUN
gsrj-21	31	122	history	history	NOUN
gsrj-21	31	123	have	have	AUX
gsrj-21	31	124	addressed	address	VERB
gsrj-21	31	125	all	all	DET
gsrj-21	31	126	stages	stage	NOUN
gsrj-21	31	127	of	of	ADP
gsrj-21	31	128	drug	drug	NOUN
gsrj-21	31	129	discovery	discovery	NOUN
gsrj-21	31	130	,	,	PUNCT
gsrj-21	31	131	including	include	VERB
gsrj-21	31	132	target	target	NOUN
gsrj-21	31	133	identification	identification	NOUN
gsrj-21	31	134	,	,	PUNCT
gsrj-21	31	135	toxicity	toxicity	NOUN
gsrj-21	31	136	,	,	PUNCT
gsrj-21	31	137	and	and	CCONJ
gsrj-21	31	138	individual	individual	ADJ
gsrj-21	31	139	patient	patient	NOUN
gsrj-21	31	140	prediction	prediction	NOUN
gsrj-21	31	141	.	.	PUNCT
gsrj-21	32	1	initial	initial	ADJ
gsrj-21	32	2	molecular	molecular	ADJ
gsrj-21	32	3	biology	biology	NOUN
gsrj-21	32	4	models	model	NOUN
gsrj-21	32	5	have	have	AUX
gsrj-21	32	6	increased	increase	VERB
gsrj-21	32	7	understanding	understanding	NOUN
gsrj-21	32	8	of	of	ADP
gsrj-21	32	9	tumor	tumor	NOUN
gsrj-21	32	10	cell	cell	NOUN
gsrj-21	32	11	biology	biology	NOUN
gsrj-21	32	12	,	,	PUNCT
gsrj-21	32	13	while	while	SCONJ
gsrj-21	32	14	new	new	ADJ
gsrj-21	32	15	model	model	NOUN
gsrj-21	32	16	systems	system	NOUN
gsrj-21	32	17	simulate	simulate	VERB
gsrj-21	32	18	functional	functional	ADJ
gsrj-21	32	19	processes	process	NOUN
gsrj-21	32	20	related	relate	VERB
gsrj-21	32	21	to	to	ADP
gsrj-21	32	22	the	the	DET
gsrj-21	32	23	development	development	NOUN
gsrj-21	32	24	and	and	CCONJ
gsrj-21	32	25	growth	growth	NOUN
gsrj-21	32	26	of	of	ADP
gsrj-21	32	27	cancer	cancer	NOUN
gsrj-21	32	28	.	.	PUNCT
gsrj-21	33	1	cell	cell	NOUN
gsrj-21	33	2	cultures	culture	NOUN
gsrj-21	33	3	,	,	PUNCT
gsrj-21	33	4	namely	namely	ADV
gsrj-21	33	5	those	those	PRON
gsrj-21	33	6	derived	derive	VERB
gsrj-21	33	7	from	from	ADP
gsrj-21	33	8	a	a	DET
gsrj-21	33	9	cervical	cervical	ADJ
gsrj-21	33	10	cancer	cancer	NOUN
gsrj-21	33	11	patient	patient	NOUN
gsrj-21	33	12	henrietta	henrietta	PROPN
gsrj-21	33	13	lacks	lack	VERB
gsrj-21	33	14	(	(	PUNCT
gsrj-21	33	15	hela	hela	PROPN
gsrj-21	33	16	)	)	PUNCT
gsrj-21	33	17	,	,	PUNCT
gsrj-21	33	18	became	become	VERB
gsrj-21	33	19	the	the	DET
gsrj-21	33	20	first	first	ADJ
gsrj-21	33	21	laboratory	laboratory	NOUN
gsrj-21	33	22	model	model	NOUN
gsrj-21	33	23	for	for	ADP
gsrj-21	33	24	cancer	cancer	NOUN
gsrj-21	33	25	research	research	NOUN
gsrj-21	33	26	in	in	ADP
gsrj-21	33	27	understanding	understand	VERB
gsrj-21	33	28	tumor	tumor	NOUN
gsrj-21	33	29	biology	biology	NOUN
gsrj-21	33	30	,	,	PUNCT
gsrj-21	33	31	drug	drug	NOUN
gsrj-21	33	32	identification	identification	NOUN
gsrj-21	33	33	,	,	PUNCT
gsrj-21	33	34	and	and	CCONJ
gsrj-21	33	35	drug	drug	NOUN
gsrj-21	33	36	development.25	development.25	NOUN
gsrj-21	33	37	in	in	ADP
gsrj-21	33	38	addition	addition	NOUN
gsrj-21	33	39	to	to	ADP
gsrj-21	33	40	2d	2d	NUM
gsrj-21	33	41	cell	cell	NOUN
gsrj-21	33	42	cultures	culture	NOUN
gsrj-21	33	43	,	,	PUNCT
gsrj-21	33	44	other	other	ADJ
gsrj-21	33	45	models	model	NOUN
gsrj-21	33	46	currently	currently	ADV
gsrj-21	33	47	in	in	ADP
gsrj-21	33	48	use	use	NOUN
gsrj-21	33	49	include	include	VERB
gsrj-21	33	50	in	in	ADP
gsrj-21	33	51	vitro	vitro	X
gsrj-21	33	52	conditionally	conditionally	ADV
gsrj-21	33	53	reprogrammed	reprogramme	VERB
gsrj-21	33	54	cell	cell	NOUN
gsrj-21	33	55	(	(	PUNCT
gsrj-21	33	56	crc	crc	NOUN
gsrj-21	33	57	)	)	PUNCT
gsrj-21	33	58	lines	line	NOUN
gsrj-21	33	59	,	,	PUNCT
gsrj-21	33	60	3d	3d	NUM
gsrj-21	33	61	cell	cell	NOUN
gsrj-21	33	62	cultures	culture	NOUN
gsrj-21	33	63	,	,	PUNCT
gsrj-21	33	64	organoids	organoid	NOUN
gsrj-21	33	65	,	,	PUNCT
gsrj-21	33	66	spheroids	spheroid	NOUN
gsrj-21	33	67	,	,	PUNCT
gsrj-21	33	68	and	and	CCONJ
gsrj-21	33	69	tumor	tumor	NOUN
gsrj-21	33	70	-	-	PUNCT
gsrj-21	33	71	on	on	ADP
gsrj-21	33	72	-	-	PUNCT
gsrj-21	33	73	the	the	DET
gsrj-21	33	74	-	-	PUNCT
gsrj-21	33	75	chip	chip	NOUN
gsrj-21	33	76	models	model	NOUN
gsrj-21	33	77	,	,	PUNCT
gsrj-21	33	78	in	in	ADP
gsrj-21	33	79	vivo	vivo	ADJ
gsrj-21	33	80	zebrafish	zebrafish	ADJ
gsrj-21	33	81	models	model	NOUN
gsrj-21	33	82	,	,	PUNCT
gsrj-21	33	83	patient	patient	NOUN
gsrj-21	33	84	-	-	PUNCT
gsrj-21	33	85	derived	derive	VERB
gsrj-21	33	86	xenograft	xenograft	NOUN
gsrj-21	33	87	(	(	PUNCT
gsrj-21	33	88	pdx	pdx	PROPN
gsrj-21	33	89	)	)	PUNCT
gsrj-21	33	90	mouse	mouse	NOUN
gsrj-21	33	91	models	model	NOUN
gsrj-21	33	92	,	,	PUNCT
gsrj-21	33	93	genetically	genetically	ADV
gsrj-21	33	94	engineered	engineer	VERB
gsrj-21	33	95	mouse	mouse	NOUN
gsrj-21	33	96	models	model	NOUN
gsrj-21	33	97	(	(	PUNCT
gsrj-21	33	98	gemms	gemms	ADJ
gsrj-21	33	99	)	)	PUNCT
gsrj-21	33	100	,	,	PUNCT
gsrj-21	33	101	and	and	CCONJ
gsrj-21	33	102	transgenic	transgenic	NOUN
gsrj-21	33	103	mouse	mouse	NOUN
gsrj-21	33	104	models	model	NOUN
gsrj-21	33	105	,	,	PUNCT
gsrj-21	33	106	as	as	ADV
gsrj-21	33	107	well	well	ADV
gsrj-21	33	108	as	as	ADP
gsrj-21	33	109	computational	computational	ADJ
gsrj-21	33	110	or	or	CCONJ
gsrj-21	33	111	mathematical	mathematical	ADJ
gsrj-21	33	112	models	model	NOUN
gsrj-21	33	113	.	.	PUNCT
gsrj-21	34	1	considering	consider	VERB
gsrj-21	34	2	how	how	SCONJ
gsrj-21	34	3	mechanisms	mechanism	NOUN
gsrj-21	34	4	for	for	ADP
gsrj-21	34	5	tumor	tumor	NOUN
gsrj-21	34	6	hypoxia	hypoxia	NOUN
gsrj-21	34	7	,	,	PUNCT
gsrj-21	34	8	senescence	senescence	NOUN
gsrj-21	34	9	,	,	PUNCT
gsrj-21	34	10	and	and	CCONJ
gsrj-21	34	11	cytoskeletal	cytoskeletal	ADJ
gsrj-21	34	12	organization	organization	NOUN
gsrj-21	34	13	vary	vary	VERB
gsrj-21	34	14	,	,	PUNCT
gsrj-21	34	15	a	a	DET
gsrj-21	34	16	current	current	ADJ
gsrj-21	34	17	challenge	challenge	NOUN
gsrj-21	34	18	in	in	ADP
gsrj-21	34	19	cancer	cancer	NOUN
gsrj-21	34	20	research	research	NOUN
gsrj-21	34	21	is	be	AUX
gsrj-21	34	22	selecting	select	VERB
gsrj-21	34	23	the	the	DET
gsrj-21	34	24	model	model	NOUN
gsrj-21	34	25	that	that	PRON
gsrj-21	34	26	best	well	ADV
gsrj-21	34	27	reflects	reflect	VERB
gsrj-21	34	28	the	the	DET
gsrj-21	34	29	given	give	VERB
gsrj-21	34	30	tumor	tumor	NOUN
gsrj-21	34	31	entity	entity	NOUN
gsrj-21	34	32	.	.	PUNCT
gsrj-21	35	1	thus	thus	ADV
gsrj-21	35	2	,	,	PUNCT
gsrj-21	35	3	the	the	DET
gsrj-21	35	4	roles	role	NOUN
gsrj-21	35	5	of	of	ADP
gsrj-21	35	6	cellular	cellular	ADJ
gsrj-21	35	7	senescence	senescence	NOUN
gsrj-21	35	8	,	,	PUNCT
gsrj-21	35	9	dormancy	dormancy	NOUN
gsrj-21	35	10	in	in	ADP
gsrj-21	35	11	tumor	tumor	NOUN
gsrj-21	35	12	formation	formation	NOUN
gsrj-21	35	13	,	,	PUNCT
gsrj-21	35	14	and	and	CCONJ
gsrj-21	35	15	therapy	therapy	NOUN
gsrj-21	35	16	resistance	resistance	NOUN
gsrj-21	35	17	have	have	AUX
gsrj-21	35	18	become	become	VERB
gsrj-21	35	19	increasingly	increasingly	ADV
gsrj-21	35	20	important	important	ADJ
gsrj-21	35	21	and	and	CCONJ
gsrj-21	35	22	relevant	relevant	ADJ
gsrj-21	35	23	in	in	ADP
gsrj-21	35	24	cancer	cancer	NOUN
gsrj-21	35	25	research.26	research.26	VERB
gsrj-21	35	26	this	this	DET
gsrj-21	35	27	paper	paper	NOUN
gsrj-21	35	28	will	will	AUX
gsrj-21	35	29	survey	survey	VERB
gsrj-21	35	30	these	these	DET
gsrj-21	35	31	topics	topic	NOUN
gsrj-21	35	32	and	and	CCONJ
gsrj-21	35	33	investigate	investigate	VERB
gsrj-21	35	34	their	their	PRON
gsrj-21	35	35	utility	utility	NOUN
gsrj-21	35	36	in	in	ADP
gsrj-21	35	37	various	various	ADJ
gsrj-21	35	38	applications	application	NOUN
gsrj-21	35	39	.	.	PUNCT
gsrj-21	36	1	3	3	X
gsrj-21	36	2	.	.	NUM
gsrj-21	36	3	models	model	NOUN
gsrj-21	36	4	in	in	ADP
gsrj-21	36	5	cancer	cancer	NOUN
gsrj-21	36	6	research	research	NOUN
gsrj-21	36	7	this	this	DET
gsrj-21	36	8	section	section	NOUN
gsrj-21	36	9	describes	describe	VERB
gsrj-21	36	10	each	each	PRON
gsrj-21	36	11	of	of	ADP
gsrj-21	36	12	four	four	NUM
gsrj-21	36	13	categories	category	NOUN
gsrj-21	36	14	of	of	ADP
gsrj-21	36	15	cancer	cancer	NOUN
gsrj-21	36	16	research	research	NOUN
gsrj-21	36	17	model	model	NOUN
gsrj-21	36	18	systems	system	NOUN
gsrj-21	36	19	:	:	PUNCT
gsrj-21	36	20	in	in	ADP
gsrj-21	36	21	vitro	vitro	X
gsrj-21	36	22	models	model	NOUN
gsrj-21	36	23	(	(	PUNCT
gsrj-21	36	24	2d	2d	NUM
gsrj-21	36	25	and	and	CCONJ
gsrj-21	36	26	3d	3d	NUM
gsrj-21	36	27	cell	cell	NOUN
gsrj-21	36	28	cultures	culture	NOUN
gsrj-21	36	29	)	)	PUNCT
gsrj-21	36	30	,	,	PUNCT
gsrj-21	36	31	in	in	ADP
gsrj-21	36	32	vivo	vivo	NOUN
gsrj-21	36	33	models	model	NOUN
gsrj-21	36	34	(	(	PUNCT
gsrj-21	36	35	pdx	pdx	NOUN
gsrj-21	36	36	,	,	PUNCT
gsrj-21	36	37	gemms	gemms	ADJ
gsrj-21	36	38	,	,	PUNCT
gsrj-21	36	39	transgenic	transgenic	NOUN
gsrj-21	36	40	)	)	PUNCT
gsrj-21	36	41	,	,	PUNCT
gsrj-21	36	42	proteomic	proteomic	NOUN
gsrj-21	36	43	models	model	NOUN
gsrj-21	36	44	,	,	PUNCT
gsrj-21	36	45	and	and	CCONJ
gsrj-21	36	46	computational	computational	ADJ
gsrj-21	36	47	or	or	CCONJ
gsrj-21	36	48	mathematical	mathematical	ADJ
gsrj-21	36	49	models	model	NOUN
gsrj-21	36	50	(	(	PUNCT
gsrj-21	36	51	figure	figure	NOUN
gsrj-21	36	52	1	1	NUM
gsrj-21	36	53	)	)	PUNCT
gsrj-21	36	54	.	.	PUNCT
gsrj-21	37	1	figure	figure	NOUN
gsrj-21	37	2	1	1	NUM
gsrj-21	37	3	.	.	PUNCT
gsrj-21	37	4	models	model	NOUN
gsrj-21	37	5	in	in	ADP
gsrj-21	37	6	cancer	cancer	NOUN
gsrj-21	37	7	research	research	NOUN
gsrj-21	37	8	46	46	NUM
gsrj-21	37	9	georgetown	georgetown	PROPN
gsrj-21	37	10	scientific	scientific	PROPN
gsrj-21	37	11	research	research	PROPN
gsrj-21	37	12	journal	journal	NOUN
gsrj-21	37	13	3.1	3.1	NUM
gsrj-21	37	14	in	in	ADP
gsrj-21	37	15	vitro	vitro	X
gsrj-21	37	16	models	model	NOUN
gsrj-21	37	17	3.1.1	3.1.1	NUM
gsrj-21	37	18	2d	2d	NUM
gsrj-21	37	19	cultures	culture	NOUN
gsrj-21	37	20	the	the	DET
gsrj-21	37	21	use	use	NOUN
gsrj-21	37	22	of	of	ADP
gsrj-21	37	23	in	in	ADP
gsrj-21	37	24	vitro	vitro	X
gsrj-21	37	25	models	model	NOUN
gsrj-21	37	26	has	have	AUX
gsrj-21	37	27	allowed	allow	VERB
gsrj-21	37	28	for	for	ADP
gsrj-21	37	29	preclinical	preclinical	ADJ
gsrj-21	37	30	and	and	CCONJ
gsrj-21	37	31	translational	translational	ADJ
gsrj-21	37	32	studies	study	NOUN
gsrj-21	37	33	of	of	ADP
gsrj-21	37	34	tumor	tumor	NOUN
gsrj-21	37	35	mutations	mutation	NOUN
gsrj-21	37	36	,	,	PUNCT
gsrj-21	37	37	aberrations	aberration	NOUN
gsrj-21	37	38	,	,	PUNCT
gsrj-21	37	39	and	and	CCONJ
gsrj-21	37	40	responses	response	NOUN
gsrj-21	37	41	to	to	ADP
gsrj-21	37	42	therapeutic	therapeutic	ADJ
gsrj-21	37	43	agents.27	agents.27	PROPN
gsrj-21	37	44	2d	2d	PROPN
gsrj-21	37	45	cell	cell	NOUN
gsrj-21	37	46	culture	culture	NOUN
gsrj-21	37	47	models	model	NOUN
gsrj-21	37	48	are	be	AUX
gsrj-21	37	49	inexpensive	inexpensive	ADJ
gsrj-21	37	50	and	and	CCONJ
gsrj-21	37	51	easy	easy	ADJ
gsrj-21	37	52	to	to	PART
gsrj-21	37	53	generate	generate	VERB
gsrj-21	37	54	and	and	CCONJ
gsrj-21	37	55	maintain	maintain	VERB
gsrj-21	37	56	,	,	PUNCT
gsrj-21	37	57	making	make	VERB
gsrj-21	37	58	them	they	PRON
gsrj-21	37	59	the	the	DET
gsrj-21	37	60	mainstay	mainstay	NOUN
gsrj-21	37	61	for	for	ADP
gsrj-21	37	62	cancer	cancer	NOUN
gsrj-21	37	63	research	research	NOUN
gsrj-21	37	64	.	.	PUNCT
gsrj-21	38	1	still	still	ADV
gsrj-21	38	2	,	,	PUNCT
gsrj-21	38	3	these	these	DET
gsrj-21	38	4	models	model	NOUN
gsrj-21	38	5	have	have	VERB
gsrj-21	38	6	limitations	limitation	NOUN
gsrj-21	38	7	,	,	PUNCT
gsrj-21	38	8	including	include	VERB
gsrj-21	38	9	induced	induced	ADJ
gsrj-21	38	10	alterations	alteration	NOUN
gsrj-21	38	11	in	in	ADP
gsrj-21	38	12	cell	cell	NOUN
gsrj-21	38	13	morphology	morphology	NOUN
gsrj-21	38	14	that	that	PRON
gsrj-21	38	15	translate	translate	VERB
gsrj-21	38	16	to	to	ADP
gsrj-21	38	17	changes	change	NOUN
gsrj-21	38	18	in	in	ADP
gsrj-21	38	19	gene	gene	NOUN
gsrj-21	38	20	and	and	CCONJ
gsrj-21	38	21	protein	protein	NOUN
gsrj-21	38	22	expression	expression	NOUN
gsrj-21	38	23	.	.	PUNCT
gsrj-21	39	1	3d	3d	NUM
gsrj-21	39	2	cell	cell	NOUN
gsrj-21	39	3	cultures	culture	NOUN
gsrj-21	39	4	have	have	AUX
gsrj-21	39	5	partially	partially	ADV
gsrj-21	39	6	overcome	overcome	VERB
gsrj-21	39	7	this	this	DET
gsrj-21	39	8	shortcoming.27	shortcoming.27	NOUN
gsrj-21	39	9	conditionally	conditionally	ADV
gsrj-21	39	10	reprogrammed	reprogramme	VERB
gsrj-21	39	11	cells	cell	NOUN
gsrj-21	39	12	(	(	PUNCT
gsrj-21	39	13	crcs	crcs	NOUN
gsrj-21	39	14	)	)	PUNCT
gsrj-21	39	15	overcome	overcome	VERB
gsrj-21	39	16	senescence	senescence	NOUN
gsrj-21	39	17	to	to	PART
gsrj-21	39	18	produce	produce	VERB
gsrj-21	39	19	immortalized	immortalize	VERB
gsrj-21	39	20	primary	primary	ADJ
gsrj-21	39	21	cell	cell	NOUN
gsrj-21	39	22	cultures	culture	NOUN
gsrj-21	39	23	through	through	ADP
gsrj-21	39	24	a	a	DET
gsrj-21	39	25	method	method	NOUN
gsrj-21	39	26	described	describe	VERB
gsrj-21	39	27	by	by	ADP
gsrj-21	39	28	liu	liu	PROPN
gsrj-21	39	29	et	et	PROPN
gsrj-21	39	30	al	al	PROPN
gsrj-21	39	31	.	.	PUNCT
gsrj-21	40	1	(	(	PUNCT
gsrj-21	40	2	the	the	DET
gsrj-21	40	3	georgetown	georgetown	PROPN
gsrj-21	40	4	method	method	NOUN
gsrj-21	40	5	)	)	PUNCT
gsrj-21	40	6	,	,	PUNCT
gsrj-21	40	7	which	which	PRON
gsrj-21	40	8	combines	combine	VERB
gsrj-21	40	9	irradiated	irradiated	ADJ
gsrj-21	40	10	mouse	mouse	NOUN
gsrj-21	40	11	fibroblasts	fibroblast	NOUN
gsrj-21	40	12	as	as	ADP
gsrj-21	40	13	a	a	DET
gsrj-21	40	14	feeder	feeder	NOUN
gsrj-21	40	15	cell	cell	NOUN
gsrj-21	40	16	layer	layer	NOUN
gsrj-21	40	17	with	with	ADP
gsrj-21	40	18	the	the	DET
gsrj-21	40	19	use	use	NOUN
gsrj-21	40	20	of	of	ADP
gsrj-21	40	21	a	a	DET
gsrj-21	40	22	rho	rho	ADJ
gsrj-21	40	23	kinase	kinase	NOUN
gsrj-21	40	24	(	(	PUNCT
gsrj-21	40	25	rock	rock	NOUN
gsrj-21	40	26	)	)	PUNCT
gsrj-21	40	27	inhibitor.28	inhibitor.28	ADJ
gsrj-21	40	28	cells	cell	NOUN
gsrj-21	40	29	can	can	AUX
gsrj-21	40	30	be	be	AUX
gsrj-21	40	31	derived	derive	VERB
gsrj-21	40	32	from	from	ADP
gsrj-21	40	33	both	both	CCONJ
gsrj-21	40	34	normal	normal	ADJ
gsrj-21	40	35	and	and	CCONJ
gsrj-21	40	36	cancer	cancer	NOUN
gsrj-21	40	37	tissues	tissue	NOUN
gsrj-21	40	38	and	and	CCONJ
gsrj-21	40	39	grown	grow	VERB
gsrj-21	40	40	indefinitely	indefinitely	ADV
gsrj-21	40	41	under	under	ADP
gsrj-21	40	42	these	these	DET
gsrj-21	40	43	conditions	condition	NOUN
gsrj-21	40	44	while	while	SCONJ
gsrj-21	40	45	maintaining	maintain	VERB
gsrj-21	40	46	a	a	DET
gsrj-21	40	47	normal	normal	ADJ
gsrj-21	40	48	phenotype.25	phenotype.25	NOUN
gsrj-21	40	49	the	the	DET
gsrj-21	40	50	irradiated	irradiated	ADJ
gsrj-21	40	51	mouse	mouse	NOUN
gsrj-21	40	52	fibroblasts	fibroblast	NOUN
gsrj-21	40	53	maintain	maintain	VERB
gsrj-21	40	54	telomerase	telomerase	NOUN
gsrj-21	40	55	reverse	reverse	ADJ
gsrj-21	40	56	transcriptase	transcriptase	NOUN
gsrj-21	40	57	(	(	PUNCT
gsrj-21	40	58	htert	htert	NOUN
gsrj-21	40	59	)	)	PUNCT
gsrj-21	40	60	expression	expression	NOUN
gsrj-21	40	61	to	to	PART
gsrj-21	40	62	prevent	prevent	VERB
gsrj-21	40	63	chromosome	chromosome	NOUN
gsrj-21	40	64	shortening	shortening	NOUN
gsrj-21	40	65	and	and	CCONJ
gsrj-21	40	66	tumorigenic	tumorigenic	ADJ
gsrj-21	40	67	cellular	cellular	ADJ
gsrj-21	40	68	transformation	transformation	NOUN
gsrj-21	40	69	of	of	ADP
gsrj-21	40	70	normal	normal	ADJ
gsrj-21	40	71	cells	cell	NOUN
gsrj-21	40	72	.	.	PUNCT
gsrj-21	41	1	furthermore	furthermore	ADV
gsrj-21	41	2	,	,	PUNCT
gsrj-21	41	3	the	the	DET
gsrj-21	41	4	use	use	NOUN
gsrj-21	41	5	of	of	ADP
gsrj-21	41	6	rock	rock	NOUN
gsrj-21	41	7	inhibitors	inhibitor	NOUN
gsrj-21	41	8	maintains	maintain	VERB
gsrj-21	41	9	the	the	DET
gsrj-21	41	10	undifferentiated	undifferentiated	ADJ
gsrj-21	41	11	and	and	CCONJ
gsrj-21	41	12	proliferative	proliferative	ADJ
gsrj-21	41	13	state	state	NOUN
gsrj-21	41	14	of	of	ADP
gsrj-21	41	15	epithelial	epithelial	ADJ
gsrj-21	41	16	cells	cell	NOUN
gsrj-21	41	17	.	.	PUNCT
gsrj-21	42	1	in	in	ADP
gsrj-21	42	2	combination	combination	NOUN
gsrj-21	42	3	with	with	ADP
gsrj-21	42	4	the	the	DET
gsrj-21	42	5	feeder	feeder	NOUN
gsrj-21	42	6	cells	cell	NOUN
gsrj-21	42	7	,	,	PUNCT
gsrj-21	42	8	rock	rock	NOUN
gsrj-21	42	9	inhibitors	inhibitor	NOUN
gsrj-21	42	10	prevent	prevent	VERB
gsrj-21	42	11	the	the	DET
gsrj-21	42	12	transformation	transformation	NOUN
gsrj-21	42	13	or	or	CCONJ
gsrj-21	42	14	senescence	senescence	NOUN
gsrj-21	42	15	of	of	ADP
gsrj-21	42	16	cultured	cultured	ADJ
gsrj-21	42	17	cells.25	cells.25	NOUN
gsrj-21	42	18	thus	thus	ADV
gsrj-21	42	19	,	,	PUNCT
gsrj-21	42	20	liu	liu	PROPN
gsrj-21	42	21	et	et	PROPN
gsrj-21	42	22	al	al	PROPN
gsrj-21	42	23	.	.	PROPN
gsrj-21	42	24	demonstrated	demonstrate	VERB
gsrj-21	42	25	that	that	SCONJ
gsrj-21	42	26	irradiated	irradiate	VERB
gsrj-21	42	27	murine	murine	ADJ
gsrj-21	42	28	fibroblasts	fibroblast	NOUN
gsrj-21	42	29	and	and	CCONJ
gsrj-21	42	30	a	a	DET
gsrj-21	42	31	rock	rock	NOUN
gsrj-21	42	32	inhibitor	inhibitor	NOUN
gsrj-21	42	33	are	be	AUX
gsrj-21	42	34	essential	essential	ADJ
gsrj-21	42	35	for	for	ADP
gsrj-21	42	36	both	both	DET
gsrj-21	42	37	initial	initial	ADJ
gsrj-21	42	38	survival	survival	NOUN
gsrj-21	42	39	,	,	PUNCT
gsrj-21	42	40	unlimited	unlimited	ADJ
gsrj-21	42	41	expansion	expansion	NOUN
gsrj-21	42	42	,	,	PUNCT
gsrj-21	42	43	and	and	CCONJ
gsrj-21	42	44	senescence	senescence	NOUN
gsrj-21	42	45	prevention.28	prevention.28	NOUN
gsrj-21	42	46	yuan	yuan	X
gsrj-21	42	47	et	et	PROPN
gsrj-21	42	48	al	al	PROPN
gsrj-21	42	49	.	.	PROPN
gsrj-21	42	50	were	be	AUX
gsrj-21	42	51	one	one	NUM
gsrj-21	42	52	of	of	ADP
gsrj-21	42	53	the	the	DET
gsrj-21	42	54	first	first	ADJ
gsrj-21	42	55	to	to	PART
gsrj-21	42	56	use	use	VERB
gsrj-21	42	57	crcs	crcs	NOUN
gsrj-21	42	58	to	to	PART
gsrj-21	42	59	generate	generate	VERB
gsrj-21	42	60	cell	cell	NOUN
gsrj-21	42	61	cultures	culture	NOUN
gsrj-21	42	62	from	from	ADP
gsrj-21	42	63	the	the	DET
gsrj-21	42	64	patient	patient	NOUN
gsrj-21	42	65	’s	’s	PART
gsrj-21	42	66	normal	normal	ADJ
gsrj-21	42	67	and	and	CCONJ
gsrj-21	42	68	tumorous	tumorous	ADJ
gsrj-21	42	69	lung	lung	NOUN
gsrj-21	42	70	tissue	tissue	NOUN
gsrj-21	42	71	and	and	CCONJ
gsrj-21	42	72	study	study	VERB
gsrj-21	42	73	tumor	tumor	NOUN
gsrj-21	42	74	progression	progression	NOUN
gsrj-21	42	75	in	in	ADP
gsrj-21	42	76	recurrent	recurrent	ADJ
gsrj-21	42	77	respiratory	respiratory	ADJ
gsrj-21	42	78	papillomatosis.29	papillomatosis.29	NOUN
gsrj-21	42	79	by	by	ADP
gsrj-21	42	80	co	co	VERB
gsrj-21	42	81	-	-	VERB
gsrj-21	42	82	culturing	culture	VERB
gsrj-21	42	83	the	the	DET
gsrj-21	42	84	primary	primary	ADJ
gsrj-21	42	85	cells	cell	NOUN
gsrj-21	42	86	with	with	ADP
gsrj-21	42	87	j2	j2	PROPN
gsrj-21	42	88	murine	murine	ADJ
gsrj-21	42	89	fibroblast	fibroblast	ADJ
gsrj-21	42	90	cells	cell	NOUN
gsrj-21	42	91	and	and	CCONJ
gsrj-21	42	92	a	a	DET
gsrj-21	42	93	medium	medium	NOUN
gsrj-21	42	94	containing	contain	VERB
gsrj-21	42	95	rock	rock	NOUN
gsrj-21	42	96	inhibitor	inhibitor	NOUN
gsrj-21	42	97	y-27632	y-27632	PROPN
gsrj-21	42	98	,	,	PUNCT
gsrj-21	42	99	they	they	PRON
gsrj-21	42	100	were	be	AUX
gsrj-21	42	101	able	able	ADJ
gsrj-21	42	102	to	to	PART
gsrj-21	42	103	detect	detect	VERB
gsrj-21	42	104	a	a	DET
gsrj-21	42	105	mutation	mutation	NOUN
gsrj-21	42	106	of	of	ADP
gsrj-21	42	107	hpv-11	hpv-11	NOUN
gsrj-21	42	108	in	in	ADP
gsrj-21	42	109	the	the	DET
gsrj-21	42	110	crcs	crcs	NOUN
gsrj-21	42	111	that	that	PRON
gsrj-21	42	112	may	may	AUX
gsrj-21	42	113	contribute	contribute	VERB
gsrj-21	42	114	to	to	ADP
gsrj-21	42	115	aggressive	aggressive	ADJ
gsrj-21	42	116	clinical	clinical	ADJ
gsrj-21	42	117	behavior	behavior	NOUN
gsrj-21	42	118	.	.	PUNCT
gsrj-21	43	1	furthermore	furthermore	ADV
gsrj-21	43	2	,	,	PUNCT
gsrj-21	43	3	the	the	DET
gsrj-21	43	4	crcs	crcs	NOUN
gsrj-21	43	5	were	be	AUX
gsrj-21	43	6	used	use	VERB
gsrj-21	43	7	in	in	ADP
gsrj-21	43	8	screening	screen	VERB
gsrj-21	43	9	potential	potential	ADJ
gsrj-21	43	10	drug	drug	NOUN
gsrj-21	43	11	therapies	therapy	NOUN
gsrj-21	43	12	,	,	PUNCT
gsrj-21	43	13	which	which	PRON
gsrj-21	43	14	allowed	allow	VERB
gsrj-21	43	15	for	for	ADP
gsrj-21	43	16	the	the	DET
gsrj-21	43	17	identification	identification	NOUN
gsrj-21	43	18	of	of	ADP
gsrj-21	43	19	vorinostat	vorinostat	NOUN
gsrj-21	43	20	as	as	ADP
gsrj-21	43	21	a	a	DET
gsrj-21	43	22	potential	potential	ADJ
gsrj-21	43	23	therapy	therapy	NOUN
gsrj-21	43	24	for	for	ADP
gsrj-21	43	25	patients	patient	NOUN
gsrj-21	43	26	with	with	ADP
gsrj-21	43	27	recurrent	recurrent	ADJ
gsrj-21	43	28	respiratory	respiratory	ADJ
gsrj-21	43	29	papillomatosis	papillomatosis	NOUN
gsrj-21	43	30	.	.	PUNCT
gsrj-21	44	1	thus	thus	ADV
gsrj-21	44	2	,	,	PUNCT
gsrj-21	44	3	this	this	DET
gsrj-21	44	4	method	method	NOUN
gsrj-21	44	5	of	of	ADP
gsrj-21	44	6	generating	generate	VERB
gsrj-21	44	7	cell	cell	NOUN
gsrj-21	44	8	cultures	culture	NOUN
gsrj-21	44	9	from	from	ADP
gsrj-21	44	10	many	many	ADJ
gsrj-21	44	11	epithelia	epithelium	NOUN
gsrj-21	44	12	can	can	AUX
gsrj-21	44	13	be	be	AUX
gsrj-21	44	14	used	use	VERB
gsrj-21	44	15	in	in	ADP
gsrj-21	44	16	personalized	personalized	ADJ
gsrj-21	44	17	medicine	medicine	NOUN
gsrj-21	44	18	and	and	CCONJ
gsrj-21	44	19	to	to	PART
gsrj-21	44	20	study	study	VERB
gsrj-21	44	21	other	other	ADJ
gsrj-21	44	22	cancers	cancer	NOUN
gsrj-21	44	23	and	and	CCONJ
gsrj-21	44	24	diseases	disease	NOUN
gsrj-21	44	25	.	.	PUNCT
gsrj-21	45	1	crcs	crcs	PROPN
gsrj-21	45	2	have	have	AUX
gsrj-21	45	3	also	also	ADV
gsrj-21	45	4	been	be	AUX
gsrj-21	45	5	used	use	VERB
gsrj-21	45	6	in	in	ADP
gsrj-21	45	7	regenerative	regenerative	ADJ
gsrj-21	45	8	medicine	medicine	NOUN
gsrj-21	45	9	,	,	PUNCT
gsrj-21	45	10	drug	drug	NOUN
gsrj-21	45	11	sensitivity	sensitivity	NOUN
gsrj-21	45	12	testing	testing	NOUN
gsrj-21	45	13	,	,	PUNCT
gsrj-21	45	14	gene	gene	NOUN
gsrj-21	45	15	expression	expression	NOUN
gsrj-21	45	16	profiling	profiling	NOUN
gsrj-21	45	17	,	,	PUNCT
gsrj-21	45	18	and	and	CCONJ
gsrj-21	45	19	xenograft	xenograft	NOUN
gsrj-21	45	20	studies.29,30,31,32	studies.29,30,31,32	VERB
gsrj-21	45	21	recent	recent	ADJ
gsrj-21	45	22	models	model	NOUN
gsrj-21	45	23	with	with	ADP
gsrj-21	45	24	crcs	crcs	NOUN
gsrj-21	45	25	include	include	VERB
gsrj-21	45	26	those	those	PRON
gsrj-21	45	27	for	for	ADP
gsrj-21	45	28	prostate	prostate	NOUN
gsrj-21	45	29	cancer	cancer	NOUN
gsrj-21	45	30	,	,	PUNCT
gsrj-21	45	31	which	which	PRON
gsrj-21	45	32	aimed	aim	VERB
gsrj-21	45	33	to	to	PART
gsrj-21	45	34	define	define	VERB
gsrj-21	45	35	potential	potential	ADJ
gsrj-21	45	36	new	new	ADJ
gsrj-21	45	37	therapies	therapy	NOUN
gsrj-21	45	38	and	and	CCONJ
gsrj-21	45	39	observe	observe	VERB
gsrj-21	45	40	drug	drug	NOUN
gsrj-21	45	41	sensitivity	sensitivity	NOUN
gsrj-21	45	42	and	and	CCONJ
gsrj-21	45	43	resistance	resistance	NOUN
gsrj-21	45	44	.	.	PUNCT
gsrj-21	46	1	naeem	naeem	PROPN
gsrj-21	46	2	et	et	PROPN
gsrj-21	46	3	al	al	PROPN
gsrj-21	46	4	.	.	PROPN
gsrj-21	46	5	modeled	model	VERB
gsrj-21	46	6	prostate	prostate	NOUN
gsrj-21	46	7	cancer	cancer	NOUN
gsrj-21	46	8	using	use	VERB
gsrj-21	46	9	crcs	crcs	NOUN
gsrj-21	46	10	of	of	ADP
gsrj-21	46	11	normal	normal	ADJ
gsrj-21	46	12	and	and	CCONJ
gsrj-21	46	13	prostate	prostate	NOUN
gsrj-21	46	14	cancer	cancer	NOUN
gsrj-21	46	15	(	(	PUNCT
gsrj-21	46	16	pca	pca	NOUN
gsrj-21	46	17	)	)	PUNCT
gsrj-21	46	18	cells	cell	NOUN
gsrj-21	46	19	derived	derive	VERB
gsrj-21	46	20	from	from	ADP
gsrj-21	46	21	treatment	treatment	NOUN
gsrj-21	46	22	-	-	PUNCT
gsrj-21	46	23	naive	naive	ADJ
gsrj-21	46	24	patients	patient	NOUN
gsrj-21	46	25	with	with	ADP
gsrj-21	46	26	primary	primary	ADJ
gsrj-21	46	27	pca.31	pca.31	NOUN
gsrj-21	46	28	using	use	VERB
gsrj-21	46	29	an	an	DET
gsrj-21	46	30	integration	integration	NOUN
gsrj-21	46	31	of	of	ADP
gsrj-21	46	32	an	an	DET
gsrj-21	46	33	in	in	ADP
gsrj-21	46	34	silico	silico	NOUN
gsrj-21	46	35	proteochemometric	proteochemometric	ADJ
gsrj-21	46	36	network	network	NOUN
gsrj-21	46	37	pharmacology	pharmacology	NOUN
gsrj-21	46	38	platform	platform	NOUN
gsrj-21	46	39	and	and	CCONJ
gsrj-21	46	40	in	in	ADP
gsrj-21	46	41	vitro	vitro	X
gsrj-21	46	42	methods	method	NOUN
gsrj-21	46	43	with	with	ADP
gsrj-21	46	44	crcs	crcs	NOUN
gsrj-21	46	45	,	,	PUNCT
gsrj-21	46	46	the	the	DET
gsrj-21	46	47	researchers	researcher	NOUN
gsrj-21	46	48	examined	examine	VERB
gsrj-21	46	49	drug	drug	NOUN
gsrj-21	46	50	response	response	NOUN
gsrj-21	46	51	in	in	ADP
gsrj-21	46	52	sensitivity	sensitivity	NOUN
gsrj-21	46	53	assays	assay	NOUN
gsrj-21	46	54	on	on	ADP
gsrj-21	46	55	pca	pca	PROPN
gsrj-21	46	56	crcs	crcs	PROPN
gsrj-21	46	57	and	and	CCONJ
gsrj-21	46	58	predicted	predict	VERB
gsrj-21	46	59	novel	novel	ADJ
gsrj-21	46	60	applications	application	NOUN
gsrj-21	46	61	for	for	ADP
gsrj-21	46	62	pca	pca	NOUN
gsrj-21	46	63	chemotherapies	chemotherapy	NOUN
gsrj-21	46	64	,	,	PUNCT
gsrj-21	46	65	including	include	VERB
gsrj-21	46	66	broad	broad	ADJ
gsrj-21	46	67	applicability	applicability	NOUN
gsrj-21	46	68	to	to	PART
gsrj-21	46	69	rapidly	rapidly	ADV
gsrj-21	46	70	identity	identity	NOUN
gsrj-21	46	71	and	and	CCONJ
gsrj-21	46	72	test	test	NOUN
gsrj-21	46	73	approved	approve	VERB
gsrj-21	46	74	drugs	drug	NOUN
gsrj-21	46	75	.	.	PUNCT
gsrj-21	47	1	additionally	additionally	ADV
gsrj-21	47	2	,	,	PUNCT
gsrj-21	47	3	tricoli	tricoli	NOUN
gsrj-21	47	4	et	et	PROPN
gsrj-21	47	5	al	al	PROPN
gsrj-21	47	6	.	.	PROPN
gsrj-21	47	7	presented	present	VERB
gsrj-21	47	8	a	a	DET
gsrj-21	47	9	3d	3d	ADJ
gsrj-21	47	10	non	non	ADJ
gsrj-21	47	11	-	-	ADJ
gsrj-21	47	12	spheroid	spheroid	ADJ
gsrj-21	47	13	model	model	NOUN
gsrj-21	47	14	using	use	VERB
gsrj-21	47	15	crcs	crcs	NOUN
gsrj-21	47	16	for	for	ADP
gsrj-21	47	17	normal	normal	ADJ
gsrj-21	47	18	and	and	CCONJ
gsrj-21	47	19	tumor	tumor	NOUN
gsrj-21	47	20	-	-	PUNCT
gsrj-21	47	21	derived	derive	VERB
gsrj-21	47	22	pca	pca	NOUN
gsrj-21	47	23	crcs	crcs	NOUN
gsrj-21	47	24	to	to	PART
gsrj-21	47	25	describe	describe	VERB
gsrj-21	47	26	the	the	DET
gsrj-21	47	27	combined	combine	VERB
gsrj-21	47	28	effects	effect	NOUN
gsrj-21	47	29	of	of	ADP
gsrj-21	47	30	a	a	DET
gsrj-21	47	31	multidimensional	multidimensional	ADJ
gsrj-21	47	32	transwell	transwell	NOUN
gsrj-21	47	33	platform	platform	NOUN
gsrj-21	47	34	and	and	CCONJ
gsrj-21	47	35	define	define	VERB
gsrj-21	47	36	culture	culture	NOUN
gsrj-21	47	37	media	medium	NOUN
gsrj-21	47	38	on	on	ADP
gsrj-21	47	39	pca	pca	NOUN
gsrj-21	47	40	cellular	cellular	ADJ
gsrj-21	47	41	proliferation	proliferation	NOUN
gsrj-21	47	42	,	,	PUNCT
gsrj-21	47	43	differentiation	differentiation	NOUN
gsrj-21	47	44	,	,	PUNCT
gsrj-21	47	45	and	and	CCONJ
gsrj-21	47	46	signaling.33	signaling.33	NOUN
gsrj-21	47	47	the	the	DET
gsrj-21	47	48	use	use	NOUN
gsrj-21	47	49	of	of	ADP
gsrj-21	47	50	a	a	DET
gsrj-21	47	51	transwell	transwell	NOUN
gsrj-21	47	52	-	-	PUNCT
gsrj-21	47	53	dish	dish	NOUN
gsrj-21	47	54	culture	culture	NOUN
gsrj-21	47	55	method	method	NOUN
gsrj-21	47	56	(	(	PUNCT
gsrj-21	47	57	tdcm	tdcm	ADJ
gsrj-21	47	58	)	)	PUNCT
gsrj-21	47	59	enables	enable	VERB
gsrj-21	47	60	multi	multi	ADJ
gsrj-21	47	61	-	-	ADJ
gsrj-21	47	62	dimensional	dimensional	ADJ
gsrj-21	47	63	culturing	culturing	NOUN
gsrj-21	47	64	of	of	ADP
gsrj-21	47	65	pca	pca	PROPN
gsrj-21	47	66	crcs	crcs	PROPN
gsrj-21	47	67	,	,	PUNCT
gsrj-21	47	68	allowing	allow	VERB
gsrj-21	47	69	for	for	ADP
gsrj-21	47	70	a	a	DET
gsrj-21	47	71	more	more	ADV
gsrj-21	47	72	mature	mature	ADJ
gsrj-21	47	73	,	,	PUNCT
gsrj-21	47	74	stratified	stratified	ADJ
gsrj-21	47	75	prostate	prostate	NOUN
gsrj-21	47	76	epithelial	epithelial	ADJ
gsrj-21	47	77	phenotype	phenotype	NOUN
gsrj-21	47	78	that	that	PRON
gsrj-21	47	79	can	can	AUX
gsrj-21	47	80	be	be	AUX
gsrj-21	47	81	used	use	VERB
gsrj-21	47	82	for	for	ADP
gsrj-21	47	83	basic	basic	ADJ
gsrj-21	47	84	and	and	CCONJ
gsrj-21	47	85	translational	translational	ADJ
gsrj-21	47	86	studies	study	NOUN
gsrj-21	47	87	of	of	ADP
gsrj-21	47	88	pca.34	pca.34	NOUN
gsrj-21	47	89	3.1.2	3.1.2	NUM
gsrj-21	47	90	3d	3d	NUM
gsrj-21	47	91	cultures	culture	NOUN
gsrj-21	47	92	while	while	SCONJ
gsrj-21	47	93	2d	2d	NOUN
gsrj-21	47	94	in	in	ADP
gsrj-21	47	95	vitro	vitro	X
gsrj-21	47	96	cell	cell	NOUN
gsrj-21	47	97	culture	culture	NOUN
gsrj-21	47	98	models	model	NOUN
gsrj-21	47	99	are	be	AUX
gsrj-21	47	100	widely	widely	ADV
gsrj-21	47	101	used	use	VERB
gsrj-21	47	102	for	for	ADP
gsrj-21	47	103	studying	study	VERB
gsrj-21	47	104	the	the	DET
gsrj-21	47	105	basic	basic	ADJ
gsrj-21	47	106	biology	biology	NOUN
gsrj-21	47	107	and	and	CCONJ
gsrj-21	47	108	tumorigenesis	tumorigenesis	NOUN
gsrj-21	47	109	of	of	ADP
gsrj-21	47	110	various	various	ADJ
gsrj-21	47	111	cancers	cancer	NOUN
gsrj-21	47	112	,	,	PUNCT
gsrj-21	47	113	3d	3d	NUM
gsrj-21	47	114	models	model	NOUN
gsrj-21	47	115	more	more	ADV
gsrj-21	47	116	accurately	accurately	ADV
gsrj-21	47	117	mimic	mimic	VERB
gsrj-21	47	118	the	the	DET
gsrj-21	47	119	native	native	ADJ
gsrj-21	47	120	cancer	cancer	NOUN
gsrj-21	47	121	tissue	tissue	NOUN
gsrj-21	47	122	by	by	ADP
gsrj-21	47	123	preserving	preserve	VERB
gsrj-21	47	124	cellular	cellular	ADJ
gsrj-21	47	125	heterogeneity	heterogeneity	NOUN
gsrj-21	47	126	and	and	CCONJ
gsrj-21	47	127	replicating	replicate	VERB
gsrj-21	47	128	some	some	PRON
gsrj-21	47	129	of	of	ADP
gsrj-21	47	130	the	the	DET
gsrj-21	47	131	specific	specific	ADJ
gsrj-21	47	132	biochemical	biochemical	ADJ
gsrj-21	47	133	and	and	CCONJ
gsrj-21	47	134	morphological	morphological	ADJ
gsrj-21	47	135	features	feature	NOUN
gsrj-21	47	136	of	of	ADP
gsrj-21	47	137	the	the	DET
gsrj-21	47	138	corresponding	corresponding	ADJ
gsrj-21	47	139	tissue	tissue	NOUN
gsrj-21	47	140	47	47	NUM
gsrj-21	47	141	georgetown	georgetown	PROPN
gsrj-21	47	142	scientific	scientific	PROPN
gsrj-21	47	143	research	research	NOUN
gsrj-21	47	144	journal	journal	PROPN
gsrj-21	47	145	in	in	ADP
gsrj-21	47	146	vivo	vivo	NOUN
gsrj-21	47	147	.	.	PUNCT
gsrj-21	48	1	this	this	DET
gsrj-21	48	2	similarity	similarity	NOUN
gsrj-21	48	3	to	to	PART
gsrj-21	48	4	in	in	ADP
gsrj-21	48	5	vivo	vivo	ADJ
gsrj-21	48	6	tissue	tissue	NOUN
gsrj-21	48	7	provides	provide	VERB
gsrj-21	48	8	an	an	DET
gsrj-21	48	9	advantage	advantage	NOUN
gsrj-21	48	10	in	in	ADP
gsrj-21	48	11	the	the	DET
gsrj-21	48	12	model	model	NOUN
gsrj-21	48	13	for	for	ADP
gsrj-21	48	14	examining	examine	VERB
gsrj-21	48	15	morphology	morphology	NOUN
gsrj-21	48	16	,	,	PUNCT
gsrj-21	48	17	tumor	tumor	NOUN
gsrj-21	48	18	microenvironment	microenvironment	NOUN
gsrj-21	48	19	,	,	PUNCT
gsrj-21	48	20	invasion	invasion	NOUN
gsrj-21	48	21	,	,	PUNCT
gsrj-21	48	22	metabolism	metabolism	NOUN
gsrj-21	48	23	,	,	PUNCT
gsrj-21	48	24	and	and	CCONJ
gsrj-21	48	25	cell	cell	NOUN
gsrj-21	48	26	-	-	PUNCT
gsrj-21	48	27	environment	environment	NOUN
gsrj-21	48	28	crosstalk	crosstalk	NOUN
gsrj-21	48	29	that	that	PRON
gsrj-21	48	30	influences	influence	VERB
gsrj-21	48	31	gene	gene	NOUN
gsrj-21	48	32	expression	expression	NOUN
gsrj-21	48	33	and	and	CCONJ
gsrj-21	48	34	cell	cell	NOUN
gsrj-21	48	35	behavior	behavior	NOUN
gsrj-21	48	36	.	.	PUNCT
gsrj-21	49	1	furthermore	furthermore	ADV
gsrj-21	49	2	,	,	PUNCT
gsrj-21	49	3	3d	3d	NUM
gsrj-21	49	4	cell	cell	NOUN
gsrj-21	49	5	cultures	culture	NOUN
gsrj-21	49	6	serve	serve	VERB
gsrj-21	49	7	as	as	ADP
gsrj-21	49	8	a	a	DET
gsrj-21	49	9	model	model	NOUN
gsrj-21	49	10	for	for	ADP
gsrj-21	49	11	experimental	experimental	ADJ
gsrj-21	49	12	therapy	therapy	NOUN
gsrj-21	49	13	studies	study	NOUN
gsrj-21	49	14	using	use	VERB
gsrj-21	49	15	radiotherapy	radiotherapy	NOUN
gsrj-21	49	16	,	,	PUNCT
gsrj-21	49	17	chemotherapy	chemotherapy	NOUN
gsrj-21	49	18	,	,	PUNCT
gsrj-21	49	19	and	and	CCONJ
gsrj-21	49	20	celland	celland	NOUN
gsrj-21	49	21	antibody	antibody	NOUN
gsrj-21	49	22	-	-	PUNCT
gsrj-21	49	23	based	base	VERB
gsrj-21	49	24	immunotherapy.26	immunotherapy.26	ADJ
gsrj-21	49	25	several	several	ADJ
gsrj-21	49	26	reports	report	NOUN
gsrj-21	49	27	demonstrate	demonstrate	VERB
gsrj-21	49	28	that	that	SCONJ
gsrj-21	49	29	cancer	cancer	NOUN
gsrj-21	49	30	cells	cell	NOUN
gsrj-21	49	31	can	can	AUX
gsrj-21	49	32	grow	grow	VERB
gsrj-21	49	33	in	in	ADP
gsrj-21	49	34	non	non	ADJ
gsrj-21	49	35	-	-	ADJ
gsrj-21	49	36	adherent	adherent	ADJ
gsrj-21	49	37	conditions	condition	NOUN
gsrj-21	49	38	,	,	PUNCT
gsrj-21	49	39	forming	form	VERB
gsrj-21	49	40	3d	3d	NUM
gsrj-21	49	41	structures	structure	NOUN
gsrj-21	49	42	,	,	PUNCT
gsrj-21	49	43	or	or	CCONJ
gsrj-21	49	44	spheroids	spheroid	NOUN
gsrj-21	49	45	,	,	PUNCT
gsrj-21	49	46	that	that	PRON
gsrj-21	49	47	show	show	VERB
gsrj-21	49	48	increased	increase	VERB
gsrj-21	49	49	resistance	resistance	NOUN
gsrj-21	49	50	to	to	ADP
gsrj-21	49	51	drugs	drug	NOUN
gsrj-21	49	52	frequently	frequently	ADV
gsrj-21	49	53	used	use	VERB
gsrj-21	49	54	for	for	ADP
gsrj-21	49	55	cancer	cancer	NOUN
gsrj-21	49	56	treatment.27	treatment.27	PROPN
gsrj-21	49	57	due	due	ADP
gsrj-21	49	58	to	to	ADP
gsrj-21	49	59	their	their	PRON
gsrj-21	49	60	flexibility	flexibility	NOUN
gsrj-21	49	61	in	in	ADP
gsrj-21	49	62	mimicking	mimic	VERB
gsrj-21	49	63	tumor	tumor	NOUN
gsrj-21	49	64	microenvironments	microenvironment	NOUN
gsrj-21	49	65	through	through	ADP
gsrj-21	49	66	modifying	modify	VERB
gsrj-21	49	67	cell	cell	NOUN
gsrj-21	49	68	culture	culture	NOUN
gsrj-21	49	69	conditions	condition	NOUN
gsrj-21	49	70	,	,	PUNCT
gsrj-21	49	71	3d	3d	NUM
gsrj-21	49	72	culture	culture	NOUN
gsrj-21	49	73	models	model	NOUN
gsrj-21	49	74	are	be	AUX
gsrj-21	49	75	useful	useful	ADJ
gsrj-21	49	76	tools	tool	NOUN
gsrj-21	49	77	for	for	ADP
gsrj-21	49	78	studying	study	VERB
gsrj-21	49	79	cancer	cancer	NOUN
gsrj-21	49	80	development	development	NOUN
gsrj-21	49	81	and	and	CCONJ
gsrj-21	49	82	potential	potential	ADJ
gsrj-21	49	83	targets	target	NOUN
gsrj-21	49	84	for	for	ADP
gsrj-21	49	85	therapeutic	therapeutic	ADJ
gsrj-21	49	86	intervention	intervention	NOUN
gsrj-21	49	87	.	.	PUNCT
gsrj-21	50	1	the	the	DET
gsrj-21	50	2	most	most	ADV
gsrj-21	50	3	innovative	innovative	ADJ
gsrj-21	50	4	and	and	CCONJ
gsrj-21	50	5	promising	promising	ADJ
gsrj-21	50	6	approach	approach	NOUN
gsrj-21	50	7	for	for	ADP
gsrj-21	50	8	in	in	ADP
gsrj-21	50	9	vitro	vitro	X
gsrj-21	50	10	modeling	model	VERB
gsrj-21	50	11	employs	employ	VERB
gsrj-21	50	12	tumor	tumor	NOUN
gsrj-21	50	13	tissue	tissue	NOUN
gsrj-21	50	14	organoids	organoid	NOUN
gsrj-21	50	15	,	,	PUNCT
gsrj-21	50	16	which	which	PRON
gsrj-21	50	17	are	be	AUX
gsrj-21	50	18	self	self	NOUN
gsrj-21	50	19	-	-	PUNCT
gsrj-21	50	20	organizing	organize	VERB
gsrj-21	50	21	,	,	PUNCT
gsrj-21	50	22	multicellular	multicellular	ADJ
gsrj-21	50	23	structures	structure	NOUN
gsrj-21	50	24	derived	derive	VERB
gsrj-21	50	25	from	from	ADP
gsrj-21	50	26	primary	primary	ADJ
gsrj-21	50	27	tissue	tissue	NOUN
gsrj-21	50	28	and	and	CCONJ
gsrj-21	50	29	grown	grow	VERB
gsrj-21	50	30	in	in	ADP
gsrj-21	50	31	well	well	ADV
gsrj-21	50	32	-	-	PUNCT
gsrj-21	50	33	defined	define	VERB
gsrj-21	50	34	conditions	condition	NOUN
gsrj-21	50	35	.	.	PUNCT
gsrj-21	51	1	several	several	ADJ
gsrj-21	51	2	methods	method	NOUN
gsrj-21	51	3	for	for	ADP
gsrj-21	51	4	developing	develop	VERB
gsrj-21	51	5	organoid	organoid	NOUN
gsrj-21	51	6	lines	line	NOUN
gsrj-21	51	7	and	and	CCONJ
gsrj-21	51	8	biobanks	biobank	NOUN
gsrj-21	51	9	have	have	AUX
gsrj-21	51	10	been	be	AUX
gsrj-21	51	11	used	use	VERB
gsrj-21	51	12	for	for	ADP
gsrj-21	51	13	prostate	prostate	NOUN
gsrj-21	51	14	cancer,35	cancer,35	NOUN
gsrj-21	51	15	pancreatic	pancreatic	ADJ
gsrj-21	51	16	cancer,36	cancer,36	NOUN
gsrj-21	51	17	and	and	CCONJ
gsrj-21	51	18	colorectal	colorectal	ADJ
gsrj-21	51	19	cancer37	cancer37	NOUN
gsrj-21	51	20	for	for	ADP
gsrj-21	51	21	in	in	ADP
gsrj-21	51	22	vitro	vitro	X
gsrj-21	51	23	drug	drug	NOUN
gsrj-21	51	24	testing	testing	NOUN
gsrj-21	51	25	.	.	PUNCT
gsrj-21	52	1	while	while	SCONJ
gsrj-21	52	2	drug	drug	NOUN
gsrj-21	52	3	sensitivity	sensitivity	NOUN
gsrj-21	52	4	is	be	AUX
gsrj-21	52	5	usually	usually	ADV
gsrj-21	52	6	exploited	exploit	VERB
gsrj-21	52	7	using	use	VERB
gsrj-21	52	8	rapid	rapid	ADJ
gsrj-21	52	9	in	in	ADP
gsrj-21	52	10	vitro	vitro	X
gsrj-21	52	11	screening	screen	VERB
gsrj-21	52	12	through	through	ADP
gsrj-21	52	13	a	a	DET
gsrj-21	52	14	short	short	ADJ
gsrj-21	52	15	-	-	PUNCT
gsrj-21	52	16	term	term	NOUN
gsrj-21	52	17	culture	culture	NOUN
gsrj-21	52	18	of	of	ADP
gsrj-21	52	19	tumor	tumor	NOUN
gsrj-21	52	20	sections	section	NOUN
gsrj-21	52	21	and	and	CCONJ
gsrj-21	52	22	in	in	ADP
gsrj-21	52	23	vivo	vivo	NOUN
gsrj-21	52	24	screening	screen	VERB
gsrj-21	52	25	through	through	ADP
gsrj-21	52	26	xenotransplantation	xenotransplantation	NOUN
gsrj-21	52	27	of	of	ADP
gsrj-21	52	28	the	the	DET
gsrj-21	52	29	tumor	tumor	NOUN
gsrj-21	52	30	into	into	ADP
gsrj-21	52	31	immunodeficient	immunodeficient	NOUN
gsrj-21	52	32	mice	mouse	NOUN
gsrj-21	52	33	,	,	PUNCT
gsrj-21	52	34	organoid	organoid	PROPN
gsrj-21	52	35	technology	technology	NOUN
gsrj-21	52	36	bridges	bridge	NOUN
gsrj-21	52	37	these	these	DET
gsrj-21	52	38	two	two	NUM
gsrj-21	52	39	approaches	approach	NOUN
gsrj-21	52	40	to	to	PART
gsrj-21	52	41	produce	produce	VERB
gsrj-21	52	42	a	a	DET
gsrj-21	52	43	feasible	feasible	ADJ
gsrj-21	52	44	medium	medium	ADJ
gsrj-21	52	45	-	-	PUNCT
gsrj-21	52	46	throughput	throughput	NOUN
gsrj-21	52	47	drug	drug	NOUN
gsrj-21	52	48	screen	screen	NOUN
gsrj-21	52	49	on	on	ADP
gsrj-21	52	50	patientderived	patientderived	ADJ
gsrj-21	52	51	organoids	organoid	NOUN
gsrj-21	52	52	(	(	PUNCT
gsrj-21	52	53	pdos).35,37	pdos).35,37	NOUN
gsrj-21	52	54	these	these	DET
gsrj-21	52	55	3d	3d	ADJ
gsrj-21	52	56	organoids	organoid	NOUN
gsrj-21	52	57	can	can	AUX
gsrj-21	52	58	maintain	maintain	VERB
gsrj-21	52	59	their	their	PRON
gsrj-21	52	60	complex	complex	ADJ
gsrj-21	52	61	architecture	architecture	NOUN
gsrj-21	52	62	and	and	CCONJ
gsrj-21	52	63	reproduce	reproduce	VERB
gsrj-21	52	64	their	their	PRON
gsrj-21	52	65	marker	marker	NOUN
gsrj-21	52	66	expression	expression	NOUN
gsrj-21	52	67	,	,	PUNCT
gsrj-21	52	68	allowing	allow	VERB
gsrj-21	52	69	several	several	ADJ
gsrj-21	52	70	research	research	NOUN
gsrj-21	52	71	groups	group	NOUN
gsrj-21	52	72	to	to	PART
gsrj-21	52	73	study	study	VERB
gsrj-21	52	74	tumor	tumor	NOUN
gsrj-21	52	75	development	development	NOUN
gsrj-21	52	76	and	and	CCONJ
gsrj-21	52	77	test	test	NOUN
gsrj-21	52	78	for	for	ADP
gsrj-21	52	79	drug	drug	NOUN
gsrj-21	52	80	efficacy.6,27,36,37,38,39,40	efficacy.6,27,36,37,38,39,40	VERB
gsrj-21	52	81	organoid	organoid	NOUN
gsrj-21	52	82	cultures	culture	NOUN
gsrj-21	52	83	typically	typically	ADV
gsrj-21	52	84	use	use	VERB
gsrj-21	52	85	matrigel	matrigel	NOUN
gsrj-21	52	86	or	or	CCONJ
gsrj-21	52	87	collagen	collagen	NOUN
gsrj-21	52	88	and	and	CCONJ
gsrj-21	52	89	support	support	VERB
gsrj-21	52	90	the	the	DET
gsrj-21	52	91	growth	growth	NOUN
gsrj-21	52	92	of	of	ADP
gsrj-21	52	93	both	both	CCONJ
gsrj-21	52	94	normal	normal	ADJ
gsrj-21	52	95	and	and	CCONJ
gsrj-21	52	96	cancer	cancer	NOUN
gsrj-21	52	97	tissue	tissue	NOUN
gsrj-21	52	98	such	such	ADJ
gsrj-21	52	99	that	that	SCONJ
gsrj-21	52	100	cultures	culture	NOUN
gsrj-21	52	101	can	can	AUX
gsrj-21	52	102	be	be	AUX
gsrj-21	52	103	manipulated	manipulate	VERB
gsrj-21	52	104	at	at	ADP
gsrj-21	52	105	the	the	DET
gsrj-21	52	106	genetic	genetic	ADJ
gsrj-21	52	107	level	level	NOUN
gsrj-21	52	108	by	by	ADP
gsrj-21	52	109	transfection.27	transfection.27	NOUN
gsrj-21	52	110	when	when	SCONJ
gsrj-21	52	111	cultured	cultured	ADJ
gsrj-21	52	112	with	with	ADP
gsrj-21	52	113	stroma	stroma	NOUN
gsrj-21	52	114	and	and	CCONJ
gsrj-21	52	115	fibroblasts	fibroblast	NOUN
gsrj-21	52	116	,	,	PUNCT
gsrj-21	52	117	organoids	organoid	NOUN
gsrj-21	52	118	have	have	VERB
gsrj-21	52	119	the	the	DET
gsrj-21	52	120	potential	potential	NOUN
gsrj-21	52	121	to	to	PART
gsrj-21	52	122	simulate	simulate	VERB
gsrj-21	52	123	the	the	DET
gsrj-21	52	124	full	full	ADJ
gsrj-21	52	125	spectrum	spectrum	NOUN
gsrj-21	52	126	of	of	ADP
gsrj-21	52	127	patient	patient	ADJ
gsrj-21	52	128	cancer	cancer	NOUN
gsrj-21	52	129	progression	progression	NOUN
gsrj-21	52	130	and	and	CCONJ
gsrj-21	52	131	study	study	VERB
gsrj-21	52	132	normal	normal	ADJ
gsrj-21	52	133	cells	cell	NOUN
gsrj-21	52	134	,	,	PUNCT
gsrj-21	52	135	preinvasive	preinvasive	ADJ
gsrj-21	52	136	carcinomas	carcinoma	NOUN
gsrj-21	52	137	,	,	PUNCT
gsrj-21	52	138	and	and	CCONJ
gsrj-21	52	139	metastatic	metastatic	ADJ
gsrj-21	52	140	cells.6,41,42	cells.6,41,42	NOUN
gsrj-21	52	141	furthermore	furthermore	ADV
gsrj-21	52	142	,	,	PUNCT
gsrj-21	52	143	pdo	pdo	PROPN
gsrj-21	52	144	cocultures	coculture	VERB
gsrj-21	52	145	with	with	ADP
gsrj-21	52	146	immune	immune	ADJ
gsrj-21	52	147	cells,43,44	cells,43,44	NOUN
gsrj-21	52	148	cancer	cancer	NOUN
gsrj-21	52	149	-	-	PUNCT
gsrj-21	52	150	associated	associate	VERB
gsrj-21	52	151	fibroblasts,45	fibroblasts,45	NOUN
gsrj-21	52	152	and	and	CCONJ
gsrj-21	52	153	stellate	stellate	ADJ
gsrj-21	52	154	cells42	cells42	NOUN
gsrj-21	52	155	can	can	AUX
gsrj-21	52	156	identify	identify	VERB
gsrj-21	52	157	tumor	tumor	NOUN
gsrj-21	52	158	microenvironment	microenvironment	ADJ
gsrj-21	52	159	characteristics	characteristic	NOUN
gsrj-21	52	160	and	and	CCONJ
gsrj-21	52	161	determine	determine	VERB
gsrj-21	52	162	mechanisms	mechanism	NOUN
gsrj-21	52	163	for	for	ADP
gsrj-21	52	164	resistance	resistance	NOUN
gsrj-21	52	165	to	to	ADP
gsrj-21	52	166	traditional	traditional	ADJ
gsrj-21	52	167	and	and	CCONJ
gsrj-21	52	168	investigational	investigational	ADJ
gsrj-21	52	169	drugs.6	drugs.6	PROPN
gsrj-21	52	170	organoids	organoid	NOUN
gsrj-21	52	171	are	be	AUX
gsrj-21	52	172	generated	generate	VERB
gsrj-21	52	173	rapidly	rapidly	ADV
gsrj-21	52	174	and	and	CCONJ
gsrj-21	52	175	reliably	reliably	ADV
gsrj-21	52	176	,	,	PUNCT
gsrj-21	52	177	especially	especially	ADV
gsrj-21	52	178	with	with	ADP
gsrj-21	52	179	endoscopic	endoscopic	ADJ
gsrj-21	52	180	ultrasound	ultrasound	NOUN
gsrj-21	52	181	(	(	PUNCT
gsrj-21	52	182	eus)guided	eus)guide	VERB
gsrj-21	52	183	tissue	tissue	NOUN
gsrj-21	52	184	acquisition	acquisition	NOUN
gsrj-21	52	185	at	at	ADP
gsrj-21	52	186	the	the	DET
gsrj-21	52	187	time	time	NOUN
gsrj-21	52	188	of	of	ADP
gsrj-21	52	189	initial	initial	ADJ
gsrj-21	52	190	diagnosis,41	diagnosis,41	NOUN
gsrj-21	52	191	making	make	VERB
gsrj-21	52	192	them	they	PRON
gsrj-21	52	193	more	more	ADV
gsrj-21	52	194	usable	usable	ADJ
gsrj-21	52	195	for	for	ADP
gsrj-21	52	196	patients	patient	NOUN
gsrj-21	52	197	who	who	PRON
gsrj-21	52	198	need	need	VERB
gsrj-21	52	199	targeted	targeted	ADJ
gsrj-21	52	200	treatment	treatment	NOUN
gsrj-21	52	201	as	as	ADV
gsrj-21	52	202	quickly	quickly	ADV
gsrj-21	52	203	as	as	ADP
gsrj-21	52	204	possible	possible	ADJ
gsrj-21	52	205	.	.	PUNCT
gsrj-21	53	1	the	the	DET
gsrj-21	53	2	development	development	NOUN
gsrj-21	53	3	of	of	ADP
gsrj-21	53	4	pdo	pdo	PROPN
gsrj-21	53	5	biobanks	biobank	NOUN
gsrj-21	53	6	also	also	ADV
gsrj-21	53	7	greatly	greatly	ADV
gsrj-21	53	8	expands	expand	VERB
gsrj-21	53	9	the	the	DET
gsrj-21	53	10	type	type	NOUN
gsrj-21	53	11	of	of	ADP
gsrj-21	53	12	patient	patient	ADJ
gsrj-21	53	13	samples	sample	NOUN
gsrj-21	53	14	that	that	PRON
gsrj-21	53	15	can	can	AUX
gsrj-21	53	16	be	be	AUX
gsrj-21	53	17	propagated	propagate	VERB
gsrj-21	53	18	and	and	CCONJ
gsrj-21	53	19	studied	study	VERB
gsrj-21	53	20	,	,	PUNCT
gsrj-21	53	21	and	and	CCONJ
gsrj-21	53	22	these	these	DET
gsrj-21	53	23	samples	sample	NOUN
gsrj-21	53	24	can	can	AUX
gsrj-21	53	25	then	then	ADV
gsrj-21	53	26	be	be	AUX
gsrj-21	53	27	used	use	VERB
gsrj-21	53	28	to	to	PART
gsrj-21	53	29	accurately	accurately	ADV
gsrj-21	53	30	predict	predict	VERB
gsrj-21	53	31	drug	drug	NOUN
gsrj-21	53	32	responses	response	NOUN
gsrj-21	53	33	in	in	ADP
gsrj-21	53	34	a	a	DET
gsrj-21	53	35	personalized	personalized	ADJ
gsrj-21	53	36	treatment	treatment	NOUN
gsrj-21	53	37	setting.6	setting.6	PROPN
gsrj-21	53	38	tumoror	tumoror	NOUN
gsrj-21	53	39	cancer	cancer	NOUN
gsrj-21	53	40	-	-	PUNCT
gsrj-21	53	41	on	on	ADP
gsrj-21	53	42	-	-	PUNCT
gsrj-21	53	43	a	a	DET
gsrj-21	53	44	-	-	PUNCT
gsrj-21	53	45	chip	chip	NOUN
gsrj-21	53	46	(	(	PUNCT
gsrj-21	53	47	coc	coc	NOUN
gsrj-21	53	48	)	)	PUNCT
gsrj-21	53	49	models	model	NOUN
gsrj-21	53	50	have	have	AUX
gsrj-21	53	51	been	be	AUX
gsrj-21	53	52	used	use	VERB
gsrj-21	53	53	more	more	ADV
gsrj-21	53	54	recently	recently	ADV
gsrj-21	53	55	to	to	PART
gsrj-21	53	56	dissect	dissect	VERB
gsrj-21	53	57	the	the	DET
gsrj-21	53	58	role	role	NOUN
gsrj-21	53	59	of	of	ADP
gsrj-21	53	60	tumor	tumor	NOUN
gsrj-21	53	61	microenvironment	microenvironment	ADJ
gsrj-21	53	62	cues	cue	NOUN
gsrj-21	53	63	and	and	CCONJ
gsrj-21	53	64	their	their	PRON
gsrj-21	53	65	role	role	NOUN
gsrj-21	53	66	in	in	ADP
gsrj-21	53	67	metastasis.22	metastasis.22	VERB
gsrj-21	53	68	these	these	DET
gsrj-21	53	69	microfluidic	microfluidic	ADJ
gsrj-21	53	70	chip	chip	NOUN
gsrj-21	53	71	device	device	NOUN
gsrj-21	53	72	models	model	NOUN
gsrj-21	53	73	enable	enable	VERB
gsrj-21	53	74	control	control	NOUN
gsrj-21	53	75	over	over	ADP
gsrj-21	53	76	local	local	ADJ
gsrj-21	53	77	gradients	gradient	NOUN
gsrj-21	53	78	,	,	PUNCT
gsrj-21	53	79	fluid	fluid	ADJ
gsrj-21	53	80	flow,46	flow,46	NOUN
gsrj-21	53	81	tissue	tissue	NOUN
gsrj-21	53	82	mechanisms111	mechanisms111	PROPN
gsrj-21	53	83	,	,	PUNCT
gsrj-21	53	84	and	and	CCONJ
gsrj-21	53	85	composition	composition	NOUN
gsrj-21	53	86	of	of	ADP
gsrj-21	53	87	the	the	DET
gsrj-21	53	88	local	local	ADJ
gsrj-21	53	89	environment	environment	NOUN
gsrj-21	53	90	through	through	ADP
gsrj-21	53	91	micrometerto	micrometerto	NOUN
gsrj-21	53	92	millimeter	millimeter	NOUN
gsrj-21	53	93	-	-	PUNCT
gsrj-21	53	94	sized	sized	ADJ
gsrj-21	53	95	compartments	compartment	NOUN
gsrj-21	53	96	and	and	CCONJ
gsrj-21	53	97	microchannels.22	microchannels.22	VERB
gsrj-21	53	98	the	the	DET
gsrj-21	53	99	small	small	ADJ
gsrj-21	53	100	chamber	chamber	NOUN
gsrj-21	53	101	for	for	ADP
gsrj-21	53	102	cell	cell	NOUN
gsrj-21	53	103	culture	culture	NOUN
gsrj-21	53	104	creates	create	VERB
gsrj-21	53	105	a	a	DET
gsrj-21	53	106	niche	niche	NOUN
gsrj-21	53	107	in	in	ADP
gsrj-21	53	108	which	which	PRON
gsrj-21	53	109	tumors	tumor	NOUN
gsrj-21	53	110	can	can	AUX
gsrj-21	53	111	grow	grow	VERB
gsrj-21	53	112	,	,	PUNCT
gsrj-21	53	113	develop	develop	VERB
gsrj-21	53	114	,	,	PUNCT
gsrj-21	53	115	and	and	CCONJ
gsrj-21	53	116	interact	interact	VERB
gsrj-21	53	117	in	in	ADP
gsrj-21	53	118	a	a	DET
gsrj-21	53	119	specified	specified	ADJ
gsrj-21	53	120	microenvironment.22	microenvironment.22	NOUN
gsrj-21	53	121	by	by	ADP
gsrj-21	53	122	making	make	VERB
gsrj-21	53	123	it	it	PRON
gsrj-21	53	124	possible	possible	ADJ
gsrj-21	53	125	to	to	PART
gsrj-21	53	126	manipulate	manipulate	VERB
gsrj-21	53	127	the	the	DET
gsrj-21	53	128	variables	variable	NOUN
gsrj-21	53	129	listed	list	VERB
gsrj-21	53	130	above	above	ADV
gsrj-21	53	131	,	,	PUNCT
gsrj-21	53	132	coc	coc	ADJ
gsrj-21	53	133	models	model	NOUN
gsrj-21	53	134	overcome	overcome	VERB
gsrj-21	53	135	some	some	PRON
gsrj-21	53	136	of	of	ADP
gsrj-21	53	137	the	the	DET
gsrj-21	53	138	limitations	limitation	NOUN
gsrj-21	53	139	of	of	ADP
gsrj-21	53	140	2d	2d	NUM
gsrj-21	53	141	or	or	CCONJ
gsrj-21	53	142	3d	3d	NUM
gsrj-21	53	143	cell	cell	NOUN
gsrj-21	53	144	cultures	culture	NOUN
gsrj-21	53	145	and	and	CCONJ
gsrj-21	53	146	animal	animal	NOUN
gsrj-21	53	147	models	model	NOUN
gsrj-21	53	148	.	.	PUNCT
gsrj-21	54	1	the	the	DET
gsrj-21	54	2	coc	coc	PROPN
gsrj-21	54	3	model	model	NOUN
gsrj-21	54	4	used	use	VERB
gsrj-21	54	5	depends	depend	VERB
gsrj-21	54	6	upon	upon	SCONJ
gsrj-21	54	7	the	the	DET
gsrj-21	54	8	particular	particular	ADJ
gsrj-21	54	9	tumor	tumor	NOUN
gsrj-21	54	10	microenvironment	microenvironment	NOUN
gsrj-21	54	11	cues	cue	VERB
gsrj-21	54	12	that	that	SCONJ
gsrj-21	54	13	researchers	researcher	NOUN
gsrj-21	54	14	aim	aim	VERB
gsrj-21	54	15	to	to	PART
gsrj-21	54	16	understand	understand	VERB
gsrj-21	54	17	.	.	PUNCT
gsrj-21	55	1	the	the	DET
gsrj-21	55	2	many	many	ADJ
gsrj-21	55	3	different	different	ADJ
gsrj-21	55	4	types	type	NOUN
gsrj-21	55	5	of	of	ADP
gsrj-21	55	6	coc	coc	NOUN
gsrj-21	55	7	models	model	NOUN
gsrj-21	55	8	include	include	VERB
gsrj-21	55	9	2d	2d	NUM
gsrj-21	55	10	chips	chip	NOUN
gsrj-21	55	11	,	,	PUNCT
gsrj-21	55	12	lumen	luman	NOUN
gsrj-21	55	13	chips	chip	NOUN
gsrj-21	55	14	for	for	ADP
gsrj-21	55	15	cafs,47	cafs,47	NOUN
gsrj-21	55	16	compartmentalized	compartmentalized	ADJ
gsrj-21	55	17	chips	chip	NOUN
gsrj-21	55	18	for	for	ADP
gsrj-21	55	19	tams,48,49,50	tams,48,49,50	NOUN
gsrj-21	55	20	cafs,32,51	cafs,32,51	NOUN
gsrj-21	55	21	y	y	NOUN
gsrj-21	55	22	chips	chip	NOUN
gsrj-21	55	23	for	for	ADP
gsrj-21	55	24	cafs,52	cafs,52	NOUN
gsrj-21	55	25	and	and	CCONJ
gsrj-21	55	26	membrane	membrane	NOUN
gsrj-21	55	27	chips	chip	NOUN
gsrj-21	55	28	.	.	PUNCT
gsrj-21	56	1	many	many	ADJ
gsrj-21	56	2	models	model	NOUN
gsrj-21	56	3	have	have	VERB
gsrj-21	56	4	a	a	DET
gsrj-21	56	5	gelfluid	gelfluid	NOUN
gsrj-21	56	6	interface	interface	NOUN
gsrj-21	56	7	lined	line	VERB
gsrj-21	56	8	with	with	ADP
gsrj-21	56	9	endothelial	endothelial	ADJ
gsrj-21	56	10	cells.48,53	cells.48,53	NOUN
gsrj-21	56	11	coc	coc	NOUN
gsrj-21	56	12	models	model	NOUN
gsrj-21	56	13	have	have	AUX
gsrj-21	56	14	helped	help	VERB
gsrj-21	56	15	better	well	ADV
gsrj-21	56	16	understand	understand	VERB
gsrj-21	56	17	the	the	DET
gsrj-21	56	18	invasion	invasion	NOUN
gsrj-21	56	19	-	-	PUNCT
gsrj-21	56	20	related	relate	VERB
gsrj-21	56	21	interactions	interaction	NOUN
gsrj-21	56	22	between	between	ADP
gsrj-21	56	23	cafs	cafs	NOUN
gsrj-21	56	24	and	and	CCONJ
gsrj-21	56	25	cancer	cancer	NOUN
gsrj-21	56	26	cells	cell	NOUN
gsrj-21	56	27	,	,	PUNCT
gsrj-21	56	28	as	as	ADV
gsrj-21	56	29	well	well	ADV
gsrj-21	56	30	as	as	ADP
gsrj-21	56	31	how	how	SCONJ
gsrj-21	56	32	activation	activation	NOUN
gsrj-21	56	33	of	of	ADP
gsrj-21	56	34	tams	tam	NOUN
gsrj-21	56	35	enhances	enhance	VERB
gsrj-21	56	36	cancer	cancer	NOUN
gsrj-21	56	37	invasion	invasion	NOUN
gsrj-21	56	38	through	through	ADP
gsrj-21	56	39	live	live	ADJ
gsrj-21	56	40	observation	observation	NOUN
gsrj-21	56	41	of	of	ADP
gsrj-21	56	42	microenvironmental	microenvironmental	ADJ
gsrj-21	56	43	dynamics	dynamic	NOUN
gsrj-21	56	44	.	.	PUNCT
gsrj-21	57	1	48	48	NUM
gsrj-21	57	2	georgetown	georgetown	PROPN
gsrj-21	57	3	scientific	scientific	PROPN
gsrj-21	57	4	research	research	NOUN
gsrj-21	57	5	journal	journal	NOUN
gsrj-21	57	6	3.2	3.2	NUM
gsrj-21	57	7	in	in	ADP
gsrj-21	57	8	vivo	vivo	NOUN
gsrj-21	57	9	models	model	NOUN
gsrj-21	57	10	an	an	PRON
gsrj-21	57	11	in	in	ADP
gsrj-21	57	12	vivo	vivo	NOUN
gsrj-21	57	13	model	model	NOUN
gsrj-21	57	14	,	,	PUNCT
gsrj-21	57	15	zebrafish	zebrafish	NUM
gsrj-21	57	16	,	,	PUNCT
gsrj-21	57	17	serves	serve	VERB
gsrj-21	57	18	as	as	ADP
gsrj-21	57	19	an	an	DET
gsrj-21	57	20	intermediate	intermediate	NOUN
gsrj-21	57	21	of	of	ADP
gsrj-21	57	22	cell	cell	NOUN
gsrj-21	57	23	culture	culture	NOUN
gsrj-21	57	24	models	model	NOUN
gsrj-21	57	25	and	and	CCONJ
gsrj-21	57	26	mammalian	mammalian	ADJ
gsrj-21	57	27	models	model	NOUN
gsrj-21	57	28	.	.	PUNCT
gsrj-21	58	1	this	this	DET
gsrj-21	58	2	zebrafish	zebrafish	ADJ
gsrj-21	58	3	model	model	NOUN
gsrj-21	58	4	allows	allow	VERB
gsrj-21	58	5	for	for	ADP
gsrj-21	58	6	extracorporeal	extracorporeal	ADJ
gsrj-21	58	7	fertilization	fertilization	NOUN
gsrj-21	58	8	and	and	CCONJ
gsrj-21	58	9	has	have	VERB
gsrj-21	58	10	a	a	DET
gsrj-21	58	11	wellresearched	wellresearche	VERB
gsrj-21	58	12	translucent	translucent	ADJ
gsrj-21	58	13	embryo	embryo	NOUN
gsrj-21	58	14	,	,	PUNCT
gsrj-21	58	15	short	short	ADJ
gsrj-21	58	16	generation	generation	NOUN
gsrj-21	58	17	time	time	NOUN
gsrj-21	58	18	,	,	PUNCT
gsrj-21	58	19	as	as	ADV
gsrj-21	58	20	well	well	ADV
gsrj-21	58	21	as	as	ADP
gsrj-21	58	22	a	a	DET
gsrj-21	58	23	well	well	ADV
gsrj-21	58	24	-	-	PUNCT
gsrj-21	58	25	developed	develop	VERB
gsrj-21	58	26	genetical	genetical	ADJ
gsrj-21	58	27	toolbox	toolbox	NOUN
gsrj-21	58	28	,	,	PUNCT
gsrj-21	58	29	which	which	PRON
gsrj-21	58	30	makes	make	VERB
gsrj-21	58	31	the	the	DET
gsrj-21	58	32	zebrafish	zebrafish	ADJ
gsrj-21	58	33	ideal	ideal	NOUN
gsrj-21	58	34	for	for	ADP
gsrj-21	58	35	studying	study	VERB
gsrj-21	58	36	development.26	development.26	NOUN
gsrj-21	58	37	zebrafish	zebrafish	ADJ
gsrj-21	58	38	melanoma	melanoma	NOUN
gsrj-21	58	39	models	model	NOUN
gsrj-21	58	40	have	have	AUX
gsrj-21	58	41	shown	show	VERB
gsrj-21	58	42	that	that	SCONJ
gsrj-21	58	43	the	the	DET
gsrj-21	58	44	cause	cause	NOUN
gsrj-21	58	45	of	of	ADP
gsrj-21	58	46	cancer	cancer	NOUN
gsrj-21	58	47	formation	formation	NOUN
gsrj-21	58	48	is	be	AUX
gsrj-21	58	49	the	the	DET
gsrj-21	58	50	dedifferentiation	dedifferentiation	NOUN
gsrj-21	58	51	of	of	ADP
gsrj-21	58	52	epithelial	epithelial	ADJ
gsrj-21	58	53	cells	cell	NOUN
gsrj-21	58	54	to	to	PART
gsrj-21	58	55	form	form	VERB
gsrj-21	58	56	embryonic	embryonic	ADJ
gsrj-21	58	57	neural	neural	ADJ
gsrj-21	58	58	crest	crest	NOUN
gsrj-21	58	59	cells.26	cells.26	NOUN
gsrj-21	58	60	moreover	moreover	ADV
gsrj-21	58	61	,	,	PUNCT
gsrj-21	58	62	zebrafish	zebrafish	ADJ
gsrj-21	58	63	xenograft	xenograft	NOUN
gsrj-21	58	64	models	model	NOUN
gsrj-21	58	65	can	can	AUX
gsrj-21	58	66	also	also	ADV
gsrj-21	58	67	be	be	AUX
gsrj-21	58	68	used	use	VERB
gsrj-21	58	69	to	to	PART
gsrj-21	58	70	determine	determine	VERB
gsrj-21	58	71	the	the	DET
gsrj-21	58	72	tumorforming	tumorforming	ADJ
gsrj-21	58	73	capacity	capacity	NOUN
gsrj-21	58	74	of	of	ADP
gsrj-21	58	75	pdac	pdac	ADJ
gsrj-21	58	76	crcs	crcs	NOUN
gsrj-21	58	77	and	and	CCONJ
gsrj-21	58	78	assess	assess	VERB
gsrj-21	58	79	whether	whether	SCONJ
gsrj-21	58	80	chemotherapeutic	chemotherapeutic	ADJ
gsrj-21	58	81	resistance	resistance	NOUN
gsrj-21	58	82	was	be	AUX
gsrj-21	58	83	retained	retain	VERB
gsrj-21	58	84	in	in	ADP
gsrj-21	58	85	vivo.54	vivo.54	ADJ
gsrj-21	58	86	therapy	therapy	NOUN
gsrj-21	58	87	-	-	PUNCT
gsrj-21	58	88	resistance	resistance	NOUN
gsrj-21	58	89	in	in	ADP
gsrj-21	58	90	vivo	vivo	NOUN
gsrj-21	58	91	animal	animal	NOUN
gsrj-21	58	92	models	model	NOUN
gsrj-21	58	93	mainly	mainly	ADV
gsrj-21	58	94	use	use	VERB
gsrj-21	58	95	mice	mouse	NOUN
gsrj-21	58	96	due	due	ADJ
gsrj-21	58	97	to	to	ADP
gsrj-21	58	98	optimal	optimal	ADJ
gsrj-21	58	99	short	short	ADJ
gsrj-21	58	100	generation	generation	NOUN
gsrj-21	58	101	time	time	NOUN
gsrj-21	58	102	(	(	PUNCT
gsrj-21	58	103	10	10	NUM
gsrj-21	58	104	weeks	week	NOUN
gsrj-21	58	105	)	)	PUNCT
gsrj-21	58	106	,	,	PUNCT
gsrj-21	58	107	average	average	ADJ
gsrj-21	58	108	life	life	NOUN
gsrj-21	58	109	expectancy	expectancy	NOUN
gsrj-21	58	110	(	(	PUNCT
gsrj-21	58	111	2.5	2.5	NUM
gsrj-21	58	112	years	year	NOUN
gsrj-21	58	113	)	)	PUNCT
gsrj-21	58	114	,	,	PUNCT
gsrj-21	58	115	the	the	DET
gsrj-21	58	116	possibilities	possibility	NOUN
gsrj-21	58	117	for	for	ADP
gsrj-21	58	118	reverse	reverse	ADJ
gsrj-21	58	119	genetics	genetic	NOUN
gsrj-21	58	120	,	,	PUNCT
gsrj-21	58	121	and	and	CCONJ
gsrj-21	58	122	the	the	DET
gsrj-21	58	123	frequent	frequent	ADJ
gsrj-21	58	124	occurrence	occurrence	NOUN
gsrj-21	58	125	of	of	ADP
gsrj-21	58	126	cancer	cancer	NOUN
gsrj-21	58	127	in	in	ADP
gsrj-21	58	128	the	the	DET
gsrj-21	58	129	absence	absence	NOUN
gsrj-21	58	130	of	of	ADP
gsrj-21	58	131	oncogenic	oncogenic	ADJ
gsrj-21	58	132	agents	agent	NOUN
gsrj-21	58	133	.	.	PUNCT
gsrj-21	59	1	the	the	DET
gsrj-21	59	2	use	use	NOUN
gsrj-21	59	3	of	of	ADP
gsrj-21	59	4	mouse	mouse	NOUN
gsrj-21	59	5	models	model	NOUN
gsrj-21	59	6	dates	date	VERB
gsrj-21	59	7	to	to	ADP
gsrj-21	59	8	the	the	DET
gsrj-21	59	9	late	late	ADJ
gsrj-21	59	10	1960s	1960	NOUN
gsrj-21	59	11	and	and	CCONJ
gsrj-21	59	12	the	the	DET
gsrj-21	59	13	development	development	NOUN
gsrj-21	59	14	of	of	ADP
gsrj-21	59	15	immunedeficient	immunedeficient	NOUN
gsrj-21	59	16	mouse	mouse	PROPN
gsrj-21	59	17	strains.26	strains.26	PROPN
gsrj-21	59	18	patient	patient	NOUN
gsrj-21	59	19	-	-	PUNCT
gsrj-21	59	20	derived	derive	VERB
gsrj-21	59	21	xenotransplants	xenotransplant	NOUN
gsrj-21	59	22	(	(	PUNCT
gsrj-21	59	23	pdx	pdx	PROPN
gsrj-21	59	24	)	)	PUNCT
gsrj-21	59	25	use	use	VERB
gsrj-21	59	26	chemotherapy	chemotherapy	NOUN
gsrj-21	59	27	-	-	ADJ
gsrj-21	59	28	naive	naive	ADJ
gsrj-21	59	29	tissue	tissue	NOUN
gsrj-21	59	30	obtained	obtain	VERB
gsrj-21	59	31	from	from	ADP
gsrj-21	59	32	surgery	surgery	NOUN
gsrj-21	59	33	or	or	CCONJ
gsrj-21	59	34	biopsies	biopsy	NOUN
gsrj-21	59	35	and	and	CCONJ
gsrj-21	59	36	transplant	transplant	VERB
gsrj-21	59	37	them	they	PRON
gsrj-21	59	38	into	into	ADP
gsrj-21	59	39	immunedeficient	immunedeficient	NOUN
gsrj-21	59	40	mouse	mouse	NOUN
gsrj-21	59	41	strains	strain	NOUN
gsrj-21	59	42	,	,	PUNCT
gsrj-21	59	43	like	like	ADP
gsrj-21	59	44	nude	nude	ADJ
gsrj-21	59	45	or	or	CCONJ
gsrj-21	59	46	severe	severe	ADJ
gsrj-21	59	47	combined	combine	VERB
gsrj-21	59	48	immunodeficiency	immunodeficiency	NOUN
gsrj-21	59	49	(	(	PUNCT
gsrj-21	59	50	scid	scid	NOUN
gsrj-21	59	51	)	)	PUNCT
gsrj-21	59	52	.	.	PUNCT
gsrj-21	60	1	26,55,56,57,58,59,6	26,55,56,57,58,59,6	NUM
gsrj-21	60	2	immunocompetent	immunocompetent	NOUN
gsrj-21	60	3	and	and	CCONJ
gsrj-21	60	4	immunodeficient	immunodeficient	NOUN
gsrj-21	60	5	mice	mouse	NOUN
gsrj-21	60	6	with	with	ADP
gsrj-21	60	7	xenografted	xenografted	ADJ
gsrj-21	60	8	tumors	tumor	NOUN
gsrj-21	60	9	are	be	AUX
gsrj-21	60	10	traditionally	traditionally	ADV
gsrj-21	60	11	transplanted	transplant	VERB
gsrj-21	60	12	subcutaneously	subcutaneously	ADV
gsrj-21	60	13	or	or	CCONJ
gsrj-21	60	14	orthotopically.61,62	orthotopically.61,62	VERB
gsrj-21	60	15	these	these	DET
gsrj-21	60	16	models	model	NOUN
gsrj-21	60	17	are	be	AUX
gsrj-21	60	18	widely	widely	ADV
gsrj-21	60	19	used	use	VERB
gsrj-21	60	20	due	due	ADP
gsrj-21	60	21	to	to	ADP
gsrj-21	60	22	their	their	PRON
gsrj-21	60	23	availability	availability	NOUN
gsrj-21	60	24	,	,	PUNCT
gsrj-21	60	25	low	low	ADJ
gsrj-21	60	26	cost	cost	NOUN
gsrj-21	60	27	,	,	PUNCT
gsrj-21	60	28	and	and	CCONJ
gsrj-21	60	29	ability	ability	NOUN
gsrj-21	60	30	to	to	PART
gsrj-21	60	31	mimic	mimic	VERB
gsrj-21	60	32	attributes	attribute	NOUN
gsrj-21	60	33	of	of	ADP
gsrj-21	60	34	human	human	ADJ
gsrj-21	60	35	malignancies	malignancy	NOUN
gsrj-21	60	36	by	by	ADP
gsrj-21	60	37	recapitulating	recapitulate	VERB
gsrj-21	60	38	neoplastic	neoplastic	ADJ
gsrj-21	60	39	cell	cell	NOUN
gsrj-21	60	40	architecture	architecture	NOUN
gsrj-21	60	41	and	and	CCONJ
gsrj-21	60	42	conserving	conserve	VERB
gsrj-21	60	43	genetic	genetic	ADJ
gsrj-21	60	44	and	and	CCONJ
gsrj-21	60	45	phenotypic	phenotypic	ADJ
gsrj-21	60	46	biology	biology	NOUN
gsrj-21	60	47	at	at	ADP
gsrj-21	60	48	the	the	DET
gsrj-21	60	49	histological	histological	ADJ
gsrj-21	60	50	and	and	CCONJ
gsrj-21	60	51	molecular	molecular	ADJ
gsrj-21	60	52	models.55	models.55	NOUN
gsrj-21	60	53	this	this	PRON
gsrj-21	60	54	makes	make	VERB
gsrj-21	60	55	pdx	pdx	PROPN
gsrj-21	60	56	models	model	NOUN
gsrj-21	60	57	the	the	DET
gsrj-21	60	58	favored	favor	VERB
gsrj-21	60	59	method	method	NOUN
gsrj-21	60	60	of	of	ADP
gsrj-21	60	61	identifying	identify	VERB
gsrj-21	60	62	drugs	drug	NOUN
gsrj-21	60	63	that	that	PRON
gsrj-21	60	64	significantly	significantly	ADV
gsrj-21	60	65	inhibit	inhibit	VERB
gsrj-21	60	66	tumor	tumor	NOUN
gsrj-21	60	67	growth	growth	NOUN
gsrj-21	60	68	,	,	PUNCT
gsrj-21	60	69	validating	validate	VERB
gsrj-21	60	70	tumor	tumor	NOUN
gsrj-21	60	71	biomarkers	biomarker	NOUN
gsrj-21	60	72	,	,	PUNCT
gsrj-21	60	73	and	and	CCONJ
gsrj-21	60	74	predicting	predict	VERB
gsrj-21	60	75	treatment	treatment	NOUN
gsrj-21	60	76	outcomes.55	outcomes.55	NOUN
gsrj-21	60	77	highly	highly	ADV
gsrj-21	60	78	sophisticated	sophisticated	ADJ
gsrj-21	60	79	transgenic	transgenic	NOUN
gsrj-21	60	80	mouse	mouse	NOUN
gsrj-21	60	81	models	model	NOUN
gsrj-21	60	82	allow	allow	VERB
gsrj-21	60	83	researchers	researcher	NOUN
gsrj-21	60	84	to	to	PART
gsrj-21	60	85	look	look	VERB
gsrj-21	60	86	at	at	ADP
gsrj-21	60	87	the	the	DET
gsrj-21	60	88	early	early	ADJ
gsrj-21	60	89	stages	stage	NOUN
gsrj-21	60	90	of	of	ADP
gsrj-21	60	91	tumor	tumor	NOUN
gsrj-21	60	92	development	development	NOUN
gsrj-21	60	93	and	and	CCONJ
gsrj-21	60	94	constitutively	constitutively	ADV
gsrj-21	60	95	or	or	CCONJ
gsrj-21	60	96	conditionally	conditionally	ADV
gsrj-21	60	97	induce	induce	VERB
gsrj-21	60	98	the	the	DET
gsrj-21	60	99	expression	expression	NOUN
gsrj-21	60	100	of	of	ADP
gsrj-21	60	101	an	an	DET
gsrj-21	60	102	oncogenic	oncogenic	ADJ
gsrj-21	60	103	mutation	mutation	NOUN
gsrj-21	60	104	at	at	ADP
gsrj-21	60	105	a	a	DET
gsrj-21	60	106	specific	specific	ADJ
gsrj-21	60	107	time	time	NOUN
gsrj-21	60	108	and	and	CCONJ
gsrj-21	60	109	in	in	ADP
gsrj-21	60	110	a	a	DET
gsrj-21	60	111	specific	specific	ADJ
gsrj-21	60	112	organ	organ	NOUN
gsrj-21	60	113	using	use	VERB
gsrj-21	60	114	conventional	conventional	ADJ
gsrj-21	60	115	methods	method	NOUN
gsrj-21	60	116	,	,	PUNCT
gsrj-21	60	117	such	such	ADJ
gsrj-21	60	118	as	as	ADP
gsrj-21	60	119	retroviral	retroviral	ADJ
gsrj-21	60	120	infection	infection	NOUN
gsrj-21	60	121	,	,	PUNCT
gsrj-21	60	122	microinjection	microinjection	NOUN
gsrj-21	60	123	of	of	ADP
gsrj-21	60	124	dna	dna	PROPN
gsrj-21	60	125	constructs	construct	VERB
gsrj-21	60	126	,	,	PUNCT
gsrj-21	60	127	and	and	CCONJ
gsrj-21	60	128	the	the	DET
gsrj-21	60	129	“	"	PUNCT
gsrj-21	60	130	gene	gene	NOUN
gsrj-21	60	131	-	-	PUNCT
gsrj-21	60	132	targeted	target	VERB
gsrj-21	60	133	transgene	transgene	NOUN
gsrj-21	60	134	”	"	PUNCT
gsrj-21	60	135	approach.26,63,64	approach.26,63,64	ADP
gsrj-21	60	136	the	the	DET
gsrj-21	60	137	use	use	NOUN
gsrj-21	60	138	of	of	ADP
gsrj-21	60	139	transgenic	transgenic	NOUN
gsrj-21	60	140	models	model	NOUN
gsrj-21	60	141	has	have	AUX
gsrj-21	60	142	been	be	AUX
gsrj-21	60	143	important	important	ADJ
gsrj-21	60	144	in	in	ADP
gsrj-21	60	145	studies	study	NOUN
gsrj-21	60	146	evaluating	evaluate	VERB
gsrj-21	60	147	the	the	DET
gsrj-21	60	148	development	development	NOUN
gsrj-21	60	149	of	of	ADP
gsrj-21	60	150	resistance	resistance	NOUN
gsrj-21	60	151	to	to	ADP
gsrj-21	60	152	therapy.63	therapy.63	PROPN
gsrj-21	60	153	knockout	knockout	NOUN
gsrj-21	60	154	transgenic	transgenic	NOUN
gsrj-21	60	155	mice	mouse	NOUN
gsrj-21	60	156	,	,	PUNCT
gsrj-21	60	157	in	in	ADP
gsrj-21	60	158	which	which	PRON
gsrj-21	60	159	the	the	DET
gsrj-21	60	160	gene	gene	NOUN
gsrj-21	60	161	is	be	AUX
gsrj-21	60	162	depleted	deplete	VERB
gsrj-21	60	163	or	or	CCONJ
gsrj-21	60	164	silenced	silence	VERB
gsrj-21	60	165	to	to	PART
gsrj-21	60	166	cause	cause	VERB
gsrj-21	60	167	a	a	DET
gsrj-21	60	168	loss	loss	NOUN
gsrj-21	60	169	of	of	ADP
gsrj-21	60	170	gene	gene	NOUN
gsrj-21	60	171	function	function	NOUN
gsrj-21	60	172	,	,	PUNCT
gsrj-21	60	173	are	be	AUX
gsrj-21	60	174	a	a	DET
gsrj-21	60	175	powerful	powerful	ADJ
gsrj-21	60	176	tool	tool	NOUN
gsrj-21	60	177	for	for	ADP
gsrj-21	60	178	assessing	assess	VERB
gsrj-21	60	179	the	the	DET
gsrj-21	60	180	potential	potential	ADJ
gsrj-21	60	181	validity	validity	NOUN
gsrj-21	60	182	of	of	ADP
gsrj-21	60	183	a	a	DET
gsrj-21	60	184	targeted	target	VERB
gsrj-21	60	185	therapy	therapy	NOUN
gsrj-21	60	186	because	because	SCONJ
gsrj-21	60	187	the	the	DET
gsrj-21	60	188	targets	target	NOUN
gsrj-21	60	189	can	can	AUX
gsrj-21	60	190	be	be	AUX
gsrj-21	60	191	precisely	precisely	ADV
gsrj-21	60	192	inactivated	inactivated	ADJ
gsrj-21	60	193	in	in	ADP
gsrj-21	60	194	the	the	DET
gsrj-21	60	195	developing	develop	VERB
gsrj-21	60	196	or	or	CCONJ
gsrj-21	60	197	developed	develop	VERB
gsrj-21	60	198	tumor.63	tumor.63	NOUN
gsrj-21	60	199	recently	recently	ADV
gsrj-21	60	200	,	,	PUNCT
gsrj-21	60	201	the	the	DET
gsrj-21	60	202	use	use	NOUN
gsrj-21	60	203	of	of	ADP
gsrj-21	60	204	crispr	crispr	ADJ
gsrj-21	60	205	/	/	SYM
gsrj-21	60	206	cas9	cas9	NOUN
gsrj-21	60	207	-	-	PUNCT
gsrj-21	60	208	based	base	VERB
gsrj-21	60	209	transgenic	transgenic	NOUN
gsrj-21	60	210	models	model	NOUN
gsrj-21	60	211	has	have	AUX
gsrj-21	60	212	allowed	allow	VERB
gsrj-21	60	213	for	for	ADP
gsrj-21	60	214	more	more	ADV
gsrj-21	60	215	effective	effective	ADJ
gsrj-21	60	216	systems	system	NOUN
gsrj-21	60	217	to	to	PART
gsrj-21	60	218	study	study	VERB
gsrj-21	60	219	human	human	PROPN
gsrj-21	60	220	cancers.63	cancers.63	PROPN
gsrj-21	60	221	due	due	ADP
gsrj-21	60	222	to	to	ADP
gsrj-21	60	223	advances	advance	NOUN
gsrj-21	60	224	in	in	ADP
gsrj-21	60	225	immunotherapy	immunotherapy	NOUN
gsrj-21	60	226	that	that	PRON
gsrj-21	60	227	have	have	AUX
gsrj-21	60	228	illuminated	illuminate	VERB
gsrj-21	60	229	the	the	DET
gsrj-21	60	230	importance	importance	NOUN
gsrj-21	60	231	of	of	ADP
gsrj-21	60	232	immune	immune	ADJ
gsrj-21	60	233	response	response	NOUN
gsrj-21	60	234	in	in	ADP
gsrj-21	60	235	tumor	tumor	NOUN
gsrj-21	60	236	progression	progression	NOUN
gsrj-21	60	237	and	and	CCONJ
gsrj-21	60	238	treatment	treatment	NOUN
gsrj-21	60	239	,	,	PUNCT
gsrj-21	60	240	new	new	ADJ
gsrj-21	60	241	pdx	pdx	PROPN
gsrj-21	60	242	models	model	NOUN
gsrj-21	60	243	,	,	PUNCT
gsrj-21	60	244	namely	namely	ADV
gsrj-21	60	245	those	those	PRON
gsrj-21	60	246	that	that	PRON
gsrj-21	60	247	interact	interact	VERB
gsrj-21	60	248	with	with	ADP
gsrj-21	60	249	the	the	DET
gsrj-21	60	250	human	human	ADJ
gsrj-21	60	251	immune	immune	ADJ
gsrj-21	60	252	system	system	NOUN
gsrj-21	60	253	,	,	PUNCT
gsrj-21	60	254	are	be	AUX
gsrj-21	60	255	necessary	necessary	ADJ
gsrj-21	60	256	.	.	PUNCT
gsrj-21	61	1	humanized	humanize	VERB
gsrj-21	61	2	mouse	mouse	PROPN
gsrj-21	61	3	xenograft	xenograft	NOUN
gsrj-21	61	4	models	model	NOUN
gsrj-21	61	5	replace	replace	VERB
gsrj-21	61	6	the	the	DET
gsrj-21	61	7	mouse	mouse	NOUN
gsrj-21	61	8	immune	immune	ADJ
gsrj-21	61	9	system	system	NOUN
gsrj-21	61	10	with	with	ADP
gsrj-21	61	11	a	a	DET
gsrj-21	61	12	human	human	ADJ
gsrj-21	61	13	immune	immune	ADJ
gsrj-21	61	14	system	system	NOUN
gsrj-21	61	15	.	.	PUNCT
gsrj-21	62	1	these	these	DET
gsrj-21	62	2	models	model	NOUN
gsrj-21	62	3	transplant	transplant	VERB
gsrj-21	62	4	cd34	cd34	PROPN
gsrj-21	62	5	+	+	ADJ
gsrj-21	62	6	human	human	ADJ
gsrj-21	62	7	hematopoietic	hematopoietic	ADJ
gsrj-21	62	8	stem	stem	NOUN
gsrj-21	62	9	cells	cell	NOUN
gsrj-21	62	10	(	(	PUNCT
gsrj-21	62	11	hscs	hsc	NOUN
gsrj-21	62	12	)	)	PUNCT
gsrj-21	62	13	into	into	ADP
gsrj-21	62	14	mice	mouse	NOUN
gsrj-21	62	15	to	to	PART
gsrj-21	62	16	produce	produce	VERB
gsrj-21	62	17	human	human	ADJ
gsrj-21	62	18	blood	blood	NOUN
gsrj-21	62	19	cells	cell	NOUN
gsrj-21	62	20	.	.	PUNCT
gsrj-21	63	1	they	they	PRON
gsrj-21	63	2	are	be	AUX
gsrj-21	63	3	potentially	potentially	ADV
gsrj-21	63	4	valuable	valuable	ADJ
gsrj-21	63	5	models	model	NOUN
gsrj-21	63	6	for	for	ADP
gsrj-21	63	7	new	new	ADJ
gsrj-21	63	8	immunotherapies	immunotherapy	NOUN
gsrj-21	63	9	because	because	SCONJ
gsrj-21	63	10	they	they	PRON
gsrj-21	63	11	mimic	mimic	VERB
gsrj-21	63	12	tumor	tumor	NOUN
gsrj-21	63	13	heterogeneity	heterogeneity	NOUN
gsrj-21	63	14	,	,	PUNCT
gsrj-21	63	15	the	the	DET
gsrj-21	63	16	tumor	tumor	NOUN
gsrj-21	63	17	microenvironment	microenvironment	NOUN
gsrj-21	63	18	,	,	PUNCT
gsrj-21	63	19	and	and	CCONJ
gsrj-21	63	20	crosstalk	crosstalk	VERB
gsrj-21	63	21	between	between	ADP
gsrj-21	63	22	the	the	DET
gsrj-21	63	23	tumor	tumor	NOUN
gsrj-21	63	24	and	and	CCONJ
gsrj-21	63	25	stromal	stromal	ADJ
gsrj-21	63	26	/	/	SYM
gsrj-21	63	27	immune	immune	ADJ
gsrj-21	63	28	cells.63	cells.63	PROPN
gsrj-21	63	29	wang	wang	PROPN
gsrj-21	63	30	et	et	PROPN
gsrj-21	63	31	al	al	PROPN
gsrj-21	63	32	.	.	PROPN
gsrj-21	63	33	developed	develop	VERB
gsrj-21	63	34	human	human	ADJ
gsrj-21	63	35	hematopoietic	hematopoietic	ADJ
gsrj-21	63	36	and	and	CCONJ
gsrj-21	63	37	immune	immune	ADJ
gsrj-21	63	38	systems	system	NOUN
gsrj-21	63	39	in	in	ADP
gsrj-21	63	40	mice	mouse	NOUN
gsrj-21	63	41	transplanted	transplant	VERB
gsrj-21	63	42	with	with	ADP
gsrj-21	63	43	human	human	ADJ
gsrj-21	63	44	(	(	PUNCT
gsrj-21	63	45	h)cd34	h)cd34	NOUN
gsrj-21	63	46	+	+	CCONJ
gsrj-21	63	47	hematopoietic	hematopoietic	ADJ
gsrj-21	63	48	progenitor	progenitor	NOUN
gsrj-21	63	49	and	and	CCONJ
gsrj-21	63	50	stem	stem	NOUN
gsrj-21	63	51	cells.65	cells.65	ADV
gsrj-21	63	52	after	after	ADP
gsrj-21	63	53	implanting	implant	VERB
gsrj-21	63	54	the	the	DET
gsrj-21	63	55	pdx	pdx	PROPN
gsrj-21	63	56	of	of	ADP
gsrj-21	63	57	nonsmall	nonsmall	PROPN
gsrj-21	63	58	cell	cell	NOUN
gsrj-21	63	59	lung	lung	NOUN
gsrj-21	63	60	cancer	cancer	NOUN
gsrj-21	63	61	(	(	PUNCT
gsrj-21	63	62	nsclc	nsclc	NOUN
gsrj-21	63	63	)	)	PUNCT
gsrj-21	63	64	,	,	PUNCT
gsrj-21	63	65	sarcoma	sarcoma	NOUN
gsrj-21	63	66	,	,	PUNCT
gsrj-21	63	67	bladder	bladder	NOUN
gsrj-21	63	68	,	,	PUNCT
gsrj-21	63	69	cancer	cancer	NOUN
gsrj-21	63	70	,	,	PUNCT
gsrj-21	63	71	and	and	CCONJ
gsrj-21	63	72	triple	triple	ADJ
gsrj-21	63	73	-	-	PUNCT
gsrj-21	63	74	negative	negative	ADJ
gsrj-21	63	75	breast	breast	NOUN
gsrj-21	63	76	cancer	cancer	NOUN
gsrj-21	63	77	into	into	ADP
gsrj-21	63	78	the	the	DET
gsrj-21	63	79	humanized	humanize	VERB
gsrj-21	63	80	nsg	nsg	PROPN
gsrj-21	63	81	(	(	PUNCT
gsrj-21	63	82	hunsg	hunsg	PROPN
gsrj-21	63	83	)	)	PUNCT
gsrj-21	63	84	mice	mouse	NOUN
gsrj-21	63	85	,	,	PUNCT
gsrj-21	63	86	the	the	DET
gsrj-21	63	87	researchers	researcher	NOUN
gsrj-21	63	88	discovered	discover	VERB
gsrj-21	63	89	that	that	SCONJ
gsrj-21	63	90	tumor	tumor	NOUN
gsrj-21	63	91	growth	growth	NOUN
gsrj-21	63	92	curves	curve	NOUN
gsrj-21	63	93	in	in	ADP
gsrj-21	63	94	the	the	DET
gsrj-21	63	95	humanized	humanize	VERB
gsrj-21	63	96	mice	mouse	NOUN
gsrj-21	63	97	were	be	AUX
gsrj-21	63	98	similar	similar	ADJ
gsrj-21	63	99	to	to	ADP
gsrj-21	63	100	those	those	PRON
gsrj-21	63	101	in	in	ADP
gsrj-21	63	102	nonhuman	nonhuman	ADJ
gsrj-21	63	103	immune	immune	ADJ
gsrj-21	63	104	cell	cell	NOUN
gsrj-21	63	105	-	-	PUNCT
gsrj-21	63	106	engrafted	engraft	VERB
gsrj-21	63	107	nsg	nsg	PROPN
gsrj-21	63	108	mice	mouse	NOUN
gsrj-21	63	109	.	.	PUNCT
gsrj-21	64	1	additionally	additionally	ADV
gsrj-21	64	2	,	,	PUNCT
gsrj-21	64	3	treatment	treatment	NOUN
gsrj-21	64	4	with	with	ADP
gsrj-21	64	5	pembrolizumab	pembrolizumab	NOUN
gsrj-21	64	6	,	,	PUNCT
gsrj-21	64	7	which	which	PRON
gsrj-21	64	8	targets	target	VERB
gsrj-21	64	9	programmed	program	VERB
gsrj-21	64	10	cell	cell	NOUN
gsrj-21	64	11	death	death	NOUN
gsrj-21	64	12	protein	protein	NOUN
gsrj-21	64	13	1	1	NUM
gsrj-21	64	14	,	,	PUNCT
gsrj-21	64	15	produced	produce	VERB
gsrj-21	64	16	significant	significant	ADJ
gsrj-21	64	17	growth	growth	NOUN
gsrj-21	64	18	inhibition	inhibition	NOUN
gsrj-21	64	19	in	in	ADP
gsrj-21	64	20	pdx	pdx	PROPN
gsrj-21	64	21	tumors	tumor	NOUN
gsrj-21	64	22	in	in	ADP
gsrj-21	64	23	hunsg	hunsg	PROPN
gsrj-21	64	24	mice	mouse	NOUN
gsrj-21	64	25	but	but	CCONJ
gsrj-21	64	26	not	not	PART
gsrj-21	64	27	in	in	ADP
gsrj-21	64	28	nsg	nsg	PROPN
gsrj-21	64	29	mice	mouse	NOUN
gsrj-21	64	30	.	.	PUNCT
gsrj-21	65	1	these	these	DET
gsrj-21	65	2	results	result	NOUN
gsrj-21	65	3	suggest	suggest	VERB
gsrj-21	65	4	that	that	SCONJ
gsrj-21	65	5	tumor	tumor	NOUN
gsrj-21	65	6	-	-	PUNCT
gsrj-21	65	7	bearing	bear	VERB
gsrj-21	65	8	hunsg	hunsg	NOUN
gsrj-21	65	9	mice	mouse	NOUN
gsrj-21	65	10	can	can	AUX
gsrj-21	65	11	serve	serve	VERB
gsrj-21	65	12	as	as	ADP
gsrj-21	65	13	a	a	DET
gsrj-21	65	14	novel	novel	ADJ
gsrj-21	65	15	platform	platform	NOUN
gsrj-21	65	16	for	for	ADP
gsrj-21	65	17	testing	test	VERB
gsrj-21	65	18	the	the	DET
gsrj-21	65	19	efficacy	efficacy	NOUN
gsrj-21	65	20	of	of	ADP
gsrj-21	65	21	immunotherapies	immunotherapy	NOUN
gsrj-21	65	22	.	.	PUNCT
gsrj-21	66	1	future	future	ADJ
gsrj-21	66	2	data	datum	NOUN
gsrj-21	66	3	collected	collect	VERB
gsrj-21	66	4	49	49	NUM
gsrj-21	66	5	georgetown	georgetown	PROPN
gsrj-21	66	6	scientific	scientific	ADJ
gsrj-21	66	7	research	research	NOUN
gsrj-21	66	8	journal	journal	NOUN
gsrj-21	66	9	from	from	ADP
gsrj-21	66	10	these	these	DET
gsrj-21	66	11	humanized	humanize	VERB
gsrj-21	66	12	mouse	mouse	NOUN
gsrj-21	66	13	models	model	NOUN
gsrj-21	66	14	will	will	AUX
gsrj-21	66	15	enable	enable	VERB
gsrj-21	66	16	the	the	DET
gsrj-21	66	17	development	development	NOUN
gsrj-21	66	18	of	of	ADP
gsrj-21	66	19	predictive	predictive	ADJ
gsrj-21	66	20	cancer	cancer	NOUN
gsrj-21	66	21	biomarkers	biomarker	NOUN
gsrj-21	66	22	of	of	ADP
gsrj-21	66	23	response	response	NOUN
gsrj-21	66	24	to	to	ADP
gsrj-21	66	25	chemotherapies	chemotherapy	NOUN
gsrj-21	66	26	.	.	PUNCT
gsrj-21	67	1	chang	chang	PROPN
gsrj-21	67	2	et	et	PROPN
gsrj-21	67	3	al	al	PROPN
gsrj-21	67	4	.	.	PROPN
gsrj-21	67	5	described	describe	VERB
gsrj-21	67	6	a	a	DET
gsrj-21	67	7	novel	novel	ADJ
gsrj-21	67	8	orthotopic	orthotopic	ADJ
gsrj-21	67	9	renal	renal	ADJ
gsrj-21	67	10	cell	cell	NOUN
gsrj-21	67	11	carcinoma	carcinoma	NOUN
gsrj-21	67	12	(	(	PUNCT
gsrj-21	67	13	rcc	rcc	PROPN
gsrj-21	67	14	)	)	PUNCT
gsrj-21	67	15	xenograft	xenograft	PROPN
gsrj-21	67	16	humanized	humanize	VERB
gsrj-21	67	17	mouse	mouse	NOUN
gsrj-21	67	18	model	model	NOUN
gsrj-21	67	19	as	as	ADP
gsrj-21	67	20	an	an	DET
gsrj-21	67	21	improved	improved	ADJ
gsrj-21	67	22	model	model	NOUN
gsrj-21	67	23	to	to	PART
gsrj-21	67	24	evaluate	evaluate	VERB
gsrj-21	67	25	in	in	ADP
gsrj-21	67	26	vivo	vivo	ADJ
gsrj-21	67	27	anti	anti	ADJ
gsrj-21	67	28	-	-	ADJ
gsrj-21	67	29	tumor	tumor	ADJ
gsrj-21	67	30	capabilities	capability	NOUN
gsrj-21	67	31	of	of	ADP
gsrj-21	67	32	fully	fully	ADV
gsrj-21	67	33	human	human	ADJ
gsrj-21	67	34	monoclonal	monoclonal	NOUN
gsrj-21	67	35	antibodies	antibody	NOUN
gsrj-21	67	36	for	for	ADP
gsrj-21	67	37	rcc	rcc	PROPN
gsrj-21	67	38	therapy.66,55	therapy.66,55	PROPN
gsrj-21	67	39	genetically	genetically	ADV
gsrj-21	67	40	engineered	engineer	VERB
gsrj-21	67	41	mouse	mouse	NOUN
gsrj-21	67	42	models	model	NOUN
gsrj-21	67	43	(	(	PUNCT
gsrj-21	67	44	gemm	gemm	NOUN
gsrj-21	67	45	)	)	PUNCT
gsrj-21	67	46	,	,	PUNCT
gsrj-21	67	47	which	which	PRON
gsrj-21	67	48	are	be	AUX
gsrj-21	67	49	produced	produce	VERB
gsrj-21	67	50	by	by	ADP
gsrj-21	67	51	modifying	modify	VERB
gsrj-21	67	52	specific	specific	ADJ
gsrj-21	67	53	genes	gene	NOUN
gsrj-21	67	54	associated	associate	VERB
gsrj-21	67	55	with	with	ADP
gsrj-21	67	56	cancer	cancer	NOUN
gsrj-21	67	57	,	,	PUNCT
gsrj-21	67	58	provide	provide	VERB
gsrj-21	67	59	an	an	DET
gsrj-21	67	60	authentic	authentic	ADJ
gsrj-21	67	61	,	,	PUNCT
gsrj-21	67	62	bridging	bridge	VERB
gsrj-21	67	63	model	model	NOUN
gsrj-21	67	64	to	to	ADP
gsrj-21	67	65	patients	patient	NOUN
gsrj-21	67	66	,	,	PUNCT
gsrj-21	67	67	as	as	SCONJ
gsrj-21	67	68	the	the	DET
gsrj-21	67	69	tumors	tumor	NOUN
gsrj-21	67	70	created	create	VERB
gsrj-21	67	71	are	be	AUX
gsrj-21	67	72	aggressive	aggressive	ADJ
gsrj-21	67	73	,	,	PUNCT
gsrj-21	67	74	heterogeneous	heterogeneous	ADJ
gsrj-21	67	75	,	,	PUNCT
gsrj-21	67	76	and	and	CCONJ
gsrj-21	67	77	stromal	stromal	ADJ
gsrj-21	67	78	(	(	PUNCT
gsrj-21	67	79	desmoplastic	desmoplastic	ADJ
gsrj-21	67	80	)	)	PUNCT
gsrj-21	67	81	in	in	ADP
gsrj-21	67	82	nature.55	nature.55	NOUN
gsrj-21	67	83	in	in	ADP
gsrj-21	67	84	addition	addition	NOUN
gsrj-21	67	85	to	to	ADP
gsrj-21	67	86	sharing	share	VERB
gsrj-21	67	87	similar	similar	ADJ
gsrj-21	67	88	genetic	genetic	ADJ
gsrj-21	67	89	,	,	PUNCT
gsrj-21	67	90	phenotypic	phenotypic	NOUN
gsrj-21	67	91	,	,	PUNCT
gsrj-21	67	92	and	and	CCONJ
gsrj-21	67	93	physiological	physiological	ADJ
gsrj-21	67	94	characteristics	characteristic	NOUN
gsrj-21	67	95	with	with	ADP
gsrj-21	67	96	humans	human	NOUN
gsrj-21	67	97	,	,	PUNCT
gsrj-21	67	98	gemms	gemms	ADJ
gsrj-21	67	99	also	also	ADV
gsrj-21	67	100	suffer	suffer	VERB
gsrj-21	67	101	from	from	ADP
gsrj-21	67	102	typical	typical	ADJ
gsrj-21	67	103	cancer	cancer	NOUN
gsrj-21	67	104	symptoms	symptom	NOUN
gsrj-21	67	105	(	(	PUNCT
gsrj-21	67	106	bodyweight	bodyweight	NOUN
gsrj-21	67	107	loss	loss	NOUN
gsrj-21	67	108	,	,	PUNCT
gsrj-21	67	109	cachexia	cachexia	NOUN
gsrj-21	67	110	,	,	PUNCT
gsrj-21	67	111	etc	etc	X
gsrj-21	67	112	.	.	X
gsrj-21	67	113	)	)	PUNCT
gsrj-21	67	114	and	and	CCONJ
gsrj-21	67	115	the	the	DET
gsrj-21	67	116	spontaneous	spontaneous	ADJ
gsrj-21	67	117	formation	formation	NOUN
gsrj-21	67	118	of	of	ADP
gsrj-21	67	119	distant	distant	ADJ
gsrj-21	67	120	metastasis.55	metastasis.55	NOUN
gsrj-21	67	121	the	the	DET
gsrj-21	67	122	development	development	NOUN
gsrj-21	67	123	of	of	ADP
gsrj-21	67	124	these	these	DET
gsrj-21	67	125	symptoms	symptom	NOUN
gsrj-21	67	126	makes	make	VERB
gsrj-21	67	127	it	it	PRON
gsrj-21	67	128	possible	possible	ADJ
gsrj-21	67	129	to	to	PART
gsrj-21	67	130	simulate	simulate	VERB
gsrj-21	67	131	different	different	ADJ
gsrj-21	67	132	stages	stage	NOUN
gsrj-21	67	133	of	of	ADP
gsrj-21	67	134	tumorigenesis	tumorigenesis	NOUN
gsrj-21	67	135	.	.	PUNCT
gsrj-21	68	1	3.3	3.3	NUM
gsrj-21	68	2	computational	computational	ADJ
gsrj-21	68	3	models	model	NOUN
gsrj-21	68	4	therapy	therapy	NOUN
gsrj-21	68	5	resistance	resistance	NOUN
gsrj-21	68	6	has	have	AUX
gsrj-21	68	7	also	also	ADV
gsrj-21	68	8	been	be	AUX
gsrj-21	68	9	studied	study	VERB
gsrj-21	68	10	through	through	ADP
gsrj-21	68	11	computational	computational	ADJ
gsrj-21	68	12	,	,	PUNCT
gsrj-21	68	13	theoretical	theoretical	ADJ
gsrj-21	68	14	,	,	PUNCT
gsrj-21	68	15	and	and	CCONJ
gsrj-21	68	16	mathematical	mathematical	ADJ
gsrj-21	68	17	models	model	NOUN
gsrj-21	68	18	.	.	PUNCT
gsrj-21	69	1	the	the	DET
gsrj-21	69	2	possibility	possibility	NOUN
gsrj-21	69	3	of	of	ADP
gsrj-21	69	4	using	use	VERB
gsrj-21	69	5	bioinformatics	bioinformatics	NOUN
gsrj-21	69	6	models	model	NOUN
gsrj-21	69	7	to	to	PART
gsrj-21	69	8	create	create	VERB
gsrj-21	69	9	personalized	personalized	ADJ
gsrj-21	69	10	medicine	medicine	NOUN
gsrj-21	69	11	applies	apply	VERB
gsrj-21	69	12	datasets	dataset	NOUN
gsrj-21	69	13	to	to	ADP
gsrj-21	69	14	tumor	tumor	NOUN
gsrj-21	69	15	material	material	NOUN
gsrj-21	69	16	,	,	PUNCT
gsrj-21	69	17	the	the	DET
gsrj-21	69	18	genome	genome	NOUN
gsrj-21	69	19	of	of	ADP
gsrj-21	69	20	the	the	DET
gsrj-21	69	21	cancer	cancer	NOUN
gsrj-21	69	22	patient	patient	NOUN
gsrj-21	69	23	,	,	PUNCT
gsrj-21	69	24	and	and	CCONJ
gsrj-21	69	25	metabolic	metabolic	NOUN
gsrj-21	69	26	pathways	pathway	NOUN
gsrj-21	69	27	.	.	PUNCT
gsrj-21	70	1	mathematical	mathematical	ADJ
gsrj-21	70	2	models	model	NOUN
gsrj-21	70	3	based	base	VERB
gsrj-21	70	4	on	on	ADP
gsrj-21	70	5	partial	partial	ADJ
gsrj-21	70	6	differential	differential	ADJ
gsrj-21	70	7	equations	equation	NOUN
gsrj-21	70	8	often	often	ADV
gsrj-21	70	9	deal	deal	VERB
gsrj-21	70	10	with	with	ADP
gsrj-21	70	11	the	the	DET
gsrj-21	70	12	growth	growth	NOUN
gsrj-21	70	13	of	of	ADP
gsrj-21	70	14	cancer	cancer	NOUN
gsrj-21	70	15	cell	cell	NOUN
gsrj-21	70	16	lines	line	NOUN
gsrj-21	70	17	in	in	ADP
gsrj-21	70	18	vitro	vitro	ADJ
gsrj-21	70	19	while	while	SCONJ
gsrj-21	70	20	considering	consider	VERB
gsrj-21	70	21	parameters	parameter	NOUN
gsrj-21	70	22	like	like	ADP
gsrj-21	70	23	initial	initial	ADJ
gsrj-21	70	24	cell	cell	NOUN
gsrj-21	70	25	density	density	NOUN
gsrj-21	70	26	and	and	CCONJ
gsrj-21	70	27	concentrations	concentration	NOUN
gsrj-21	70	28	of	of	ADP
gsrj-21	70	29	cell	cell	NOUN
gsrj-21	70	30	cycle	cycle	NOUN
gsrj-21	70	31	inhibitors.26	inhibitors.26	VERB
gsrj-21	70	32	these	these	DET
gsrj-21	70	33	simulations	simulation	NOUN
gsrj-21	70	34	can	can	AUX
gsrj-21	70	35	predict	predict	VERB
gsrj-21	70	36	the	the	DET
gsrj-21	70	37	conditions	condition	NOUN
gsrj-21	70	38	in	in	ADP
gsrj-21	70	39	which	which	PRON
gsrj-21	70	40	the	the	DET
gsrj-21	70	41	tumor	tumor	NOUN
gsrj-21	70	42	cells	cell	NOUN
gsrj-21	70	43	will	will	AUX
gsrj-21	70	44	die	die	VERB
gsrj-21	70	45	out	out	ADP
gsrj-21	70	46	.	.	PUNCT
gsrj-21	71	1	3.4	3.4	NUM
gsrj-21	71	2	gemcitabine	gemcitabine	NOUN
gsrj-21	71	3	resistance	resistance	NOUN
gsrj-21	71	4	and	and	CCONJ
gsrj-21	71	5	pdac	pdac	NOUN
gsrj-21	71	6	models	model	NOUN
gsrj-21	71	7	gem	gem	NOUN
gsrj-21	71	8	is	be	AUX
gsrj-21	71	9	a	a	DET
gsrj-21	71	10	nucleoside	nucleoside	ADJ
gsrj-21	71	11	analog	analog	NOUN
gsrj-21	71	12	used	use	VERB
gsrj-21	71	13	in	in	ADP
gsrj-21	71	14	chemotherapy	chemotherapy	NOUN
gsrj-21	71	15	for	for	ADP
gsrj-21	71	16	non	non	ADJ
gsrj-21	71	17	-	-	ADJ
gsrj-21	71	18	small	small	ADJ
gsrj-21	71	19	cell	cell	NOUN
gsrj-21	71	20	lung	lung	NOUN
gsrj-21	71	21	,	,	PUNCT
gsrj-21	71	22	pancreatic	pancreatic	ADJ
gsrj-21	71	23	,	,	PUNCT
gsrj-21	71	24	bladder	bladder	NOUN
gsrj-21	71	25	,	,	PUNCT
gsrj-21	71	26	and	and	CCONJ
gsrj-21	71	27	breast	breast	NOUN
gsrj-21	71	28	cancers.72	cancers.72	NOUN
gsrj-21	71	29	since	since	SCONJ
gsrj-21	71	30	its	its	PRON
gsrj-21	71	31	approval	approval	NOUN
gsrj-21	71	32	by	by	ADP
gsrj-21	71	33	the	the	DET
gsrj-21	71	34	fda	fda	PROPN
gsrj-21	71	35	in	in	ADP
gsrj-21	71	36	1996	1996	NUM
gsrj-21	71	37	,	,	PUNCT
gsrj-21	71	38	gem	gem	NOUN
gsrj-21	71	39	has	have	AUX
gsrj-21	71	40	been	be	AUX
gsrj-21	71	41	used	use	VERB
gsrj-21	71	42	as	as	ADP
gsrj-21	71	43	a	a	DET
gsrj-21	71	44	firstline	firstline	ADJ
gsrj-21	71	45	treatment	treatment	NOUN
gsrj-21	71	46	for	for	ADP
gsrj-21	71	47	patients	patient	NOUN
gsrj-21	71	48	with	with	ADP
gsrj-21	71	49	locally	locally	ADV
gsrj-21	71	50	advanced	advanced	ADJ
gsrj-21	71	51	(	(	PUNCT
gsrj-21	71	52	nonresectable	nonresectable	ADJ
gsrj-21	71	53	stage	stage	NOUN
gsrj-21	71	54	i	i	PROPN
gsrj-21	71	55	/	/	SYM
gsrj-21	71	56	ii	ii	PROPN
gsrj-21	71	57	)	)	PUNCT
gsrj-21	71	58	or	or	CCONJ
gsrj-21	71	59	metastatic	metastatic	ADJ
gsrj-21	71	60	(	(	PUNCT
gsrj-21	71	61	stage	stage	NOUN
gsrj-21	71	62	iv	iv	NUM
gsrj-21	71	63	)	)	PUNCT
gsrj-21	71	64	pdac	pdac	NOUN
gsrj-21	71	65	and	and	CCONJ
gsrj-21	71	66	remains	remain	VERB
gsrj-21	71	67	the	the	DET
gsrj-21	71	68	first	first	ADJ
gsrj-21	71	69	-	-	PUNCT
gsrj-21	71	70	choice	choice	NOUN
gsrj-21	71	71	treatment	treatment	NOUN
gsrj-21	71	72	for	for	ADP
gsrj-21	71	73	pdac	pdac	NOUN
gsrj-21	71	74	.	.	PUNCT
gsrj-21	72	1	gem	gem	NOUN
gsrj-21	72	2	inhibits	inhibit	VERB
gsrj-21	72	3	dna	dna	PROPN
gsrj-21	72	4	synthesis	synthesis	NOUN
gsrj-21	72	5	,	,	PUNCT
gsrj-21	72	6	acting	act	VERB
gsrj-21	72	7	as	as	ADP
gsrj-21	72	8	an	an	DET
gsrj-21	72	9	analog	analog	NOUN
gsrj-21	72	10	of	of	ADP
gsrj-21	72	11	cytidine	cytidine	NOUN
gsrj-21	72	12	to	to	PART
gsrj-21	72	13	prevent	prevent	VERB
gsrj-21	72	14	chain	chain	NOUN
gsrj-21	72	15	elongation	elongation	NOUN
gsrj-21	72	16	,	,	PUNCT
gsrj-21	72	17	and	and	CCONJ
gsrj-21	72	18	further	far	ADV
gsrj-21	72	19	induces	induce	VERB
gsrj-21	72	20	apoptosis	apoptosis	NOUN
gsrj-21	72	21	in	in	ADP
gsrj-21	72	22	cancer	cancer	NOUN
gsrj-21	72	23	cells	cell	NOUN
gsrj-21	72	24	via	via	ADP
gsrj-21	72	25	caspase	caspase	PROPN
gsrj-21	72	26	signaling.73	signaling.73	PROPN
gsrj-21	72	27	however	however	ADV
gsrj-21	72	28	,	,	PUNCT
gsrj-21	72	29	gem	gem	NOUN
gsrj-21	72	30	treatment	treatment	NOUN
gsrj-21	72	31	resistance	resistance	NOUN
gsrj-21	72	32	along	along	ADP
gsrj-21	72	33	with	with	ADP
gsrj-21	72	34	the	the	DET
gsrj-21	72	35	poor	poor	ADJ
gsrj-21	72	36	pharmacokinetic	pharmacokinetic	ADJ
gsrj-21	72	37	profile	profile	NOUN
gsrj-21	72	38	of	of	ADP
gsrj-21	72	39	gem	gem	NOUN
gsrj-21	72	40	(	(	PUNCT
gsrj-21	72	41	8	8	NUM
gsrj-21	72	42	-	-	SYM
gsrj-21	72	43	12	12	NUM
gsrj-21	72	44	mins	min	NOUN
gsrj-21	72	45	in	in	ADP
gsrj-21	72	46	humans	human	NOUN
gsrj-21	72	47	due	due	ADP
gsrj-21	72	48	to	to	ADP
gsrj-21	72	49	rapid	rapid	ADJ
gsrj-21	72	50	metabolism	metabolism	NOUN
gsrj-21	72	51	)	)	PUNCT
gsrj-21	72	52	has	have	AUX
gsrj-21	72	53	resulted	result	VERB
gsrj-21	72	54	in	in	ADP
gsrj-21	72	55	poor	poor	ADJ
gsrj-21	72	56	treatment	treatment	NOUN
gsrj-21	72	57	outcomes	outcome	NOUN
gsrj-21	72	58	and	and	CCONJ
gsrj-21	72	59	drug	drug	NOUN
gsrj-21	72	60	resistance	resistance	NOUN
gsrj-21	72	61	development	development	NOUN
gsrj-21	72	62	over	over	ADP
gsrj-21	72	63	time.71,74	time.71,74	NOUN
gsrj-21	72	64	4	4	NUM
gsrj-21	72	65	.	.	PUNCT
gsrj-21	72	66	gemcitabine	gemcitabine	NOUN
gsrj-21	72	67	resistance	resistance	NOUN
gsrj-21	72	68	and	and	CCONJ
gsrj-21	72	69	in	in	ADP
gsrj-21	72	70	vitro	vitro	X
gsrj-21	72	71	models	model	NOUN
gsrj-21	72	72	4.1	4.1	NUM
gsrj-21	72	73	gemcitabine	gemcitabine	NOUN
gsrj-21	72	74	resistance	resistance	NOUN
gsrj-21	72	75	and	and	CCONJ
gsrj-21	72	76	2d	2d	NOUN
gsrj-21	72	77	cultures	culture	NOUN
gsrj-21	72	78	panc-1	panc-1	NOUN
gsrj-21	72	79	,	,	PUNCT
gsrj-21	72	80	miapaca-2	miapaca-2	PROPN
gsrj-21	72	81	,	,	PUNCT
gsrj-21	72	82	sw1990	sw1990	NOUN
gsrj-21	72	83	,	,	PUNCT
gsrj-21	72	84	and	and	CCONJ
gsrj-21	72	85	capan-2	capan-2	NOUN
gsrj-21	72	86	are	be	AUX
gsrj-21	72	87	2d	2d	NUM
gsrj-21	72	88	cell	cell	NOUN
gsrj-21	72	89	cultures	culture	NOUN
gsrj-21	72	90	that	that	PRON
gsrj-21	72	91	remain	remain	VERB
gsrj-21	72	92	platforms	platform	NOUN
gsrj-21	72	93	used	use	VERB
gsrj-21	72	94	to	to	PART
gsrj-21	72	95	study	study	VERB
gsrj-21	72	96	gem	gem	NOUN
gsrj-21	72	97	resistance	resistance	NOUN
gsrj-21	72	98	mechanisms	mechanism	NOUN
gsrj-21	72	99	and	and	CCONJ
gsrj-21	72	100	improve	improve	VERB
gsrj-21	72	101	the	the	DET
gsrj-21	72	102	efficacy	efficacy	NOUN
gsrj-21	72	103	of	of	ADP
gsrj-21	72	104	gem	gem	NOUN
gsrj-21	72	105	in	in	ADP
gsrj-21	72	106	combination	combination	NOUN
gsrj-21	72	107	with	with	ADP
gsrj-21	72	108	other	other	ADJ
gsrj-21	72	109	therapies.55,72	therapies.55,72	NOUN
gsrj-21	72	110	these	these	DET
gsrj-21	72	111	cancer	cancer	NOUN
gsrj-21	72	112	cells	cell	NOUN
gsrj-21	72	113	have	have	VERB
gsrj-21	72	114	the	the	DET
gsrj-21	72	115	capability	capability	NOUN
gsrj-21	72	116	to	to	PART
gsrj-21	72	117	generate	generate	VERB
gsrj-21	72	118	high	high	ADJ
gsrj-21	72	119	-	-	PUNCT
gsrj-21	72	120	fidelity	fidelity	NOUN
gsrj-21	72	121	in	in	ADP
gsrj-21	72	122	vitro	vitro	X
gsrj-21	72	123	models	model	NOUN
gsrj-21	72	124	to	to	PART
gsrj-21	72	125	explore	explore	VERB
gsrj-21	72	126	the	the	DET
gsrj-21	72	127	efficacy	efficacy	NOUN
gsrj-21	72	128	of	of	ADP
gsrj-21	72	129	anticancer	anticancer	NOUN
gsrj-21	72	130	drugs	drug	NOUN
gsrj-21	72	131	.	.	PUNCT
gsrj-21	73	1	pancreatic	pancreatic	ADJ
gsrj-21	73	2	cell	cell	NOUN
gsrj-21	73	3	lines	line	NOUN
gsrj-21	73	4	(	(	PUNCT
gsrj-21	73	5	capan-1	capan-1	PROPN
gsrj-21	73	6	,	,	PUNCT
gsrj-21	73	7	t3m4	t3m4	NOUN
gsrj-21	73	8	,	,	PUNCT
gsrj-21	73	9	miapaca-2	miapaca-2	PROPN
gsrj-21	73	10	)	)	PUNCT
gsrj-21	73	11	with	with	ADP
gsrj-21	73	12	acquired	acquire	VERB
gsrj-21	73	13	gem	gem	NOUN
gsrj-21	73	14	resistance	resistance	NOUN
gsrj-21	73	15	(	(	PUNCT
gsrj-21	73	16	gem	gem	NOUN
gsrj-21	73	17	-	-	PUNCT
gsrj-21	73	18	r	r	NOUN
gsrj-21	73	19	)	)	PUNCT
gsrj-21	73	20	have	have	AUX
gsrj-21	73	21	elucidated	elucidate	VERB
gsrj-21	73	22	resistance	resistance	NOUN
gsrj-21	73	23	mechanisms	mechanism	NOUN
gsrj-21	73	24	that	that	PRON
gsrj-21	73	25	include	include	VERB
gsrj-21	73	26	signaling	signal	VERB
gsrj-21	73	27	crosstalk	crosstalk	NOUN
gsrj-21	73	28	to	to	ADP
gsrj-21	73	29	increases	increase	NOUN
gsrj-21	73	30	glucose	glucose	NOUN
gsrj-21	73	31	uptake75	uptake75	NOUN
gsrj-21	73	32	and	and	CCONJ
gsrj-21	73	33	kinase	kinase	VERB
gsrj-21	73	34	inhibitors	inhibitor	NOUN
gsrj-21	73	35	capable	capable	ADJ
gsrj-21	73	36	of	of	ADP
gsrj-21	73	37	inhibiting	inhibit	VERB
gsrj-21	73	38	the	the	DET
gsrj-21	73	39	growth	growth	NOUN
gsrj-21	73	40	of	of	ADP
gsrj-21	73	41	gem	gem	NOUN
gsrj-21	73	42	-	-	PUNCT
gsrj-21	73	43	resistant	resistant	ADJ
gsrj-21	73	44	miapaca-2	miapaca-2	PROPN
gsrj-21	73	45	cells.76	cells.76	PROPN
gsrj-21	73	46	affram	affram	NOUN
gsrj-21	73	47	et	et	PROPN
gsrj-21	73	48	al	al	PROPN
gsrj-21	73	49	.	.	PROPN
gsrj-21	73	50	investigated	investigate	VERB
gsrj-21	73	51	the	the	DET
gsrj-21	73	52	cytotoxic	cytotoxic	ADJ
gsrj-21	73	53	effects	effect	NOUN
gsrj-21	73	54	of	of	ADP
gsrj-21	73	55	an	an	DET
gsrj-21	73	56	alternative	alternative	ADJ
gsrj-21	73	57	drug	drug	NOUN
gsrj-21	73	58	delivery	delivery	NOUN
gsrj-21	73	59	system	system	NOUN
gsrj-21	73	60	in	in	ADP
gsrj-21	73	61	the	the	DET
gsrj-21	73	62	form	form	NOUN
gsrj-21	73	63	of	of	ADP
gsrj-21	73	64	gem	gem	NOUN
gsrj-21	73	65	-	-	PUNCT
gsrj-21	73	66	loaded	load	VERB
gsrj-21	73	67	solid	solid	ADJ
gsrj-21	73	68	lipid	lipid	NOUN
gsrj-21	73	69	nanoparticle	nanoparticle	NOUN
gsrj-21	73	70	(	(	PUNCT
gsrj-21	73	71	gemsln	gemsln	NOUN
gsrj-21	73	72	)	)	PUNCT
gsrj-21	73	73	on	on	ADP
gsrj-21	73	74	patient	patient	NOUN
gsrj-21	73	75	-	-	PUNCT
gsrj-21	73	76	derived	derive	VERB
gsrj-21	73	77	primary	primary	ADJ
gsrj-21	73	78	pancreatic	pancreatic	NOUN
gsrj-21	73	79	cell	cell	NOUN
gsrj-21	73	80	lines	line	NOUN
gsrj-21	73	81	(	(	PUNCT
gsrj-21	73	82	ppcl-46	ppcl-46	PROPN
gsrj-21	73	83	)	)	PUNCT
gsrj-21	73	84	and	and	CCONJ
gsrj-21	73	85	miapaca-2	miapaca-2	PROPN
gsrj-21	73	86	pancreatic	pancreatic	ADJ
gsrj-21	73	87	cancer	cancer	NOUN
gsrj-21	73	88	cells.72	cells.72	PROPN
gsrj-21	73	89	solid	solid	ADJ
gsrj-21	73	90	lipid	lipid	NOUN
gsrj-21	73	91	nanoparticles	nanoparticle	NOUN
gsrj-21	73	92	(	(	PUNCT
gsrj-21	73	93	slns	slns	NOUN
gsrj-21	73	94	)	)	PUNCT
gsrj-21	73	95	are	be	AUX
gsrj-21	73	96	nanocarriers	nanocarrier	NOUN
gsrj-21	73	97	that	that	PRON
gsrj-21	73	98	can	can	AUX
gsrj-21	73	99	be	be	AUX
gsrj-21	73	100	used	use	VERB
gsrj-21	73	101	as	as	ADP
gsrj-21	73	102	an	an	DET
gsrj-21	73	103	alternative	alternative	ADJ
gsrj-21	73	104	drug	drug	NOUN
gsrj-21	73	105	delivery	delivery	NOUN
gsrj-21	73	106	system	system	NOUN
gsrj-21	73	107	to	to	PART
gsrj-21	73	108	improve	improve	VERB
gsrj-21	73	109	therapeutic	therapeutic	ADJ
gsrj-21	73	110	effectiveness	effectiveness	NOUN
gsrj-21	73	111	for	for	ADP
gsrj-21	73	112	drugs	drug	NOUN
gsrj-21	73	113	,	,	PUNCT
gsrj-21	73	114	like	like	ADP
gsrj-21	73	115	gem	gem	NOUN
gsrj-21	73	116	,	,	PUNCT
gsrj-21	73	117	with	with	ADP
gsrj-21	73	118	a	a	DET
gsrj-21	73	119	short	short	ADJ
gsrj-21	73	120	half	half	ADJ
gsrj-21	73	121	-	-	PUNCT
gsrj-21	73	122	life	life	NOUN
gsrj-21	73	123	that	that	PRON
gsrj-21	73	124	requires	require	VERB
gsrj-21	73	125	continuous	continuous	ADJ
gsrj-21	73	126	parenteral	parenteral	ADJ
gsrj-21	73	127	administration	administration	NOUN
gsrj-21	73	128	.	.	PUNCT
gsrj-21	74	1	the	the	DET
gsrj-21	74	2	researchers	researcher	NOUN
gsrj-21	74	3	’	’	PART
gsrj-21	74	4	cytotoxicity	cytotoxicity	NOUN
gsrj-21	74	5	studies	study	NOUN
gsrj-21	74	6	found	find	VERB
gsrj-21	74	7	a	a	DET
gsrj-21	74	8	greater	great	ADJ
gsrj-21	74	9	cytotoxic	cytotoxic	ADJ
gsrj-21	74	10	effect	effect	NOUN
gsrj-21	74	11	of	of	ADP
gsrj-21	74	12	gemsln	gemsln	NOUN
gsrj-21	74	13	treated	treat	VERB
gsrj-21	74	14	ppcl-46	ppcl-46	PROPN
gsrj-21	74	15	than	than	ADP
gsrj-21	74	16	of	of	ADP
gsrj-21	74	17	gem	gem	NOUN
gsrj-21	74	18	hydrochloride	hydrochloride	NOUN
gsrj-21	74	19	(	(	PUNCT
gsrj-21	74	20	gem	gem	NOUN
gsrj-21	74	21	-	-	PUNCT
gsrj-21	74	22	hcl	hcl	NOUN
gsrj-21	74	23	)	)	PUNCT
gsrj-21	74	24	treated	treat	VERB
gsrj-21	74	25	ppcl-46	ppcl-46	ADJ
gsrj-21	74	26	cultures	culture	NOUN
gsrj-21	74	27	.	.	PUNCT
gsrj-21	75	1	a	a	DET
gsrj-21	75	2	similar	similar	ADJ
gsrj-21	75	3	trend	trend	NOUN
gsrj-21	75	4	of	of	ADP
gsrj-21	75	5	higher	high	ADJ
gsrj-21	75	6	gem	gem	NOUN
gsrj-21	75	7	-	-	PUNCT
gsrj-21	75	8	sln	sln	NOUN
gsrj-21	75	9	inhibition	inhibition	NOUN
gsrj-21	75	10	was	be	AUX
gsrj-21	75	11	found	find	VERB
gsrj-21	75	12	in	in	ADP
gsrj-21	75	13	miapaca-2	miapaca-2	PROPN
gsrj-21	75	14	cultures	culture	NOUN
gsrj-21	75	15	as	as	ADV
gsrj-21	75	16	well	well	ADV
gsrj-21	75	17	.	.	PUNCT
gsrj-21	76	1	these	these	DET
gsrj-21	76	2	results	result	NOUN
gsrj-21	76	3	indicate	indicate	VERB
gsrj-21	76	4	the	the	DET
gsrj-21	76	5	potential	potential	NOUN
gsrj-21	76	6	for	for	ADP
gsrj-21	76	7	enhanced	enhance	VERB
gsrj-21	76	8	gem	gem	NOUN
gsrj-21	76	9	delivery	delivery	NOUN
gsrj-21	76	10	and	and	CCONJ
gsrj-21	76	11	improved	improved	ADJ
gsrj-21	76	12	anticancer	anticancer	NOUN
gsrj-21	76	13	activity	activity	NOUN
gsrj-21	76	14	through	through	ADP
gsrj-21	76	15	gem	gem	NOUN
gsrj-21	76	16	-	-	PUNCT
gsrj-21	76	17	sln	sln	PROPN
gsrj-21	76	18	.	.	PUNCT
gsrj-21	77	1	additionally	additionally	ADV
gsrj-21	77	2	,	,	PUNCT
gsrj-21	77	3	gem	gem	NOUN
gsrj-21	77	4	-	-	PUNCT
gsrj-21	77	5	sln	sln	PROPN
gsrj-21	77	6	is	be	AUX
gsrj-21	77	7	effective	effective	ADJ
gsrj-21	77	8	on	on	ADP
gsrj-21	77	9	both	both	DET
gsrj-21	77	10	ppcl-46	ppcl-46	ADJ
gsrj-21	77	11	cultures	culture	NOUN
gsrj-21	77	12	and	and	CCONJ
gsrj-21	77	13	established	establish	VERB
gsrj-21	77	14	commercially	commercially	ADV
gsrj-21	77	15	available	available	ADJ
gsrj-21	77	16	cell	cell	NOUN
gsrj-21	77	17	lines	line	NOUN
gsrj-21	77	18	,	,	PUNCT
gsrj-21	77	19	50	50	NUM
gsrj-21	77	20	georgetown	georgetown	NOUN
gsrj-21	77	21	scientific	scientific	ADJ
gsrj-21	77	22	research	research	NOUN
gsrj-21	77	23	journal	journal	NOUN
gsrj-21	77	24	indicating	indicate	VERB
gsrj-21	77	25	moderate	moderate	ADJ
gsrj-21	77	26	effectiveness	effectiveness	NOUN
gsrj-21	77	27	in	in	ADP
gsrj-21	77	28	addressing	address	VERB
gsrj-21	77	29	the	the	DET
gsrj-21	77	30	heterogeneity	heterogeneity	NOUN
gsrj-21	77	31	of	of	ADP
gsrj-21	77	32	pancreatic	pancreatic	ADJ
gsrj-21	77	33	cancer	cancer	NOUN
gsrj-21	77	34	cells	cell	NOUN
gsrj-21	77	35	.	.	PUNCT
gsrj-21	78	1	4.1.1	4.1.1	NUM
gsrj-21	78	2	gemcitabine	gemcitabine	NOUN
gsrj-21	78	3	resistance	resistance	NOUN
gsrj-21	78	4	and	and	CCONJ
gsrj-21	78	5	2d	2d	NOUN
gsrj-21	78	6	co	co	NOUN
gsrj-21	78	7	-	-	NOUN
gsrj-21	78	8	cultures	culture	NOUN
gsrj-21	78	9	pancreatic	pancreatic	ADJ
gsrj-21	78	10	stellate	stellate	ADJ
gsrj-21	78	11	cells	cell	NOUN
gsrj-21	78	12	(	(	PUNCT
gsrj-21	78	13	psc	psc	PROPN
gsrj-21	78	14	)	)	PUNCT
gsrj-21	78	15	are	be	AUX
gsrj-21	78	16	often	often	ADV
gsrj-21	78	17	used	use	VERB
gsrj-21	78	18	in	in	ADP
gsrj-21	78	19	co	co	ADJ
gsrj-21	78	20	-	-	NOUN
gsrj-21	78	21	culture	culture	ADJ
gsrj-21	78	22	experiments	experiment	NOUN
gsrj-21	78	23	with	with	ADP
gsrj-21	78	24	pdac	pdac	NOUN
gsrj-21	78	25	cells	cell	NOUN
gsrj-21	78	26	to	to	PART
gsrj-21	78	27	illuminate	illuminate	VERB
gsrj-21	78	28	microenvironmental	microenvironmental	ADJ
gsrj-21	78	29	issues	issue	NOUN
gsrj-21	78	30	and	and	CCONJ
gsrj-21	78	31	provide	provide	VERB
gsrj-21	78	32	a	a	DET
gsrj-21	78	33	more	more	ADV
gsrj-21	78	34	accurate	accurate	ADJ
gsrj-21	78	35	model	model	NOUN
gsrj-21	78	36	than	than	ADP
gsrj-21	78	37	a	a	DET
gsrj-21	78	38	single	single	ADJ
gsrj-21	78	39	epithelial	epithelial	ADJ
gsrj-21	78	40	monolayer	monolayer	NOUN
gsrj-21	78	41	model.77,78,79,80	model.77,78,79,80	PROPN
gsrj-21	78	42	pdac	pdac	NOUN
gsrj-21	78	43	often	often	ADV
gsrj-21	78	44	displays	display	VERB
gsrj-21	78	45	a	a	DET
gsrj-21	78	46	dense	dense	ADJ
gsrj-21	78	47	desmoplastic	desmoplastic	ADJ
gsrj-21	78	48	stroma	stroma	NOUN
gsrj-21	78	49	,	,	PUNCT
gsrj-21	78	50	which	which	PRON
gsrj-21	78	51	has	have	AUX
gsrj-21	78	52	been	be	AUX
gsrj-21	78	53	associated	associate	VERB
gsrj-21	78	54	with	with	ADP
gsrj-21	78	55	chemoresistance	chemoresistance	NOUN
gsrj-21	78	56	and	and	CCONJ
gsrj-21	78	57	inhibition	inhibition	NOUN
gsrj-21	78	58	of	of	ADP
gsrj-21	78	59	drug	drug	NOUN
gsrj-21	78	60	penetration.81	penetration.81	NOUN
gsrj-21	78	61	3d	3d	NUM
gsrj-21	78	62	matrices	matrix	NOUN
gsrj-21	78	63	of	of	ADP
gsrj-21	78	64	psc	psc	PROPN
gsrj-21	78	65	cells	cell	NOUN
gsrj-21	78	66	stimulate	stimulate	VERB
gsrj-21	78	67	life	life	NOUN
gsrj-21	78	68	-	-	PUNCT
gsrj-21	78	69	like	like	ADJ
gsrj-21	78	70	settings	setting	NOUN
gsrj-21	78	71	and	and	CCONJ
gsrj-21	78	72	studies	study	NOUN
gsrj-21	78	73	on	on	ADP
gsrj-21	78	74	these	these	DET
gsrj-21	78	75	matrices	matrix	NOUN
gsrj-21	78	76	reveal	reveal	VERB
gsrj-21	78	77	that	that	SCONJ
gsrj-21	78	78	additional	additional	ADJ
gsrj-21	78	79	tumor	tumor	NOUN
gsrj-21	78	80	stroma	stroma	ADJ
gsrj-21	78	81	components	component	NOUN
gsrj-21	78	82	(	(	PUNCT
gsrj-21	78	83	fibroblasts	fibroblast	NOUN
gsrj-21	78	84	,	,	PUNCT
gsrj-21	78	85	macrophages	macrophage	NOUN
gsrj-21	78	86	,	,	PUNCT
gsrj-21	78	87	immune	immune	ADJ
gsrj-21	78	88	cells	cell	NOUN
gsrj-21	78	89	,	,	PUNCT
gsrj-21	78	90	and	and	CCONJ
gsrj-21	78	91	endothelial	endothelial	ADJ
gsrj-21	78	92	cells	cell	NOUN
gsrj-21	78	93	)	)	PUNCT
gsrj-21	78	94	play	play	VERB
gsrj-21	78	95	an	an	DET
gsrj-21	78	96	important	important	ADJ
gsrj-21	78	97	role	role	NOUN
gsrj-21	78	98	in	in	ADP
gsrj-21	78	99	therapy	therapy	NOUN
gsrj-21	78	100	resistance.55	resistance.55	NOUN
gsrj-21	78	101	karnevi	karnevi	VERB
gsrj-21	78	102	et	et	PROPN
gsrj-21	78	103	al	al	PROPN
gsrj-21	78	104	.	.	PROPN
gsrj-21	78	105	highlighted	highlight	VERB
gsrj-21	78	106	the	the	DET
gsrj-21	78	107	role	role	NOUN
gsrj-21	78	108	of	of	ADP
gsrj-21	78	109	pscs	psc	NOUN
gsrj-21	78	110	in	in	ADP
gsrj-21	78	111	the	the	DET
gsrj-21	78	112	epithelial	epithelial	ADJ
gsrj-21	78	113	-	-	PUNCT
gsrj-21	78	114	mesenchymal	mesenchymal	NOUN
gsrj-21	78	115	transition	transition	NOUN
gsrj-21	78	116	(	(	PUNCT
gsrj-21	78	117	emt	emt	PROPN
gsrj-21	78	118	)	)	PUNCT
gsrj-21	78	119	as	as	ADP
gsrj-21	78	120	an	an	DET
gsrj-21	78	121	intrinsic	intrinsic	ADJ
gsrj-21	78	122	part	part	NOUN
gsrj-21	78	123	of	of	ADP
gsrj-21	78	124	cancer	cancer	NOUN
gsrj-21	78	125	progression	progression	NOUN
gsrj-21	78	126	that	that	PRON
gsrj-21	78	127	downregulates	downregulate	VERB
gsrj-21	78	128	epithelial	epithelial	ADJ
gsrj-21	78	129	phenotype	phenotype	NOUN
gsrj-21	78	130	and	and	CCONJ
gsrj-21	78	131	cell	cell	NOUN
gsrj-21	78	132	-	-	PUNCT
gsrj-21	78	133	cell	cell	NOUN
gsrj-21	78	134	adhesions.24	adhesions.24	NOUN
gsrj-21	78	135	co	co	NOUN
gsrj-21	78	136	-	-	NOUN
gsrj-21	78	137	cultures	culture	NOUN
gsrj-21	78	138	of	of	ADP
gsrj-21	78	139	immortalized	immortalized	ADJ
gsrj-21	78	140	primary	primary	ADJ
gsrj-21	78	141	pscs	psc	NOUN
gsrj-21	78	142	with	with	ADP
gsrj-21	78	143	panc-1	panc-1	NOUN
gsrj-21	78	144	,	,	PUNCT
gsrj-21	78	145	miapaca-2	miapaca-2	PROPN
gsrj-21	78	146	,	,	PUNCT
gsrj-21	78	147	and	and	CCONJ
gsrj-21	78	148	bxpc-3	bxpc-3	NUM
gsrj-21	78	149	revealed	reveal	VERB
gsrj-21	78	150	down	down	ADV
gsrj-21	78	151	-	-	PUNCT
gsrj-21	78	152	regulated	regulate	VERB
gsrj-21	78	153	e	e	NOUN
gsrj-21	78	154	-	-	NOUN
gsrj-21	78	155	cadherin	cadherin	NOUN
gsrj-21	78	156	levels	level	NOUN
gsrj-21	78	157	and	and	CCONJ
gsrj-21	78	158	increased	increase	VERB
gsrj-21	78	159	expression	expression	NOUN
gsrj-21	78	160	of	of	ADP
gsrj-21	78	161	vimentin	vimentin	NOUN
gsrj-21	78	162	,	,	PUNCT
gsrj-21	78	163	both	both	PRON
gsrj-21	78	164	of	of	ADP
gsrj-21	78	165	which	which	PRON
gsrj-21	78	166	indicate	indicate	VERB
gsrj-21	78	167	the	the	DET
gsrj-21	78	168	role	role	NOUN
gsrj-21	78	169	of	of	ADP
gsrj-21	78	170	pscs	psc	NOUN
gsrj-21	78	171	in	in	ADP
gsrj-21	78	172	modulating	modulate	VERB
gsrj-21	78	173	the	the	DET
gsrj-21	78	174	epithelial	epithelial	ADJ
gsrj-21	78	175	-	-	PUNCT
gsrj-21	78	176	mesenchymal	mesenchymal	NOUN
gsrj-21	78	177	transition	transition	NOUN
gsrj-21	78	178	(	(	PUNCT
gsrj-21	78	179	emt	emt	PROPN
gsrj-21	78	180	)	)	PUNCT
gsrj-21	78	181	.	.	PUNCT
gsrj-21	79	1	more	more	ADV
gsrj-21	79	2	recently	recently	ADV
gsrj-21	79	3	,	,	PUNCT
gsrj-21	79	4	xiao	xiao	PROPN
gsrj-21	79	5	et	et	PROPN
gsrj-21	79	6	al	al	PROPN
gsrj-21	79	7	.	.	PROPN
gsrj-21	79	8	found	find	VERB
gsrj-21	79	9	increased	increase	VERB
gsrj-21	79	10	expression	expression	NOUN
gsrj-21	79	11	of	of	ADP
gsrj-21	79	12	yes	yes	ADV
gsrj-21	79	13	-	-	PUNCT
gsrj-21	79	14	associated	associate	VERB
gsrj-21	79	15	protein	protein	NOUN
gsrj-21	79	16	1	1	NUM
gsrj-21	79	17	(	(	PUNCT
gsrj-21	79	18	yap1	yap1	PROPN
gsrj-21	79	19	)	)	PUNCT
gsrj-21	79	20	,	,	PUNCT
gsrj-21	79	21	a	a	DET
gsrj-21	79	22	protein	protein	NOUN
gsrj-21	79	23	known	know	VERB
gsrj-21	79	24	to	to	PART
gsrj-21	79	25	induce	induce	VERB
gsrj-21	79	26	cancer	cancer	NOUN
gsrj-21	79	27	-	-	PUNCT
gsrj-21	79	28	associated	associate	VERB
gsrj-21	79	29	fibroblast	fibroblast	ADJ
gsrj-21	79	30	activation	activation	NOUN
gsrj-21	79	31	in	in	ADP
gsrj-21	79	32	liver	liver	NOUN
gsrj-21	79	33	and	and	CCONJ
gsrj-21	79	34	breast	breast	NOUN
gsrj-21	79	35	tissues	tissue	NOUN
gsrj-21	79	36	,	,	PUNCT
gsrj-21	79	37	in	in	ADP
gsrj-21	79	38	pscs.82	pscs.82	VERB
gsrj-21	79	39	a	a	DET
gsrj-21	79	40	co	co	NOUN
gsrj-21	79	41	-	-	NOUN
gsrj-21	79	42	culture	culture	NOUN
gsrj-21	79	43	with	with	ADP
gsrj-21	79	44	miapaca-2	miapaca-2	PROPN
gsrj-21	79	45	and	and	CCONJ
gsrj-21	79	46	human	human	ADJ
gsrj-21	79	47	pscs	psc	NOUN
gsrj-21	79	48	from	from	ADP
gsrj-21	79	49	residual	residual	ADJ
gsrj-21	79	50	surgical	surgical	ADJ
gsrj-21	79	51	specimens	specimen	NOUN
gsrj-21	79	52	revealed	reveal	VERB
gsrj-21	79	53	that	that	SCONJ
gsrj-21	79	54	yap1	yap1	PROPN
gsrj-21	79	55	may	may	AUX
gsrj-21	79	56	play	play	VERB
gsrj-21	79	57	a	a	DET
gsrj-21	79	58	critical	critical	ADJ
gsrj-21	79	59	role	role	NOUN
gsrj-21	79	60	in	in	ADP
gsrj-21	79	61	the	the	DET
gsrj-21	79	62	regulation	regulation	NOUN
gsrj-21	79	63	of	of	ADP
gsrj-21	79	64	psc	psc	NOUN
gsrj-21	79	65	activation	activation	NOUN
gsrj-21	79	66	,	,	PUNCT
gsrj-21	79	67	indicating	indicate	VERB
gsrj-21	79	68	a	a	DET
gsrj-21	79	69	novel	novel	ADJ
gsrj-21	79	70	rationale	rationale	NOUN
gsrj-21	79	71	for	for	ADP
gsrj-21	79	72	targeting	target	VERB
gsrj-21	79	73	yap1	yap1	NOUN
gsrj-21	79	74	to	to	PART
gsrj-21	79	75	reprogram	reprogram	VERB
gsrj-21	79	76	the	the	DET
gsrj-21	79	77	pdac	pdac	NOUN
gsrj-21	79	78	microenvironment.82	microenvironment.82	NOUN
gsrj-21	79	79	in	in	ADP
gsrj-21	79	80	addition	addition	NOUN
gsrj-21	79	81	to	to	ADP
gsrj-21	79	82	yap1	yap1	PROPN
gsrj-21	79	83	,	,	PUNCT
gsrj-21	79	84	it	it	PRON
gsrj-21	79	85	is	be	AUX
gsrj-21	79	86	speculated	speculate	VERB
gsrj-21	79	87	that	that	SCONJ
gsrj-21	79	88	secreted	secrete	VERB
gsrj-21	79	89	protein	protein	NOUN
gsrj-21	79	90	acidic	acidic	ADJ
gsrj-21	79	91	and	and	CCONJ
gsrj-21	79	92	cysteine	cysteine	NOUN
gsrj-21	79	93	-	-	PUNCT
gsrj-21	79	94	rich	rich	ADJ
gsrj-21	79	95	(	(	PUNCT
gsrj-21	79	96	sparc	sparc	NOUN
gsrj-21	79	97	)	)	PUNCT
gsrj-21	79	98	,	,	PUNCT
gsrj-21	79	99	a	a	DET
gsrj-21	79	100	matricellular	matricellular	ADJ
gsrj-21	79	101	glycoprotein	glycoprotein	NOUN
gsrj-21	79	102	used	use	VERB
gsrj-21	79	103	in	in	ADP
gsrj-21	79	104	ecm	ecm	PROPN
gsrj-21	79	105	assembly	assembly	NOUN
gsrj-21	79	106	and	and	CCONJ
gsrj-21	79	107	cellmatrix	cellmatrix	NOUN
gsrj-21	79	108	communication	communication	NOUN
gsrj-21	79	109	during	during	ADP
gsrj-21	79	110	tumor	tumor	NOUN
gsrj-21	79	111	progression	progression	NOUN
gsrj-21	79	112	,	,	PUNCT
gsrj-21	79	113	may	may	AUX
gsrj-21	79	114	also	also	ADV
gsrj-21	79	115	be	be	AUX
gsrj-21	79	116	related	relate	VERB
gsrj-21	79	117	to	to	ADP
gsrj-21	79	118	psc	psc	NOUN
gsrj-21	79	119	activation	activation	NOUN
gsrj-21	79	120	.	.	PUNCT
gsrj-21	80	1	high	high	ADJ
gsrj-21	80	2	levels	level	NOUN
gsrj-21	80	3	of	of	ADP
gsrj-21	80	4	sparc	sparc	NOUN
gsrj-21	80	5	expression	expression	NOUN
gsrj-21	80	6	in	in	ADP
gsrj-21	80	7	stromal	stromal	ADJ
gsrj-21	80	8	cells	cell	NOUN
gsrj-21	80	9	indicated	indicate	VERB
gsrj-21	80	10	poor	poor	ADJ
gsrj-21	80	11	prognosis	prognosis	NOUN
gsrj-21	80	12	of	of	ADP
gsrj-21	80	13	pdac	pdac	NOUN
gsrj-21	80	14	patients	patient	NOUN
gsrj-21	80	15	and	and	CCONJ
gsrj-21	80	16	acted	act	VERB
gsrj-21	80	17	as	as	ADP
gsrj-21	80	18	a	a	DET
gsrj-21	80	19	negative	negative	ADJ
gsrj-21	80	20	predictive	predictive	ADJ
gsrj-21	80	21	biomarker	biomarker	NOUN
gsrj-21	80	22	in	in	ADP
gsrj-21	80	23	patients	patient	NOUN
gsrj-21	80	24	treated	treat	VERB
gsrj-21	80	25	with	with	ADP
gsrj-21	80	26	gem	gem	NOUN
gsrj-21	80	27	based	base	VERB
gsrj-21	80	28	chemotherapy.81	chemotherapy.81	NOUN
gsrj-21	80	29	new	new	ADJ
gsrj-21	80	30	cell	cell	NOUN
gsrj-21	80	31	lines	line	NOUN
gsrj-21	80	32	,	,	PUNCT
gsrj-21	80	33	of	of	ADP
gsrj-21	80	34	human	human	ADJ
gsrj-21	80	35	and	and	CCONJ
gsrj-21	80	36	murine	murine	ADJ
gsrj-21	80	37	origin	origin	NOUN
gsrj-21	80	38	,	,	PUNCT
gsrj-21	80	39	are	be	AUX
gsrj-21	80	40	continually	continually	ADV
gsrj-21	80	41	being	be	AUX
gsrj-21	80	42	established	establish	VERB
gsrj-21	80	43	and	and	CCONJ
gsrj-21	80	44	characterized	characterize	VERB
gsrj-21	80	45	for	for	ADP
gsrj-21	80	46	use	use	NOUN
gsrj-21	80	47	in	in	ADP
gsrj-21	80	48	screening	screen	VERB
gsrj-21	80	49	novel	novel	ADJ
gsrj-21	80	50	drug	drug	NOUN
gsrj-21	80	51	candidates	candidate	NOUN
gsrj-21	80	52	and	and	CCONJ
gsrj-21	80	53	elucidating	elucidate	VERB
gsrj-21	80	54	signaling	signal	VERB
gsrj-21	80	55	pathways	pathway	NOUN
gsrj-21	80	56	or	or	CCONJ
gsrj-21	80	57	(	(	PUNCT
gsrj-21	80	58	epi)genetic	epi)genetic	ADJ
gsrj-21	80	59	events	event	NOUN
gsrj-21	80	60	involved	involve	VERB
gsrj-21	80	61	in	in	ADP
gsrj-21	80	62	tumor	tumor	NOUN
gsrj-21	80	63	development	development	NOUN
gsrj-21	80	64	,	,	PUNCT
gsrj-21	80	65	progression	progression	NOUN
gsrj-21	80	66	,	,	PUNCT
gsrj-21	80	67	and	and	CCONJ
gsrj-21	80	68	the	the	DET
gsrj-21	80	69	outcomes	outcome	NOUN
gsrj-21	80	70	of	of	ADP
gsrj-21	80	71	therapy.55	therapy.55	NOUN
gsrj-21	80	72	4.1.2	4.1.2	NUM
gsrj-21	80	73	gemcitabine	gemcitabine	NOUN
gsrj-21	80	74	resistance	resistance	NOUN
gsrj-21	80	75	and	and	CCONJ
gsrj-21	80	76	conditionally	conditionally	ADV
gsrj-21	80	77	reprogrammed	reprogramme	VERB
gsrj-21	80	78	cell	cell	NOUN
gsrj-21	80	79	lines	line	NOUN
gsrj-21	80	80	studies	study	NOUN
gsrj-21	80	81	on	on	ADP
gsrj-21	80	82	pdac	pdac	NOUN
gsrj-21	80	83	crcs	crcs	PROPN
gsrj-21	80	84	have	have	AUX
gsrj-21	80	85	been	be	AUX
gsrj-21	80	86	investigated	investigate	VERB
gsrj-21	80	87	with	with	ADP
gsrj-21	80	88	nab	nab	NOUN
gsrj-21	80	89	-	-	PUNCT
gsrj-21	80	90	paclitaxel	paclitaxel	NOUN
gsrj-21	80	91	,	,	PUNCT
gsrj-21	80	92	but	but	CCONJ
gsrj-21	80	93	not	not	PART
gsrj-21	80	94	gem.34	gem.34	NOUN
gsrj-21	80	95	drug	drug	NOUN
gsrj-21	80	96	sensitivity	sensitivity	NOUN
gsrj-21	80	97	screens	screen	NOUN
gsrj-21	80	98	were	be	AUX
gsrj-21	80	99	conducted	conduct	VERB
gsrj-21	80	100	for	for	ADP
gsrj-21	80	101	cultures	culture	NOUN
gsrj-21	80	102	of	of	ADP
gsrj-21	80	103	muscle	muscle	NOUN
gsrj-21	80	104	-	-	PUNCT
gsrj-21	80	105	invasive	invasive	ADJ
gsrj-21	80	106	bladder	bladder	NOUN
gsrj-21	80	107	cancer	cancer	NOUN
gsrj-21	80	108	that	that	PRON
gsrj-21	80	109	revealed	reveal	VERB
gsrj-21	80	110	sensitivity	sensitivity	NOUN
gsrj-21	80	111	to	to	ADP
gsrj-21	80	112	gem	gem	NOUN
gsrj-21	80	113	.	.	PUNCT
gsrj-21	81	1	these	these	DET
gsrj-21	81	2	results	result	NOUN
gsrj-21	81	3	showed	show	VERB
gsrj-21	81	4	that	that	SCONJ
gsrj-21	81	5	crcs	crcs	NOUN
gsrj-21	81	6	are	be	AUX
gsrj-21	81	7	a	a	DET
gsrj-21	81	8	feasible	feasible	ADJ
gsrj-21	81	9	platform	platform	NOUN
gsrj-21	81	10	for	for	ADP
gsrj-21	81	11	personalized	personalized	ADJ
gsrj-21	81	12	drug	drug	NOUN
gsrj-21	81	13	sensitivity	sensitivity	NOUN
gsrj-21	81	14	testing	testing	NOUN
gsrj-21	81	15	for	for	ADP
gsrj-21	81	16	bladder	bladder	NOUN
gsrj-21	81	17	cancer.83	cancer.83	NOUN
gsrj-21	81	18	4.2	4.2	NUM
gsrj-21	81	19	gemcitabine	gemcitabine	NOUN
gsrj-21	81	20	resistance	resistance	NOUN
gsrj-21	81	21	and	and	CCONJ
gsrj-21	81	22	3d	3d	NOUN
gsrj-21	81	23	models	model	NOUN
gsrj-21	81	24	the	the	DET
gsrj-21	81	25	application	application	NOUN
gsrj-21	81	26	of	of	ADP
gsrj-21	81	27	3d	3d	PROPN
gsrj-21	81	28	models	model	NOUN
gsrj-21	81	29	has	have	AUX
gsrj-21	81	30	been	be	AUX
gsrj-21	81	31	a	a	DET
gsrj-21	81	32	growing	grow	VERB
gsrj-21	81	33	trend	trend	NOUN
gsrj-21	81	34	in	in	ADP
gsrj-21	81	35	pdac	pdac	NOUN
gsrj-21	81	36	studies	study	NOUN
gsrj-21	81	37	,	,	PUNCT
gsrj-21	81	38	especially	especially	ADV
gsrj-21	81	39	with	with	ADP
gsrj-21	81	40	developing	develop	VERB
gsrj-21	81	41	models	model	NOUN
gsrj-21	81	42	for	for	ADP
gsrj-21	81	43	drug	drug	NOUN
gsrj-21	81	44	screening	screening	NOUN
gsrj-21	81	45	.	.	PUNCT
gsrj-21	82	1	oftentimes	oftentime	NOUN
gsrj-21	82	2	,	,	PUNCT
gsrj-21	82	3	chemotherapeutics	chemotherapeutic	NOUN
gsrj-21	82	4	that	that	PRON
gsrj-21	82	5	were	be	AUX
gsrj-21	82	6	effective	effective	ADJ
gsrj-21	82	7	in	in	ADP
gsrj-21	82	8	2d	2d	NUM
gsrj-21	82	9	models	model	NOUN
gsrj-21	82	10	do	do	AUX
gsrj-21	82	11	not	not	PART
gsrj-21	82	12	remain	remain	VERB
gsrj-21	82	13	effective	effective	ADJ
gsrj-21	82	14	in	in	ADP
gsrj-21	82	15	3d	3d	PROPN
gsrj-21	82	16	models	model	NOUN
gsrj-21	82	17	.	.	PUNCT
gsrj-21	83	1	different	different	ADJ
gsrj-21	83	2	ic50	ic50	PROPN
gsrj-21	83	3	values	value	NOUN
gsrj-21	83	4	between	between	ADP
gsrj-21	83	5	2d	2d	NUM
gsrj-21	83	6	and	and	CCONJ
gsrj-21	83	7	3d	3d	NUM
gsrj-21	83	8	models	model	NOUN
gsrj-21	83	9	point	point	VERB
gsrj-21	83	10	to	to	ADP
gsrj-21	83	11	the	the	DET
gsrj-21	83	12	clear	clear	ADJ
gsrj-21	83	13	discrepancy	discrepancy	NOUN
gsrj-21	83	14	between	between	ADP
gsrj-21	83	15	the	the	DET
gsrj-21	83	16	commonly	commonly	ADV
gsrj-21	83	17	used	use	VERB
gsrj-21	83	18	2d	2d	NUM
gsrj-21	83	19	drug	drug	NOUN
gsrj-21	83	20	screening	screening	NOUN
gsrj-21	83	21	versus	versus	ADP
gsrj-21	83	22	the	the	DET
gsrj-21	83	23	more	more	ADV
gsrj-21	83	24	complex	complex	ADJ
gsrj-21	83	25	3d	3d	NOUN
gsrj-21	83	26	and	and	CCONJ
gsrj-21	83	27	co	co	NOUN
gsrj-21	83	28	-	-	NOUN
gsrj-21	83	29	culture	culture	NOUN
gsrj-21	83	30	models	model	NOUN
gsrj-21	83	31	.	.	PUNCT
gsrj-21	84	1	furthermore	furthermore	ADV
gsrj-21	84	2	,	,	PUNCT
gsrj-21	84	3	2d	2d	NUM
gsrj-21	84	4	cell	cell	NOUN
gsrj-21	84	5	culture	culture	NOUN
gsrj-21	84	6	is	be	AUX
gsrj-21	84	7	known	know	VERB
gsrj-21	84	8	to	to	PART
gsrj-21	84	9	not	not	PART
gsrj-21	84	10	fully	fully	ADV
gsrj-21	84	11	recapitulate	recapitulate	VERB
gsrj-21	84	12	tumor	tumor	NOUN
gsrj-21	84	13	biology.73	biology.73	PROPN
gsrj-21	84	14	3d	3d	PROPN
gsrj-21	84	15	culture	culture	NOUN
gsrj-21	84	16	models	model	NOUN
gsrj-21	84	17	better	well	ADV
gsrj-21	84	18	reflect	reflect	VERB
gsrj-21	84	19	actual	actual	ADJ
gsrj-21	84	20	tumor	tumor	NOUN
gsrj-21	84	21	drug	drug	NOUN
gsrj-21	84	22	responses	response	NOUN
gsrj-21	84	23	and	and	CCONJ
gsrj-21	84	24	aid	aid	NOUN
gsrj-21	84	25	in	in	ADP
gsrj-21	84	26	the	the	DET
gsrj-21	84	27	identification	identification	NOUN
gsrj-21	84	28	of	of	ADP
gsrj-21	84	29	novel	novel	ADJ
gsrj-21	84	30	compounds	compound	NOUN
gsrj-21	84	31	that	that	PRON
gsrj-21	84	32	are	be	AUX
gsrj-21	84	33	more	more	ADV
gsrj-21	84	34	effective.76	effective.76	PROPN
gsrj-21	84	35	differences	difference	NOUN
gsrj-21	84	36	between	between	ADP
gsrj-21	84	37	pancreatic	pancreatic	ADJ
gsrj-21	84	38	cell	cell	NOUN
gsrj-21	84	39	lines	line	NOUN
gsrj-21	84	40	in	in	ADP
gsrj-21	84	41	the	the	DET
gsrj-21	84	42	morphology	morphology	NOUN
gsrj-21	84	43	of	of	ADP
gsrj-21	84	44	both	both	CCONJ
gsrj-21	84	45	2d	2d	NOUN
gsrj-21	84	46	and	and	CCONJ
gsrj-21	84	47	3d	3d	NUM
gsrj-21	84	48	cultures	culture	NOUN
gsrj-21	84	49	can	can	AUX
gsrj-21	84	50	be	be	AUX
gsrj-21	84	51	attributed	attribute	VERB
gsrj-21	84	52	to	to	ADP
gsrj-21	84	53	differences	difference	NOUN
gsrj-21	84	54	in	in	ADP
gsrj-21	84	55	origination	origination	NOUN
gsrj-21	84	56	site	site	NOUN
gsrj-21	84	57	.	.	PUNCT
gsrj-21	85	1	bxpc-3	bxpc-3	PRON
gsrj-21	85	2	obtained	obtain	VERB
gsrj-21	85	3	from	from	ADP
gsrj-21	85	4	pdac	pdac	NOUN
gsrj-21	85	5	lacks	lack	NOUN
gsrj-21	85	6	metastatic	metastatic	ADJ
gsrj-21	85	7	potential	potential	NOUN
gsrj-21	85	8	,	,	PUNCT
gsrj-21	85	9	while	while	SCONJ
gsrj-21	85	10	miapaca-2	miapaca-2	PROPN
gsrj-21	85	11	and	and	CCONJ
gsrj-21	85	12	panc-1	panc-1	NOUN
gsrj-21	85	13	,	,	PUNCT
gsrj-21	85	14	both	both	PRON
gsrj-21	85	15	of	of	ADP
gsrj-21	85	16	which	which	PRON
gsrj-21	85	17	are	be	AUX
gsrj-21	85	18	also	also	ADV
gsrj-21	85	19	derived	derive	VERB
gsrj-21	85	20	from	from	ADP
gsrj-21	85	21	pdac	pdac	NOUN
gsrj-21	85	22	,	,	PUNCT
gsrj-21	85	23	demonstrate	demonstrate	VERB
gsrj-21	85	24	a	a	DET
gsrj-21	85	25	predisposition	predisposition	NOUN
gsrj-21	85	26	to	to	ADP
gsrj-21	85	27	metastasis.84	metastasis.84	ADV
gsrj-21	85	28	colo-357	colo-357	ADV
gsrj-21	85	29	and	and	CCONJ
gsrj-21	85	30	aspc	aspc	NOUN
gsrj-21	85	31	are	be	AUX
gsrj-21	85	32	obtained	obtain	VERB
gsrj-21	85	33	from	from	ADP
gsrj-21	85	34	metastatic	metastatic	ADJ
gsrj-21	85	35	sites	site	NOUN
gsrj-21	85	36	,	,	PUNCT
gsrj-21	85	37	while	while	SCONJ
gsrj-21	85	38	t3m4	t3m4	NUM
gsrj-21	85	39	cells	cell	NOUN
gsrj-21	85	40	are	be	AUX
gsrj-21	85	41	derived	derive	VERB
gsrj-21	85	42	from	from	ADP
gsrj-21	85	43	the	the	DET
gsrj-21	85	44	lymph	lymph	NOUN
gsrj-21	85	45	node	node	ADJ
gsrj-21	85	46	metastatic	metastatic	ADJ
gsrj-21	85	47	mass	mass	NOUN
gsrj-21	85	48	and	and	CCONJ
gsrj-21	85	49	resemble	resemble	VERB
gsrj-21	85	50	bxpc-3.84	bxpc-3.84	PROPN
gsrj-21	85	51	many	many	ADJ
gsrj-21	85	52	models	model	NOUN
gsrj-21	85	53	are	be	AUX
gsrj-21	85	54	based	base	VERB
gsrj-21	85	55	on	on	ADP
gsrj-21	85	56	co	co	NOUN
gsrj-21	85	57	-	-	NOUN
gsrj-21	85	58	cultures	culture	NOUN
gsrj-21	85	59	with	with	ADP
gsrj-21	85	60	other	other	ADJ
gsrj-21	85	61	cell	cell	NOUN
gsrj-21	85	62	types	type	NOUN
gsrj-21	85	63	or	or	CCONJ
gsrj-21	85	64	cells	cell	NOUN
gsrj-21	85	65	believed	believe	VERB
gsrj-21	85	66	to	to	PART
gsrj-21	85	67	contribute	contribute	VERB
gsrj-21	85	68	to	to	ADP
gsrj-21	85	69	the	the	DET
gsrj-21	85	70	transformed	transform	VERB
gsrj-21	85	71	phenotype	phenotype	NOUN
gsrj-21	85	72	and	and	CCONJ
gsrj-21	85	73	invasiveness	invasiveness	NOUN
gsrj-21	85	74	of	of	ADP
gsrj-21	85	75	the	the	DET
gsrj-21	85	76	51	51	NUM
gsrj-21	85	77	georgetown	georgetown	PROPN
gsrj-21	85	78	scientific	scientific	ADJ
gsrj-21	85	79	research	research	NOUN
gsrj-21	85	80	journal	journal	NOUN
gsrj-21	85	81	cells	cell	NOUN
gsrj-21	85	82	.	.	PUNCT
gsrj-21	86	1	notably	notably	ADV
gsrj-21	86	2	,	,	PUNCT
gsrj-21	86	3	stromal	stromal	ADJ
gsrj-21	86	4	-	-	PUNCT
gsrj-21	86	5	tumor	tumor	NOUN
gsrj-21	86	6	cell	cell	NOUN
gsrj-21	86	7	interactions	interaction	NOUN
gsrj-21	86	8	are	be	AUX
gsrj-21	86	9	actively	actively	ADV
gsrj-21	86	10	studied	study	VERB
gsrj-21	86	11	in	in	ADP
gsrj-21	86	12	pdac	pdac	NOUN
gsrj-21	86	13	drug	drug	NOUN
gsrj-21	86	14	resistance.72	resistance.72	PROPN
gsrj-21	86	15	recent	recent	ADJ
gsrj-21	86	16	research	research	NOUN
gsrj-21	86	17	considers	consider	VERB
gsrj-21	86	18	the	the	DET
gsrj-21	86	19	tumor	tumor	NOUN
gsrj-21	86	20	microenvironment	microenvironment	NOUN
gsrj-21	86	21	that	that	PRON
gsrj-21	86	22	has	have	AUX
gsrj-21	86	23	been	be	AUX
gsrj-21	86	24	associated	associate	VERB
gsrj-21	86	25	with	with	ADP
gsrj-21	86	26	metastatic	metastatic	ADJ
gsrj-21	86	27	progression	progression	NOUN
gsrj-21	86	28	and	and	CCONJ
gsrj-21	86	29	vascularization	vascularization	NOUN
gsrj-21	86	30	.	.	PUNCT
gsrj-21	87	1	these	these	DET
gsrj-21	87	2	complex	complex	ADJ
gsrj-21	87	3	systems	system	NOUN
gsrj-21	87	4	are	be	AUX
gsrj-21	87	5	easier	easy	ADJ
gsrj-21	87	6	to	to	PART
gsrj-21	87	7	model	model	VERB
gsrj-21	87	8	using	use	VERB
gsrj-21	87	9	3d	3d	NUM
gsrj-21	87	10	structures	structure	NOUN
gsrj-21	87	11	,	,	PUNCT
gsrj-21	87	12	such	such	ADJ
gsrj-21	87	13	as	as	ADP
gsrj-21	87	14	multicellular	multicellular	ADJ
gsrj-21	87	15	tumor	tumor	NOUN
gsrj-21	87	16	spheroids	spheroid	NOUN
gsrj-21	87	17	(	(	PUNCT
gsrj-21	87	18	mcts	mcts	PROPN
gsrj-21	87	19	)	)	PUNCT
gsrj-21	87	20	84	84	NUM
gsrj-21	87	21	and	and	CCONJ
gsrj-21	87	22	organoids.6	organoids.6	NOUN
gsrj-21	87	23	while	while	SCONJ
gsrj-21	87	24	spheroids	spheroid	NOUN
gsrj-21	87	25	and	and	CCONJ
gsrj-21	87	26	organoids	organoid	NOUN
gsrj-21	87	27	both	both	PRON
gsrj-21	87	28	form	form	VERB
gsrj-21	87	29	3d	3d	NUM
gsrj-21	87	30	models	model	NOUN
gsrj-21	87	31	,	,	PUNCT
gsrj-21	87	32	they	they	PRON
gsrj-21	87	33	differ	differ	VERB
gsrj-21	87	34	in	in	ADP
gsrj-21	87	35	their	their	PRON
gsrj-21	87	36	morphology	morphology	NOUN
gsrj-21	87	37	.	.	PUNCT
gsrj-21	88	1	derived	derive	VERB
gsrj-21	88	2	from	from	ADP
gsrj-21	88	3	tissue	tissue	NOUN
gsrj-21	88	4	or	or	CCONJ
gsrj-21	88	5	cancer	cancer	NOUN
gsrj-21	88	6	stem	stem	NOUN
gsrj-21	88	7	cells	cell	NOUN
gsrj-21	88	8	,	,	PUNCT
gsrj-21	88	9	spheroids	spheroid	NOUN
gsrj-21	88	10	grow	grow	VERB
gsrj-21	88	11	in	in	ADP
gsrj-21	88	12	a	a	DET
gsrj-21	88	13	minimum	minimum	ADJ
gsrj-21	88	14	serum	serum	NOUN
gsrj-21	88	15	-	-	PUNCT
gsrj-21	88	16	free	free	ADJ
gsrj-21	88	17	medium	medium	NOUN
gsrj-21	88	18	.	.	PUNCT
gsrj-21	89	1	they	they	PRON
gsrj-21	89	2	trigger	trigger	VERB
gsrj-21	89	3	an	an	DET
gsrj-21	89	4	oxygen	oxygen	NOUN
gsrj-21	89	5	and	and	CCONJ
gsrj-21	89	6	nutrient	nutrient	NOUN
gsrj-21	89	7	gradient	gradient	NOUN
gsrj-21	89	8	that	that	PRON
gsrj-21	89	9	leads	lead	VERB
gsrj-21	89	10	to	to	ADP
gsrj-21	89	11	massive	massive	ADJ
gsrj-21	89	12	cell	cell	NOUN
gsrj-21	89	13	death	death	NOUN
gsrj-21	89	14	in	in	ADP
gsrj-21	89	15	the	the	DET
gsrj-21	89	16	center	center	NOUN
gsrj-21	89	17	of	of	ADP
gsrj-21	89	18	the	the	DET
gsrj-21	89	19	structure	structure	NOUN
gsrj-21	89	20	,	,	PUNCT
gsrj-21	89	21	which	which	PRON
gsrj-21	89	22	is	be	AUX
gsrj-21	89	23	why	why	SCONJ
gsrj-21	89	24	they	they	PRON
gsrj-21	89	25	can	can	AUX
gsrj-21	89	26	not	not	PART
gsrj-21	89	27	form	form	VERB
gsrj-21	89	28	tissue	tissue	NOUN
gsrj-21	89	29	-	-	PUNCT
gsrj-21	89	30	like	like	ADJ
gsrj-21	89	31	structures	structure	NOUN
gsrj-21	89	32	.	.	PUNCT
gsrj-21	90	1	in	in	ADP
gsrj-21	90	2	contrast	contrast	NOUN
gsrj-21	90	3	,	,	PUNCT
gsrj-21	90	4	organoids	organoid	NOUN
gsrj-21	90	5	require	require	VERB
gsrj-21	90	6	stem	stem	NOUN
gsrj-21	90	7	cell	cell	NOUN
gsrj-21	90	8	niche	niche	NOUN
gsrj-21	90	9	factors	factor	NOUN
gsrj-21	90	10	and	and	CCONJ
gsrj-21	90	11	extracellular	extracellular	ADJ
gsrj-21	90	12	matrices	matrix	NOUN
gsrj-21	90	13	,	,	PUNCT
gsrj-21	90	14	which	which	PRON
gsrj-21	90	15	allow	allow	VERB
gsrj-21	90	16	the	the	DET
gsrj-21	90	17	organoids	organoid	NOUN
gsrj-21	90	18	to	to	PART
gsrj-21	90	19	differentiate	differentiate	VERB
gsrj-21	90	20	and	and	CCONJ
gsrj-21	90	21	self	self	NOUN
gsrj-21	90	22	-	-	PUNCT
gsrj-21	90	23	organize	organize	NOUN
gsrj-21	90	24	.	.	PUNCT
gsrj-21	91	1	additionally	additionally	ADV
gsrj-21	91	2	,	,	PUNCT
gsrj-21	91	3	organoids	organoid	NOUN
gsrj-21	91	4	do	do	AUX
gsrj-21	91	5	not	not	PART
gsrj-21	91	6	exhibit	exhibit	VERB
gsrj-21	91	7	a	a	DET
gsrj-21	91	8	hypoxic	hypoxic	ADJ
gsrj-21	91	9	or	or	CCONJ
gsrj-21	91	10	nutrient	nutrient	ADJ
gsrj-21	91	11	gradient.85	gradient.85	NOUN
gsrj-21	91	12	4.2.1	4.2.1	NUM
gsrj-21	91	13	gemcitabine	gemcitabine	NOUN
gsrj-21	91	14	resistance	resistance	NOUN
gsrj-21	91	15	and	and	CCONJ
gsrj-21	91	16	tumor	tumor	NOUN
gsrj-21	91	17	spheroids	spheroid	NOUN
gsrj-21	91	18	mcts	mct	NOUN
gsrj-21	91	19	serve	serve	VERB
gsrj-21	91	20	as	as	ADP
gsrj-21	91	21	models	model	NOUN
gsrj-21	91	22	of	of	ADP
gsrj-21	91	23	pdac	pdac	ADJ
gsrj-21	91	24	tumors	tumor	NOUN
gsrj-21	91	25	superior	superior	ADJ
gsrj-21	91	26	to	to	ADP
gsrj-21	91	27	flat	flat	ADJ
gsrj-21	91	28	cell	cell	NOUN
gsrj-21	91	29	monolayers	monolayer	NOUN
gsrj-21	91	30	(	(	PUNCT
gsrj-21	91	31	2d	2d	NUM
gsrj-21	91	32	cultures	culture	NOUN
gsrj-21	91	33	)	)	PUNCT
gsrj-21	91	34	due	due	ADP
gsrj-21	91	35	to	to	ADP
gsrj-21	91	36	different	different	ADJ
gsrj-21	91	37	geometry	geometry	NOUN
gsrj-21	91	38	that	that	PRON
gsrj-21	91	39	leads	lead	VERB
gsrj-21	91	40	to	to	ADP
gsrj-21	91	41	changes	change	NOUN
gsrj-21	91	42	in	in	ADP
gsrj-21	91	43	nutrient	nutrient	NOUN
gsrj-21	91	44	and	and	CCONJ
gsrj-21	91	45	oxygen	oxygen	NOUN
gsrj-21	91	46	turnover	turnover	NOUN
gsrj-21	91	47	as	as	ADV
gsrj-21	91	48	well	well	ADV
gsrj-21	91	49	as	as	ADP
gsrj-21	91	50	cell	cell	NOUN
gsrj-21	91	51	crosstalk	crosstalk	NOUN
gsrj-21	91	52	.	.	PUNCT
gsrj-21	92	1	current	current	ADJ
gsrj-21	92	2	mcts	mct	NOUN
gsrj-21	92	3	models	model	NOUN
gsrj-21	92	4	are	be	AUX
gsrj-21	92	5	derived	derive	VERB
gsrj-21	92	6	from	from	ADP
gsrj-21	92	7	several	several	ADJ
gsrj-21	92	8	epithelial	epithelial	ADJ
gsrj-21	92	9	cell	cell	NOUN
gsrj-21	92	10	lines	line	NOUN
gsrj-21	92	11	,	,	PUNCT
gsrj-21	92	12	including	include	VERB
gsrj-21	92	13	aspc-1	aspc-1	NOUN
gsrj-21	92	14	,	,	PUNCT
gsrj-21	92	15	bxpc-3	bxpc-3	PROPN
gsrj-21	92	16	,	,	PUNCT
gsrj-21	92	17	capan-1	capan-1	PROPN
gsrj-21	92	18	,	,	PUNCT
gsrj-21	92	19	miapaca-2	miapaca-2	PROPN
gsrj-21	92	20	,	,	PUNCT
gsrj-21	92	21	and	and	CCONJ
gsrj-21	92	22	panc-1.84	panc-1.84	PROPN
gsrj-21	92	23	svirshchevskaya	svirshchevskaya	NOUN
gsrj-21	93	1	et	et	PROPN
gsrj-21	93	2	al	al	PROPN
gsrj-21	93	3	.	.	PROPN
gsrj-21	93	4	identified	identify	VERB
gsrj-21	93	5	three	three	NUM
gsrj-21	93	6	types	type	NOUN
gsrj-21	93	7	of	of	ADP
gsrj-21	93	8	mcts	mct	NOUN
gsrj-21	93	9	:	:	PUNCT
gsrj-21	93	10	while	while	SCONJ
gsrj-21	93	11	type	type	VERB
gsrj-21	93	12	i	i	PRON
gsrj-21	93	13	,	,	PUNCT
gsrj-21	93	14	bxpc-3	bxpc-3	PROPN
gsrj-21	93	15	,	,	PUNCT
gsrj-21	93	16	and	and	CCONJ
gsrj-21	93	17	t3m4	t3m4	AUX
gsrj-21	93	18	formed	form	VERB
gsrj-21	93	19	a	a	DET
gsrj-21	93	20	small	small	ADJ
gsrj-21	93	21	number	number	NOUN
gsrj-21	93	22	of	of	ADP
gsrj-21	93	23	large	large	ADJ
gsrj-21	93	24	and	and	CCONJ
gsrj-21	93	25	dense	dense	ADJ
gsrj-21	93	26	spheroids	spheroid	NOUN
gsrj-21	93	27	,	,	PUNCT
gsrj-21	93	28	type	type	NOUN
gsrj-21	93	29	ii	ii	PROPN
gsrj-21	93	30	,	,	PUNCT
gsrj-21	93	31	colo-357	colo-357	ADV
gsrj-21	93	32	,	,	PUNCT
gsrj-21	93	33	and	and	CCONJ
gsrj-21	93	34	aspc-1	aspc-1	NOUN
gsrj-21	93	35	,	,	PUNCT
gsrj-21	93	36	generated	generate	VERB
gsrj-21	93	37	by	by	ADP
gsrj-21	93	38	e	e	NOUN
gsrj-21	93	39	-	-	NOUN
gsrj-21	93	40	cadherin	cadherin	NOUN
gsrj-21	93	41	contacts	contact	NOUN
gsrj-21	93	42	,	,	PUNCT
gsrj-21	93	43	formed	form	VERB
gsrj-21	93	44	multiple	multiple	ADJ
gsrj-21	93	45	and	and	CCONJ
gsrj-21	93	46	loose	loose	ADJ
gsrj-21	93	47	mcts	mct	NOUN
gsrj-21	93	48	of	of	ADP
gsrj-21	93	49	different	different	ADJ
gsrj-21	93	50	sizes84	sizes84	NOUN
gsrj-21	93	51	.	.	PUNCT
gsrj-21	94	1	type	type	NOUN
gsrj-21	94	2	iii	iii	PROPN
gsrj-21	94	3	,	,	PUNCT
gsrj-21	94	4	miapaca-2	miapaca-2	PROPN
gsrj-21	94	5	,	,	PUNCT
gsrj-21	94	6	and	and	CCONJ
gsrj-21	94	7	panc-1	panc-1	NOUN
gsrj-21	94	8	cells	cell	NOUN
gsrj-21	94	9	grew	grow	VERB
gsrj-21	94	10	as	as	ADP
gsrj-21	94	11	floating	float	VERB
gsrj-21	94	12	monolayer	monolayer	NOUN
gsrj-21	94	13	films	film	NOUN
gsrj-21	94	14	as	as	SCONJ
gsrj-21	94	15	they	they	PRON
gsrj-21	94	16	were	be	AUX
gsrj-21	94	17	unable	unable	ADJ
gsrj-21	94	18	to	to	PART
gsrj-21	94	19	form	form	VERB
gsrj-21	94	20	mcts	mct	NOUN
gsrj-21	94	21	.	.	PUNCT
gsrj-21	94	22	cell	cell	NOUN
gsrj-21	94	23	growth	growth	NOUN
gsrj-21	94	24	for	for	ADP
gsrj-21	94	25	these	these	DET
gsrj-21	94	26	3d	3d	ADJ
gsrj-21	94	27	cultures	culture	NOUN
gsrj-21	94	28	and	and	CCONJ
gsrj-21	94	29	monolayers	monolayer	NOUN
gsrj-21	94	30	revealed	reveal	VERB
gsrj-21	94	31	a	a	DET
gsrj-21	94	32	dramatic	dramatic	ADJ
gsrj-21	94	33	(	(	PUNCT
gsrj-21	94	34	2	2	NUM
gsrj-21	94	35	order	order	NOUN
gsrj-21	94	36	)	)	PUNCT
gsrj-21	94	37	reduction	reduction	NOUN
gsrj-21	94	38	in	in	ADP
gsrj-21	94	39	cell	cell	NOUN
gsrj-21	94	40	proliferation	proliferation	NOUN
gsrj-21	94	41	for	for	ADP
gsrj-21	94	42	3d	3d	NUM
gsrj-21	94	43	type	type	NOUN
gsrj-21	94	44	i	i	PRON
gsrj-21	94	45	cell	cell	NOUN
gsrj-21	94	46	line	line	NOUN
gsrj-21	94	47	cultures	culture	NOUN
gsrj-21	94	48	treated	treat	VERB
gsrj-21	94	49	with	with	ADP
gsrj-21	94	50	gem	gem	NOUN
gsrj-21	94	51	.	.	PUNCT
gsrj-21	95	1	drug	drug	NOUN
gsrj-21	95	2	resistance	resistance	NOUN
gsrj-21	95	3	in	in	ADP
gsrj-21	95	4	the	the	DET
gsrj-21	95	5	type	type	NOUN
gsrj-21	95	6	i	i	PRON
gsrj-21	95	7	3d	3d	NUM
gsrj-21	95	8	cultures	culture	NOUN
gsrj-21	95	9	was	be	AUX
gsrj-21	95	10	found	find	VERB
gsrj-21	95	11	to	to	PART
gsrj-21	95	12	be	be	AUX
gsrj-21	95	13	associated	associate	VERB
gsrj-21	95	14	with	with	ADP
gsrj-21	95	15	a	a	DET
gsrj-21	95	16	quiescent	quiescent	ADJ
gsrj-21	95	17	state	state	NOUN
gsrj-21	95	18	(	(	PUNCT
gsrj-21	95	19	decreased	decrease	VERB
gsrj-21	95	20	proliferation	proliferation	NOUN
gsrj-21	95	21	)	)	PUNCT
gsrj-21	95	22	and	and	CCONJ
gsrj-21	95	23	a	a	DET
gsrj-21	95	24	high	high	ADJ
gsrj-21	95	25	level	level	NOUN
gsrj-21	95	26	of	of	ADP
gsrj-21	95	27	spontaneous	spontaneous	ADJ
gsrj-21	95	28	apoptosis	apoptosis	NOUN
gsrj-21	95	29	in	in	ADP
gsrj-21	95	30	cells	cell	NOUN
gsrj-21	95	31	.	.	PUNCT
gsrj-21	96	1	meanwhile	meanwhile	ADV
gsrj-21	96	2	,	,	PUNCT
gsrj-21	96	3	type	type	NOUN
gsrj-21	96	4	ii	ii	PROPN
gsrj-21	96	5	and	and	CCONJ
gsrj-21	96	6	iii	iii	NUM
gsrj-21	96	7	mcts	mct	NOUN
gsrj-21	96	8	had	have	VERB
gsrj-21	96	9	comparable	comparable	ADJ
gsrj-21	96	10	sensitivity	sensitivity	NOUN
gsrj-21	96	11	to	to	ADP
gsrj-21	96	12	the	the	DET
gsrj-21	96	13	antitumor	antitumor	PROPN
gsrj-21	96	14	drugs	drug	NOUN
gsrj-21	96	15	.	.	PUNCT
gsrj-21	97	1	ware	ware	VERB
gsrj-21	97	2	et	et	PROPN
gsrj-21	97	3	al	al	PROPN
gsrj-21	97	4	.	.	PROPN
gsrj-21	98	1	describe	describe	VERB
gsrj-21	98	2	the	the	DET
gsrj-21	98	3	generation	generation	NOUN
gsrj-21	98	4	of	of	ADP
gsrj-21	98	5	a	a	DET
gsrj-21	98	6	3d	3d	NUM
gsrj-21	98	7	pdac	pdac	NOUN
gsrj-21	98	8	in	in	ADP
gsrj-21	98	9	vitro	vitro	X
gsrj-21	98	10	micro	micro	ADJ
gsrj-21	98	11	-	-	ADJ
gsrj-21	98	12	tumor	tumor	ADJ
gsrj-21	98	13	model	model	NOUN
gsrj-21	98	14	that	that	PRON
gsrj-21	98	15	encompasses	encompass	VERB
gsrj-21	98	16	a	a	DET
gsrj-21	98	17	stromal	stromal	ADJ
gsrj-21	98	18	component	component	NOUN
gsrj-21	98	19	using	use	VERB
gsrj-21	98	20	pscs	psc	NOUN
gsrj-21	98	21	,	,	PUNCT
gsrj-21	98	22	which	which	PRON
gsrj-21	98	23	are	be	AUX
gsrj-21	98	24	myofibroblast	myofibroblast	ADJ
gsrj-21	98	25	-	-	PUNCT
gsrj-21	98	26	like	like	ADJ
gsrj-21	98	27	cells	cell	NOUN
gsrj-21	98	28	located	locate	VERB
gsrj-21	98	29	in	in	ADP
gsrj-21	98	30	the	the	DET
gsrj-21	98	31	exocrine	exocrine	NOUN
gsrj-21	98	32	areas	area	NOUN
gsrj-21	98	33	of	of	ADP
gsrj-21	98	34	the	the	DET
gsrj-21	98	35	pancreas.62	pancreas.62	NOUN
gsrj-21	98	36	pscs	psc	NOUN
gsrj-21	98	37	play	play	VERB
gsrj-21	98	38	a	a	DET
gsrj-21	98	39	role	role	NOUN
gsrj-21	98	40	in	in	ADP
gsrj-21	98	41	normal	normal	ADJ
gsrj-21	98	42	pancreatic	pancreatic	ADJ
gsrj-21	98	43	architecture	architecture	NOUN
gsrj-21	98	44	as	as	SCONJ
gsrj-21	98	45	they	they	PRON
gsrj-21	98	46	secrete	secrete	VERB
gsrj-21	98	47	extracellular	extracellular	ADJ
gsrj-21	98	48	matrix	matrix	NOUN
gsrj-21	98	49	(	(	PUNCT
gsrj-21	98	50	ecm	ecm	NOUN
gsrj-21	98	51	)	)	PUNCT
gsrj-21	98	52	components	component	NOUN
gsrj-21	98	53	and	and	CCONJ
gsrj-21	98	54	are	be	AUX
gsrj-21	98	55	the	the	DET
gsrj-21	98	56	principal	principal	ADJ
gsrj-21	98	57	source	source	NOUN
gsrj-21	98	58	of	of	ADP
gsrj-21	98	59	fibrosis	fibrosis	NOUN
gsrj-21	98	60	in	in	ADP
gsrj-21	98	61	the	the	DET
gsrj-21	98	62	stroma	stroma	NOUN
gsrj-21	98	63	.	.	PUNCT
gsrj-21	99	1	additionally	additionally	ADV
gsrj-21	99	2	,	,	PUNCT
gsrj-21	99	3	sequestration	sequestration	NOUN
gsrj-21	99	4	of	of	ADP
gsrj-21	99	5	chemotherapeutic	chemotherapeutic	ADJ
gsrj-21	99	6	agents	agent	NOUN
gsrj-21	99	7	,	,	PUNCT
gsrj-21	99	8	such	such	ADJ
gsrj-21	99	9	as	as	ADP
gsrj-21	99	10	gem	gem	NOUN
gsrj-21	99	11	,	,	PUNCT
gsrj-21	99	12	occurs	occur	VERB
gsrj-21	99	13	in	in	ADP
gsrj-21	99	14	the	the	DET
gsrj-21	99	15	tumor	tumor	NOUN
gsrj-21	99	16	stroma	stroma	NOUN
gsrj-21	99	17	,	,	PUNCT
gsrj-21	99	18	effectively	effectively	ADV
gsrj-21	99	19	reducing	reduce	VERB
gsrj-21	99	20	the	the	DET
gsrj-21	99	21	amount	amount	NOUN
gsrj-21	99	22	of	of	ADP
gsrj-21	99	23	drug	drug	NOUN
gsrj-21	99	24	that	that	PRON
gsrj-21	99	25	can	can	AUX
gsrj-21	99	26	reach	reach	VERB
gsrj-21	99	27	cancer	cancer	NOUN
gsrj-21	99	28	cells	cell	NOUN
gsrj-21	99	29	.	.	PUNCT
gsrj-21	100	1	their	their	PRON
gsrj-21	100	2	pdac	pdac	ADJ
gsrj-21	100	3	stroma	stroma	NOUN
gsrj-21	100	4	spheroids	spheroid	NOUN
gsrj-21	100	5	model	model	NOUN
gsrj-21	100	6	presented	present	VERB
gsrj-21	100	7	decreased	decrease	VERB
gsrj-21	100	8	cytostaticity	cytostaticity	NOUN
gsrj-21	100	9	of	of	ADP
gsrj-21	100	10	gem	gem	NOUN
gsrj-21	100	11	when	when	SCONJ
gsrj-21	100	12	compared	compare	VERB
gsrj-21	100	13	with	with	ADP
gsrj-21	100	14	spheroids	spheroid	NOUN
gsrj-21	100	15	grown	grow	VERB
gsrj-21	100	16	without	without	ADP
gsrj-21	100	17	pscs	psc	NOUN
gsrj-21	100	18	.	.	PUNCT
gsrj-21	101	1	a	a	DET
gsrj-21	101	2	study	study	NOUN
gsrj-21	101	3	by	by	ADP
gsrj-21	101	4	lee	lee	PROPN
gsrj-21	101	5	et	et	PROPN
gsrj-21	101	6	al	al	PROPN
gsrj-21	101	7	.	.	PROPN
gsrj-21	101	8	corroborates	corroborate	VERB
gsrj-21	101	9	these	these	DET
gsrj-21	101	10	findings.86	findings.86	NOUN
gsrj-21	101	11	this	this	DET
gsrj-21	101	12	model	model	NOUN
gsrj-21	101	13	will	will	AUX
gsrj-21	101	14	allow	allow	VERB
gsrj-21	101	15	for	for	ADP
gsrj-21	101	16	improved	improved	ADJ
gsrj-21	101	17	knowledge	knowledge	NOUN
gsrj-21	101	18	of	of	ADP
gsrj-21	101	19	pdac	pdac	NOUN
gsrj-21	101	20	biology	biology	NOUN
gsrj-21	101	21	and	and	CCONJ
gsrj-21	101	22	can	can	AUX
gsrj-21	101	23	be	be	AUX
gsrj-21	101	24	used	use	VERB
gsrj-21	101	25	to	to	PART
gsrj-21	101	26	investigate	investigate	VERB
gsrj-21	101	27	pathways	pathway	NOUN
gsrj-21	101	28	that	that	PRON
gsrj-21	101	29	can	can	AUX
gsrj-21	101	30	be	be	AUX
gsrj-21	101	31	therapeutically	therapeutically	ADV
gsrj-21	101	32	targeted	target	VERB
gsrj-21	101	33	to	to	PART
gsrj-21	101	34	inhibit	inhibit	VERB
gsrj-21	101	35	psc	psc	ADJ
gsrj-21	101	36	activation	activation	NOUN
gsrj-21	101	37	and	and	CCONJ
gsrj-21	101	38	subsequent	subsequent	ADJ
gsrj-21	101	39	development	development	NOUN
gsrj-21	101	40	of	of	ADP
gsrj-21	101	41	fibrosis	fibrosis	NOUN
gsrj-21	101	42	in	in	ADP
gsrj-21	101	43	pdac	pdac	NOUN
gsrj-21	101	44	.	.	PUNCT
gsrj-21	102	1	4.2.2	4.2.2	NUM
gsrj-21	102	2	gemcitabine	gemcitabine	NOUN
gsrj-21	102	3	resistance	resistance	NOUN
gsrj-21	102	4	and	and	CCONJ
gsrj-21	102	5	organoids	organoid	NOUN
gsrj-21	102	6	pancreatic	pancreatic	ADJ
gsrj-21	102	7	ductal	ductal	ADJ
gsrj-21	102	8	organoids	organoid	NOUN
gsrj-21	102	9	are	be	AUX
gsrj-21	102	10	ex	ex	ADJ
gsrj-21	102	11	-	-	ADJ
gsrj-21	102	12	vivo	vivo	ADJ
gsrj-21	102	13	models	model	NOUN
gsrj-21	102	14	that	that	PRON
gsrj-21	102	15	can	can	AUX
gsrj-21	102	16	be	be	AUX
gsrj-21	102	17	established	establish	VERB
gsrj-21	102	18	using	use	VERB
gsrj-21	102	19	very	very	ADV
gsrj-21	102	20	small	small	ADJ
gsrj-21	102	21	biopsies	biopsy	NOUN
gsrj-21	102	22	,	,	PUNCT
gsrj-21	102	23	such	such	ADJ
gsrj-21	102	24	as	as	ADP
gsrj-21	102	25	fine	fine	ADJ
gsrj-21	102	26	-	-	PUNCT
gsrj-21	102	27	needle	needle	NOUN
gsrj-21	102	28	aspirates	aspirate	NOUN
gsrj-21	102	29	36,41	36,41	NUM
gsrj-21	102	30	and	and	CCONJ
gsrj-21	102	31	allow	allow	VERB
gsrj-21	102	32	for	for	ADP
gsrj-21	102	33	the	the	DET
gsrj-21	102	34	study	study	NOUN
gsrj-21	102	35	of	of	ADP
gsrj-21	102	36	localized	localized	ADJ
gsrj-21	102	37	,	,	PUNCT
gsrj-21	102	38	advanced	advanced	ADJ
gsrj-21	102	39	,	,	PUNCT
gsrj-21	102	40	and	and	CCONJ
gsrj-21	102	41	metastatic	metastatic	ADJ
gsrj-21	102	42	patients	patient	NOUN
gsrj-21	102	43	.	.	PUNCT
gsrj-21	103	1	boj	boj	NOUN
gsrj-21	103	2	et	et	PROPN
gsrj-21	103	3	al	al	PROPN
gsrj-21	103	4	.	.	PROPN
gsrj-21	103	5	established	establish	VERB
gsrj-21	103	6	organoid	organoid	NOUN
gsrj-21	103	7	models	model	NOUN
gsrj-21	103	8	from	from	ADP
gsrj-21	103	9	normal	normal	ADJ
gsrj-21	103	10	and	and	CCONJ
gsrj-21	103	11	malignant	malignant	ADJ
gsrj-21	103	12	murine	murine	ADJ
gsrj-21	103	13	and	and	CCONJ
gsrj-21	103	14	human	human	ADJ
gsrj-21	103	15	pancreas	pancreas	NOUN
gsrj-21	103	16	tissues	tissue	NOUN
gsrj-21	103	17	to	to	PART
gsrj-21	103	18	investigate	investigate	VERB
gsrj-21	103	19	the	the	DET
gsrj-21	103	20	pathogenesis	pathogenesis	NOUN
gsrj-21	103	21	and	and	CCONJ
gsrj-21	103	22	address	address	VERB
gsrj-21	103	23	the	the	DET
gsrj-21	103	24	deficiency	deficiency	NOUN
gsrj-21	103	25	in	in	ADP
gsrj-21	103	26	a	a	DET
gsrj-21	103	27	comprehensive	comprehensive	ADJ
gsrj-21	103	28	3d	3d	NUM
gsrj-21	103	29	cell	cell	NOUN
gsrj-21	103	30	culture	culture	NOUN
gsrj-21	103	31	model	model	NOUN
gsrj-21	103	32	of	of	ADP
gsrj-21	103	33	murine	murine	ADJ
gsrj-21	103	34	and	and	CCONJ
gsrj-21	103	35	human	human	ADJ
gsrj-21	103	36	pdac	pdac	NOUN
gsrj-21	103	37	progression.36	progression.36	NOUN
gsrj-21	103	38	this	this	DET
gsrj-21	103	39	model	model	NOUN
gsrj-21	103	40	was	be	AUX
gsrj-21	103	41	used	use	VERB
gsrj-21	103	42	to	to	PART
gsrj-21	103	43	identify	identify	VERB
gsrj-21	103	44	genetic	genetic	ADJ
gsrj-21	103	45	drivers	driver	NOUN
gsrj-21	103	46	,	,	PUNCT
gsrj-21	103	47	therapeutic	therapeutic	ADJ
gsrj-21	103	48	targets	target	NOUN
gsrj-21	103	49	,	,	PUNCT
gsrj-21	103	50	diagnostics	diagnostic	NOUN
gsrj-21	103	51	,	,	PUNCT
gsrj-21	103	52	and	and	CCONJ
gsrj-21	103	53	progression	progression	NOUN
gsrj-21	103	54	for	for	ADP
gsrj-21	103	55	pdac	pdac	NOUN
gsrj-21	103	56	.	.	PUNCT
gsrj-21	104	1	tiriac	tiriac	PROPN
gsrj-21	104	2	et	et	PROPN
gsrj-21	104	3	al	al	PROPN
gsrj-21	104	4	.	.	PROPN
gsrj-21	104	5	used	use	VERB
gsrj-21	104	6	eus	eus	PROPN
gsrj-21	104	7	fine	fine	ADJ
gsrj-21	104	8	-	-	PUNCT
gsrj-21	104	9	needle	needle	NOUN
gsrj-21	104	10	biopsy	biopsy	NOUN
gsrj-21	104	11	(	(	PUNCT
gsrj-21	104	12	eus	eus	PROPN
gsrj-21	104	13	-	-	PROPN
gsrj-21	104	14	fnb	fnb	NOUN
gsrj-21	104	15	)	)	PUNCT
gsrj-21	104	16	sampling	sample	VERB
gsrj-21	104	17	to	to	PART
gsrj-21	104	18	rapidly	rapidly	ADV
gsrj-21	104	19	establish	establish	VERB
gsrj-21	104	20	human	human	ADJ
gsrj-21	104	21	pdac	pdac	NOUN
gsrj-21	104	22	organoids	organoid	NOUN
gsrj-21	104	23	within	within	ADP
gsrj-21	104	24	2	2	NUM
gsrj-21	104	25	weeks	week	NOUN
gsrj-21	104	26	of	of	ADP
gsrj-21	104	27	the	the	DET
gsrj-21	104	28	eus	eus	NOUN
gsrj-21	104	29	procedure	procedure	NOUN
gsrj-21	104	30	and	and	CCONJ
gsrj-21	104	31	assessed	assess	VERB
gsrj-21	104	32	the	the	DET
gsrj-21	104	33	feasibility	feasibility	NOUN
gsrj-21	104	34	of	of	ADP
gsrj-21	104	35	this	this	DET
gsrj-21	104	36	model	model	NOUN
gsrj-21	104	37	in	in	ADP
gsrj-21	104	38	creating	create	VERB
gsrj-21	104	39	personalized	personalized	ADJ
gsrj-21	104	40	treatment	treatment	NOUN
gsrj-21	104	41	strategies	strategy	NOUN
gsrj-21	104	42	at	at	ADP
gsrj-21	104	43	the	the	DET
gsrj-21	104	44	time	time	NOUN
gsrj-21	104	45	of	of	ADP
gsrj-21	104	46	initial	initial	ADJ
gsrj-21	104	47	tumor	tumor	NOUN
gsrj-21	104	48	diagnosis	diagnosis	NOUN
gsrj-21	104	49	and	and	CCONJ
gsrj-21	104	50	over	over	ADP
gsrj-21	104	51	the	the	DET
gsrj-21	104	52	course	course	NOUN
gsrj-21	104	53	of	of	ADP
gsrj-21	104	54	a	a	DET
gsrj-21	104	55	patient	patient	NOUN
gsrj-21	104	56	’s	’s	PART
gsrj-21	104	57	treatment	treatment	NOUN
gsrj-21	104	58	.	.	PUNCT
gsrj-21	105	1	pdac	pdac	NOUN
gsrj-21	105	2	patients	patient	NOUN
gsrj-21	105	3	are	be	AUX
gsrj-21	105	4	ideal	ideal	ADJ
gsrj-21	105	5	for	for	ADP
gsrj-21	105	6	eus	eus	PROPN
gsrj-21	105	7	-	-	PROPN
gsrj-21	105	8	fnb	fnb	ADJ
gsrj-21	105	9	derived	derive	VERB
gsrj-21	105	10	organoids	organoid	NOUN
gsrj-21	105	11	as	as	SCONJ
gsrj-21	105	12	most	most	ADJ
gsrj-21	105	13	patients	patient	NOUN
gsrj-21	105	14	will	will	AUX
gsrj-21	105	15	not	not	PART
gsrj-21	105	16	undergo	undergo	VERB
gsrj-21	105	17	surgery	surgery	NOUN
gsrj-21	105	18	,	,	PUNCT
gsrj-21	105	19	all	all	DET
gsrj-21	105	20	patients	patient	NOUN
gsrj-21	105	21	need	need	VERB
gsrj-21	105	22	a	a	DET
gsrj-21	105	23	tissue	tissue	NOUN
gsrj-21	105	24	diagnosis	diagnosis	NOUN
gsrj-21	105	25	before	before	SCONJ
gsrj-21	105	26	therapies	therapy	NOUN
gsrj-21	105	27	are	be	AUX
gsrj-21	105	28	initiated	initiate	VERB
gsrj-21	105	29	,	,	PUNCT
gsrj-21	105	30	and	and	CCONJ
gsrj-21	105	31	only	only	ADV
gsrj-21	105	32	a	a	DET
gsrj-21	105	33	small	small	ADJ
gsrj-21	105	34	amount	amount	NOUN
gsrj-21	105	35	of	of	ADP
gsrj-21	105	36	tissue	tissue	NOUN
gsrj-21	105	37	is	be	AUX
gsrj-21	105	38	needed	need	VERB
gsrj-21	105	39	for	for	ADP
gsrj-21	105	40	organoid	organoid	NOUN
gsrj-21	105	41	creation	creation	NOUN
gsrj-21	105	42	.	.	PUNCT
gsrj-21	106	1	successful	successful	ADJ
gsrj-21	106	2	organoid	organoid	NOUN
gsrj-21	106	3	generation	generation	NOUN
gsrj-21	106	4	is	be	AUX
gsrj-21	106	5	52	52	NUM
gsrj-21	106	6	georgetown	georgetown	PROPN
gsrj-21	106	7	scientific	scientific	ADJ
gsrj-21	106	8	research	research	NOUN
gsrj-21	106	9	journal	journal	NOUN
gsrj-21	106	10	necessary	necessary	ADJ
gsrj-21	106	11	for	for	ADP
gsrj-21	106	12	developing	develop	VERB
gsrj-21	106	13	personalized	personalized	ADJ
gsrj-21	106	14	medicine	medicine	NOUN
gsrj-21	106	15	platforms	platform	NOUN
gsrj-21	106	16	for	for	ADP
gsrj-21	106	17	pdac	pdac	NOUN
gsrj-21	106	18	patients.41	patients.41	NOUN
gsrj-21	106	19	these	these	DET
gsrj-21	106	20	3d	3d	PROPN
gsrj-21	106	21	primary	primary	NOUN
gsrj-21	106	22	ex	ex	X
gsrj-21	106	23	vivo	vivo	NOUN
gsrj-21	106	24	culture	culture	NOUN
gsrj-21	106	25	systems	system	NOUN
gsrj-21	106	26	model	model	VERB
gsrj-21	106	27	a	a	DET
gsrj-21	106	28	spectrum	spectrum	NOUN
gsrj-21	106	29	of	of	ADP
gsrj-21	106	30	tumor	tumor	NOUN
gsrj-21	106	31	stages	stage	NOUN
gsrj-21	106	32	and	and	CCONJ
gsrj-21	106	33	have	have	AUX
gsrj-21	106	34	elucidated	elucidate	VERB
gsrj-21	106	35	important	important	ADJ
gsrj-21	106	36	disease	disease	NOUN
gsrj-21	106	37	progression	progression	NOUN
gsrj-21	106	38	findings	finding	NOUN
gsrj-21	106	39	.	.	PUNCT
gsrj-21	107	1	profiling	profiling	NOUN
gsrj-21	107	2	with	with	ADP
gsrj-21	107	3	next	next	ADJ
gsrj-21	107	4	-	-	PUNCT
gsrj-21	107	5	generation	generation	NOUN
gsrj-21	107	6	sequencing	sequencing	NOUN
gsrj-21	107	7	of	of	ADP
gsrj-21	107	8	dna	dna	NOUN
gsrj-21	107	9	and	and	CCONJ
gsrj-21	107	10	rna	rna	NOUN
gsrj-21	107	11	in	in	ADP
gsrj-21	107	12	combination	combination	NOUN
gsrj-21	107	13	with	with	ADP
gsrj-21	107	14	pharmacotyping	pharmacotyping	NOUN
gsrj-21	107	15	can	can	AUX
gsrj-21	107	16	be	be	AUX
gsrj-21	107	17	used	use	VERB
gsrj-21	107	18	to	to	PART
gsrj-21	107	19	predict	predict	VERB
gsrj-21	107	20	responses	response	NOUN
gsrj-21	107	21	in	in	ADP
gsrj-21	107	22	pdac	pdac	NOUN
gsrj-21	107	23	patients	patient	NOUN
gsrj-21	107	24	and	and	CCONJ
gsrj-21	107	25	provide	provide	VERB
gsrj-21	107	26	a	a	DET
gsrj-21	107	27	pathway	pathway	NOUN
gsrj-21	107	28	for	for	ADP
gsrj-21	107	29	prioritizing	prioritize	VERB
gsrj-21	107	30	therapy.87	therapy.87	NOUN
gsrj-21	107	31	4.2.3	4.2.3	NUM
gsrj-21	107	32	gemcitabine	gemcitabine	NOUN
gsrj-21	107	33	resistance	resistance	NOUN
gsrj-21	107	34	and	and	CCONJ
gsrj-21	107	35	tumor	tumor	NOUN
gsrj-21	107	36	-	-	PUNCT
gsrj-21	107	37	on	on	ADP
gsrj-21	107	38	-	-	PUNCT
gsrj-21	107	39	a	a	DET
gsrj-21	107	40	-	-	PUNCT
gsrj-21	107	41	chip	chip	NOUN
gsrj-21	107	42	to	to	PART
gsrj-21	107	43	overcome	overcome	VERB
gsrj-21	107	44	limitations	limitation	NOUN
gsrj-21	107	45	of	of	ADP
gsrj-21	107	46	traditional	traditional	ADJ
gsrj-21	107	47	disease	disease	NOUN
gsrj-21	107	48	model	model	NOUN
gsrj-21	107	49	systems	system	NOUN
gsrj-21	107	50	,	,	PUNCT
gsrj-21	107	51	organor	organor	PROPN
gsrj-21	107	52	tumor	tumor	NOUN
gsrj-21	107	53	-	-	PUNCT
gsrj-21	107	54	on	on	ADP
gsrj-21	107	55	-	-	PUNCT
gsrj-21	107	56	a	a	DET
gsrj-21	107	57	-	-	PUNCT
gsrj-21	107	58	chip	chip	NOUN
gsrj-21	107	59	systems	system	NOUN
gsrj-21	107	60	aim	aim	VERB
gsrj-21	107	61	to	to	PART
gsrj-21	107	62	fully	fully	ADV
gsrj-21	107	63	recapitulate	recapitulate	VERB
gsrj-21	107	64	the	the	DET
gsrj-21	107	65	physiology	physiology	NOUN
gsrj-21	107	66	and	and	CCONJ
gsrj-21	107	67	microenvironment	microenvironment	NOUN
gsrj-21	107	68	of	of	ADP
gsrj-21	107	69	tissues	tissue	NOUN
gsrj-21	107	70	through	through	ADP
gsrj-21	107	71	spatial	spatial	ADJ
gsrj-21	107	72	and	and	CCONJ
gsrj-21	107	73	fluid	fluid	ADJ
gsrj-21	107	74	control	control	NOUN
gsrj-21	107	75	of	of	ADP
gsrj-21	107	76	tissue	tissue	NOUN
gsrj-21	107	77	architecture	architecture	NOUN
gsrj-21	107	78	.	.	PUNCT
gsrj-21	108	1	kramer	kramer	PROPN
gsrj-21	108	2	et	et	PROPN
gsrj-21	108	3	al	al	PROPN
gsrj-21	108	4	.	.	PROPN
gsrj-21	108	5	examined	examine	VERB
gsrj-21	108	6	the	the	DET
gsrj-21	108	7	effect	effect	NOUN
gsrj-21	108	8	of	of	ADP
gsrj-21	108	9	interstitial	interstitial	ADJ
gsrj-21	108	10	flow	flow	NOUN
gsrj-21	108	11	on	on	ADP
gsrj-21	108	12	gem	gem	NOUN
gsrj-21	108	13	resistance	resistance	NOUN
gsrj-21	108	14	in	in	ADP
gsrj-21	108	15	pdac	pdac	NOUN
gsrj-21	108	16	using	use	VERB
gsrj-21	108	17	a	a	DET
gsrj-21	108	18	3d	3d	NUM
gsrj-21	108	19	microfluidic	microfluidic	ADJ
gsrj-21	108	20	platform	platform	NOUN
gsrj-21	108	21	.	.	PUNCT
gsrj-21	109	1	interstitial	interstitial	ADJ
gsrj-21	109	2	pressure	pressure	NOUN
gsrj-21	109	3	and	and	CCONJ
gsrj-21	109	4	flow	flow	NOUN
gsrj-21	109	5	are	be	AUX
gsrj-21	109	6	hallmarks	hallmark	NOUN
gsrj-21	109	7	of	of	ADP
gsrj-21	109	8	pdac	pdac	NOUN
gsrj-21	109	9	pathogenesis.73	pathogenesis.73	NOUN
gsrj-21	109	10	the	the	DET
gsrj-21	109	11	study	study	NOUN
gsrj-21	109	12	used	use	VERB
gsrj-21	109	13	3d	3d	NUM
gsrj-21	109	14	cultures	culture	NOUN
gsrj-21	109	15	of	of	ADP
gsrj-21	109	16	s2	s2	PROPN
gsrj-21	109	17	-	-	PUNCT
gsrj-21	109	18	028	028	NUM
gsrj-21	109	19	cells	cell	NOUN
gsrj-21	109	20	,	,	PUNCT
gsrj-21	109	21	a	a	DET
gsrj-21	109	22	nonmetastatic	nonmetastatic	ADJ
gsrj-21	109	23	pancreatic	pancreatic	ADJ
gsrj-21	109	24	cancer	cancer	NOUN
gsrj-21	109	25	line	line	NOUN
gsrj-21	109	26	,	,	PUNCT
gsrj-21	109	27	and	and	CCONJ
gsrj-21	109	28	found	find	VERB
gsrj-21	109	29	an	an	DET
gsrj-21	109	30	increase	increase	NOUN
gsrj-21	109	31	in	in	ADP
gsrj-21	109	32	mrna	mrna	PROPN
gsrj-21	109	33	expression	expression	NOUN
gsrj-21	109	34	of	of	ADP
gsrj-21	109	35	5	5	NUM
gsrj-21	109	36	multidrug	multidrug	NOUN
gsrj-21	109	37	resistance	resistance	NOUN
gsrj-21	109	38	proteins	protein	NOUN
gsrj-21	109	39	(	(	PUNCT
gsrj-21	109	40	mrps	mrps	PROPN
gsrj-21	109	41	)	)	PUNCT
gsrj-21	109	42	when	when	SCONJ
gsrj-21	109	43	the	the	DET
gsrj-21	109	44	pdac	pdac	NOUN
gsrj-21	109	45	cells	cell	NOUN
gsrj-21	109	46	were	be	AUX
gsrj-21	109	47	subjected	subject	VERB
gsrj-21	109	48	to	to	ADP
gsrj-21	109	49	interstitial	interstitial	ADJ
gsrj-21	109	50	flow	flow	NOUN
gsrj-21	109	51	.	.	PUNCT
gsrj-21	110	1	this	this	DET
gsrj-21	110	2	flowinduced	flowinduce	VERB
gsrj-21	110	3	mrp	mrp	NOUN
gsrj-21	110	4	expression	expression	NOUN
gsrj-21	110	5	hints	hint	NOUN
gsrj-21	110	6	towards	towards	ADP
gsrj-21	110	7	another	another	DET
gsrj-21	110	8	factor	factor	NOUN
gsrj-21	110	9	that	that	PRON
gsrj-21	110	10	contributes	contribute	VERB
gsrj-21	110	11	to	to	ADP
gsrj-21	110	12	gem	gem	NOUN
gsrj-21	110	13	resistance	resistance	NOUN
gsrj-21	110	14	via	via	ADP
gsrj-21	110	15	elevation	elevation	NOUN
gsrj-21	110	16	of	of	ADP
gsrj-21	110	17	drug	drug	NOUN
gsrj-21	110	18	efflux	efflux	NOUN
gsrj-21	110	19	transport	transport	NOUN
gsrj-21	110	20	.	.	PUNCT
gsrj-21	111	1	5	5	X
gsrj-21	111	2	.	.	X
gsrj-21	111	3	gemcitabine	gemcitabine	NOUN
gsrj-21	111	4	resistance	resistance	NOUN
gsrj-21	111	5	and	and	CCONJ
gsrj-21	111	6	in	in	ADP
gsrj-21	111	7	vivo	vivo	NOUN
gsrj-21	111	8	models	model	NOUN
gsrj-21	111	9	5.1	5.1	NUM
gsrj-21	111	10	gemcitabine	gemcitabine	NOUN
gsrj-21	111	11	resistance	resistance	NOUN
gsrj-21	111	12	and	and	CCONJ
gsrj-21	111	13	xenograft	xenograft	NOUN
gsrj-21	111	14	models	model	NOUN
gsrj-21	111	15	cell	cell	NOUN
gsrj-21	111	16	line	line	NOUN
gsrj-21	111	17	-	-	PUNCT
gsrj-21	111	18	derived	derive	VERB
gsrj-21	111	19	xenograft	xenograft	NOUN
gsrj-21	111	20	models	model	NOUN
gsrj-21	111	21	,	,	PUNCT
gsrj-21	111	22	such	such	ADJ
gsrj-21	111	23	as	as	ADP
gsrj-21	111	24	bxpc-3	bxpc-3	PROPN
gsrj-21	111	25	,	,	PUNCT
gsrj-21	111	26	miapaca-2	miapaca-2	PROPN
gsrj-21	111	27	,	,	PUNCT
gsrj-21	111	28	and	and	CCONJ
gsrj-21	111	29	panc-1	panc-1	NOUN
gsrj-21	111	30	xenografts	xenograft	NOUN
gsrj-21	111	31	,	,	PUNCT
gsrj-21	111	32	are	be	AUX
gsrj-21	111	33	popular	popular	ADJ
gsrj-21	111	34	for	for	ADP
gsrj-21	111	35	drug	drug	NOUN
gsrj-21	111	36	screening	screening	NOUN
gsrj-21	111	37	and	and	CCONJ
gsrj-21	111	38	resistance	resistance	NOUN
gsrj-21	111	39	studies	study	NOUN
gsrj-21	111	40	in	in	ADP
gsrj-21	111	41	pdac	pdac	NOUN
gsrj-21	111	42	that	that	PRON
gsrj-21	111	43	can	can	AUX
gsrj-21	111	44	be	be	AUX
gsrj-21	111	45	applied	apply	VERB
gsrj-21	111	46	to	to	ADP
gsrj-21	111	47	increasing	increase	VERB
gsrj-21	111	48	patient	patient	ADJ
gsrj-21	111	49	survival	survival	NOUN
gsrj-21	111	50	.	.	PUNCT
gsrj-21	112	1	novel	novel	ADJ
gsrj-21	112	2	tumor	tumor	NOUN
gsrj-21	112	3	growth	growth	NOUN
gsrj-21	112	4	-	-	PUNCT
gsrj-21	112	5	inhibiting	inhibit	VERB
gsrj-21	112	6	compounds	compound	NOUN
gsrj-21	112	7	derived	derive	VERB
gsrj-21	112	8	from	from	ADP
gsrj-21	112	9	gemcitabine	gemcitabine	NOUN
gsrj-21	112	10	have	have	AUX
gsrj-21	112	11	been	be	AUX
gsrj-21	112	12	applied	apply	VERB
gsrj-21	112	13	to	to	ADP
gsrj-21	112	14	panc-1	panc-1	NOUN
gsrj-21	112	15	and	and	CCONJ
gsrj-21	112	16	miapaca-2	miapaca-2	PROPN
gsrj-21	112	17	bearing	bear	VERB
gsrj-21	112	18	mice.88	mice.88	PROPN
gsrj-21	112	19	xenograft	xenograft	NOUN
gsrj-21	112	20	tumor	tumor	NOUN
gsrj-21	112	21	assays	assay	NOUN
gsrj-21	112	22	have	have	AUX
gsrj-21	112	23	demonstrated	demonstrate	VERB
gsrj-21	112	24	that	that	SCONJ
gsrj-21	112	25	the	the	DET
gsrj-21	112	26	tetracyclic	tetracyclic	NOUN
gsrj-21	112	27	diterpenoid	diterpenoid	PROPN
gsrj-21	112	28	compound	compound	NOUN
gsrj-21	112	29	ordonin	ordonin	NOUN
gsrj-21	112	30	overcomes	overcome	VERB
gsrj-21	112	31	gemcitabine	gemcitabine	NOUN
gsrj-21	112	32	resistance	resistance	NOUN
gsrj-21	112	33	in	in	ADP
gsrj-21	112	34	gemcitabine	gemcitabine	NOUN
gsrj-21	112	35	-	-	PUNCT
gsrj-21	112	36	resistant	resistant	ADJ
gsrj-21	112	37	panc-1	panc-1	NOUN
gsrj-21	112	38	cells	cell	NOUN
gsrj-21	112	39	(	(	PUNCT
gsrj-21	112	40	panc1	panc1	NOUN
gsrj-21	112	41	/	/	SYM
gsrj-21	112	42	gem	gem	NOUN
gsrj-21	112	43	)	)	PUNCT
gsrj-21	112	44	through	through	ADP
gsrj-21	112	45	suppressing	suppress	VERB
gsrj-21	112	46	tumorigenicity	tumorigenicity	NOUN
gsrj-21	112	47	in	in	ADP
gsrj-21	112	48	nude	nude	ADJ
gsrj-21	112	49	mice	mouse	NOUN
gsrj-21	112	50	.	.	PUNCT
gsrj-21	113	1	additionally	additionally	ADV
gsrj-21	113	2	,	,	PUNCT
gsrj-21	113	3	a	a	DET
gsrj-21	113	4	combination	combination	NOUN
gsrj-21	113	5	treatment	treatment	NOUN
gsrj-21	113	6	of	of	ADP
gsrj-21	113	7	oridonin	oridonin	NOUN
gsrj-21	113	8	and	and	CCONJ
gsrj-21	113	9	gemcitabine	gemcitabine	NOUN
gsrj-21	113	10	decreased	decrease	VERB
gsrj-21	113	11	tumor	tumor	NOUN
gsrj-21	113	12	growth.88	growth.88	ADJ
gsrj-21	113	13	gemcitabine	gemcitabine	NOUN
gsrj-21	113	14	resistance	resistance	NOUN
gsrj-21	113	15	is	be	AUX
gsrj-21	113	16	mediated	mediate	VERB
gsrj-21	113	17	by	by	ADP
gsrj-21	113	18	a	a	DET
gsrj-21	113	19	special	special	ADJ
gsrj-21	113	20	at	at	ADP
gsrj-21	113	21	-	-	PUNCT
gsrj-21	113	22	rich	rich	ADJ
gsrj-21	113	23	sequence	sequence	NOUN
gsrj-21	113	24	binding	bind	VERB
gsrj-21	113	25	protein	protein	NOUN
gsrj-21	113	26	1	1	NUM
gsrj-21	113	27	(	(	PUNCT
gsrj-21	113	28	satb-1	satb-1	NOUN
gsrj-21	113	29	)	)	PUNCT
gsrj-21	113	30	,	,	PUNCT
gsrj-21	113	31	a	a	DET
gsrj-21	113	32	chromatin	chromatin	NOUN
gsrj-21	113	33	organizer	organizer	NOUN
gsrj-21	113	34	that	that	PRON
gsrj-21	113	35	is	be	AUX
gsrj-21	113	36	secreted	secrete	VERB
gsrj-21	113	37	by	by	ADP
gsrj-21	113	38	cancer	cancer	NOUN
gsrj-21	113	39	-	-	PUNCT
gsrj-21	113	40	associated	associate	VERB
gsrj-21	113	41	fibroblasts	fibroblast	NOUN
gsrj-21	113	42	(	(	PUNCT
gsrj-21	113	43	cafs).89	cafs).89	PROPN
gsrj-21	113	44	satb1	satb1	PROPN
gsrj-21	113	45	plays	play	VERB
gsrj-21	113	46	a	a	DET
gsrj-21	113	47	vital	vital	ADJ
gsrj-21	113	48	role	role	NOUN
gsrj-21	113	49	in	in	ADP
gsrj-21	113	50	the	the	DET
gsrj-21	113	51	proliferation	proliferation	NOUN
gsrj-21	113	52	capacity	capacity	NOUN
gsrj-21	113	53	of	of	ADP
gsrj-21	113	54	sw1990	sw1990	PROPN
gsrj-21	113	55	tumor	tumor	NOUN
gsrj-21	113	56	cells	cell	NOUN
gsrj-21	113	57	in	in	ADP
gsrj-21	113	58	mouse	mouse	NOUN
gsrj-21	113	59	xenograft	xenograft	NOUN
gsrj-21	113	60	models	model	NOUN
gsrj-21	113	61	.	.	PUNCT
gsrj-21	114	1	satb-1	satb-1	NUM
gsrj-21	114	2	has	have	AUX
gsrj-21	114	3	been	be	AUX
gsrj-21	114	4	associated	associate	VERB
gsrj-21	114	5	with	with	ADP
gsrj-21	114	6	poor	poor	ADJ
gsrj-21	114	7	prognosis	prognosis	NOUN
gsrj-21	114	8	and	and	CCONJ
gsrj-21	114	9	tumorigenesis	tumorigenesis	NOUN
gsrj-21	114	10	in	in	ADP
gsrj-21	114	11	pancreatic	pancreatic	ADJ
gsrj-21	114	12	cancer.89,90,91	cancer.89,90,91	ADJ
gsrj-21	114	13	xenograft	xenograft	NOUN
gsrj-21	114	14	models	model	NOUN
gsrj-21	114	15	have	have	AUX
gsrj-21	114	16	also	also	ADV
gsrj-21	114	17	revealed	reveal	VERB
gsrj-21	114	18	the	the	DET
gsrj-21	114	19	role	role	NOUN
gsrj-21	114	20	of	of	ADP
gsrj-21	114	21	prolactin	prolactin	ADJ
gsrj-21	114	22	receptors	receptor	NOUN
gsrj-21	114	23	in	in	ADP
gsrj-21	114	24	suppressing	suppress	VERB
gsrj-21	114	25	tumor	tumor	NOUN
gsrj-21	114	26	growth	growth	NOUN
gsrj-21	114	27	.	.	PUNCT
gsrj-21	115	1	dandawate	dandawate	PROPN
gsrj-21	115	2	et	et	PROPN
gsrj-21	115	3	al	al	PROPN
gsrj-21	115	4	.	.	PROPN
gsrj-21	115	5	studied	study	VERB
gsrj-21	115	6	the	the	DET
gsrj-21	115	7	role	role	NOUN
gsrj-21	115	8	of	of	ADP
gsrj-21	115	9	prolactin	prolactin	ADJ
gsrj-21	115	10	receptors	receptor	NOUN
gsrj-21	115	11	in	in	ADP
gsrj-21	115	12	pdac	pdac	NOUN
gsrj-21	115	13	through	through	ADP
gsrj-21	115	14	the	the	DET
gsrj-21	115	15	injection	injection	NOUN
gsrj-21	115	16	of	of	ADP
gsrj-21	115	17	a	a	DET
gsrj-21	115	18	diphenylbutylpiperidine	diphenylbutylpiperidine	ADJ
gsrj-21	115	19	-	-	PUNCT
gsrj-21	115	20	class	class	NOUN
gsrj-21	115	21	antipsychotic	antipsychotic	ADJ
gsrj-21	115	22	drug	drug	NOUN
gsrj-21	115	23	,	,	PUNCT
gsrj-21	115	24	penfluridol	penfluridol	NOUN
gsrj-21	115	25	,	,	PUNCT
gsrj-21	115	26	which	which	PRON
gsrj-21	115	27	binds	bind	VERB
gsrj-21	115	28	to	to	PART
gsrj-21	115	29	prolactin	prolactin	VERB
gsrj-21	115	30	receptors.92	receptors.92	ADJ
gsrj-21	115	31	penfluridol	penfluridol	NOUN
gsrj-21	115	32	slowed	slow	VERB
gsrj-21	115	33	the	the	DET
gsrj-21	115	34	growth	growth	NOUN
gsrj-21	115	35	and	and	CCONJ
gsrj-21	115	36	volume	volume	NOUN
gsrj-21	115	37	of	of	ADP
gsrj-21	115	38	tumors	tumor	NOUN
gsrj-21	115	39	in	in	ADP
gsrj-21	115	40	panc-1	panc-1	VERB
gsrj-21	115	41	xenografts	xenograft	NOUN
gsrj-21	115	42	in	in	ADP
gsrj-21	115	43	athymic	athymic	ADJ
gsrj-21	115	44	nude	nude	ADJ
gsrj-21	115	45	mice	mouse	NOUN
gsrj-21	115	46	and	and	CCONJ
gsrj-21	115	47	pdx	pdx	PROPN
gsrj-21	115	48	in	in	ADP
gsrj-21	115	49	immunodeficient	immunodeficient	PROPN
gsrj-21	115	50	nsg	nsg	PROPN
gsrj-21	115	51	.	.	PUNCT
gsrj-21	116	1	western	western	ADJ
gsrj-21	116	2	blot	blot	NOUN
gsrj-21	116	3	analyses	analysis	NOUN
gsrj-21	116	4	suggested	suggest	VERB
gsrj-21	116	5	that	that	SCONJ
gsrj-21	116	6	penfluridol	penfluridol	NOUN
gsrj-21	116	7	induces	induce	VERB
gsrj-21	116	8	autophagy	autophagy	ADV
gsrj-21	116	9	-	-	PUNCT
gsrj-21	116	10	related	relate	VERB
gsrj-21	116	11	proteins	protein	NOUN
gsrj-21	116	12	p62	p62	NOUN
gsrj-21	116	13	,	,	PUNCT
gsrj-21	116	14	atg-5	atg-5	NUM
gsrj-21	116	15	,	,	PUNCT
gsrj-21	116	16	atg-7	atg-7	NOUN
gsrj-21	116	17	,	,	PUNCT
gsrj-21	116	18	atg-12	atg-12	NOUN
gsrj-21	116	19	,	,	PUNCT
gsrj-21	116	20	lc3b	lc3b	NOUN
gsrj-21	116	21	,	,	PUNCT
gsrj-21	116	22	and	and	CCONJ
gsrj-21	116	23	beclin-1	beclin-1	VERB
gsrj-21	116	24	to	to	PART
gsrj-21	116	25	suppress	suppress	VERB
gsrj-21	116	26	pdac	pdac	ADJ
gsrj-21	116	27	tumor	tumor	NOUN
gsrj-21	116	28	growth.92	growth.92	NOUN
gsrj-21	116	29	additionally	additionally	ADV
gsrj-21	116	30	,	,	PUNCT
gsrj-21	116	31	cysteine	cysteine	NOUN
gsrj-21	116	32	transport	transport	NOUN
gsrj-21	116	33	,	,	PUNCT
gsrj-21	116	34	xct	xct	PROPN
gsrj-21	116	35	,	,	PUNCT
gsrj-21	116	36	is	be	AUX
gsrj-21	116	37	key	key	ADJ
gsrj-21	116	38	to	to	ADP
gsrj-21	116	39	tumor	tumor	NOUN
gsrj-21	116	40	growth	growth	NOUN
gsrj-21	116	41	.	.	PUNCT
gsrj-21	117	1	tumor	tumor	NOUN
gsrj-21	117	2	xenograft	xenograft	PROPN
gsrj-21	117	3	growth	growth	NOUN
gsrj-21	117	4	of	of	ADP
gsrj-21	117	5	genomic	genomic	ADJ
gsrj-21	117	6	knockouts	knockout	NOUN
gsrj-21	117	7	of	of	ADP
gsrj-21	117	8	xct	xct	PROPN
gsrj-21	117	9	was	be	AUX
gsrj-21	117	10	delayed	delay	VERB
gsrj-21	117	11	but	but	CCONJ
gsrj-21	117	12	not	not	PART
gsrj-21	117	13	suppressed	suppress	VERB
gsrj-21	117	14	,	,	PUNCT
gsrj-21	117	15	indicating	indicate	VERB
gsrj-21	117	16	the	the	DET
gsrj-21	117	17	key	key	ADJ
gsrj-21	117	18	role	role	NOUN
gsrj-21	117	19	of	of	ADP
gsrj-21	117	20	xct	xct	PROPN
gsrj-21	117	21	and	and	CCONJ
gsrj-21	117	22	the	the	DET
gsrj-21	117	23	presence	presence	NOUN
gsrj-21	117	24	of	of	ADP
gsrj-21	117	25	additional	additional	ADJ
gsrj-21	117	26	mechanisms	mechanism	NOUN
gsrj-21	117	27	for	for	ADP
gsrj-21	117	28	cysteine	cysteine	NOUN
gsrj-21	117	29	homeostasis	homeostasis	NOUN
gsrj-21	117	30	in	in	ADP
gsrj-21	117	31	vivo.93	vivo.93	NOUN
gsrj-21	117	32	patient	patient	NOUN
gsrj-21	117	33	-	-	PUNCT
gsrj-21	117	34	derived	derive	VERB
gsrj-21	117	35	xenograft	xenograft	NOUN
gsrj-21	117	36	(	(	PUNCT
gsrj-21	117	37	pdx	pdx	PROPN
gsrj-21	117	38	)	)	PUNCT
gsrj-21	117	39	models	model	NOUN
gsrj-21	117	40	are	be	AUX
gsrj-21	117	41	widely	widely	ADV
gsrj-21	117	42	used	use	VERB
gsrj-21	117	43	for	for	ADP
gsrj-21	117	44	various	various	ADJ
gsrj-21	117	45	solid	solid	ADJ
gsrj-21	117	46	tumors	tumor	NOUN
gsrj-21	117	47	.	.	PUNCT
gsrj-21	118	1	typically	typically	ADV
gsrj-21	118	2	,	,	PUNCT
gsrj-21	118	3	chemotherapy	chemotherapy	NOUN
gsrj-21	118	4	-	-	ADJ
gsrj-21	118	5	naive	naive	ADJ
gsrj-21	118	6	tumor	tumor	NOUN
gsrj-21	118	7	tissue	tissue	NOUN
gsrj-21	118	8	obtained	obtain	VERB
gsrj-21	118	9	from	from	ADP
gsrj-21	118	10	surgery	surgery	NOUN
gsrj-21	118	11	or	or	CCONJ
gsrj-21	118	12	biopsies	biopsy	NOUN
gsrj-21	118	13	is	be	AUX
gsrj-21	118	14	transplanted	transplant	VERB
gsrj-21	118	15	directly	directly	ADV
gsrj-21	118	16	into	into	ADP
gsrj-21	118	17	immuno	immuno	ADJ
gsrj-21	118	18	-	-	PUNCT
gsrj-21	118	19	deficient	deficient	ADJ
gsrj-21	118	20	mice.55	mice.55	NOUN
gsrj-21	118	21	pdx	pdx	NOUN
gsrj-21	118	22	models	model	NOUN
gsrj-21	118	23	for	for	ADP
gsrj-21	118	24	pancreatic	pancreatic	ADJ
gsrj-21	118	25	cancer	cancer	NOUN
gsrj-21	118	26	are	be	AUX
gsrj-21	118	27	used	use	VERB
gsrj-21	118	28	to	to	PART
gsrj-21	118	29	identify	identify	VERB
gsrj-21	118	30	drugs	drug	NOUN
gsrj-21	118	31	that	that	PRON
gsrj-21	118	32	significantly	significantly	ADV
gsrj-21	118	33	inhibit	inhibit	VERB
gsrj-21	118	34	tumor	tumor	NOUN
gsrj-21	118	35	growth	growth	NOUN
gsrj-21	118	36	or	or	CCONJ
gsrj-21	118	37	to	to	PART
gsrj-21	118	38	validate	validate	VERB
gsrj-21	118	39	prognostic	prognostic	ADJ
gsrj-21	118	40	biomarkers	biomarker	NOUN
gsrj-21	118	41	,	,	PUNCT
gsrj-21	118	42	as	as	SCONJ
gsrj-21	118	43	these	these	DET
gsrj-21	118	44	models	model	NOUN
gsrj-21	118	45	are	be	AUX
gsrj-21	118	46	highly	highly	ADV
gsrj-21	118	47	representative	representative	ADJ
gsrj-21	118	48	of	of	ADP
gsrj-21	118	49	their	their	PRON
gsrj-21	118	50	respective	respective	ADJ
gsrj-21	118	51	tumors	tumor	NOUN
gsrj-21	118	52	due	due	ADP
gsrj-21	118	53	to	to	ADP
gsrj-21	118	54	a	a	DET
gsrj-21	118	55	high	high	ADJ
gsrj-21	118	56	degree	degree	NOUN
gsrj-21	118	57	of	of	ADP
gsrj-21	118	58	genetic	genetic	ADJ
gsrj-21	118	59	stability	stability	NOUN
gsrj-21	118	60	observed	observe	VERB
gsrj-21	118	61	by	by	ADP
gsrj-21	118	62	short	short	ADJ
gsrj-21	118	63	tandem	tandem	PROPN
gsrj-21	118	64	repeat	repeat	NOUN
gsrj-21	118	65	(	(	PUNCT
gsrj-21	118	66	str	str	NOUN
gsrj-21	118	67	)	)	PUNCT
gsrj-21	118	68	profiling	profiling	NOUN
gsrj-21	118	69	and	and	CCONJ
gsrj-21	118	70	mutation	mutation	NOUN
gsrj-21	118	71	analysis.94	analysis.94	VERB
gsrj-21	118	72	well	well	ADV
gsrj-21	118	73	-	-	PUNCT
gsrj-21	118	74	defined	define	VERB
gsrj-21	118	75	pdx	pdx	NOUN
gsrj-21	118	76	collections	collection	NOUN
gsrj-21	118	77	can	can	AUX
gsrj-21	118	78	be	be	AUX
gsrj-21	118	79	used	use	VERB
gsrj-21	118	80	to	to	PART
gsrj-21	118	81	associate	associate	VERB
gsrj-21	118	82	biomarkers	biomarker	NOUN
gsrj-21	118	83	with	with	ADP
gsrj-21	118	84	drug	drug	NOUN
gsrj-21	118	85	sensitivity	sensitivity	NOUN
gsrj-21	118	86	and	and	CCONJ
gsrj-21	118	87	resistance	resistance	NOUN
gsrj-21	118	88	to	to	ADP
gsrj-21	118	89	facilitate	facilitate	VERB
gsrj-21	118	90	precision	precision	NOUN
gsrj-21	118	91	cancer	cancer	NOUN
gsrj-21	118	92	medicine	medicine	NOUN
gsrj-21	118	93	.	.	PUNCT
gsrj-21	119	1	most	most	ADJ
gsrj-21	119	2	publications	publication	NOUN
gsrj-21	119	3	on	on	ADP
gsrj-21	119	4	pancreatic	pancreatic	ADJ
gsrj-21	119	5	pdx	pdx	PROPN
gsrj-21	119	6	models	model	NOUN
gsrj-21	119	7	describe	describe	VERB
gsrj-21	119	8	the	the	DET
gsrj-21	119	9	establishment	establishment	NOUN
gsrj-21	119	10	,	,	PUNCT
gsrj-21	119	11	characterization	characterization	NOUN
gsrj-21	119	12	,	,	PUNCT
gsrj-21	119	13	and	and	CCONJ
gsrj-21	119	14	preclinical	preclinical	ADJ
gsrj-21	119	15	application	application	NOUN
gsrj-21	119	16	of	of	ADP
gsrj-21	119	17	53	53	NUM
gsrj-21	119	18	georgetown	georgetown	PROPN
gsrj-21	119	19	scientific	scientific	PROPN
gsrj-21	119	20	research	research	PROPN
gsrj-21	119	21	journal	journal	NOUN
gsrj-21	119	22	pdxs	pdxs	PROPN
gsrj-21	119	23	,	,	PUNCT
gsrj-21	119	24	but	but	CCONJ
gsrj-21	119	25	they	they	PRON
gsrj-21	119	26	have	have	VERB
gsrj-21	119	27	yet	yet	ADV
gsrj-21	119	28	to	to	PART
gsrj-21	119	29	be	be	AUX
gsrj-21	119	30	applied	apply	VERB
gsrj-21	119	31	towards	towards	ADP
gsrj-21	119	32	clinical	clinical	ADJ
gsrj-21	119	33	studies	study	NOUN
gsrj-21	119	34	.	.	PUNCT
gsrj-21	120	1	tang	tang	PROPN
gsrj-21	120	2	et	et	PROPN
gsrj-21	121	1	al	al	PROPN
gsrj-21	121	2	.	.	PROPN
gsrj-21	121	3	used	use	VERB
gsrj-21	121	4	gem	gem	NOUN
gsrj-21	121	5	treated	treat	VERB
gsrj-21	121	6	pdx	pdx	PROPN
gsrj-21	121	7	models	model	NOUN
gsrj-21	121	8	to	to	PART
gsrj-21	121	9	show	show	VERB
gsrj-21	121	10	that	that	SCONJ
gsrj-21	121	11	m6a	m6a	PROPN
gsrj-21	121	12	demethylase	demethylase	PROPN
gsrj-21	121	13	alkbh5	alkbh5	PROPN
gsrj-21	121	14	is	be	AUX
gsrj-21	121	15	downregulated	downregulate	VERB
gsrj-21	121	16	.	.	PUNCT
gsrj-21	122	1	overexpression	overexpression	NOUN
gsrj-21	122	2	of	of	ADP
gsrj-21	122	3	this	this	DET
gsrj-21	122	4	demethylase	demethylase	NOUN
gsrj-21	122	5	sensitizes	sensitize	VERB
gsrj-21	122	6	pdac	pdac	NOUN
gsrj-21	122	7	cells	cell	NOUN
gsrj-21	122	8	to	to	ADP
gsrj-21	122	9	chemotherapy	chemotherapy	NOUN
gsrj-21	122	10	.	.	PUNCT
gsrj-21	123	1	thus	thus	ADV
gsrj-21	123	2	,	,	PUNCT
gsrj-21	123	3	lower	low	ADJ
gsrj-21	123	4	levels	level	NOUN
gsrj-21	123	5	of	of	ADP
gsrj-21	123	6	alkbh5	alkbh5	PROPN
gsrj-21	123	7	predict	predict	VERB
gsrj-21	123	8	poor	poor	ADJ
gsrj-21	123	9	clinical	clinical	ADJ
gsrj-21	123	10	outcomes	outcome	NOUN
gsrj-21	123	11	in	in	ADP
gsrj-21	123	12	pdac	pdac	NOUN
gsrj-21	123	13	and	and	CCONJ
gsrj-21	123	14	other	other	ADJ
gsrj-21	123	15	cancers.95	cancers.95	PROPN
gsrj-21	123	16	wei	wei	PROPN
gsrj-21	123	17	et	et	PROPN
gsrj-21	123	18	al	al	PROPN
gsrj-21	123	19	.	.	PROPN
gsrj-21	124	1	used	use	VERB
gsrj-21	124	2	in	in	ADP
gsrj-21	124	3	vivo	vivo	ADJ
gsrj-21	124	4	crispr	crispr	ADJ
gsrj-21	124	5	gene	gene	NOUN
gsrj-21	124	6	knockout	knockout	NOUN
gsrj-21	124	7	screening	screen	VERB
gsrj-21	124	8	in	in	ADP
gsrj-21	124	9	pdx	pdx	PROPN
gsrj-21	124	10	mice	mouse	NOUN
gsrj-21	124	11	to	to	PART
gsrj-21	124	12	identify	identify	VERB
gsrj-21	124	13	effective	effective	ADJ
gsrj-21	124	14	lethal	lethal	ADJ
gsrj-21	124	15	drug	drug	NOUN
gsrj-21	124	16	combinations	combination	NOUN
gsrj-21	124	17	that	that	PRON
gsrj-21	124	18	synergize	synergize	VERB
gsrj-21	124	19	with	with	ADP
gsrj-21	124	20	gem	gem	NOUN
gsrj-21	124	21	for	for	ADP
gsrj-21	124	22	treating	treat	VERB
gsrj-21	124	23	pdac.96	pdac.96	NOUN
gsrj-21	124	24	using	use	VERB
gsrj-21	124	25	a	a	DET
gsrj-21	124	26	clinically	clinically	ADV
gsrj-21	124	27	relevant	relevant	ADJ
gsrj-21	124	28	pdx	pdx	PROPN
gsrj-21	124	29	model	model	NOUN
gsrj-21	124	30	of	of	ADP
gsrj-21	124	31	pdac	pdac	NOUN
gsrj-21	124	32	with	with	ADP
gsrj-21	124	33	a	a	DET
gsrj-21	124	34	patient	patient	ADJ
gsrj-21	124	35	tumor	tumor	NOUN
gsrj-21	124	36	being	be	AUX
gsrj-21	124	37	propagated	propagate	VERB
gsrj-21	124	38	within	within	ADP
gsrj-21	124	39	the	the	DET
gsrj-21	124	40	pancreas	pancrea	NOUN
gsrj-21	124	41	of	of	ADP
gsrj-21	124	42	athymic	athymic	ADJ
gsrj-21	124	43	nude	nude	ADJ
gsrj-21	124	44	mice	mouse	NOUN
gsrj-21	124	45	,	,	PUNCT
gsrj-21	124	46	they	they	PRON
gsrj-21	124	47	screened	screen	VERB
gsrj-21	124	48	for	for	ADP
gsrj-21	124	49	chromatin	chromatin	NOUN
gsrj-21	124	50	regulators	regulator	NOUN
gsrj-21	124	51	whose	whose	DET
gsrj-21	124	52	depletion	depletion	NOUN
gsrj-21	124	53	may	may	AUX
gsrj-21	124	54	create	create	VERB
gsrj-21	124	55	conditional	conditional	ADJ
gsrj-21	124	56	lethality	lethality	NOUN
gsrj-21	124	57	with	with	ADP
gsrj-21	124	58	gem	gem	NOUN
gsrj-21	124	59	.	.	PUNCT
gsrj-21	125	1	they	they	PRON
gsrj-21	125	2	found	find	VERB
gsrj-21	125	3	that	that	SCONJ
gsrj-21	125	4	inhibition	inhibition	NOUN
gsrj-21	125	5	of	of	ADP
gsrj-21	125	6	the	the	DET
gsrj-21	125	7	protein	protein	NOUN
gsrj-21	125	8	prmt5	prmt5	NOUN
gsrj-21	125	9	led	lead	VERB
gsrj-21	125	10	to	to	ADP
gsrj-21	125	11	synergistic	synergistic	ADJ
gsrj-21	125	12	vulnerability	vulnerability	NOUN
gsrj-21	125	13	of	of	ADP
gsrj-21	125	14	pdac	pdac	NOUN
gsrj-21	125	15	cells	cell	NOUN
gsrj-21	125	16	to	to	ADP
gsrj-21	125	17	gem	gem	NOUN
gsrj-21	125	18	.	.	PUNCT
gsrj-21	126	1	prmt5	prmt5	NOUN
gsrj-21	126	2	has	have	AUX
gsrj-21	126	3	been	be	AUX
gsrj-21	126	4	considered	consider	VERB
gsrj-21	126	5	as	as	ADP
gsrj-21	126	6	a	a	DET
gsrj-21	126	7	critical	critical	ADJ
gsrj-21	126	8	driver	driver	NOUN
gsrj-21	126	9	of	of	ADP
gsrj-21	126	10	cancer	cancer	NOUN
gsrj-21	126	11	progression	progression	NOUN
gsrj-21	126	12	for	for	ADP
gsrj-21	126	13	multiple	multiple	ADJ
gsrj-21	126	14	advanced	advanced	ADJ
gsrj-21	126	15	-	-	PUNCT
gsrj-21	126	16	stage	stage	NOUN
gsrj-21	126	17	cancers	cancer	NOUN
gsrj-21	126	18	.	.	PUNCT
gsrj-21	127	1	this	this	DET
gsrj-21	127	2	study	study	NOUN
gsrj-21	127	3	suggests	suggest	VERB
gsrj-21	127	4	that	that	SCONJ
gsrj-21	127	5	gem	gem	NOUN
gsrj-21	127	6	treatment	treatment	NOUN
gsrj-21	127	7	combined	combine	VERB
gsrj-21	127	8	with	with	ADP
gsrj-21	127	9	inhibition	inhibition	NOUN
gsrj-21	127	10	of	of	ADP
gsrj-21	127	11	prmt5	prmt5	NOUN
gsrj-21	127	12	will	will	AUX
gsrj-21	127	13	have	have	VERB
gsrj-21	127	14	stronger	strong	ADJ
gsrj-21	127	15	effects	effect	NOUN
gsrj-21	127	16	and	and	CCONJ
gsrj-21	127	17	selectivity	selectivity	NOUN
gsrj-21	127	18	towards	towards	ADP
gsrj-21	127	19	pdac.96	pdac.96	PROPN
gsrj-21	127	20	5.2	5.2	NUM
gsrj-21	127	21	gemcitabine	gemcitabine	NOUN
gsrj-21	127	22	resistance	resistance	NOUN
gsrj-21	127	23	and	and	CCONJ
gsrj-21	127	24	genetically	genetically	ADV
gsrj-21	127	25	engineered	engineer	VERB
gsrj-21	127	26	/	/	SYM
gsrj-21	127	27	transgenic	transgenic	NOUN
gsrj-21	127	28	models	model	NOUN
gsrj-21	127	29	a	a	DET
gsrj-21	127	30	major	major	ADJ
gsrj-21	127	31	drawback	drawback	NOUN
gsrj-21	127	32	of	of	ADP
gsrj-21	127	33	pdx	pdx	PROPN
gsrj-21	127	34	models	model	NOUN
gsrj-21	127	35	is	be	AUX
gsrj-21	127	36	the	the	DET
gsrj-21	127	37	use	use	NOUN
gsrj-21	127	38	of	of	ADP
gsrj-21	127	39	immunodeficient	immunodeficient	NOUN
gsrj-21	127	40	mice	mouse	NOUN
gsrj-21	127	41	that	that	PRON
gsrj-21	127	42	lack	lack	VERB
gsrj-21	127	43	a	a	DET
gsrj-21	127	44	competent	competent	ADJ
gsrj-21	127	45	immune	immune	ADJ
gsrj-21	127	46	system	system	NOUN
gsrj-21	127	47	to	to	PART
gsrj-21	127	48	investigate	investigate	VERB
gsrj-21	127	49	immunotherapeutics	immunotherapeutic	NOUN
gsrj-21	127	50	.	.	PUNCT
gsrj-21	128	1	tumor	tumor	NOUN
gsrj-21	128	2	cells	cell	NOUN
gsrj-21	128	3	used	use	VERB
gsrj-21	128	4	in	in	ADP
gsrj-21	128	5	pdx	pdx	PROPN
gsrj-21	128	6	have	have	AUX
gsrj-21	128	7	also	also	ADV
gsrj-21	128	8	been	be	AUX
gsrj-21	128	9	passaged	passage	VERB
gsrj-21	128	10	extensively	extensively	ADV
gsrj-21	128	11	in	in	ADP
gsrj-21	128	12	vitro	vitro	X
gsrj-21	128	13	,	,	PUNCT
gsrj-21	128	14	limiting	limit	VERB
gsrj-21	128	15	tumor	tumor	NOUN
gsrj-21	128	16	cell	cell	NOUN
gsrj-21	128	17	heterogeneity	heterogeneity	NOUN
gsrj-21	128	18	and	and	CCONJ
gsrj-21	128	19	potential	potential	ADJ
gsrj-21	128	20	biological	biological	ADJ
gsrj-21	128	21	relevance	relevance	NOUN
gsrj-21	128	22	.	.	PUNCT
gsrj-21	129	1	thus	thus	ADV
gsrj-21	129	2	,	,	PUNCT
gsrj-21	129	3	genetically	genetically	ADV
gsrj-21	129	4	engineered	engineer	VERB
gsrj-21	129	5	mice	mouse	NOUN
gsrj-21	129	6	that	that	PRON
gsrj-21	129	7	spontaneously	spontaneously	ADV
gsrj-21	129	8	develop	develop	VERB
gsrj-21	129	9	pdac	pdac	NOUN
gsrj-21	129	10	are	be	AUX
gsrj-21	129	11	appealing	appeal	VERB
gsrj-21	129	12	for	for	ADP
gsrj-21	129	13	drug	drug	NOUN
gsrj-21	129	14	discovery	discovery	NOUN
gsrj-21	129	15	,	,	PUNCT
gsrj-21	129	16	especially	especially	ADV
gsrj-21	129	17	since	since	SCONJ
gsrj-21	129	18	tumors	tumor	NOUN
gsrj-21	129	19	arise	arise	VERB
gsrj-21	129	20	in	in	ADP
gsrj-21	129	21	competent	competent	ADJ
gsrj-21	129	22	and	and	CCONJ
gsrj-21	129	23	fully	fully	ADV
gsrj-21	129	24	intact	intact	ADJ
gsrj-21	129	25	immune	immune	ADJ
gsrj-21	129	26	systems	system	NOUN
gsrj-21	129	27	.	.	PUNCT
gsrj-21	130	1	gemms	gemms	PROPN
gsrj-21	130	2	are	be	AUX
gsrj-21	130	3	similar	similar	ADJ
gsrj-21	130	4	to	to	ADP
gsrj-21	130	5	humans	human	NOUN
gsrj-21	130	6	in	in	ADP
gsrj-21	130	7	terms	term	NOUN
gsrj-21	130	8	of	of	ADP
gsrj-21	130	9	genetic	genetic	ADJ
gsrj-21	130	10	,	,	PUNCT
gsrj-21	130	11	phenotypic	phenotypic	ADJ
gsrj-21	130	12	,	,	PUNCT
gsrj-21	130	13	and	and	CCONJ
gsrj-21	130	14	physiological	physiological	ADJ
gsrj-21	130	15	characteristics	characteristic	NOUN
gsrj-21	130	16	.	.	PUNCT
gsrj-21	131	1	models	model	NOUN
gsrj-21	131	2	include	include	VERB
gsrj-21	131	3	kc	kc	PROPN
gsrj-21	131	4	(	(	PUNCT
gsrj-21	131	5	kraslsl.g12d/+	kraslsl.g12d/+	NOUN
gsrj-21	131	6	and	and	CCONJ
gsrj-21	131	7	pdxcre	pdxcre	ADJ
gsrj-21	131	8	)	)	PUNCT
gsrj-21	131	9	mice	mouse	NOUN
gsrj-21	131	10	and	and	CCONJ
gsrj-21	131	11	kpc	kpc	NOUN
gsrj-21	131	12	mice	mouse	NOUN
gsrj-21	131	13	that	that	PRON
gsrj-21	131	14	have	have	AUX
gsrj-21	131	15	been	be	AUX
gsrj-21	131	16	used	use	VERB
gsrj-21	131	17	to	to	PART
gsrj-21	131	18	investigate	investigate	VERB
gsrj-21	131	19	the	the	DET
gsrj-21	131	20	influence	influence	NOUN
gsrj-21	131	21	of	of	ADP
gsrj-21	131	22	kras.55	kras.55	PROPN
gsrj-21	131	23	kc	kc	PROPN
gsrj-21	131	24	mice	mouse	NOUN
gsrj-21	131	25	have	have	VERB
gsrj-21	131	26	normal	normal	ADJ
gsrj-21	131	27	pancreatic	pancreatic	ADJ
gsrj-21	131	28	organogenesis	organogenesis	NOUN
gsrj-21	131	29	and	and	CCONJ
gsrj-21	131	30	develop	develop	VERB
gsrj-21	131	31	intraepithelial	intraepithelial	ADJ
gsrj-21	131	32	neoplasia	neoplasia	NOUN
gsrj-21	131	33	(	(	PUNCT
gsrj-21	131	34	panin	panin	PROPN
gsrj-21	131	35	)	)	PUNCT
gsrj-21	131	36	that	that	PRON
gsrj-21	131	37	eventually	eventually	ADV
gsrj-21	131	38	progress	progress	VERB
gsrj-21	131	39	to	to	ADP
gsrj-21	131	40	pdac	pdac	PROPN
gsrj-21	131	41	.	.	PUNCT
gsrj-21	132	1	kpc	kpc	PROPN
gsrj-21	132	2	(	(	PUNCT
gsrj-21	132	3	kraslsl.g12d/+	kraslsl.g12d/+	PROPN
gsrj-21	132	4	,	,	PUNCT
gsrj-21	132	5	p53r172h/+	p53r172h/+	PROPN
gsrj-21	132	6	,	,	PUNCT
gsrj-21	132	7	and	and	CCONJ
gsrj-21	132	8	pdxcre	pdxcre	ADJ
gsrj-21	132	9	)	)	PUNCT
gsrj-21	132	10	mice	mouse	NOUN
gsrj-21	132	11	have	have	VERB
gsrj-21	132	12	a	a	DET
gsrj-21	132	13	conditional	conditional	ADJ
gsrj-21	132	14	expression	expression	NOUN
gsrj-21	132	15	of	of	ADP
gsrj-21	132	16	the	the	DET
gsrj-21	132	17	r72h	r72h	NOUN
gsrj-21	132	18	mutation	mutation	NOUN
gsrj-21	132	19	in	in	ADP
gsrj-21	132	20	the	the	DET
gsrj-21	132	21	p53	p53	NOUN
gsrj-21	132	22	gene	gene	NOUN
gsrj-21	132	23	in	in	ADP
gsrj-21	132	24	the	the	DET
gsrj-21	132	25	krasg12d	krasg12d	NOUN
gsrj-21	132	26	context	context	NOUN
gsrj-21	132	27	.	.	PUNCT
gsrj-21	133	1	kpc	kpc	PROPN
gsrj-21	133	2	is	be	AUX
gsrj-21	133	3	the	the	DET
gsrj-21	133	4	most	most	ADV
gsrj-21	133	5	extensively	extensively	ADV
gsrj-21	133	6	studied	study	VERB
gsrj-21	133	7	genetic	genetic	ADJ
gsrj-21	133	8	model	model	NOUN
gsrj-21	133	9	of	of	ADP
gsrj-21	133	10	pdac	pdac	NOUN
gsrj-21	133	11	for	for	ADP
gsrj-21	133	12	the	the	DET
gsrj-21	133	13	evaluation	evaluation	NOUN
gsrj-21	133	14	of	of	ADP
gsrj-21	133	15	immunotherapy.97	immunotherapy.97	NOUN
gsrj-21	133	16	at	at	ADP
gsrj-21	133	17	least	least	ADV
gsrj-21	133	18	40	40	NUM
gsrj-21	133	19	gemm	gemm	NOUN
gsrj-21	133	20	have	have	AUX
gsrj-21	133	21	been	be	AUX
gsrj-21	133	22	generated	generate	VERB
gsrj-21	133	23	for	for	ADP
gsrj-21	133	24	analysis	analysis	NOUN
gsrj-21	133	25	of	of	ADP
gsrj-21	133	26	gene	gene	NOUN
gsrj-21	133	27	function	function	NOUN
gsrj-21	133	28	in	in	ADP
gsrj-21	133	29	pdac.98,99	pdac.98,99	NOUN
gsrj-21	133	30	tadros	tadro	NOUN
gsrj-21	133	31	et	et	PROPN
gsrj-21	133	32	al	al	PROPN
gsrj-21	133	33	.	.	PROPN
gsrj-21	133	34	observed	observe	VERB
gsrj-21	133	35	an	an	DET
gsrj-21	133	36	increase	increase	NOUN
gsrj-21	133	37	in	in	ADP
gsrj-21	133	38	fatty	fatty	NOUN
gsrj-21	133	39	acid	acid	NOUN
gsrj-21	133	40	synthase	synthase	NOUN
gsrj-21	133	41	expression	expression	NOUN
gsrj-21	133	42	that	that	PRON
gsrj-21	133	43	corresponded	correspond	VERB
gsrj-21	133	44	with	with	ADP
gsrj-21	133	45	increased	increase	VERB
gsrj-21	133	46	disease	disease	NOUN
gsrj-21	133	47	progression	progression	NOUN
gsrj-21	133	48	in	in	ADP
gsrj-21	133	49	pdac	pdac	PROPN
gsrj-21	133	50	gemms.100	gemms.100	NOUN
gsrj-21	133	51	based	base	VERB
gsrj-21	133	52	on	on	ADP
gsrj-21	133	53	analysis	analysis	NOUN
gsrj-21	133	54	and	and	CCONJ
gsrj-21	133	55	identification	identification	NOUN
gsrj-21	133	56	of	of	ADP
gsrj-21	133	57	the	the	DET
gsrj-21	133	58	lipid	lipid	NOUN
gsrj-21	133	59	metabolism	metabolism	NOUN
gsrj-21	133	60	pathway	pathway	NOUN
gsrj-21	133	61	to	to	PART
gsrj-21	133	62	be	be	AUX
gsrj-21	133	63	the	the	DET
gsrj-21	133	64	most	most	ADV
gsrj-21	133	65	significantly	significantly	ADV
gsrj-21	133	66	enriched	enrich	VERB
gsrj-21	133	67	in	in	ADP
gsrj-21	133	68	tumors	tumor	NOUN
gsrj-21	133	69	from	from	ADP
gsrj-21	133	70	patients	patient	NOUN
gsrj-21	133	71	with	with	ADP
gsrj-21	133	72	pdac	pdac	NOUN
gsrj-21	133	73	,	,	PUNCT
gsrj-21	133	74	they	they	PRON
gsrj-21	133	75	manipulated	manipulate	VERB
gsrj-21	133	76	the	the	DET
gsrj-21	133	77	fatty	fatty	NOUN
gsrj-21	133	78	acid	acid	NOUN
gsrj-21	133	79	biosynthesis	biosynthesis	NOUN
gsrj-21	133	80	pathway	pathway	NOUN
gsrj-21	133	81	.	.	PUNCT
gsrj-21	134	1	fatty	fatty	NOUN
gsrj-21	134	2	acid	acid	NOUN
gsrj-21	134	3	synthesis	synthesis	NOUN
gsrj-21	134	4	is	be	AUX
gsrj-21	134	5	also	also	ADV
gsrj-21	134	6	regulated	regulate	VERB
gsrj-21	134	7	by	by	ADP
gsrj-21	134	8	multiple	multiple	ADJ
gsrj-21	134	9	transcriptional	transcriptional	ADJ
gsrj-21	134	10	regulators	regulator	NOUN
gsrj-21	134	11	,	,	PUNCT
gsrj-21	134	12	including	include	VERB
gsrj-21	134	13	c	c	NOUN
gsrj-21	134	14	-	-	PUNCT
gsrj-21	134	15	myc	myc	NOUN
gsrj-21	134	16	,	,	PUNCT
gsrj-21	134	17	which	which	PRON
gsrj-21	134	18	is	be	AUX
gsrj-21	134	19	significantly	significantly	ADV
gsrj-21	134	20	amplified	amplify	VERB
gsrj-21	134	21	in	in	ADP
gsrj-21	134	22	pdac.54	pdac.54	PROPN
gsrj-21	134	23	through	through	ADP
gsrj-21	134	24	treatment	treatment	NOUN
gsrj-21	134	25	with	with	ADP
gsrj-21	134	26	orlistat	orlistat	NOUN
gsrj-21	134	27	,	,	PUNCT
gsrj-21	134	28	the	the	DET
gsrj-21	134	29	researchers	researcher	NOUN
gsrj-21	134	30	demonstrated	demonstrate	VERB
gsrj-21	134	31	a	a	DET
gsrj-21	134	32	way	way	NOUN
gsrj-21	134	33	to	to	PART
gsrj-21	134	34	overcome	overcome	VERB
gsrj-21	134	35	gem	gem	NOUN
gsrj-21	134	36	resistance	resistance	NOUN
gsrj-21	134	37	in	in	ADP
gsrj-21	134	38	pancreatic	pancreatic	ADJ
gsrj-21	134	39	cancer	cancer	NOUN
gsrj-21	134	40	by	by	ADP
gsrj-21	134	41	regulating	regulate	VERB
gsrj-21	134	42	endoplasmic	endoplasmic	ADJ
gsrj-21	134	43	reticulum	reticulum	NOUN
gsrj-21	134	44	stress	stress	NOUN
gsrj-21	134	45	and	and	CCONJ
gsrj-21	134	46	stemness	stemness	NOUN
gsrj-21	134	47	.	.	PUNCT
gsrj-21	135	1	buccholz	buccholz	PROPN
gsrj-21	135	2	et	et	PROPN
gsrj-21	136	1	al	al	PROPN
gsrj-21	136	2	.	.	PROPN
gsrj-21	136	3	showed	show	VERB
gsrj-21	136	4	that	that	DET
gsrj-21	136	5	depletion	depletion	NOUN
gsrj-21	136	6	of	of	ADP
gsrj-21	136	7	pharmacological	pharmacological	ADJ
gsrj-21	136	8	tumor	tumor	NOUN
gsrj-21	136	9	-	-	PUNCT
gsrj-21	136	10	associated	associate	VERB
gsrj-21	136	11	macrophages	macrophage	NOUN
gsrj-21	136	12	(	(	PUNCT
gsrj-21	136	13	tams	tam	NOUN
gsrj-21	136	14	)	)	PUNCT
gsrj-21	136	15	improves	improve	VERB
gsrj-21	136	16	therapeutic	therapeutic	ADJ
gsrj-21	136	17	response	response	NOUN
gsrj-21	136	18	to	to	ADP
gsrj-21	136	19	gem	gem	NOUN
gsrj-21	136	20	in	in	ADP
gsrj-21	136	21	kpc	kpc	NOUN
gsrj-21	136	22	mice.101	mice.101	NOUN
gsrj-21	136	23	macrophages	macrophage	NOUN
gsrj-21	136	24	are	be	AUX
gsrj-21	136	25	abundant	abundant	ADJ
gsrj-21	136	26	in	in	ADP
gsrj-21	136	27	fibro	fibro	NOUN
gsrj-21	136	28	-	-	PUNCT
gsrj-21	136	29	inflammatory	inflammatory	ADJ
gsrj-21	136	30	tme	tme	NOUN
gsrj-21	136	31	of	of	ADP
gsrj-21	136	32	kc	kc	PROPN
gsrj-21	136	33	and	and	CCONJ
gsrj-21	136	34	kpc	kpc	PROPN
gsrj-21	136	35	mice	mouse	NOUN
gsrj-21	136	36	,	,	PUNCT
gsrj-21	136	37	which	which	PRON
gsrj-21	136	38	has	have	AUX
gsrj-21	136	39	been	be	AUX
gsrj-21	136	40	shown	show	VERB
gsrj-21	136	41	to	to	PART
gsrj-21	136	42	correlate	correlate	VERB
gsrj-21	136	43	with	with	ADP
gsrj-21	136	44	a	a	DET
gsrj-21	136	45	worse	bad	ADJ
gsrj-21	136	46	prognosis	prognosis	NOUN
gsrj-21	136	47	in	in	ADP
gsrj-21	136	48	pdac.102	pdac.102	NOUN
gsrj-21	136	49	following	follow	VERB
gsrj-21	136	50	enrollment	enrollment	NOUN
gsrj-21	136	51	of	of	ADP
gsrj-21	136	52	kpc	kpc	NOUN
gsrj-21	136	53	mice	mouse	NOUN
gsrj-21	136	54	that	that	PRON
gsrj-21	136	55	had	have	AUX
gsrj-21	136	56	developed	develop	VERB
gsrj-21	136	57	pancreatic	pancreatic	ADJ
gsrj-21	136	58	tumors	tumor	NOUN
gsrj-21	136	59	with	with	ADP
gsrj-21	136	60	liposomal	liposomal	ADJ
gsrj-21	136	61	clodronate	clodronate	NOUN
gsrj-21	136	62	to	to	PART
gsrj-21	136	63	deplete	deplete	VERB
gsrj-21	136	64	intratumoral	intratumoral	ADJ
gsrj-21	136	65	tams	tam	NOUN
gsrj-21	136	66	and	and	CCONJ
gsrj-21	136	67	gem	gem	NOUN
gsrj-21	136	68	,	,	PUNCT
gsrj-21	136	69	they	they	PRON
gsrj-21	136	70	demonstrated	demonstrate	VERB
gsrj-21	136	71	improved	improved	ADJ
gsrj-21	136	72	efficacy	efficacy	NOUN
gsrj-21	136	73	of	of	ADP
gsrj-21	136	74	gem	gem	NOUN
gsrj-21	136	75	in	in	ADP
gsrj-21	136	76	the	the	DET
gsrj-21	136	77	kpc	kpc	NOUN
gsrj-21	136	78	.	.	PUNCT
gsrj-21	137	1	these	these	DET
gsrj-21	137	2	results	result	NOUN
gsrj-21	137	3	point	point	VERB
gsrj-21	137	4	to	to	ADP
gsrj-21	137	5	another	another	DET
gsrj-21	137	6	instance	instance	NOUN
gsrj-21	137	7	of	of	ADP
gsrj-21	137	8	the	the	DET
gsrj-21	137	9	role	role	NOUN
gsrj-21	137	10	of	of	ADP
gsrj-21	137	11	the	the	DET
gsrj-21	137	12	tme	tme	NOUN
gsrj-21	137	13	in	in	ADP
gsrj-21	137	14	gem	gem	NOUN
gsrj-21	137	15	resistance	resistance	NOUN
gsrj-21	137	16	.	.	PUNCT
gsrj-21	138	1	principe	principe	NOUN
gsrj-21	138	2	et	et	PROPN
gsrj-21	138	3	al	al	PROPN
gsrj-21	138	4	.	.	PROPN
gsrj-21	138	5	evaluated	evaluate	VERB
gsrj-21	138	6	the	the	DET
gsrj-21	138	7	effects	effect	NOUN
gsrj-21	138	8	of	of	ADP
gsrj-21	138	9	prolonged	prolong	VERB
gsrj-21	138	10	gem	gem	NOUN
gsrj-21	138	11	treatment	treatment	NOUN
gsrj-21	138	12	using	use	VERB
gsrj-21	138	13	kpc	kpc	NOUN
gsrj-21	138	14	mice	mouse	NOUN
gsrj-21	138	15	and	and	CCONJ
gsrj-21	138	16	found	find	VERB
gsrj-21	138	17	increased	increase	VERB
gsrj-21	138	18	ccl	ccl	PROPN
gsrj-21	138	19	/	/	SYM
gsrj-21	138	20	cxcl	cxcl	NOUN
gsrj-21	138	21	cytokine	cytokine	NOUN
gsrj-21	138	22	/	/	SYM
gsrj-21	138	23	chemokine	chemokine	ADJ
gsrj-21	138	24	secretion	secretion	NOUN
gsrj-21	138	25	and	and	CCONJ
gsrj-21	138	26	upregulation	upregulation	NOUN
gsrj-21	138	27	of	of	ADP
gsrj-21	138	28	immune	immune	ADJ
gsrj-21	138	29	surface	surface	NOUN
gsrj-21	138	30	proteins	protein	NOUN
gsrj-21	138	31	,	,	PUNCT
gsrj-21	138	32	including	include	VERB
gsrj-21	138	33	transforming	transform	VERB
gsrj-21	138	34	growth	growth	NOUN
gsrj-21	138	35	factor	factor	NOUN
gsrj-21	138	36	β	β	X
gsrj-21	138	37	(	(	PUNCT
gsrj-21	138	38	tgfβ)-associated	tgfβ)-associated	ADJ
gsrj-21	138	39	signals	signal	NOUN
gsrj-21	138	40	,	,	PUNCT
gsrj-21	138	41	in	in	ADP
gsrj-21	138	42	the	the	DET
gsrj-21	138	43	tumor	tumor	NOUN
gsrj-21	138	44	stroma.103	stroma.103	PROPN
gsrj-21	138	45	tgfβ	tgfβ	ADV
gsrj-21	138	46	-	-	PUNCT
gsrj-21	138	47	associated	associate	VERB
gsrj-21	138	48	signals	signal	NOUN
gsrj-21	138	49	confer	confer	VERB
gsrj-21	138	50	drug	drug	NOUN
gsrj-21	138	51	-	-	PUNCT
gsrj-21	138	52	resistant	resistant	ADJ
gsrj-21	138	53	phenotypes	phenotype	NOUN
gsrj-21	138	54	to	to	ADP
gsrj-21	138	55	neighboring	neighbor	VERB
gsrj-21	138	56	stromal	stromal	ADJ
gsrj-21	138	57	cells	cell	NOUN
gsrj-21	138	58	and	and	CCONJ
gsrj-21	138	59	further	far	ADV
gsrj-21	138	60	enhance	enhance	VERB
gsrj-21	138	61	the	the	DET
gsrj-21	138	62	production	production	NOUN
gsrj-21	138	63	of	of	ADP
gsrj-21	138	64	inflammatory	inflammatory	ADJ
gsrj-21	138	65	cytokines	cytokine	NOUN
gsrj-21	138	66	/	/	SYM
gsrj-21	138	67	chemokines	chemokine	NOUN
gsrj-21	138	68	.	.	PUNCT
gsrj-21	139	1	halbrook	halbrook	NOUN
gsrj-21	139	2	et	et	PROPN
gsrj-21	139	3	al	al	PROPN
gsrj-21	139	4	.	.	PROPN
gsrj-21	139	5	examined	examine	VERB
gsrj-21	139	6	how	how	SCONJ
gsrj-21	139	7	tumorassociated	tumorassociate	VERB
gsrj-21	139	8	macrophages	macrophage	NOUN
gsrj-21	139	9	(	(	PUNCT
gsrj-21	139	10	tams	tam	NOUN
gsrj-21	139	11	)	)	PUNCT
gsrj-21	139	12	drive	drive	VERB
gsrj-21	139	13	resistance	resistance	NOUN
gsrj-21	139	14	54	54	NUM
gsrj-21	139	15	georgetown	georgetown	PROPN
gsrj-21	139	16	scientific	scientific	PROPN
gsrj-21	139	17	research	research	NOUN
gsrj-21	139	18	journal	journal	NOUN
gsrj-21	139	19	to	to	ADP
gsrj-21	139	20	gem	gem	NOUN
gsrj-21	139	21	in	in	ADP
gsrj-21	139	22	pdac	pdac	NOUN
gsrj-21	139	23	cell	cell	NOUN
gsrj-21	139	24	lines	line	NOUN
gsrj-21	139	25	.	.	PUNCT
gsrj-21	140	1	they	they	PRON
gsrj-21	140	2	found	find	VERB
gsrj-21	140	3	that	that	SCONJ
gsrj-21	140	4	tams	tam	NOUN
gsrj-21	140	5	release	release	VERB
gsrj-21	140	6	a	a	DET
gsrj-21	140	7	spectrum	spectrum	NOUN
gsrj-21	140	8	of	of	ADP
gsrj-21	140	9	pyrimidine	pyrimidine	NOUN
gsrj-21	140	10	species	specie	NOUN
gsrj-21	140	11	,	,	PUNCT
gsrj-21	140	12	such	such	ADJ
gsrj-21	140	13	as	as	ADP
gsrj-21	140	14	deoxycytidine	deoxycytidine	NOUN
gsrj-21	140	15	,	,	PUNCT
gsrj-21	140	16	that	that	PRON
gsrj-21	140	17	inhibit	inhibit	VERB
gsrj-21	140	18	gem	gem	NOUN
gsrj-21	140	19	through	through	ADP
gsrj-21	140	20	direct	direct	ADJ
gsrj-21	140	21	competition	competition	NOUN
gsrj-21	140	22	,	,	PUNCT
gsrj-21	140	23	hindering	hinder	VERB
gsrj-21	140	24	drug	drug	NOUN
gsrj-21	140	25	efficacy	efficacy	NOUN
gsrj-21	140	26	.	.	PUNCT
gsrj-21	141	1	kpc	kpc	NOUN
gsrj-21	141	2	mice	mouse	NOUN
gsrj-21	141	3	treated	treat	VERB
gsrj-21	141	4	with	with	ADP
gsrj-21	141	5	gem	gem	NOUN
gsrj-21	141	6	combination	combination	NOUN
gsrj-21	141	7	treatments	treatment	NOUN
gsrj-21	141	8	had	have	VERB
gsrj-21	141	9	prolonged	prolonged	ADJ
gsrj-21	141	10	survival	survival	NOUN
gsrj-21	141	11	compared	compare	VERB
gsrj-21	141	12	to	to	ADP
gsrj-21	141	13	control	control	NOUN
gsrj-21	141	14	mice	mouse	NOUN
gsrj-21	141	15	,	,	PUNCT
gsrj-21	141	16	indicating	indicate	VERB
gsrj-21	141	17	that	that	SCONJ
gsrj-21	141	18	inhibiting	inhibit	VERB
gsrj-21	141	19	macrophage	macrophage	ADJ
gsrj-21	141	20	recruitment	recruitment	NOUN
gsrj-21	141	21	has	have	VERB
gsrj-21	141	22	the	the	DET
gsrj-21	141	23	potential	potential	NOUN
gsrj-21	141	24	to	to	PART
gsrj-21	141	25	improve	improve	VERB
gsrj-21	141	26	current	current	ADJ
gsrj-21	141	27	pdac	pdac	NOUN
gsrj-21	141	28	therapies	therapy	NOUN
gsrj-21	141	29	,	,	PUNCT
gsrj-21	141	30	as	as	SCONJ
gsrj-21	141	31	seen	see	VERB
gsrj-21	141	32	with	with	ADP
gsrj-21	141	33	folfirinox.104	folfirinox.104	PROPN
gsrj-21	141	34	özdemir	özdemir	PROPN
gsrj-21	141	35	et	et	PROPN
gsrj-21	141	36	al	al	PROPN
gsrj-21	141	37	.	.	PROPN
gsrj-21	142	1	used	use	VERB
gsrj-21	142	2	transgenic	transgenic	NOUN
gsrj-21	142	3	(	(	PUNCT
gsrj-21	142	4	ptf1acre/+;lsl	ptf1acre/+;lsl	NOUN
gsrj-21	142	5	-	-	PUNCT
gsrj-21	142	6	krasg12d/+;tgfbr2flox	krasg12d/+;tgfbr2flox	PROPN
gsrj-21	142	7	/	/	SYM
gsrj-21	142	8	flox	flox	NOUN
gsrj-21	142	9	)	)	PUNCT
gsrj-21	142	10	mice	mouse	NOUN
gsrj-21	142	11	with	with	ADP
gsrj-21	142	12	deleted	delete	VERB
gsrj-21	142	13	αsma+	αsma+	ADP
gsrj-21	142	14	myofibroblasts	myofibroblast	NOUN
gsrj-21	142	15	in	in	ADP
gsrj-21	142	16	pancreatic	pancreatic	ADJ
gsrj-21	142	17	cancer	cancer	NOUN
gsrj-21	142	18	.	.	PUNCT
gsrj-21	143	1	myofibroblast	myofibroblast	PROPN
gsrj-21	143	2	depleted	deplete	VERB
gsrj-21	143	3	tumors	tumor	NOUN
gsrj-21	143	4	did	do	AUX
gsrj-21	143	5	not	not	PART
gsrj-21	143	6	respond	respond	VERB
gsrj-21	143	7	to	to	ADP
gsrj-21	143	8	gem	gem	NOUN
gsrj-21	143	9	and	and	CCONJ
gsrj-21	143	10	resulted	result	VERB
gsrj-21	143	11	in	in	ADP
gsrj-21	143	12	multiple	multiple	ADJ
gsrj-21	143	13	adverse	adverse	ADJ
gsrj-21	143	14	outcomes	outcome	NOUN
gsrj-21	143	15	.	.	PUNCT
gsrj-21	144	1	their	their	PRON
gsrj-21	144	2	results	result	NOUN
gsrj-21	144	3	suggest	suggest	VERB
gsrj-21	144	4	that	that	SCONJ
gsrj-21	144	5	fibrosis	fibrosis	NOUN
gsrj-21	144	6	associated	associate	VERB
gsrj-21	144	7	with	with	ADP
gsrj-21	144	8	myofibroblasts	myofibroblast	NOUN
gsrj-21	144	9	and	and	CCONJ
gsrj-21	144	10	type	type	NOUN
gsrj-21	144	11	i	i	PRON
gsrj-21	144	12	collagen	collagen	NOUN
gsrj-21	144	13	constitutes	constitute	VERB
gsrj-21	144	14	a	a	DET
gsrj-21	144	15	protective	protective	ADJ
gsrj-21	144	16	response	response	NOUN
gsrj-21	144	17	from	from	ADP
gsrj-21	144	18	the	the	DET
gsrj-21	144	19	host	host	NOUN
gsrj-21	144	20	rather	rather	ADV
gsrj-21	144	21	than	than	ADP
gsrj-21	144	22	offering	offer	VERB
gsrj-21	144	23	an	an	DET
gsrj-21	144	24	oncogenic	oncogenic	ADJ
gsrj-21	144	25	supportive	supportive	ADJ
gsrj-21	144	26	role.105	role.105	NOUN
gsrj-21	144	27	6	6	NUM
gsrj-21	144	28	.	.	PUNCT
gsrj-21	145	1	gemcitabine	gemcitabine	NOUN
gsrj-21	145	2	resistance	resistance	NOUN
gsrj-21	145	3	and	and	CCONJ
gsrj-21	145	4	proteomic	proteomic	NOUN
gsrj-21	145	5	and	and	CCONJ
gsrj-21	145	6	computational	computational	ADJ
gsrj-21	145	7	models	model	NOUN
gsrj-21	145	8	gem	gem	NOUN
gsrj-21	145	9	resistance	resistance	NOUN
gsrj-21	145	10	has	have	AUX
gsrj-21	145	11	also	also	ADV
gsrj-21	145	12	been	be	AUX
gsrj-21	145	13	investigated	investigate	VERB
gsrj-21	145	14	using	use	VERB
gsrj-21	145	15	proteomic	proteomic	ADJ
gsrj-21	145	16	and	and	CCONJ
gsrj-21	145	17	computational	computational	ADJ
gsrj-21	145	18	models	model	NOUN
gsrj-21	145	19	.	.	PUNCT
gsrj-21	146	1	while	while	SCONJ
gsrj-21	146	2	biological	biological	ADJ
gsrj-21	146	3	processes	process	NOUN
gsrj-21	146	4	of	of	ADP
gsrj-21	146	5	drug	drug	NOUN
gsrj-21	146	6	resistance	resistance	NOUN
gsrj-21	146	7	have	have	AUX
gsrj-21	146	8	been	be	AUX
gsrj-21	146	9	described	describe	VERB
gsrj-21	146	10	before	before	ADV
gsrj-21	146	11	,	,	PUNCT
gsrj-21	146	12	proteomics	proteomic	NOUN
gsrj-21	146	13	serves	serve	VERB
gsrj-21	146	14	as	as	ADP
gsrj-21	146	15	a	a	DET
gsrj-21	146	16	powerful	powerful	ADJ
gsrj-21	146	17	tool	tool	NOUN
gsrj-21	146	18	for	for	ADP
gsrj-21	146	19	better	well	ADJ
gsrj-21	146	20	understanding	understand	VERB
gsrj-21	146	21	molecular	molecular	ADJ
gsrj-21	146	22	mechanisms	mechanism	NOUN
gsrj-21	146	23	of	of	ADP
gsrj-21	146	24	gem	gem	NOUN
gsrj-21	146	25	resistance.106	resistance.106	NOUN
gsrj-21	146	26	proteomics	proteomic	NOUN
gsrj-21	146	27	investigates	investigate	VERB
gsrj-21	146	28	proteins	protein	NOUN
gsrj-21	146	29	whose	whose	DET
gsrj-21	146	30	expressions	expression	NOUN
gsrj-21	146	31	differ	differ	VERB
gsrj-21	146	32	between	between	ADP
gsrj-21	146	33	drug	drug	NOUN
gsrj-21	146	34	-	-	PUNCT
gsrj-21	146	35	sensitive	sensitive	ADJ
gsrj-21	146	36	and	and	CCONJ
gsrj-21	146	37	drug	drug	NOUN
gsrj-21	146	38	-	-	PUNCT
gsrj-21	146	39	resistance	resistance	NOUN
gsrj-21	146	40	cells	cell	NOUN
gsrj-21	146	41	.	.	PUNCT
gsrj-21	147	1	this	this	DET
gsrj-21	147	2	method	method	NOUN
gsrj-21	147	3	can	can	AUX
gsrj-21	147	4	provide	provide	VERB
gsrj-21	147	5	system	system	NOUN
gsrj-21	147	6	-	-	PUNCT
gsrj-21	147	7	wide	wide	ADJ
gsrj-21	147	8	views	view	NOUN
gsrj-21	147	9	of	of	ADP
gsrj-21	147	10	signaling	signal	VERB
gsrj-21	147	11	networks	network	NOUN
gsrj-21	147	12	to	to	PART
gsrj-21	147	13	better	well	ADV
gsrj-21	147	14	understand	understand	VERB
gsrj-21	147	15	drug	drug	NOUN
gsrj-21	147	16	mechanisms	mechanism	NOUN
gsrj-21	147	17	of	of	ADP
gsrj-21	147	18	actions	action	NOUN
gsrj-21	147	19	and	and	CCONJ
gsrj-21	147	20	interactions.106	interactions.106	NOUN
gsrj-21	147	21	proteomics	proteomic	NOUN
gsrj-21	147	22	also	also	ADV
gsrj-21	147	23	provides	provide	VERB
gsrj-21	147	24	the	the	DET
gsrj-21	147	25	knowledge	knowledge	NOUN
gsrj-21	147	26	needed	need	VERB
gsrj-21	147	27	to	to	PART
gsrj-21	147	28	identify	identify	VERB
gsrj-21	147	29	biomarkers	biomarker	NOUN
gsrj-21	147	30	and	and	CCONJ
gsrj-21	147	31	for	for	ADP
gsrj-21	147	32	targeting	target	VERB
gsrj-21	147	33	specific	specific	ADJ
gsrj-21	147	34	protein	protein	NOUN
gsrj-21	147	35	pathways.106	pathways.106	NUM
gsrj-21	147	36	chen	chen	PROPN
gsrj-21	147	37	et	et	PROPN
gsrj-21	147	38	al	al	PROPN
gsrj-21	147	39	.	.	PROPN
gsrj-21	147	40	examined	examine	VERB
gsrj-21	147	41	mechanisms	mechanism	NOUN
gsrj-21	147	42	associated	associate	VERB
gsrj-21	147	43	with	with	ADP
gsrj-21	147	44	gem	gem	NOUN
gsrj-21	147	45	-	-	PUNCT
gsrj-21	147	46	induced	induce	VERB
gsrj-21	147	47	resistance	resistance	NOUN
gsrj-21	147	48	using	use	VERB
gsrj-21	147	49	2d	2d	NOUN
gsrj-21	147	50	-	-	PUNCT
gsrj-21	147	51	dige	dige	NOUN
gsrj-21	147	52	and	and	CCONJ
gsrj-21	147	53	maldi	maldi	PROPN
gsrj-21	147	54	-	-	PUNCT
gsrj-21	147	55	tof	tof	PRON
gsrj-21	147	56	mass	mass	ADJ
gsrj-21	147	57	spectrometry	spectrometry	NOUN
gsrj-21	147	58	and	and	CCONJ
gsrj-21	147	59	compared	compare	VERB
gsrj-21	147	60	the	the	DET
gsrj-21	147	61	proteomic	proteomic	ADJ
gsrj-21	147	62	alternations	alternation	NOUN
gsrj-21	147	63	of	of	ADP
gsrj-21	147	64	a	a	DET
gsrj-21	147	65	panel	panel	NOUN
gsrj-21	147	66	of	of	ADP
gsrj-21	147	67	differential	differential	ADJ
gsrj-21	147	68	gem	gem	NOUN
gsrj-21	147	69	-	-	PUNCT
gsrj-21	147	70	resistant	resistant	ADJ
gsrj-21	147	71	panc-1	panc-1	NOUN
gsrj-21	147	72	cells	cell	NOUN
gsrj-21	147	73	and	and	CCONJ
gsrj-21	147	74	gem	gem	NOUN
gsrj-21	147	75	-	-	PUNCT
gsrj-21	147	76	sensitive	sensitive	ADJ
gsrj-21	147	77	pancreatic	pancreatic	ADJ
gsrj-21	147	78	cells	cell	NOUN
gsrj-21	147	79	.	.	PUNCT
gsrj-21	148	1	they	they	PRON
gsrj-21	148	2	found	find	VERB
gsrj-21	148	3	that	that	SCONJ
gsrj-21	148	4	33	33	NUM
gsrj-21	148	5	proteins	protein	NOUN
gsrj-21	148	6	were	be	AUX
gsrj-21	148	7	differentially	differentially	ADV
gsrj-21	148	8	expressed	express	VERB
gsrj-21	148	9	between	between	ADP
gsrj-21	148	10	gem	gem	NOUN
gsrj-21	148	11	-	-	PUNCT
gsrj-21	148	12	sensitive	sensitive	ADJ
gsrj-21	148	13	and	and	CCONJ
gsrj-21	148	14	gem	gem	NOUN
gsrj-21	148	15	-	-	PUNCT
gsrj-21	148	16	resistant	resistant	ADJ
gsrj-21	148	17	cells.107	cells.107	NOUN
gsrj-21	149	1	zhu	zhu	X
gsrj-21	149	2	et	et	PROPN
gsrj-21	149	3	al	al	PROPN
gsrj-21	149	4	.	.	PROPN
gsrj-21	149	5	studied	study	VERB
gsrj-21	149	6	gem	gem	NOUN
gsrj-21	149	7	with	with	ADP
gsrj-21	149	8	birinapant	birinapant	NOUN
gsrj-21	149	9	in	in	ADP
gsrj-21	149	10	pdac	pdac	NOUN
gsrj-21	149	11	.	.	PUNCT
gsrj-21	150	1	they	they	PRON
gsrj-21	150	2	identified	identify	VERB
gsrj-21	150	3	4069	4069	NUM
gsrj-21	150	4	drug	drug	NOUN
gsrj-21	150	5	-	-	PUNCT
gsrj-21	150	6	responsive	responsive	ADJ
gsrj-21	150	7	proteins	protein	NOUN
gsrj-21	150	8	and	and	CCONJ
gsrj-21	150	9	quantified	quantify	VERB
gsrj-21	150	10	them	they	PRON
gsrj-21	150	11	in	in	ADP
gsrj-21	150	12	a	a	DET
gsrj-21	150	13	time	time	NOUN
gsrj-21	150	14	-	-	PUNCT
gsrj-21	150	15	series	series	NOUN
gsrj-21	150	16	proteome	proteome	ADJ
gsrj-21	150	17	analysis	analysis	NOUN
gsrj-21	150	18	to	to	PART
gsrj-21	150	19	highlight	highlight	VERB
gsrj-21	150	20	and	and	CCONJ
gsrj-21	150	21	quantify	quantify	VERB
gsrj-21	150	22	signaling	signal	VERB
gsrj-21	150	23	pathways	pathway	NOUN
gsrj-21	150	24	.	.	PUNCT
gsrj-21	151	1	pathways	pathway	NOUN
gsrj-21	151	2	related	relate	VERB
gsrj-21	151	3	to	to	ADP
gsrj-21	151	4	dna	dna	PROPN
gsrj-21	151	5	damage	damage	NOUN
gsrj-21	151	6	response	response	NOUN
gsrj-21	151	7	,	,	PUNCT
gsrj-21	151	8	dna	dna	PROPN
gsrj-21	151	9	repair	repair	NOUN
gsrj-21	151	10	,	,	PUNCT
gsrj-21	151	11	anti	anti	ADJ
gsrj-21	151	12	-	-	ADJ
gsrj-21	151	13	apoptosis	apoptosis	ADJ
gsrj-21	151	14	,	,	PUNCT
gsrj-21	151	15	pro	pro	ADJ
gsrj-21	151	16	-	-	ADJ
gsrj-21	151	17	migration	migration	ADJ
gsrj-21	151	18	/	/	SYM
gsrj-21	151	19	invasion	invasion	NOUN
gsrj-21	151	20	were	be	AUX
gsrj-21	151	21	implicated	implicate	VERB
gsrj-21	151	22	as	as	ADP
gsrj-21	151	23	underlying	underlying	ADJ
gsrj-21	151	24	mechanisms	mechanism	NOUN
gsrj-21	151	25	for	for	ADP
gsrj-21	151	26	gemcitabine	gemcitabine	NOUN
gsrj-21	151	27	resistance	resistance	NOUN
gsrj-21	151	28	.	.	PUNCT
gsrj-21	152	1	this	this	DET
gsrj-21	152	2	study	study	NOUN
gsrj-21	152	3	identified	identify	VERB
gsrj-21	152	4	promising	promise	VERB
gsrj-21	152	5	drug	drug	NOUN
gsrj-21	152	6	targets	target	NOUN
gsrj-21	152	7	for	for	ADP
gsrj-21	152	8	future	future	ADJ
gsrj-21	152	9	investigation.106	investigation.106	NOUN
gsrj-21	152	10	law	law	NOUN
gsrj-21	152	11	et	et	PROPN
gsrj-21	152	12	al	al	PROPN
gsrj-21	152	13	.	.	PROPN
gsrj-21	152	14	analyzed	analyze	VERB
gsrj-21	152	15	clinical	clinical	ADJ
gsrj-21	152	16	pdac	pdac	NOUN
gsrj-21	152	17	liver	liver	NOUN
gsrj-21	152	18	metastases	metastasis	NOUN
gsrj-21	152	19	with	with	ADP
gsrj-21	152	20	quantitative	quantitative	ADJ
gsrj-21	152	21	proteomics	proteomic	NOUN
gsrj-21	152	22	.	.	PUNCT
gsrj-21	153	1	their	their	PRON
gsrj-21	153	2	proteomic	proteomic	ADJ
gsrj-21	153	3	analysis	analysis	NOUN
gsrj-21	153	4	of	of	ADP
gsrj-21	153	5	molecular	molecular	ADJ
gsrj-21	153	6	signatures	signature	NOUN
gsrj-21	153	7	unique	unique	ADJ
gsrj-21	153	8	to	to	ADP
gsrj-21	153	9	the	the	DET
gsrj-21	153	10	disease	disease	NOUN
gsrj-21	153	11	subtypes	subtype	NOUN
gsrj-21	153	12	identified	identify	VERB
gsrj-21	153	13	gem	gem	NOUN
gsrj-21	153	14	-	-	PUNCT
gsrj-21	153	15	induced	induce	VERB
gsrj-21	153	16	alterations	alteration	NOUN
gsrj-21	153	17	in	in	ADP
gsrj-21	153	18	proteins	protein	NOUN
gsrj-21	153	19	,	,	PUNCT
gsrj-21	153	20	such	such	ADJ
gsrj-21	153	21	as	as	ADP
gsrj-21	153	22	serine	serine	ADJ
gsrj-21	153	23	hydroxymethyltransferase	hydroxymethyltransferase	NOUN
gsrj-21	153	24	1	1	NUM
gsrj-21	153	25	,	,	PUNCT
gsrj-21	153	26	that	that	PRON
gsrj-21	153	27	are	be	AUX
gsrj-21	153	28	associated	associate	VERB
gsrj-21	153	29	with	with	ADP
gsrj-21	153	30	drug	drug	NOUN
gsrj-21	153	31	resistance.108	resistance.108	PRON
gsrj-21	153	32	pdac	pdac	NOUN
gsrj-21	153	33	subtypes	subtype	NOUN
gsrj-21	153	34	can	can	AUX
gsrj-21	153	35	be	be	AUX
gsrj-21	153	36	characterized	characterize	VERB
gsrj-21	153	37	using	use	VERB
gsrj-21	153	38	proteomics	proteomic	NOUN
gsrj-21	153	39	and	and	CCONJ
gsrj-21	153	40	can	can	AUX
gsrj-21	153	41	be	be	AUX
gsrj-21	153	42	used	use	VERB
gsrj-21	153	43	to	to	PART
gsrj-21	153	44	inform	inform	VERB
gsrj-21	153	45	first	first	ADJ
gsrj-21	153	46	-	-	PUNCT
gsrj-21	153	47	line	line	NOUN
gsrj-21	153	48	cancer	cancer	NOUN
gsrj-21	153	49	treatment	treatment	NOUN
gsrj-21	153	50	.	.	PUNCT
gsrj-21	154	1	these	these	DET
gsrj-21	154	2	efforts	effort	NOUN
gsrj-21	154	3	illustrate	illustrate	VERB
gsrj-21	154	4	the	the	DET
gsrj-21	154	5	potential	potential	NOUN
gsrj-21	154	6	of	of	ADP
gsrj-21	154	7	applying	apply	VERB
gsrj-21	154	8	proteomics	proteomic	NOUN
gsrj-21	154	9	to	to	PART
gsrj-21	154	10	improve	improve	VERB
gsrj-21	154	11	pdac	pdac	ADJ
gsrj-21	154	12	subtype	subtype	NOUN
gsrj-21	154	13	classification	classification	NOUN
gsrj-21	154	14	and	and	CCONJ
gsrj-21	154	15	therefore	therefore	ADV
gsrj-21	154	16	early	early	ADJ
gsrj-21	154	17	detection	detection	NOUN
gsrj-21	154	18	and	and	CCONJ
gsrj-21	154	19	treatment	treatment	NOUN
gsrj-21	154	20	of	of	ADP
gsrj-21	154	21	pdac	pdac	NOUN
gsrj-21	154	22	.	.	PUNCT
gsrj-21	155	1	computational	computational	ADJ
gsrj-21	155	2	modeling	modeling	NOUN
gsrj-21	155	3	of	of	ADP
gsrj-21	155	4	gemcitabinebased	gemcitabinebased	ADJ
gsrj-21	155	5	therapies	therapy	NOUN
gsrj-21	155	6	has	have	AUX
gsrj-21	155	7	also	also	ADV
gsrj-21	155	8	been	be	AUX
gsrj-21	155	9	conducted	conduct	VERB
gsrj-21	155	10	to	to	PART
gsrj-21	155	11	determine	determine	VERB
gsrj-21	155	12	optimal	optimal	ADJ
gsrj-21	155	13	intervention	intervention	NOUN
gsrj-21	155	14	strategies.109	strategies.109	VERB
gsrj-21	155	15	furthermore	furthermore	ADV
gsrj-21	155	16	,	,	PUNCT
gsrj-21	155	17	transcriptomics	transcriptomic	NOUN
gsrj-21	155	18	has	have	AUX
gsrj-21	155	19	been	be	AUX
gsrj-21	155	20	implemented	implement	VERB
gsrj-21	155	21	to	to	PART
gsrj-21	155	22	better	well	ADV
gsrj-21	155	23	under	under	ADP
gsrj-21	155	24	the	the	DET
gsrj-21	155	25	tumor	tumor	NOUN
gsrj-21	155	26	microenvironment	microenvironment	NOUN
gsrj-21	155	27	and	and	CCONJ
gsrj-21	155	28	chart	chart	NOUN
gsrj-21	155	29	changes	change	NOUN
gsrj-21	155	30	in	in	ADP
gsrj-21	155	31	the	the	DET
gsrj-21	155	32	fibroblastic	fibroblastic	ADJ
gsrj-21	155	33	landscape	landscape	NOUN
gsrj-21	155	34	in	in	ADP
gsrj-21	155	35	pdac	pdac	ADJ
gsrj-21	155	36	progression.110	progression.110	NOUN
gsrj-21	155	37	7	7	NUM
gsrj-21	155	38	.	.	PUNCT
gsrj-21	155	39	conclusion	conclusion	NOUN
gsrj-21	155	40	models	model	NOUN
gsrj-21	155	41	are	be	AUX
gsrj-21	155	42	essential	essential	ADJ
gsrj-21	155	43	to	to	ADP
gsrj-21	155	44	addressing	address	VERB
gsrj-21	155	45	issues	issue	NOUN
gsrj-21	155	46	of	of	ADP
gsrj-21	155	47	drug	drug	NOUN
gsrj-21	155	48	resistance	resistance	NOUN
gsrj-21	155	49	in	in	ADP
gsrj-21	155	50	cancer	cancer	NOUN
gsrj-21	155	51	phenotypes	phenotype	NOUN
gsrj-21	155	52	.	.	PUNCT
gsrj-21	156	1	while	while	SCONJ
gsrj-21	156	2	gem	gem	NOUN
gsrj-21	156	3	resistance	resistance	NOUN
gsrj-21	156	4	in	in	ADP
gsrj-21	156	5	pdac	pdac	PROPN
gsrj-21	156	6	continues	continue	VERB
gsrj-21	156	7	to	to	PART
gsrj-21	156	8	result	result	VERB
gsrj-21	156	9	in	in	ADP
gsrj-21	156	10	dire	dire	ADJ
gsrj-21	156	11	outcomes	outcome	NOUN
gsrj-21	156	12	for	for	ADP
gsrj-21	156	13	patients	patient	NOUN
gsrj-21	156	14	,	,	PUNCT
gsrj-21	156	15	models	model	NOUN
gsrj-21	156	16	can	can	AUX
gsrj-21	156	17	serve	serve	VERB
gsrj-21	156	18	as	as	ADP
gsrj-21	156	19	a	a	DET
gsrj-21	156	20	step	step	NOUN
gsrj-21	156	21	towards	towards	ADP
gsrj-21	156	22	elucidating	elucidate	VERB
gsrj-21	156	23	resistance	resistance	NOUN
gsrj-21	156	24	mechanisms	mechanism	NOUN
gsrj-21	156	25	to	to	PART
gsrj-21	156	26	improve	improve	VERB
gsrj-21	156	27	treatment	treatment	NOUN
gsrj-21	156	28	protocols	protocol	NOUN
gsrj-21	156	29	.	.	PUNCT
gsrj-21	157	1	the	the	DET
gsrj-21	157	2	number	number	NOUN
gsrj-21	157	3	of	of	ADP
gsrj-21	157	4	models	model	NOUN
gsrj-21	157	5	currently	currently	ADV
gsrj-21	157	6	in	in	ADP
gsrj-21	157	7	use	use	NOUN
gsrj-21	157	8	can	can	AUX
gsrj-21	157	9	reproduce	reproduce	VERB
gsrj-21	157	10	a	a	DET
gsrj-21	157	11	wide	wide	ADJ
gsrj-21	157	12	range	range	NOUN
gsrj-21	157	13	of	of	ADP
gsrj-21	157	14	tumor	tumor	NOUN
gsrj-21	157	15	mechanisms	mechanism	NOUN
gsrj-21	157	16	to	to	PART
gsrj-21	157	17	ultimately	ultimately	ADV
gsrj-21	157	18	understand	understand	VERB
gsrj-21	157	19	factors	factor	NOUN
gsrj-21	157	20	such	such	ADJ
gsrj-21	157	21	as	as	ADP
gsrj-21	157	22	cell	cell	NOUN
gsrj-21	157	23	-	-	PUNCT
gsrj-21	157	24	cell	cell	NOUN
gsrj-21	157	25	interactions	interaction	NOUN
gsrj-21	157	26	and	and	CCONJ
gsrj-21	157	27	the	the	DET
gsrj-21	157	28	tumor	tumor	NOUN
gsrj-21	157	29	microenvironment	microenvironment	NOUN
gsrj-21	157	30	.	.	PUNCT
gsrj-21	158	1	the	the	DET
gsrj-21	158	2	use	use	NOUN
gsrj-21	158	3	of	of	ADP
gsrj-21	158	4	various	various	ADJ
gsrj-21	158	5	in	in	ADP
gsrj-21	158	6	vivo	vivo	NOUN
gsrj-21	158	7	,	,	PUNCT
gsrj-21	158	8	in	in	ADP
gsrj-21	158	9	vitro	vitro	X
gsrj-21	158	10	,	,	PUNCT
gsrj-21	158	11	proteomic	proteomic	NOUN
gsrj-21	158	12	,	,	PUNCT
gsrj-21	158	13	and	and	CCONJ
gsrj-21	158	14	computational	computational	ADJ
gsrj-21	158	15	models	model	NOUN
gsrj-21	158	16	will	will	AUX
gsrj-21	158	17	be	be	AUX
gsrj-21	158	18	crucial	crucial	ADJ
gsrj-21	158	19	in	in	ADP
gsrj-21	158	20	making	make	VERB
gsrj-21	158	21	a	a	DET
gsrj-21	158	22	clinical	clinical	ADJ
gsrj-21	158	23	impact	impact	NOUN
gsrj-21	158	24	and	and	CCONJ
gsrj-21	158	25	55	55	NUM
gsrj-21	158	26	georgetown	georgetown	NOUN
gsrj-21	158	27	scientific	scientific	PROPN
gsrj-21	158	28	research	research	NOUN
gsrj-21	158	29	journal	journal	NOUN
gsrj-21	158	30	benefiting	benefit	VERB
gsrj-21	158	31	pdac	pdac	NOUN
gsrj-21	158	32	patients	patient	NOUN
gsrj-21	158	33	with	with	ADP
gsrj-21	158	34	better	well	ADJ
gsrj-21	158	35	platforms	platform	NOUN
gsrj-21	158	36	for	for	ADP
gsrj-21	158	37	treatment	treatment	NOUN
gsrj-21	158	38	and	and	CCONJ
gsrj-21	158	39	diagnosis	diagnosis	NOUN
gsrj-21	158	40	.	.	PUNCT
gsrj-21	159	1	references	reference	NOUN
gsrj-21	159	2	1	1	NUM
gsrj-21	159	3	.	.	PUNCT
gsrj-21	160	1	kroemer	kroemer	PROPN
gsrj-21	160	2	,	,	PUNCT
gsrj-21	160	3	g.	g.	PROPN
gsrj-21	160	4	,	,	PUNCT
gsrj-21	160	5	&	&	CCONJ
gsrj-21	160	6	pouyssegur	pouyssegur	PROPN
gsrj-21	160	7	,	,	PUNCT
gsrj-21	160	8	j.	j.	PROPN
gsrj-21	160	9	(	(	PUNCT
gsrj-21	160	10	2008	2008	NUM
gsrj-21	160	11	)	)	PUNCT
gsrj-21	160	12	.	.	PUNCT
gsrj-21	161	1	tumor	tumor	NOUN
gsrj-21	161	2	cell	cell	NOUN
gsrj-21	161	3	metabolism	metabolism	NOUN
gsrj-21	161	4	:	:	PUNCT
gsrj-21	161	5	cancer	cancer	NOUN
gsrj-21	161	6	's	's	PART
gsrj-21	161	7	achilles	achille	NOUN
gsrj-21	161	8	'	'	PART
gsrj-21	161	9	heel	heel	NOUN
gsrj-21	161	10	.	.	PUNCT
gsrj-21	162	1	cancer	cancer	NOUN
gsrj-21	162	2	cell	cell	NOUN
gsrj-21	162	3	,	,	PUNCT
gsrj-21	162	4	13(6	13(6	PROPN
gsrj-21	162	5	)	)	PUNCT
gsrj-21	162	6	,	,	PUNCT
gsrj-21	162	7	472	472	NUM
gsrj-21	162	8	-	-	SYM
gsrj-21	162	9	482	482	NUM
gsrj-21	162	10	.	.	PUNCT
gsrj-21	163	1	https://doi.org/10.1016/j.ccr.2008.05.005	https://doi.org/10.1016/j.ccr.2008.05.005	PROPN
gsrj-21	163	2	2	2	NUM
gsrj-21	163	3	.	.	X
gsrj-21	163	4	hammerlindl	hammerlindl	PROPN
gsrj-21	163	5	,	,	PUNCT
gsrj-21	163	6	h.	h.	PROPN
gsrj-21	163	7	,	,	PUNCT
gsrj-21	163	8	&	&	CCONJ
gsrj-21	163	9	schaider	schaider	NOUN
gsrj-21	163	10	,	,	PUNCT
gsrj-21	163	11	h.	h.	PROPN
gsrj-21	163	12	(	(	PUNCT
gsrj-21	163	13	2018	2018	NUM
gsrj-21	163	14	)	)	PUNCT
gsrj-21	163	15	.	.	PUNCT
gsrj-21	164	1	tumor	tumor	NOUN
gsrj-21	164	2	cell	cell	NOUN
gsrj-21	164	3	-	-	PUNCT
gsrj-21	164	4	intrinsic	intrinsic	ADJ
gsrj-21	164	5	phenotypic	phenotypic	NOUN
gsrj-21	164	6	plasticity	plasticity	NOUN
gsrj-21	164	7	facilitates	facilitate	VERB
gsrj-21	164	8	adaptive	adaptive	ADJ
gsrj-21	164	9	cellular	cellular	ADJ
gsrj-21	164	10	reprogramming	reprogramme	VERB
gsrj-21	164	11	driving	driving	NOUN
gsrj-21	164	12	acquired	acquire	VERB
gsrj-21	164	13	drug	drug	NOUN
gsrj-21	164	14	resistance	resistance	NOUN
gsrj-21	164	15	.	.	PUNCT
gsrj-21	165	1	journal	journal	NOUN
gsrj-21	165	2	of	of	ADP
gsrj-21	165	3	cell	cell	NOUN
gsrj-21	165	4	communication	communication	NOUN
gsrj-21	165	5	and	and	CCONJ
gsrj-21	165	6	signaling	signal	VERB
gsrj-21	165	7	,	,	PUNCT
gsrj-21	165	8	12(1	12(1	NUM
gsrj-21	165	9	)	)	PUNCT
gsrj-21	165	10	,	,	PUNCT
gsrj-21	165	11	133	133	NUM
gsrj-21	165	12	-	-	SYM
gsrj-21	165	13	141	141	NUM
gsrj-21	165	14	.	.	PUNCT
gsrj-21	166	1	https://doi.org/10.1007/s12079-017-0435-1	https://doi.org/10.1007/s12079-017-0435-1	NUM
gsrj-21	166	2	3	3	NUM
gsrj-21	166	3	.	.	X
gsrj-21	166	4	kelderman	kelderman	NOUN
gsrj-21	166	5	,	,	PUNCT
gsrj-21	166	6	s.	s.	PROPN
gsrj-21	166	7	,	,	PUNCT
gsrj-21	166	8	schumacher	schumacher	PROPN
gsrj-21	166	9	,	,	PUNCT
gsrj-21	166	10	t.	t.	PROPN
gsrj-21	166	11	n.	n.	PROPN
gsrj-21	166	12	m.	m.	PROPN
gsrj-21	166	13	,	,	PUNCT
gsrj-21	166	14	&	&	CCONJ
gsrj-21	166	15	haanen	haanen	PROPN
gsrj-21	166	16	,	,	PUNCT
gsrj-21	166	17	john	john	PROPN
gsrj-21	166	18	b.	b.	PROPN
gsrj-21	166	19	a.	a.	PROPN
gsrj-21	166	20	g.	g.	PROPN
gsrj-21	166	21	(	(	PUNCT
gsrj-21	166	22	2015	2015	NUM
gsrj-21	166	23	)	)	PUNCT
gsrj-21	166	24	.	.	PUNCT
gsrj-21	167	1	sciencedirect	sciencedirect	PROPN
gsrj-21	167	2	.	.	PUNCT
gsrj-21	168	1	clinical	clinical	ADJ
gsrj-21	168	2	microbiology	microbiology	NOUN
gsrj-21	168	3	newsletter	newsletter	NOUN
gsrj-21	168	4	,	,	PUNCT
gsrj-21	168	5	37(4	37(4	PROPN
gsrj-21	168	6	)	)	PUNCT
gsrj-21	168	7	,	,	PUNCT
gsrj-21	168	8	33	33	NUM
gsrj-21	168	9	.	.	PUNCT
gsrj-21	169	1	https://doi.org/10.1016/j.clinmicnews.2015.01.008	https://doi.org/10.1016/j.clinmicnews.2015.01.008	NOUN
gsrj-21	169	2	4	4	NUM
gsrj-21	169	3	.	.	X
gsrj-21	169	4	ireland	ireland	PROPN
gsrj-21	169	5	,	,	PUNCT
gsrj-21	169	6	l.	l.	PROPN
gsrj-21	169	7	,	,	PUNCT
gsrj-21	169	8	santos	santos	PROPN
gsrj-21	169	9	,	,	PUNCT
gsrj-21	169	10	a.	a.	NOUN
gsrj-21	169	11	,	,	PUNCT
gsrj-21	169	12	ahmed	ahmed	PROPN
gsrj-21	169	13	,	,	PUNCT
gsrj-21	169	14	m.	m.	NOUN
gsrj-21	169	15	s.	s.	PROPN
gsrj-21	169	16	,	,	PUNCT
gsrj-21	169	17	rainer	rainer	NOUN
gsrj-21	169	18	,	,	PUNCT
gsrj-21	169	19	c.	c.	PROPN
gsrj-21	169	20	,	,	PUNCT
gsrj-21	169	21	nielsen	nielsen	PROPN
gsrj-21	169	22	,	,	PUNCT
gsrj-21	169	23	s.	s.	PROPN
gsrj-21	169	24	r.	r.	PROPN
gsrj-21	169	25	,	,	PUNCT
gsrj-21	169	26	quaranta	quaranta	PROPN
gsrj-21	169	27	,	,	PUNCT
gsrj-21	169	28	v.	v.	PROPN
gsrj-21	169	29	,	,	PUNCT
gsrj-21	169	30	et	et	PROPN
gsrj-21	169	31	al	al	PROPN
gsrj-21	169	32	.	.	PUNCT
gsrj-21	169	33	(	(	PUNCT
gsrj-21	169	34	2016	2016	NUM
gsrj-21	169	35	)	)	PUNCT
gsrj-21	169	36	.	.	PUNCT
gsrj-21	170	1	chemoresistance	chemoresistance	NOUN
gsrj-21	170	2	in	in	ADP
gsrj-21	170	3	pancreatic	pancreatic	ADJ
gsrj-21	170	4	cancer	cancer	NOUN
gsrj-21	170	5	is	be	AUX
gsrj-21	170	6	driven	drive	VERB
gsrj-21	170	7	by	by	ADP
gsrj-21	170	8	stroma	stroma	NOUN
gsrj-21	170	9	-	-	PUNCT
gsrj-21	170	10	derived	derive	VERB
gsrj-21	170	11	insulin	insulin	NOUN
gsrj-21	170	12	-	-	PUNCT
gsrj-21	170	13	like	like	ADJ
gsrj-21	170	14	growth	growth	NOUN
gsrj-21	170	15	factors	factor	NOUN
gsrj-21	170	16	.	.	PUNCT
gsrj-21	171	1	cancer	cancer	NOUN
gsrj-21	171	2	research	research	NOUN
gsrj-21	171	3	,	,	PUNCT
gsrj-21	171	4	76(23	76(23	NOUN
gsrj-21	171	5	)	)	PUNCT
gsrj-21	171	6	,	,	PUNCT
gsrj-21	171	7	6851	6851	NUM
gsrj-21	171	8	-	-	SYM
gsrj-21	171	9	6863	6863	NUM
gsrj-21	171	10	.	.	PUNCT
gsrj-21	172	1	5	5	NUM
gsrj-21	172	2	.	.	X
gsrj-21	172	3	holohan	holohan	PROPN
gsrj-21	172	4	,	,	PUNCT
gsrj-21	172	5	c.	c.	PROPN
gsrj-21	172	6	,	,	PUNCT
gsrj-21	172	7	van	van	PROPN
gsrj-21	172	8	schaeybroeck	schaeybroeck	PROPN
gsrj-21	172	9	,	,	PUNCT
gsrj-21	172	10	s.	s.	PROPN
gsrj-21	172	11	,	,	PUNCT
gsrj-21	172	12	longley	longley	PROPN
gsrj-21	172	13	,	,	PUNCT
gsrj-21	172	14	d.	d.	PROPN
gsrj-21	172	15	b.	b.	PROPN
gsrj-21	172	16	,	,	PUNCT
gsrj-21	172	17	&	&	CCONJ
gsrj-21	172	18	johnston	johnston	PROPN
gsrj-21	172	19	,	,	PUNCT
gsrj-21	172	20	p.	p.	PROPN
gsrj-21	172	21	g.	g.	PROPN
gsrj-21	173	1	(	(	PUNCT
gsrj-21	173	2	2013	2013	NUM
gsrj-21	173	3	)	)	PUNCT
gsrj-21	173	4	.	.	PUNCT
gsrj-21	174	1	cancer	cancer	NOUN
gsrj-21	174	2	drug	drug	NOUN
gsrj-21	174	3	resistance	resistance	NOUN
gsrj-21	174	4	:	:	PUNCT
gsrj-21	174	5	an	an	DET
gsrj-21	174	6	evolving	evolve	VERB
gsrj-21	174	7	paradigm	paradigm	NOUN
gsrj-21	174	8	.	.	PUNCT
gsrj-21	175	1	nature	nature	NOUN
gsrj-21	175	2	reviews	review	NOUN
gsrj-21	175	3	.	.	PUNCT
gsrj-21	176	1	cancer	cancer	NOUN
gsrj-21	176	2	,	,	PUNCT
gsrj-21	176	3	13(10	13(10	NUM
gsrj-21	176	4	)	)	PUNCT
gsrj-21	176	5	,	,	PUNCT
gsrj-21	176	6	714	714	NUM
gsrj-21	176	7	-	-	SYM
gsrj-21	176	8	726	726	NUM
gsrj-21	176	9	.	.	PUNCT
gsrj-21	176	10	https://doi.org/10.1038/nrc3599	https://doi.org/10.1038/nrc3599	PROPN
gsrj-21	176	11	6	6	NUM
gsrj-21	176	12	.	.	PUNCT
gsrj-21	176	13	tuveson	tuveson	PROPN
gsrj-21	176	14	,	,	PUNCT
gsrj-21	176	15	d.	d.	PROPN
gsrj-21	176	16	,	,	PUNCT
gsrj-21	176	17	&	&	CCONJ
gsrj-21	176	18	clevers	clevers	PROPN
gsrj-21	176	19	,	,	PUNCT
gsrj-21	176	20	h.	h.	PROPN
gsrj-21	176	21	(	(	PUNCT
gsrj-21	176	22	2019	2019	NUM
gsrj-21	176	23	)	)	PUNCT
gsrj-21	176	24	.	.	PUNCT
gsrj-21	177	1	cancer	cancer	NOUN
gsrj-21	177	2	modeling	modeling	NOUN
gsrj-21	177	3	meets	meet	VERB
gsrj-21	177	4	human	human	ADJ
gsrj-21	177	5	organoid	organoid	PROPN
gsrj-21	177	6	technology	technology	NOUN
gsrj-21	177	7	.	.	PUNCT
gsrj-21	178	1	science	science	NOUN
gsrj-21	178	2	(	(	PUNCT
gsrj-21	178	3	american	american	PROPN
gsrj-21	178	4	association	association	PROPN
gsrj-21	178	5	for	for	ADP
gsrj-21	178	6	the	the	DET
gsrj-21	178	7	advancement	advancement	NOUN
gsrj-21	178	8	of	of	ADP
gsrj-21	178	9	science	science	NOUN
gsrj-21	178	10	)	)	PUNCT
gsrj-21	178	11	,	,	PUNCT
gsrj-21	178	12	364(6444	364(6444	NUM
gsrj-21	178	13	)	)	PUNCT
gsrj-21	178	14	,	,	PUNCT
gsrj-21	178	15	952	952	NUM
gsrj-21	178	16	-	-	SYM
gsrj-21	178	17	955	955	NUM
gsrj-21	178	18	.	.	PUNCT
gsrj-21	179	1	https://doi.org/10.1126/science.aaw6985	https://doi.org/10.1126/science.aaw6985	PROPN
gsrj-21	179	2	7	7	NUM
gsrj-21	179	3	.	.	PUNCT
gsrj-21	180	1	zeng	zeng	PROPN
gsrj-21	180	2	,	,	PUNCT
gsrj-21	180	3	pöttler	pöttler	PROPN
gsrj-21	180	4	,	,	PUNCT
gsrj-21	180	5	lan	lan	PROPN
gsrj-21	180	6	,	,	PUNCT
gsrj-21	180	7	grützmann	grützmann	PROPN
gsrj-21	180	8	,	,	PUNCT
gsrj-21	180	9	pilarsky	pilarsky	ADJ
gsrj-21	180	10	,	,	PUNCT
gsrj-21	180	11	&	&	CCONJ
gsrj-21	180	12	yang	yang	PROPN
gsrj-21	180	13	.	.	PUNCT
gsrj-21	181	1	(	(	PUNCT
gsrj-21	181	2	2019	2019	NUM
gsrj-21	181	3	)	)	PUNCT
gsrj-21	181	4	.	.	PUNCT
gsrj-21	182	1	chemoresistance	chemoresistance	NOUN
gsrj-21	182	2	in	in	ADP
gsrj-21	182	3	pancreatic	pancreatic	ADJ
gsrj-21	182	4	cancer	cancer	NOUN
gsrj-21	182	5	.	.	PUNCT
gsrj-21	183	1	international	international	ADJ
gsrj-21	183	2	journal	journal	NOUN
gsrj-21	183	3	of	of	ADP
gsrj-21	183	4	molecular	molecular	ADJ
gsrj-21	183	5	sciences	science	NOUN
gsrj-21	183	6	,	,	PUNCT
gsrj-21	183	7	20(18	20(18	NUM
gsrj-21	183	8	)	)	PUNCT
gsrj-21	183	9	,	,	PUNCT
gsrj-21	183	10	4504	4504	NUM
gsrj-21	183	11	.	.	PUNCT
gsrj-21	184	1	https://doi.org/10.3390/ijms20184504	https://doi.org/10.3390/ijms20184504	PROPN
gsrj-21	184	2	8	8	NUM
gsrj-21	184	3	.	.	PUNCT
gsrj-21	185	1	bissell	bissell	PROPN
gsrj-21	185	2	,	,	PUNCT
gsrj-21	185	3	m.	m.	PROPN
gsrj-21	185	4	j.	j.	PROPN
gsrj-21	185	5	,	,	PUNCT
gsrj-21	185	6	hall	hall	PROPN
gsrj-21	185	7	,	,	PUNCT
gsrj-21	185	8	h.	h.	PROPN
gsrj-21	185	9	g.	g.	PROPN
gsrj-21	185	10	,	,	PUNCT
gsrj-21	185	11	&	&	CCONJ
gsrj-21	185	12	parry	parry	PROPN
gsrj-21	185	13	,	,	PUNCT
gsrj-21	185	14	g.	g.	PROPN
gsrj-21	185	15	(	(	PUNCT
gsrj-21	185	16	1982	1982	NUM
gsrj-21	185	17	)	)	PUNCT
gsrj-21	185	18	.	.	PUNCT
gsrj-21	186	1	how	how	SCONJ
gsrj-21	186	2	does	do	AUX
gsrj-21	186	3	the	the	DET
gsrj-21	186	4	extracellular	extracellular	ADJ
gsrj-21	186	5	matrix	matrix	NOUN
gsrj-21	186	6	direct	direct	ADJ
gsrj-21	186	7	gene	gene	NOUN
gsrj-21	186	8	expression	expression	NOUN
gsrj-21	186	9	?	?	PUNCT
gsrj-21	187	1	journal	journal	NOUN
gsrj-21	187	2	of	of	ADP
gsrj-21	187	3	theoretical	theoretical	ADJ
gsrj-21	187	4	biology	biology	NOUN
gsrj-21	187	5	,	,	PUNCT
gsrj-21	187	6	99(1	99(1	NUM
gsrj-21	187	7	)	)	PUNCT
gsrj-21	187	8	,	,	PUNCT
gsrj-21	187	9	3168	3168	NUM
gsrj-21	187	10	.	.	PUNCT
gsrj-21	188	1	https://doi.org/0022-5193(82)90388-5	https://doi.org/0022-5193(82)90388-5	PROPN
gsrj-21	188	2	9	9	NUM
gsrj-21	188	3	.	.	X
gsrj-21	188	4	lu	lu	PROPN
gsrj-21	188	5	,	,	PUNCT
gsrj-21	188	6	p.	p.	NOUN
gsrj-21	188	7	,	,	PUNCT
gsrj-21	188	8	weaver	weaver	PROPN
gsrj-21	188	9	,	,	PUNCT
gsrj-21	188	10	v.	v.	ADP
gsrj-21	188	11	m.	m.	NOUN
gsrj-21	188	12	,	,	PUNCT
gsrj-21	188	13	&	&	CCONJ
gsrj-21	188	14	werb	werb	ADJ
gsrj-21	188	15	,	,	PUNCT
gsrj-21	188	16	z.	z.	PROPN
gsrj-21	188	17	(	(	PUNCT
gsrj-21	188	18	2012	2012	NUM
gsrj-21	188	19	)	)	PUNCT
gsrj-21	188	20	.	.	PUNCT
gsrj-21	189	1	the	the	DET
gsrj-21	189	2	extracellular	extracellular	ADJ
gsrj-21	189	3	matrix	matrix	NOUN
gsrj-21	189	4	:	:	PUNCT
gsrj-21	189	5	a	a	DET
gsrj-21	189	6	dynamic	dynamic	ADJ
gsrj-21	189	7	niche	niche	NOUN
gsrj-21	189	8	in	in	ADP
gsrj-21	189	9	cancer	cancer	NOUN
gsrj-21	189	10	progression	progression	NOUN
gsrj-21	189	11	.	.	PUNCT
gsrj-21	190	1	the	the	DET
gsrj-21	190	2	journal	journal	NOUN
gsrj-21	190	3	of	of	ADP
gsrj-21	190	4	cell	cell	NOUN
gsrj-21	190	5	biology	biology	NOUN
gsrj-21	190	6	,	,	PUNCT
gsrj-21	190	7	196(4	196(4	NUM
gsrj-21	190	8	)	)	PUNCT
gsrj-21	190	9	,	,	PUNCT
gsrj-21	190	10	395	395	NUM
gsrj-21	190	11	-	-	SYM
gsrj-21	190	12	406	406	NUM
gsrj-21	190	13	.	.	PUNCT
gsrj-21	191	1	https://doi.org/10.1083/jcb.201102147	https://doi.org/10.1083/jcb.201102147	PROPN
gsrj-21	191	2	10	10	NUM
gsrj-21	191	3	.	.	PUNCT
gsrj-21	191	4	butcher	butcher	NOUN
gsrj-21	191	5	,	,	PUNCT
gsrj-21	191	6	d.	d.	PROPN
gsrj-21	191	7	t.	t.	PROPN
gsrj-21	191	8	,	,	PUNCT
gsrj-21	191	9	alliston	alliston	PROPN
gsrj-21	191	10	,	,	PUNCT
gsrj-21	191	11	t.	t.	PROPN
gsrj-21	191	12	,	,	PUNCT
gsrj-21	191	13	&	&	CCONJ
gsrj-21	191	14	weaver	weaver	PROPN
gsrj-21	191	15	,	,	PUNCT
gsrj-21	191	16	v.	v.	ADP
gsrj-21	191	17	m.	m.	NOUN
gsrj-21	191	18	(	(	PUNCT
gsrj-21	191	19	2009	2009	NUM
gsrj-21	191	20	)	)	PUNCT
gsrj-21	191	21	.	.	PUNCT
gsrj-21	192	1	a	a	DET
gsrj-21	192	2	tense	tense	ADJ
gsrj-21	192	3	situation	situation	NOUN
gsrj-21	192	4	:	:	PUNCT
gsrj-21	192	5	forcing	force	VERB
gsrj-21	192	6	tumour	tumour	NOUN
gsrj-21	192	7	progression	progression	NOUN
gsrj-21	192	8	.	.	PUNCT
gsrj-21	193	1	nature	nature	NOUN
gsrj-21	193	2	reviews	review	NOUN
gsrj-21	193	3	.	.	PUNCT
gsrj-21	194	1	cancer	cancer	NOUN
gsrj-21	194	2	,	,	PUNCT
gsrj-21	194	3	9(2	9(2	NUM
gsrj-21	194	4	)	)	PUNCT
gsrj-21	194	5	,	,	PUNCT
gsrj-21	194	6	108122	108122	NUM
gsrj-21	194	7	.	.	PUNCT
gsrj-21	195	1	https://doi.org/10.1038/nrc2544	https://doi.org/10.1038/nrc2544	PROPN
gsrj-21	195	2	11	11	NUM
gsrj-21	195	3	.	.	PUNCT
gsrj-21	196	1	kumar	kumar	PROPN
gsrj-21	196	2	,	,	PUNCT
gsrj-21	196	3	s.	s.	PROPN
gsrj-21	196	4	,	,	PUNCT
gsrj-21	196	5	&	&	CCONJ
gsrj-21	196	6	weaver	weaver	PROPN
gsrj-21	196	7	,	,	PUNCT
gsrj-21	196	8	v.	v.	ADP
gsrj-21	196	9	m.	m.	NOUN
gsrj-21	196	10	(	(	PUNCT
gsrj-21	196	11	2009	2009	NUM
gsrj-21	196	12	)	)	PUNCT
gsrj-21	196	13	.	.	PUNCT
gsrj-21	197	1	mechanics	mechanic	NOUN
gsrj-21	197	2	,	,	PUNCT
gsrj-21	197	3	malignancy	malignancy	NOUN
gsrj-21	197	4	,	,	PUNCT
gsrj-21	197	5	and	and	CCONJ
gsrj-21	197	6	metastasis	metastasis	NOUN
gsrj-21	197	7	:	:	PUNCT
gsrj-21	197	8	the	the	DET
gsrj-21	197	9	force	force	NOUN
gsrj-21	197	10	journey	journey	NOUN
gsrj-21	197	11	of	of	ADP
gsrj-21	197	12	a	a	DET
gsrj-21	197	13	tumor	tumor	NOUN
gsrj-21	197	14	cell	cell	NOUN
gsrj-21	197	15	.	.	PUNCT
gsrj-21	198	1	cancer	cancer	NOUN
gsrj-21	198	2	metastasis	metastasis	NOUN
gsrj-21	198	3	reviews	review	NOUN
gsrj-21	198	4	,	,	PUNCT
gsrj-21	198	5	28(1	28(1	NOUN
gsrj-21	198	6	-	-	SYM
gsrj-21	198	7	2	2	NUM
gsrj-21	198	8	)	)	PUNCT
gsrj-21	198	9	,	,	PUNCT
gsrj-21	198	10	113	113	NUM
gsrj-21	198	11	-	-	SYM
gsrj-21	198	12	127	127	NUM
gsrj-21	198	13	.	.	PUNCT
gsrj-21	199	1	https://doi.org/10.1007/s10555-0089173-4	https://doi.org/10.1007/s10555-0089173-4	NOUN
gsrj-21	199	2	12	12	NUM
gsrj-21	199	3	.	.	PUNCT
gsrj-21	200	1	paszek	paszek	NOUN
gsrj-21	200	2	,	,	PUNCT
gsrj-21	200	3	m.	m.	NOUN
gsrj-21	200	4	j.	j.	PROPN
gsrj-21	200	5	,	,	PUNCT
gsrj-21	200	6	&	&	CCONJ
gsrj-21	200	7	weaver	weaver	PROPN
gsrj-21	200	8	,	,	PUNCT
gsrj-21	200	9	v.	v.	ADP
gsrj-21	200	10	m.	m.	NOUN
gsrj-21	200	11	(	(	PUNCT
gsrj-21	200	12	2004	2004	NUM
gsrj-21	200	13	)	)	PUNCT
gsrj-21	200	14	.	.	PUNCT
gsrj-21	201	1	the	the	DET
gsrj-21	201	2	tension	tension	NOUN
gsrj-21	201	3	mounts	mount	NOUN
gsrj-21	201	4	:	:	PUNCT
gsrj-21	201	5	mechanics	mechanic	NOUN
gsrj-21	201	6	meets	meet	VERB
gsrj-21	201	7	morphogenesis	morphogenesis	NOUN
gsrj-21	201	8	and	and	CCONJ
gsrj-21	201	9	malignancy	malignancy	NOUN
gsrj-21	201	10	.	.	PUNCT
gsrj-21	202	1	journal	journal	NOUN
gsrj-21	202	2	of	of	ADP
gsrj-21	202	3	mammary	mammary	ADJ
gsrj-21	202	4	gland	gland	NOUN
gsrj-21	202	5	biology	biology	NOUN
gsrj-21	202	6	and	and	CCONJ
gsrj-21	202	7	neoplasia	neoplasia	NOUN
gsrj-21	202	8	,	,	PUNCT
gsrj-21	202	9	9(4	9(4	NUM
gsrj-21	202	10	)	)	PUNCT
gsrj-21	202	11	,	,	PUNCT
gsrj-21	202	12	325	325	NUM
gsrj-21	202	13	-	-	SYM
gsrj-21	202	14	342	342	NUM
gsrj-21	202	15	.	.	PUNCT
gsrj-21	203	1	https://doi.org/10.1007/s10911-004-1404-x	https://doi.org/10.1007/s10911-004-1404-x	ADV
gsrj-21	203	2	13	13	NUM
gsrj-21	203	3	.	.	PUNCT
gsrj-21	204	1	xouri	xouri	PROPN
gsrj-21	204	2	,	,	PUNCT
gsrj-21	204	3	g.	g.	PROPN
gsrj-21	204	4	,	,	PUNCT
gsrj-21	204	5	&	&	CCONJ
gsrj-21	204	6	christian	christian	PROPN
gsrj-21	204	7	,	,	PUNCT
gsrj-21	204	8	s.	s.	PROPN
gsrj-21	204	9	(	(	PUNCT
gsrj-21	204	10	2010	2010	NUM
gsrj-21	204	11	)	)	PUNCT
gsrj-21	204	12	.	.	PUNCT
gsrj-21	205	1	origin	origin	NOUN
gsrj-21	205	2	and	and	CCONJ
gsrj-21	205	3	function	function	NOUN
gsrj-21	205	4	of	of	ADP
gsrj-21	205	5	tumor	tumor	NOUN
gsrj-21	205	6	stroma	stroma	ADJ
gsrj-21	205	7	fibroblasts	fibroblast	NOUN
gsrj-21	205	8	.	.	PUNCT
gsrj-21	206	1	seminars	seminar	NOUN
gsrj-21	206	2	in	in	ADP
gsrj-21	206	3	cell	cell	NOUN
gsrj-21	206	4	&	&	CCONJ
gsrj-21	206	5	developmental	developmental	ADJ
gsrj-21	206	6	biology	biology	NOUN
gsrj-21	206	7	,	,	PUNCT
gsrj-21	206	8	21(1	21(1	NUM
gsrj-21	206	9	)	)	PUNCT
gsrj-21	206	10	,	,	PUNCT
gsrj-21	206	11	40	40	NUM
gsrj-21	206	12	-	-	SYM
gsrj-21	206	13	46	46	NUM
gsrj-21	206	14	.	.	PUNCT
gsrj-21	207	1	https://doi.org/10.1016/j.semcdb.2009.11.017	https://doi.org/10.1016/j.semcdb.2009.11.017	NUM
gsrj-21	207	2	14	14	NUM
gsrj-21	207	3	.	.	PUNCT
gsrj-21	208	1	cirri	cirri	NOUN
gsrj-21	208	2	,	,	PUNCT
gsrj-21	208	3	p.	p.	NOUN
gsrj-21	208	4	,	,	PUNCT
gsrj-21	208	5	&	&	CCONJ
gsrj-21	208	6	chiarugi	chiarugi	PROPN
gsrj-21	208	7	,	,	PUNCT
gsrj-21	208	8	p.	p.	NOUN
gsrj-21	208	9	(	(	PUNCT
gsrj-21	208	10	2012	2012	NUM
gsrj-21	208	11	)	)	PUNCT
gsrj-21	208	12	.	.	PUNCT
gsrj-21	209	1	cancerassociated	cancerassociate	VERB
gsrj-21	209	2	-	-	PUNCT
gsrj-21	209	3	fibroblasts	fibroblast	NOUN
gsrj-21	209	4	and	and	CCONJ
gsrj-21	209	5	tumour	tumour	NOUN
gsrj-21	209	6	cells	cell	NOUN
gsrj-21	209	7	:	:	PUNCT
gsrj-21	209	8	a	a	DET
gsrj-21	209	9	diabolic	diabolic	ADJ
gsrj-21	209	10	liaison	liaison	NOUN
gsrj-21	209	11	driving	drive	VERB
gsrj-21	209	12	cancer	cancer	NOUN
gsrj-21	209	13	progression	progression	NOUN
gsrj-21	209	14	.	.	PUNCT
gsrj-21	210	1	cancer	cancer	NOUN
gsrj-21	210	2	metastasis	metastasis	NOUN
gsrj-21	210	3	reviews	review	NOUN
gsrj-21	210	4	,	,	PUNCT
gsrj-21	210	5	31(1	31(1	NUM
gsrj-21	210	6	-	-	SYM
gsrj-21	210	7	2	2	NUM
gsrj-21	210	8	)	)	PUNCT
gsrj-21	210	9	,	,	PUNCT
gsrj-21	210	10	195	195	NUM
gsrj-21	210	11	-	-	SYM
gsrj-21	210	12	208	208	NUM
gsrj-21	210	13	.	.	PUNCT
gsrj-21	211	1	https://doi.org/10.1007/s10555-011-9340-x	https://doi.org/10.1007/s10555-011-9340-x	PROPN
gsrj-21	211	2	15	15	NUM
gsrj-21	211	3	.	.	PUNCT
gsrj-21	212	1	kalluri	kalluri	PROPN
gsrj-21	212	2	,	,	PUNCT
gsrj-21	212	3	r.	r.	PROPN
gsrj-21	212	4	,	,	PUNCT
gsrj-21	212	5	&	&	CCONJ
gsrj-21	212	6	zeisberg	zeisberg	PROPN
gsrj-21	212	7	,	,	PUNCT
gsrj-21	212	8	m.	m.	NOUN
gsrj-21	212	9	(	(	PUNCT
gsrj-21	212	10	2006	2006	NUM
gsrj-21	212	11	)	)	PUNCT
gsrj-21	212	12	.	.	PUNCT
gsrj-21	213	1	fibroblasts	fibroblast	NOUN
gsrj-21	213	2	in	in	ADP
gsrj-21	213	3	cancer	cancer	NOUN
gsrj-21	213	4	.	.	PUNCT
gsrj-21	214	1	nature	nature	PROPN
gsrj-21	214	2	reviews.cancer	reviews.cancer	NOUN
gsrj-21	214	3	,	,	PUNCT
gsrj-21	214	4	6(5	6(5	NUM
gsrj-21	214	5	)	)	PUNCT
gsrj-21	214	6	,	,	PUNCT
gsrj-21	214	7	392	392	NUM
gsrj-21	214	8	-	-	SYM
gsrj-21	214	9	401	401	NUM
gsrj-21	214	10	.	.	PUNCT
gsrj-21	215	1	https://doi.org/nrc1877	https://doi.org/nrc1877	ADJ
gsrj-21	215	2	16	16	NUM
gsrj-21	215	3	.	.	PUNCT
gsrj-21	216	1	balkwill	balkwill	PROPN
gsrj-21	216	2	,	,	PUNCT
gsrj-21	216	3	f.	f.	PROPN
gsrj-21	216	4	,	,	PUNCT
gsrj-21	216	5	&	&	CCONJ
gsrj-21	216	6	mantovani	mantovani	PROPN
gsrj-21	216	7	,	,	PUNCT
gsrj-21	216	8	a.	a.	NOUN
gsrj-21	216	9	(	(	PUNCT
gsrj-21	216	10	2001	2001	NUM
gsrj-21	216	11	)	)	PUNCT
gsrj-21	216	12	.	.	PUNCT
gsrj-21	217	1	inflammation	inflammation	NOUN
gsrj-21	217	2	and	and	CCONJ
gsrj-21	217	3	cancer	cancer	NOUN
gsrj-21	217	4	:	:	PUNCT
gsrj-21	217	5	back	back	ADV
gsrj-21	217	6	to	to	ADP
gsrj-21	217	7	virchow	virchow	NOUN
gsrj-21	217	8	?	?	PUNCT
gsrj-21	218	1	lancet	lancet	PROPN
gsrj-21	218	2	(	(	PUNCT
gsrj-21	218	3	london	london	PROPN
gsrj-21	218	4	,	,	PUNCT
gsrj-21	218	5	england	england	PROPN
gsrj-21	218	6	)	)	PUNCT
gsrj-21	218	7	,	,	PUNCT
gsrj-21	218	8	357(9255	357(9255	NUM
gsrj-21	218	9	)	)	PUNCT
gsrj-21	218	10	,	,	PUNCT
gsrj-21	218	11	539	539	NUM
gsrj-21	218	12	-	-	SYM
gsrj-21	218	13	545	545	NUM
gsrj-21	218	14	.	.	PUNCT
gsrj-21	219	1	https://doi.org/10.1016/s0140-6736(00)04046-0	https://doi.org/10.1016/s0140-6736(00)04046-0	PROPN
gsrj-21	219	2	17	17	NUM
gsrj-21	219	3	.	.	PUNCT
gsrj-21	220	1	coussens	coussens	PROPN
gsrj-21	220	2	,	,	PUNCT
gsrj-21	220	3	l.	l.	PROPN
gsrj-21	220	4	m.	m.	PROPN
gsrj-21	220	5	,	,	PUNCT
gsrj-21	220	6	&	&	CCONJ
gsrj-21	220	7	werb	werb	ADJ
gsrj-21	220	8	,	,	PUNCT
gsrj-21	220	9	z.	z.	PROPN
gsrj-21	220	10	(	(	PUNCT
gsrj-21	220	11	2002	2002	NUM
gsrj-21	220	12	)	)	PUNCT
gsrj-21	220	13	.	.	PUNCT
gsrj-21	221	1	inflammation	inflammation	NOUN
gsrj-21	221	2	and	and	CCONJ
gsrj-21	221	3	cancer	cancer	NOUN
gsrj-21	221	4	.	.	PUNCT
gsrj-21	222	1	nature	nature	NOUN
gsrj-21	222	2	,	,	PUNCT
gsrj-21	222	3	420(6917	420(6917	NOUN
gsrj-21	222	4	)	)	PUNCT
gsrj-21	222	5	,	,	PUNCT
gsrj-21	222	6	860867	860867	NUM
gsrj-21	222	7	.	.	PUNCT
gsrj-21	223	1	https://doi.org/10.1038/nature01322	https://doi.org/10.1038/nature01322	PROPN
gsrj-21	223	2	18	18	NUM
gsrj-21	223	3	.	.	PUNCT
gsrj-21	224	1	mantovani	mantovani	PROPN
gsrj-21	224	2	,	,	PUNCT
gsrj-21	224	3	a.	a.	NOUN
gsrj-21	224	4	,	,	PUNCT
gsrj-21	224	5	allavena	allavena	ADJ
gsrj-21	224	6	,	,	PUNCT
gsrj-21	224	7	p.	p.	PROPN
gsrj-21	224	8	,	,	PUNCT
gsrj-21	224	9	sica	sica	PROPN
gsrj-21	224	10	,	,	PUNCT
gsrj-21	224	11	a.	a.	PROPN
gsrj-21	224	12	,	,	PUNCT
gsrj-21	224	13	&	&	CCONJ
gsrj-21	224	14	balkwill	balkwill	PROPN
gsrj-21	224	15	,	,	PUNCT
gsrj-21	224	16	f.	f.	PROPN
gsrj-21	224	17	(	(	PUNCT
gsrj-21	224	18	2008	2008	NUM
gsrj-21	224	19	)	)	PUNCT
gsrj-21	224	20	.	.	PUNCT
gsrj-21	225	1	cancer	cancer	NOUN
gsrj-21	225	2	-	-	PUNCT
gsrj-21	225	3	related	relate	VERB
gsrj-21	225	4	inflammation	inflammation	NOUN
gsrj-21	225	5	.	.	PUNCT
gsrj-21	226	1	nature	nature	NOUN
gsrj-21	226	2	,	,	PUNCT
gsrj-21	226	3	454(7203	454(7203	NUM
gsrj-21	226	4	)	)	PUNCT
gsrj-21	226	5	,	,	PUNCT
gsrj-21	226	6	436	436	NUM
gsrj-21	226	7	-	-	SYM
gsrj-21	226	8	444	444	NUM
gsrj-21	226	9	.	.	PUNCT
gsrj-21	226	10	https://doi.org/10.1038/nature07205	https://doi.org/10.1038/nature07205	NOUN
gsrj-21	226	11	19	19	NUM
gsrj-21	226	12	.	.	PUNCT
gsrj-21	227	1	hu	hu	PROPN
gsrj-21	227	2	,	,	PUNCT
gsrj-21	227	3	w.	w.	PROPN
gsrj-21	227	4	,	,	PUNCT
gsrj-21	227	5	li	li	PROPN
gsrj-21	227	6	,	,	PUNCT
gsrj-21	227	7	x.	x.	PROPN
gsrj-21	227	8	,	,	PUNCT
gsrj-21	227	9	zhang	zhang	PROPN
gsrj-21	227	10	,	,	PUNCT
gsrj-21	227	11	c.	c.	PROPN
gsrj-21	227	12	,	,	PUNCT
gsrj-21	227	13	yang	yang	PROPN
gsrj-21	227	14	,	,	PUNCT
gsrj-21	227	15	y.	y.	PROPN
gsrj-21	227	16	,	,	PUNCT
gsrj-21	227	17	jiang	jiang	PROPN
gsrj-21	227	18	,	,	PUNCT
gsrj-21	227	19	j.	j.	PROPN
gsrj-21	227	20	,	,	PUNCT
gsrj-21	227	21	&	&	CCONJ
gsrj-21	227	22	wu	wu	PROPN
gsrj-21	227	23	,	,	PUNCT
gsrj-21	227	24	c.	c.	PROPN
gsrj-21	227	25	(	(	PUNCT
gsrj-21	227	26	2016	2016	NUM
gsrj-21	227	27	)	)	PUNCT
gsrj-21	227	28	.	.	PUNCT
gsrj-21	228	1	tumor	tumor	NOUN
gsrj-21	228	2	-	-	PUNCT
gsrj-21	228	3	associated	associate	VERB
gsrj-21	228	4	macrophages	macrophage	NOUN
gsrj-21	228	5	in	in	ADP
gsrj-21	228	6	cancers	cancer	NOUN
gsrj-21	228	7	.	.	PUNCT
gsrj-21	229	1	clinical	clinical	ADJ
gsrj-21	229	2	&	&	CCONJ
gsrj-21	229	3	translational	translational	ADJ
gsrj-21	229	4	oncology	oncology	NOUN
gsrj-21	229	5	:	:	PUNCT
gsrj-21	229	6	official	official	ADJ
gsrj-21	229	7	publication	publication	NOUN
gsrj-21	229	8	of	of	ADP
gsrj-21	229	9	the	the	DET
gsrj-21	229	10	federation	federation	NOUN
gsrj-21	229	11	of	of	ADP
gsrj-21	229	12	spanish	spanish	ADJ
gsrj-21	229	13	oncology	oncology	NOUN
gsrj-21	229	14	societies	society	NOUN
gsrj-21	229	15	and	and	CCONJ
gsrj-21	229	16	of	of	ADP
gsrj-21	229	17	the	the	DET
gsrj-21	229	18	national	national	PROPN
gsrj-21	229	19	cancer	cancer	PROPN
gsrj-21	229	20	institute	institute	PROPN
gsrj-21	229	21	of	of	ADP
gsrj-21	229	22	mexico	mexico	PROPN
gsrj-21	229	23	,	,	PUNCT
gsrj-21	229	24	18(3	18(3	NUM
gsrj-21	229	25	)	)	PUNCT
gsrj-21	229	26	,	,	PUNCT
gsrj-21	229	27	251	251	NUM
gsrj-21	229	28	-	-	SYM
gsrj-21	229	29	258	258	NUM
gsrj-21	229	30	.	.	PUNCT
gsrj-21	230	1	https://doi.org/10.1007/s12094-015-1373-0	https://doi.org/10.1007/s12094-015-1373-0	NUM
gsrj-21	230	2	20	20	NUM
gsrj-21	230	3	.	.	PUNCT
gsrj-21	231	1	mantovani	mantovani	PROPN
gsrj-21	231	2	,	,	PUNCT
gsrj-21	231	3	a.	a.	PROPN
gsrj-21	231	4	,	,	PUNCT
gsrj-21	231	5	&	&	CCONJ
gsrj-21	231	6	sica	sica	PROPN
gsrj-21	231	7	,	,	PUNCT
gsrj-21	231	8	a.	a.	NOUN
gsrj-21	231	9	(	(	PUNCT
gsrj-21	231	10	2010	2010	NUM
gsrj-21	231	11	)	)	PUNCT
gsrj-21	231	12	.	.	PUNCT
gsrj-21	232	1	macrophages	macrophage	NOUN
gsrj-21	232	2	,	,	PUNCT
gsrj-21	232	3	innate	innate	ADJ
gsrj-21	232	4	immunity	immunity	NOUN
gsrj-21	232	5	and	and	CCONJ
gsrj-21	232	6	cancer	cancer	NOUN
gsrj-21	232	7	:	:	PUNCT
gsrj-21	232	8	balance	balance	NOUN
gsrj-21	232	9	,	,	PUNCT
gsrj-21	232	10	tolerance	tolerance	NOUN
gsrj-21	232	11	,	,	PUNCT
gsrj-21	232	12	and	and	CCONJ
gsrj-21	232	13	diversity	diversity	NOUN
gsrj-21	232	14	.	.	PUNCT
gsrj-21	233	1	current	current	ADJ
gsrj-21	233	2	opinion	opinion	NOUN
gsrj-21	233	3	in	in	ADP
gsrj-21	233	4	immunology	immunology	NOUN
gsrj-21	233	5	,	,	PUNCT
gsrj-21	233	6	56	56	NUM
gsrj-21	233	7	georgetown	georgetown	PROPN
gsrj-21	233	8	scientific	scientific	PROPN
gsrj-21	233	9	research	research	PROPN
gsrj-21	233	10	journal	journal	PROPN
gsrj-21	233	11	22(2	22(2	NUM
gsrj-21	233	12	)	)	PUNCT
gsrj-21	233	13	,	,	PUNCT
gsrj-21	233	14	231	231	NUM
gsrj-21	233	15	-	-	SYM
gsrj-21	233	16	237	237	NUM
gsrj-21	233	17	.	.	PUNCT
gsrj-21	234	1	https://doi.org/10.1016/j.coi.2010.01.009	https://doi.org/10.1016/j.coi.2010.01.009	PROPN
gsrj-21	234	2	21	21	NUM
gsrj-21	234	3	.	.	PUNCT
gsrj-21	234	4	shieh	shieh	PROPN
gsrj-21	234	5	,	,	PUNCT
gsrj-21	234	6	a.	a.	PROPN
gsrj-21	234	7	c.	c.	PROPN
gsrj-21	234	8	,	,	PUNCT
gsrj-21	234	9	&	&	CCONJ
gsrj-21	234	10	swartz	swartz	PROPN
gsrj-21	234	11	,	,	PUNCT
gsrj-21	234	12	m.	m.	NOUN
gsrj-21	234	13	a.	a.	NOUN
gsrj-21	234	14	(	(	PUNCT
gsrj-21	234	15	2011	2011	NUM
gsrj-21	234	16	)	)	PUNCT
gsrj-21	234	17	.	.	PUNCT
gsrj-21	235	1	regulation	regulation	NOUN
gsrj-21	235	2	of	of	ADP
gsrj-21	235	3	tumor	tumor	NOUN
gsrj-21	235	4	invasion	invasion	NOUN
gsrj-21	235	5	by	by	ADP
gsrj-21	235	6	interstitial	interstitial	ADJ
gsrj-21	235	7	fluid	fluid	ADJ
gsrj-21	235	8	flow	flow	NOUN
gsrj-21	235	9	.	.	PUNCT
gsrj-21	236	1	physical	physical	ADJ
gsrj-21	236	2	biology	biology	NOUN
gsrj-21	236	3	,	,	PUNCT
gsrj-21	236	4	8(1	8(1	NOUN
gsrj-21	236	5	)	)	PUNCT
gsrj-21	236	6	,	,	PUNCT
gsrj-21	236	7	015012	015012	NUM
gsrj-21	236	8	.	.	PUNCT
gsrj-21	237	1	https://doi.org/10.1088/1478-3975/8/1/015012	https://doi.org/10.1088/1478-3975/8/1/015012	NOUN
gsrj-21	238	1	22	22	NUM
gsrj-21	238	2	.	.	PUNCT
gsrj-21	238	3	sleeboom	sleeboom	PROPN
gsrj-21	238	4	,	,	PUNCT
gsrj-21	238	5	j.	j.	PROPN
gsrj-21	238	6	j.	j.	PROPN
gsrj-21	238	7	f.	f.	PROPN
gsrj-21	238	8	,	,	PUNCT
gsrj-21	238	9	eslami	eslami	ADJ
gsrj-21	238	10	amirabadi	amirabadi	PROPN
gsrj-21	238	11	,	,	PUNCT
gsrj-21	238	12	h.	h.	PROPN
gsrj-21	238	13	,	,	PUNCT
gsrj-21	238	14	nair	nair	NOUN
gsrj-21	238	15	,	,	PUNCT
gsrj-21	238	16	p.	p.	PROPN
gsrj-21	238	17	,	,	PUNCT
gsrj-21	238	18	sahlgren	sahlgren	PROPN
gsrj-21	238	19	,	,	PUNCT
gsrj-21	238	20	c.	c.	PROPN
gsrj-21	238	21	m.	m.	NOUN
gsrj-21	238	22	,	,	PUNCT
gsrj-21	238	23	&	&	CCONJ
gsrj-21	238	24	den	den	PROPN
gsrj-21	238	25	toonder	toonder	PROPN
gsrj-21	238	26	,	,	PUNCT
gsrj-21	238	27	jaap	jaap	PROPN
gsrj-21	238	28	m.	m.	PROPN
gsrj-21	238	29	j.	j.	PROPN
gsrj-21	238	30	(	(	PUNCT
gsrj-21	238	31	2018	2018	NUM
gsrj-21	238	32	)	)	PUNCT
gsrj-21	238	33	.	.	PUNCT
gsrj-21	239	1	metastasis	metastasis	NOUN
gsrj-21	239	2	in	in	ADP
gsrj-21	239	3	context	context	NOUN
gsrj-21	239	4	:	:	PUNCT
gsrj-21	239	5	modeling	model	VERB
gsrj-21	239	6	the	the	DET
gsrj-21	239	7	tumor	tumor	NOUN
gsrj-21	239	8	microenvironment	microenvironment	NOUN
gsrj-21	239	9	with	with	ADP
gsrj-21	239	10	cancer	cancer	NOUN
gsrj-21	239	11	-	-	PUNCT
gsrj-21	239	12	on	on	ADP
gsrj-21	239	13	-	-	PUNCT
gsrj-21	239	14	a	a	DET
gsrj-21	239	15	-	-	PUNCT
gsrj-21	239	16	chip	chip	NOUN
gsrj-21	239	17	approaches	approach	NOUN
gsrj-21	239	18	.	.	PUNCT
gsrj-21	240	1	disease	disease	NOUN
gsrj-21	240	2	models	model	NOUN
gsrj-21	240	3	&	&	CCONJ
gsrj-21	240	4	mechanisms	mechanism	NOUN
gsrj-21	240	5	,	,	PUNCT
gsrj-21	240	6	11(3	11(3	NUM
gsrj-21	240	7	)	)	PUNCT
gsrj-21	240	8	https://doi.org/10.1242/dmm.033100	https://doi.org/10.1242/dmm.033100	PROPN
gsrj-21	240	9	23	23	NUM
gsrj-21	240	10	.	.	PUNCT
gsrj-21	241	1	fuchs	fuchs	PROPN
gsrj-21	241	2	,	,	PUNCT
gsrj-21	241	3	b.	b.	PROPN
gsrj-21	241	4	c.	c.	PROPN
gsrj-21	241	5	,	,	PUNCT
gsrj-21	241	6	fujii	fujii	PROPN
gsrj-21	241	7	,	,	PUNCT
gsrj-21	241	8	t.	t.	PROPN
gsrj-21	241	9	,	,	PUNCT
gsrj-21	241	10	dorfman	dorfman	PROPN
gsrj-21	241	11	,	,	PUNCT
gsrj-21	241	12	j.	j.	PROPN
gsrj-21	241	13	d.	d.	PROPN
gsrj-21	241	14	,	,	PUNCT
gsrj-21	241	15	goodwin	goodwin	PROPN
gsrj-21	241	16	,	,	PUNCT
gsrj-21	241	17	j.	j.	PROPN
gsrj-21	241	18	m.	m.	PROPN
gsrj-21	241	19	,	,	PUNCT
gsrj-21	241	20	zhu	zhu	PROPN
gsrj-21	241	21	,	,	PUNCT
gsrj-21	241	22	a.	a.	PROPN
gsrj-21	241	23	x.	x.	PROPN
gsrj-21	241	24	,	,	PUNCT
gsrj-21	241	25	lanuti	lanuti	PROPN
gsrj-21	241	26	,	,	PUNCT
gsrj-21	241	27	m.	m.	NOUN
gsrj-21	241	28	,	,	PUNCT
gsrj-21	241	29	et	et	PROPN
gsrj-21	241	30	al	al	PROPN
gsrj-21	241	31	.	.	PUNCT
gsrj-21	241	32	(	(	PUNCT
gsrj-21	241	33	2008	2008	NUM
gsrj-21	241	34	)	)	PUNCT
gsrj-21	241	35	.	.	PUNCT
gsrj-21	242	1	epithelial	epithelial	ADJ
gsrj-21	242	2	-	-	PUNCT
gsrj-21	242	3	to	to	ADP
gsrj-21	242	4	-	-	PUNCT
gsrj-21	242	5	mesenchymal	mesenchymal	NOUN
gsrj-21	242	6	transition	transition	NOUN
gsrj-21	242	7	and	and	CCONJ
gsrj-21	242	8	integrin	integrin	NOUN
gsrj-21	242	9	-	-	PUNCT
gsrj-21	242	10	linked	link	VERB
gsrj-21	242	11	kinase	kinase	NOUN
gsrj-21	242	12	mediate	mediate	VERB
gsrj-21	242	13	sensitivity	sensitivity	NOUN
gsrj-21	242	14	to	to	ADP
gsrj-21	242	15	epidermal	epidermal	ADJ
gsrj-21	242	16	growth	growth	NOUN
gsrj-21	242	17	factor	factor	NOUN
gsrj-21	242	18	receptor	receptor	NOUN
gsrj-21	242	19	inhibition	inhibition	NOUN
gsrj-21	242	20	in	in	ADP
gsrj-21	242	21	human	human	ADJ
gsrj-21	242	22	hepatoma	hepatoma	NOUN
gsrj-21	242	23	cells	cell	NOUN
gsrj-21	242	24	.	.	PUNCT
gsrj-21	243	1	cancer	cancer	NOUN
gsrj-21	243	2	research	research	NOUN
gsrj-21	243	3	,	,	PUNCT
gsrj-21	243	4	68(7	68(7	NUM
gsrj-21	243	5	)	)	PUNCT
gsrj-21	243	6	,	,	PUNCT
gsrj-21	243	7	2391	2391	NUM
gsrj-21	243	8	-	-	SYM
gsrj-21	243	9	2399	2399	NUM
gsrj-21	243	10	.	.	PUNCT
gsrj-21	244	1	24	24	NUM
gsrj-21	244	2	.	.	PUNCT
gsrj-21	244	3	karnevi	karnevi	PROPN
gsrj-21	244	4	,	,	PUNCT
gsrj-21	244	5	e.	e.	PROPN
gsrj-21	244	6	,	,	PUNCT
gsrj-21	244	7	rosendahl	rosendahl	PROPN
gsrj-21	244	8	,	,	PUNCT
gsrj-21	244	9	a.	a.	PROPN
gsrj-21	244	10	h.	h.	PROPN
gsrj-21	244	11	,	,	PUNCT
gsrj-21	244	12	hilmersson	hilmersson	PROPN
gsrj-21	244	13	,	,	PUNCT
gsrj-21	244	14	k.	k.	PROPN
gsrj-21	244	15	s.	s.	PROPN
gsrj-21	244	16	,	,	PUNCT
gsrj-21	244	17	saleem	saleem	PROPN
gsrj-21	244	18	,	,	PUNCT
gsrj-21	244	19	m.	m.	NOUN
gsrj-21	244	20	a.	a.	PROPN
gsrj-21	244	21	,	,	PUNCT
gsrj-21	244	22	&	&	CCONJ
gsrj-21	244	23	andersson	andersson	PROPN
gsrj-21	244	24	,	,	PUNCT
gsrj-21	244	25	r.	r.	PROPN
gsrj-21	244	26	(	(	PUNCT
gsrj-21	244	27	2016	2016	NUM
gsrj-21	244	28	)	)	PUNCT
gsrj-21	244	29	.	.	PUNCT
gsrj-21	245	1	impact	impact	NOUN
gsrj-21	245	2	by	by	ADP
gsrj-21	245	3	pancreatic	pancreatic	ADJ
gsrj-21	245	4	stellate	stellate	ADJ
gsrj-21	245	5	cells	cell	NOUN
gsrj-21	245	6	on	on	ADP
gsrj-21	245	7	epithelialmesenchymal	epithelialmesenchymal	ADJ
gsrj-21	245	8	transition	transition	NOUN
gsrj-21	245	9	and	and	CCONJ
gsrj-21	245	10	pancreatic	pancreatic	ADJ
gsrj-21	245	11	cancer	cancer	NOUN
gsrj-21	245	12	cell	cell	NOUN
gsrj-21	245	13	invasion	invasion	NOUN
gsrj-21	245	14	:	:	PUNCT
gsrj-21	245	15	adding	add	VERB
gsrj-21	245	16	a	a	DET
gsrj-21	245	17	third	third	ADJ
gsrj-21	245	18	dimension	dimension	NOUN
gsrj-21	245	19	in	in	ADP
gsrj-21	245	20	vitro	vitro	X
gsrj-21	245	21	.	.	PUNCT
gsrj-21	246	1	experimental	experimental	ADJ
gsrj-21	246	2	cell	cell	NOUN
gsrj-21	246	3	research	research	NOUN
gsrj-21	246	4	,	,	PUNCT
gsrj-21	246	5	346(2	346(2	NUM
gsrj-21	246	6	)	)	PUNCT
gsrj-21	246	7	,	,	PUNCT
gsrj-21	246	8	206	206	NUM
gsrj-21	246	9	-	-	SYM
gsrj-21	246	10	215	215	NUM
gsrj-21	246	11	.	.	PUNCT
gsrj-21	247	1	https://doi.org/10.1016/j.yexcr.2016.07.017	https://doi.org/10.1016/j.yexcr.2016.07.017	NUM
gsrj-21	247	2	25	25	NUM
gsrj-21	247	3	.	.	PUNCT
gsrj-21	247	4	agarwal	agarwal	PROPN
gsrj-21	247	5	,	,	PUNCT
gsrj-21	247	6	s.	s.	PROPN
gsrj-21	247	7	,	,	PUNCT
gsrj-21	247	8	&	&	CCONJ
gsrj-21	247	9	rimm	rimm	PROPN
gsrj-21	247	10	,	,	PUNCT
gsrj-21	247	11	d.	d.	PROPN
gsrj-21	247	12	l.	l.	PROPN
gsrj-21	247	13	(	(	PUNCT
gsrj-21	247	14	2012	2012	NUM
gsrj-21	247	15	)	)	PUNCT
gsrj-21	247	16	.	.	PUNCT
gsrj-21	248	1	making	make	VERB
gsrj-21	248	2	every	every	DET
gsrj-21	248	3	cell	cell	NOUN
gsrj-21	248	4	like	like	ADP
gsrj-21	248	5	hela	hela	PROPN
gsrj-21	248	6	:	:	PUNCT
gsrj-21	248	7	a	a	DET
gsrj-21	248	8	giant	giant	ADJ
gsrj-21	248	9	step	step	NOUN
gsrj-21	248	10	for	for	ADP
gsrj-21	248	11	cell	cell	NOUN
gsrj-21	248	12	culture	culture	NOUN
gsrj-21	248	13	.	.	PUNCT
gsrj-21	249	1	the	the	DET
gsrj-21	249	2	american	american	PROPN
gsrj-21	249	3	journal	journal	PROPN
gsrj-21	249	4	of	of	ADP
gsrj-21	249	5	pathology	pathology	PROPN
gsrj-21	249	6	,	,	PUNCT
gsrj-21	249	7	180(2	180(2	NUM
gsrj-21	249	8	)	)	PUNCT
gsrj-21	249	9	,	,	PUNCT
gsrj-21	249	10	443	443	NUM
gsrj-21	249	11	-	-	SYM
gsrj-21	249	12	445	445	NUM
gsrj-21	249	13	.	.	PUNCT
gsrj-21	250	1	https://doi.org/10.1016/j.ajpath.2011.12.001	https://doi.org/10.1016/j.ajpath.2011.12.001	PROPN
gsrj-21	250	2	26	26	NUM
gsrj-21	250	3	.	.	PUNCT
gsrj-21	251	1	breitenbach	breitenbach	NOUN
gsrj-21	251	2	,	,	PUNCT
gsrj-21	251	3	m.	m.	NOUN
gsrj-21	251	4	,	,	PUNCT
gsrj-21	251	5	&	&	CCONJ
gsrj-21	251	6	hoffmann	hoffmann	PROPN
gsrj-21	251	7	,	,	PUNCT
gsrj-21	251	8	j.	j.	PROPN
gsrj-21	251	9	(	(	PUNCT
gsrj-21	251	10	2018	2018	NUM
gsrj-21	251	11	)	)	PUNCT
gsrj-21	251	12	.	.	PUNCT
gsrj-21	252	1	editorial	editorial	NOUN
gsrj-21	252	2	:	:	PUNCT
gsrj-21	252	3	cancer	cancer	NOUN
gsrj-21	252	4	models	model	NOUN
gsrj-21	252	5	.	.	PUNCT
gsrj-21	253	1	frontiers	frontier	NOUN
gsrj-21	253	2	in	in	ADP
gsrj-21	253	3	oncology	oncology	NOUN
gsrj-21	253	4	,	,	PUNCT
gsrj-21	253	5	8	8	NUM
gsrj-21	253	6	https://doi.org/10.3389/fonc.2018.00401	https://doi.org/10.3389/fonc.2018.00401	PROPN
gsrj-21	253	7	27	27	NUM
gsrj-21	253	8	.	.	PUNCT
gsrj-21	254	1	gaebler	gaebler	NOUN
gsrj-21	254	2	,	,	PUNCT
gsrj-21	254	3	m.	m.	NOUN
gsrj-21	254	4	,	,	PUNCT
gsrj-21	254	5	silvestri	silvestri	PROPN
gsrj-21	254	6	,	,	PUNCT
gsrj-21	254	7	a.	a.	PROPN
gsrj-21	254	8	,	,	PUNCT
gsrj-21	254	9	haybaeck	haybaeck	PROPN
gsrj-21	254	10	,	,	PUNCT
gsrj-21	254	11	j.	j.	PROPN
gsrj-21	254	12	,	,	PUNCT
gsrj-21	254	13	reichardt	reichardt	PROPN
gsrj-21	254	14	,	,	PUNCT
gsrj-21	254	15	p.	p.	NOUN
gsrj-21	254	16	,	,	PUNCT
gsrj-21	254	17	lowery	lowery	PROPN
gsrj-21	254	18	,	,	PUNCT
gsrj-21	254	19	c.	c.	PROPN
gsrj-21	254	20	d.	d.	PROPN
gsrj-21	254	21	,	,	PUNCT
gsrj-21	254	22	stancato	stancato	PROPN
gsrj-21	254	23	,	,	PUNCT
gsrj-21	254	24	l.	l.	PROPN
gsrj-21	254	25	f.	f.	PROPN
gsrj-21	254	26	,	,	PUNCT
gsrj-21	254	27	et	et	PROPN
gsrj-21	254	28	al	al	PROPN
gsrj-21	254	29	.	.	PUNCT
gsrj-21	254	30	(	(	PUNCT
gsrj-21	254	31	2017	2017	NUM
gsrj-21	254	32	)	)	PUNCT
gsrj-21	254	33	.	.	PUNCT
gsrj-21	255	1	three	three	NUM
gsrj-21	255	2	-	-	PUNCT
gsrj-21	255	3	dimensional	dimensional	ADJ
gsrj-21	255	4	patient	patient	NOUN
gsrj-21	255	5	-	-	PUNCT
gsrj-21	255	6	derived	derive	VERB
gsrj-21	255	7	in	in	ADP
gsrj-21	255	8	vitro	vitro	X
gsrj-21	255	9	sarcoma	sarcoma	NOUN
gsrj-21	255	10	models	model	NOUN
gsrj-21	255	11	:	:	PUNCT
gsrj-21	255	12	promising	promise	VERB
gsrj-21	255	13	tools	tool	NOUN
gsrj-21	255	14	for	for	ADP
gsrj-21	255	15	improving	improve	VERB
gsrj-21	255	16	clinical	clinical	ADJ
gsrj-21	255	17	tumor	tumor	NOUN
gsrj-21	255	18	management	management	NOUN
gsrj-21	255	19	.	.	PUNCT
gsrj-21	256	1	frontiers	frontier	NOUN
gsrj-21	256	2	in	in	ADP
gsrj-21	256	3	oncology	oncology	NOUN
gsrj-21	256	4	,	,	PUNCT
gsrj-21	256	5	7	7	NUM
gsrj-21	256	6	https://doi.org/10.3389/fonc.2017.00203	https://doi.org/10.3389/fonc.2017.00203	PROPN
gsrj-21	256	7	28	28	NUM
gsrj-21	256	8	.	.	PUNCT
gsrj-21	257	1	liu	liu	PROPN
gsrj-21	257	2	,	,	PUNCT
gsrj-21	257	3	x.	x.	PROPN
gsrj-21	257	4	,	,	PUNCT
gsrj-21	257	5	ory	ory	NOUN
gsrj-21	257	6	,	,	PUNCT
gsrj-21	257	7	v.	v.	PROPN
gsrj-21	257	8	,	,	PUNCT
gsrj-21	257	9	chapman	chapman	PROPN
gsrj-21	257	10	,	,	PUNCT
gsrj-21	257	11	s.	s.	PROPN
gsrj-21	257	12	,	,	PUNCT
gsrj-21	257	13	yuan	yuan	PROPN
gsrj-21	257	14	,	,	PUNCT
gsrj-21	257	15	h.	h.	PROPN
gsrj-21	257	16	,	,	PUNCT
gsrj-21	257	17	albanese	albanese	PROPN
gsrj-21	257	18	,	,	PUNCT
gsrj-21	257	19	c.	c.	NOUN
gsrj-21	257	20	,	,	PUNCT
gsrj-21	257	21	kallakury	kallakury	PROPN
gsrj-21	257	22	,	,	PUNCT
gsrj-21	257	23	b.	b.	PROPN
gsrj-21	257	24	,	,	PUNCT
gsrj-21	257	25	et	et	PROPN
gsrj-21	257	26	al	al	PROPN
gsrj-21	257	27	.	.	PUNCT
gsrj-21	257	28	(	(	PUNCT
gsrj-21	257	29	2012	2012	NUM
gsrj-21	257	30	)	)	PUNCT
gsrj-21	257	31	.	.	PUNCT
gsrj-21	258	1	rock	rock	NOUN
gsrj-21	258	2	inhibitor	inhibitor	NOUN
gsrj-21	258	3	and	and	CCONJ
gsrj-21	258	4	feeder	feeder	NOUN
gsrj-21	258	5	cells	cell	NOUN
gsrj-21	258	6	induce	induce	VERB
gsrj-21	258	7	the	the	DET
gsrj-21	258	8	conditional	conditional	ADJ
gsrj-21	258	9	reprogramming	reprogramming	NOUN
gsrj-21	258	10	of	of	ADP
gsrj-21	258	11	epithelial	epithelial	ADJ
gsrj-21	258	12	cells	cell	NOUN
gsrj-21	258	13	.	.	PUNCT
gsrj-21	259	1	the	the	DET
gsrj-21	259	2	american	american	PROPN
gsrj-21	259	3	journal	journal	PROPN
gsrj-21	259	4	of	of	ADP
gsrj-21	259	5	pathology	pathology	PROPN
gsrj-21	259	6	,	,	PUNCT
gsrj-21	259	7	180(2	180(2	NUM
gsrj-21	259	8	)	)	PUNCT
gsrj-21	259	9	,	,	PUNCT
gsrj-21	259	10	599	599	NUM
gsrj-21	259	11	-	-	SYM
gsrj-21	259	12	607	607	NUM
gsrj-21	259	13	.	.	PUNCT
gsrj-21	260	1	https://doi.org/10.1016/j.ajpath.2011.10.036	https://doi.org/10.1016/j.ajpath.2011.10.036	NOUN
gsrj-21	260	2	29	29	NUM
gsrj-21	260	3	.	.	PUNCT
gsrj-21	261	1	yuan	yuan	PROPN
gsrj-21	261	2	,	,	PUNCT
gsrj-21	261	3	h.	h.	PROPN
gsrj-21	261	4	,	,	PUNCT
gsrj-21	261	5	myers	myers	PROPN
gsrj-21	261	6	,	,	PUNCT
gsrj-21	261	7	s.	s.	PROPN
gsrj-21	261	8	,	,	PUNCT
gsrj-21	261	9	wang	wang	PROPN
gsrj-21	261	10	,	,	PUNCT
gsrj-21	261	11	j.	j.	PROPN
gsrj-21	261	12	,	,	PUNCT
gsrj-21	261	13	zhou	zhou	PROPN
gsrj-21	261	14	,	,	PUNCT
gsrj-21	261	15	d.	d.	PROPN
gsrj-21	261	16	,	,	PUNCT
gsrj-21	261	17	woo	woo	PROPN
gsrj-21	261	18	,	,	PUNCT
gsrj-21	261	19	j.	j.	PROPN
gsrj-21	261	20	a.	a.	PROPN
gsrj-21	261	21	,	,	PUNCT
gsrj-21	261	22	kallakury	kallakury	PROPN
gsrj-21	261	23	,	,	PUNCT
gsrj-21	261	24	b.	b.	PROPN
gsrj-21	261	25	,	,	PUNCT
gsrj-21	261	26	et	et	PROPN
gsrj-21	261	27	al	al	PROPN
gsrj-21	261	28	.	.	PUNCT
gsrj-21	261	29	(	(	PUNCT
gsrj-21	261	30	2012	2012	NUM
gsrj-21	261	31	)	)	PUNCT
gsrj-21	261	32	.	.	PUNCT
gsrj-21	262	1	use	use	NOUN
gsrj-21	262	2	of	of	ADP
gsrj-21	262	3	reprogrammed	reprogrammed	ADJ
gsrj-21	262	4	cells	cell	NOUN
gsrj-21	262	5	to	to	PART
gsrj-21	262	6	identify	identify	VERB
gsrj-21	262	7	therapy	therapy	NOUN
gsrj-21	262	8	for	for	ADP
gsrj-21	262	9	respiratory	respiratory	ADJ
gsrj-21	262	10	papillomatosis	papillomatosis	NOUN
gsrj-21	262	11	.	.	PUNCT
gsrj-21	263	1	the	the	DET
gsrj-21	263	2	new	new	PROPN
gsrj-21	263	3	england	england	PROPN
gsrj-21	263	4	journal	journal	PROPN
gsrj-21	263	5	of	of	ADP
gsrj-21	263	6	medicine	medicine	NOUN
gsrj-21	263	7	,	,	PUNCT
gsrj-21	263	8	367(13	367(13	NUM
gsrj-21	263	9	)	)	PUNCT
gsrj-21	263	10	,	,	PUNCT
gsrj-21	263	11	1220	1220	NUM
gsrj-21	263	12	-	-	SYM
gsrj-21	263	13	1227	1227	NUM
gsrj-21	263	14	.	.	PUNCT
gsrj-21	264	1	https://doi.org/10.1056/nejmoa1203055	https://doi.org/10.1056/nejmoa1203055	PROPN
gsrj-21	264	2	30	30	NUM
gsrj-21	264	3	.	.	PUNCT
gsrj-21	265	1	tricoli	tricoli	PROPN
gsrj-21	265	2	,	,	PUNCT
gsrj-21	265	3	l.	l.	PROPN
gsrj-21	265	4	,	,	PUNCT
gsrj-21	265	5	naeem	naeem	PROPN
gsrj-21	265	6	,	,	PUNCT
gsrj-21	265	7	a.	a.	NOUN
gsrj-21	265	8	,	,	PUNCT
gsrj-21	265	9	parasido	parasido	NOUN
gsrj-21	265	10	,	,	PUNCT
gsrj-21	265	11	e.	e.	PROPN
gsrj-21	265	12	,	,	PUNCT
gsrj-21	265	13	mikhaiel	mikhaiel	PROPN
gsrj-21	265	14	,	,	PUNCT
gsrj-21	265	15	j.	j.	PROPN
gsrj-21	265	16	p.	p.	PROPN
gsrj-21	265	17	,	,	PUNCT
gsrj-21	265	18	choudhry	choudhry	NOUN
gsrj-21	265	19	,	,	PUNCT
gsrj-21	265	20	m.	m.	NOUN
gsrj-21	265	21	u.	u.	PROPN
gsrj-21	265	22	,	,	PUNCT
gsrj-21	265	23	berry	berry	VERB
gsrj-21	265	24	,	,	PUNCT
gsrj-21	265	25	d.	d.	PROPN
gsrj-21	265	26	l.	l.	PROPN
gsrj-21	265	27	,	,	PUNCT
gsrj-21	265	28	et	et	PROPN
gsrj-21	265	29	al	al	PROPN
gsrj-21	265	30	.	.	PUNCT
gsrj-21	266	1	(	(	PUNCT
gsrj-21	266	2	2018	2018	NUM
gsrj-21	266	3	)	)	PUNCT
gsrj-21	266	4	.	.	PUNCT
gsrj-21	267	1	characterization	characterization	NOUN
gsrj-21	267	2	of	of	ADP
gsrj-21	267	3	the	the	DET
gsrj-21	267	4	effects	effect	NOUN
gsrj-21	267	5	of	of	ADP
gsrj-21	267	6	defined	define	VERB
gsrj-21	267	7	,	,	PUNCT
gsrj-21	267	8	multidimensional	multidimensional	ADJ
gsrj-21	267	9	culture	culture	NOUN
gsrj-21	267	10	conditions	condition	NOUN
gsrj-21	267	11	on	on	ADP
gsrj-21	267	12	conditionally	conditionally	ADV
gsrj-21	267	13	reprogrammed	reprogramme	VERB
gsrj-21	267	14	primary	primary	ADJ
gsrj-21	267	15	human	human	ADJ
gsrj-21	267	16	prostate	prostate	NOUN
gsrj-21	267	17	cells	cell	NOUN
gsrj-21	267	18	.	.	PUNCT
gsrj-21	268	1	oncotarget	oncotarget	NOUN
gsrj-21	268	2	,	,	PUNCT
gsrj-21	268	3	9(2	9(2	NUM
gsrj-21	268	4	)	)	PUNCT
gsrj-21	268	5	,	,	PUNCT
gsrj-21	268	6	2193	2193	NUM
gsrj-21	268	7	-	-	SYM
gsrj-21	268	8	2207	2207	NUM
gsrj-21	268	9	.	.	PUNCT
gsrj-21	269	1	https://doi.org/10.18632/oncotarget.23363	https://doi.org/10.18632/oncotarget.23363	NOUN
gsrj-21	269	2	31	31	NUM
gsrj-21	269	3	.	.	PUNCT
gsrj-21	270	1	naeem	naeem	PROPN
gsrj-21	270	2	,	,	PUNCT
gsrj-21	270	3	a.	a.	PROPN
gsrj-21	270	4	,	,	PUNCT
gsrj-21	270	5	dakshanamurthy	dakshanamurthy	ADJ
gsrj-21	270	6	,	,	PUNCT
gsrj-21	270	7	s.	s.	PROPN
gsrj-21	270	8	,	,	PUNCT
gsrj-21	270	9	walthieu	walthieu	PROPN
gsrj-21	270	10	,	,	PUNCT
gsrj-21	270	11	h.	h.	PROPN
gsrj-21	270	12	,	,	PUNCT
gsrj-21	270	13	parasido	parasido	PROPN
gsrj-21	270	14	,	,	PUNCT
gsrj-21	270	15	e.	e.	PROPN
gsrj-21	270	16	,	,	PUNCT
gsrj-21	270	17	avantaggiati	avantaggiati	PROPN
gsrj-21	270	18	,	,	PUNCT
gsrj-21	270	19	m.	m.	NOUN
gsrj-21	270	20	,	,	PUNCT
gsrj-21	270	21	tricoli	tricoli	NOUN
gsrj-21	270	22	,	,	PUNCT
gsrj-21	270	23	l.	l.	PROPN
gsrj-21	270	24	,	,	PUNCT
gsrj-21	270	25	et	et	PROPN
gsrj-21	270	26	al	al	PROPN
gsrj-21	270	27	.	.	PROPN
gsrj-21	270	28	(	(	PUNCT
gsrj-21	270	29	2020	2020	NUM
gsrj-21	270	30	)	)	PUNCT
gsrj-21	270	31	.	.	PUNCT
gsrj-21	271	1	predicting	predict	VERB
gsrj-21	271	2	new	new	ADJ
gsrj-21	271	3	drug	drug	NOUN
gsrj-21	271	4	indications	indication	NOUN
gsrj-21	271	5	for	for	ADP
gsrj-21	271	6	prostate	prostate	NOUN
gsrj-21	271	7	cancer	cancer	NOUN
gsrj-21	271	8	:	:	PUNCT
gsrj-21	271	9	the	the	DET
gsrj-21	271	10	integration	integration	NOUN
gsrj-21	271	11	of	of	ADP
gsrj-21	271	12	an	an	PRON
gsrj-21	271	13	in	in	ADP
gsrj-21	271	14	silico	silico	NOUN
gsrj-21	271	15	proteochemometric	proteochemometric	ADJ
gsrj-21	271	16	network	network	NOUN
gsrj-21	271	17	pharmacology	pharmacology	NOUN
gsrj-21	271	18	platform	platform	NOUN
gsrj-21	271	19	with	with	ADP
gsrj-21	271	20	patient	patient	NOUN
gsrj-21	271	21	-	-	PUNCT
gsrj-21	271	22	derived	derive	VERB
gsrj-21	271	23	primary	primary	ADJ
gsrj-21	271	24	prostate	prostate	NOUN
gsrj-21	271	25	cells	cell	NOUN
gsrj-21	271	26	.	.	PUNCT
gsrj-21	272	1	the	the	DET
gsrj-21	272	2	prostate	prostate	NOUN
gsrj-21	272	3	,	,	PUNCT
gsrj-21	272	4	80(14	80(14	NOUN
gsrj-21	272	5	)	)	PUNCT
gsrj-21	272	6	,	,	PUNCT
gsrj-21	272	7	1233	1233	NUM
gsrj-21	272	8	-	-	SYM
gsrj-21	272	9	1243	1243	NUM
gsrj-21	272	10	.	.	PUNCT
gsrj-21	273	1	https://doi.org.10.1002	https://doi.org.10.1002	PROPN
gsrj-21	273	2	/	/	SYM
gsrj-21	273	3	pros.24050	pros.24050	PROPN
gsrj-21	273	4	32	32	NUM
gsrj-21	273	5	.	.	PUNCT
gsrj-21	274	1	liu	liu	PROPN
gsrj-21	274	2	,	,	PUNCT
gsrj-21	274	3	x.	x.	PROPN
gsrj-21	274	4	,	,	PUNCT
gsrj-21	274	5	krawczyk	krawczyk	PROPN
gsrj-21	274	6	,	,	PUNCT
gsrj-21	274	7	e.	e.	PROPN
gsrj-21	274	8	,	,	PUNCT
gsrj-21	274	9	suprynowicz	suprynowicz	NOUN
gsrj-21	274	10	,	,	PUNCT
gsrj-21	274	11	f.	f.	PROPN
gsrj-21	274	12	a.	a.	PROPN
gsrj-21	274	13	,	,	PUNCT
gsrj-21	274	14	palechor	palechor	NOUN
gsrj-21	274	15	-	-	PUNCT
gsrj-21	274	16	ceron	ceron	NOUN
gsrj-21	274	17	,	,	PUNCT
gsrj-21	274	18	n.	n.	NOUN
gsrj-21	274	19	,	,	PUNCT
gsrj-21	274	20	yuan	yuan	PROPN
gsrj-21	274	21	,	,	PUNCT
gsrj-21	274	22	h.	h.	PROPN
gsrj-21	274	23	,	,	PUNCT
gsrj-21	274	24	dakic	dakic	PROPN
gsrj-21	274	25	,	,	PUNCT
gsrj-21	274	26	a.	a.	PROPN
gsrj-21	274	27	,	,	PUNCT
gsrj-21	274	28	et	et	PROPN
gsrj-21	274	29	al	al	PROPN
gsrj-21	274	30	.	.	PUNCT
gsrj-21	274	31	(	(	PUNCT
gsrj-21	274	32	2017	2017	NUM
gsrj-21	274	33	)	)	PUNCT
gsrj-21	274	34	.	.	PUNCT
gsrj-21	275	1	conditional	conditional	ADJ
gsrj-21	275	2	reprogramming	reprogramming	ADJ
gsrj-21	275	3	and	and	CCONJ
gsrj-21	275	4	long	long	ADJ
gsrj-21	275	5	-	-	PUNCT
gsrj-21	275	6	term	term	NOUN
gsrj-21	275	7	expansion	expansion	NOUN
gsrj-21	275	8	of	of	ADP
gsrj-21	275	9	normal	normal	ADJ
gsrj-21	275	10	and	and	CCONJ
gsrj-21	275	11	tumor	tumor	NOUN
gsrj-21	275	12	cells	cell	NOUN
gsrj-21	275	13	from	from	ADP
gsrj-21	275	14	human	human	ADJ
gsrj-21	275	15	biospecimens	biospecimen	NOUN
gsrj-21	275	16	.	.	PUNCT
gsrj-21	276	1	nature	nature	NOUN
gsrj-21	276	2	protocols	protocol	NOUN
gsrj-21	276	3	,	,	PUNCT
gsrj-21	276	4	12(2	12(2	NUM
gsrj-21	276	5	)	)	PUNCT
gsrj-21	276	6	,	,	PUNCT
gsrj-21	276	7	439	439	NUM
gsrj-21	276	8	-	-	SYM
gsrj-21	276	9	451	451	NUM
gsrj-21	276	10	.	.	PUNCT
gsrj-21	277	1	https://doi.org/10.1038/nprot.2016.174	https://doi.org/10.1038/nprot.2016.174	NOUN
gsrj-21	277	2	33	33	NUM
gsrj-21	277	3	.	.	PUNCT
gsrj-21	278	1	tricoli	tricoli	PROPN
gsrj-21	278	2	,	,	PUNCT
gsrj-21	278	3	l.	l.	PROPN
gsrj-21	278	4	,	,	PUNCT
gsrj-21	278	5	berry	berry	PROPN
gsrj-21	278	6	,	,	PUNCT
gsrj-21	278	7	d.	d.	PROPN
gsrj-21	278	8	l.	l.	PROPN
gsrj-21	278	9	,	,	PUNCT
gsrj-21	278	10	&	&	CCONJ
gsrj-21	278	11	albanese	albanese	PROPN
gsrj-21	278	12	,	,	PUNCT
gsrj-21	278	13	c.	c.	NOUN
gsrj-21	278	14	(	(	PUNCT
gsrj-21	278	15	2017	2017	NUM
gsrj-21	278	16	)	)	PUNCT
gsrj-21	278	17	.	.	PUNCT
gsrj-21	279	1	a	a	DET
gsrj-21	279	2	rapid	rapid	ADJ
gsrj-21	279	3	filter	filter	NOUN
gsrj-21	279	4	insert	insert	NOUN
gsrj-21	279	5	-	-	PUNCT
gsrj-21	279	6	based	base	VERB
gsrj-21	279	7	3d	3d	NOUN
gsrj-21	279	8	culture	culture	NOUN
gsrj-21	279	9	system	system	NOUN
gsrj-21	279	10	for	for	ADP
gsrj-21	279	11	primary	primary	ADJ
gsrj-21	279	12	prostate	prostate	NOUN
gsrj-21	279	13	cell	cell	NOUN
gsrj-21	279	14	differentiation	differentiation	NOUN
gsrj-21	279	15	.	.	PUNCT
gsrj-21	280	1	journal	journal	NOUN
gsrj-21	280	2	of	of	ADP
gsrj-21	280	3	visualized	visualized	ADJ
gsrj-21	280	4	experiments	experiment	NOUN
gsrj-21	280	5	,	,	PUNCT
gsrj-21	280	6	(	(	PUNCT
gsrj-21	280	7	120	120	NUM
gsrj-21	280	8	)	)	PUNCT
gsrj-21	280	9	https://doi.org/10.3791/55279	https://doi.org/10.3791/55279	NOUN
gsrj-21	280	10	34	34	NUM
gsrj-21	280	11	.	.	PUNCT
gsrj-21	281	1	ringer	ringer	NOUN
gsrj-21	281	2	,	,	PUNCT
gsrj-21	281	3	l.	l.	PROPN
gsrj-21	281	4	,	,	PUNCT
gsrj-21	281	5	sirajuddin	sirajuddin	ADV
gsrj-21	281	6	,	,	PUNCT
gsrj-21	281	7	p.	p.	NOUN
gsrj-21	281	8	,	,	PUNCT
gsrj-21	281	9	tricoli	tricoli	PROPN
gsrj-21	281	10	,	,	PUNCT
gsrj-21	281	11	l.	l.	PROPN
gsrj-21	281	12	,	,	PUNCT
gsrj-21	281	13	waye	waye	NOUN
gsrj-21	281	14	,	,	PUNCT
gsrj-21	281	15	s.	s.	PROPN
gsrj-21	281	16	,	,	PUNCT
gsrj-21	281	17	choudhry	choudhry	NOUN
gsrj-21	281	18	,	,	PUNCT
gsrj-21	281	19	m.	m.	NOUN
gsrj-21	281	20	u.	u.	PROPN
gsrj-21	281	21	,	,	PUNCT
gsrj-21	281	22	parasido	parasido	NOUN
gsrj-21	281	23	,	,	PUNCT
gsrj-21	281	24	e.	e.	PROPN
gsrj-21	281	25	,	,	PUNCT
gsrj-21	281	26	et	et	PROPN
gsrj-21	281	27	al	al	PROPN
gsrj-21	281	28	.	.	PUNCT
gsrj-21	282	1	(	(	PUNCT
gsrj-21	282	2	2014	2014	NUM
gsrj-21	282	3	)	)	PUNCT
gsrj-21	282	4	.	.	PUNCT
gsrj-21	283	1	the	the	DET
gsrj-21	283	2	induction	induction	NOUN
gsrj-21	283	3	of	of	ADP
gsrj-21	283	4	the	the	DET
gsrj-21	283	5	p53	p53	NOUN
gsrj-21	283	6	tumor	tumor	NOUN
gsrj-21	283	7	suppressor	suppressor	NOUN
gsrj-21	283	8	protein	protein	NOUN
gsrj-21	283	9	bridges	bridge	VERB
gsrj-21	283	10	the	the	DET
gsrj-21	283	11	apoptotic	apoptotic	ADJ
gsrj-21	283	12	and	and	CCONJ
gsrj-21	283	13	autophagic	autophagic	ADJ
gsrj-21	283	14	signaling	signal	VERB
gsrj-21	283	15	pathways	pathway	NOUN
gsrj-21	283	16	to	to	PART
gsrj-21	283	17	regulate	regulate	VERB
gsrj-21	283	18	cell	cell	NOUN
gsrj-21	283	19	death	death	NOUN
gsrj-21	283	20	in	in	ADP
gsrj-21	283	21	prostate	prostate	NOUN
gsrj-21	283	22	cancer	cancer	NOUN
gsrj-21	283	23	cells	cell	NOUN
gsrj-21	283	24	.	.	PUNCT
gsrj-21	284	1	oncotarget	oncotarget	NOUN
gsrj-21	284	2	,	,	PUNCT
gsrj-21	284	3	5(21	5(21	NUM
gsrj-21	284	4	)	)	PUNCT
gsrj-21	284	5	,	,	PUNCT
gsrj-21	284	6	10678	10678	NUM
gsrj-21	284	7	-	-	SYM
gsrj-21	284	8	10691	10691	NUM
gsrj-21	284	9	.	.	PUNCT
gsrj-21	285	1	https://doi.org/10.18632/oncotarget.2528	https://doi.org/10.18632/oncotarget.2528	PROPN
gsrj-21	285	2	35	35	NUM
gsrj-21	285	3	.	.	PUNCT
gsrj-21	286	1	gao	gao	PROPN
gsrj-21	286	2	,	,	PUNCT
gsrj-21	286	3	d.	d.	PROPN
gsrj-21	286	4	,	,	PUNCT
gsrj-21	286	5	vela	vela	PROPN
gsrj-21	286	6	,	,	PUNCT
gsrj-21	286	7	i.	i.	PROPN
gsrj-21	286	8	,	,	PUNCT
gsrj-21	286	9	sboner	sboner	NOUN
gsrj-21	286	10	,	,	PUNCT
gsrj-21	286	11	a.	a.	NOUN
gsrj-21	286	12	,	,	PUNCT
gsrj-21	286	13	iaquinta	iaquinta	VERB
gsrj-21	286	14	,	,	PUNCT
gsrj-21	286	15	p.	p.	PROPN
gsrj-21	286	16	j.	j.	PROPN
gsrj-21	286	17	,	,	PUNCT
gsrj-21	286	18	karthaus	karthaus	PROPN
gsrj-21	286	19	,	,	PUNCT
gsrj-21	286	20	w.	w.	PROPN
gsrj-21	286	21	r.	r.	PROPN
gsrj-21	286	22	,	,	PUNCT
gsrj-21	286	23	gopalan	gopalan	PROPN
gsrj-21	286	24	,	,	PUNCT
gsrj-21	286	25	a.	a.	PROPN
gsrj-21	286	26	,	,	PUNCT
gsrj-21	286	27	et	et	PROPN
gsrj-21	286	28	al	al	PROPN
gsrj-21	286	29	.	.	PUNCT
gsrj-21	287	1	(	(	PUNCT
gsrj-21	287	2	2014	2014	NUM
gsrj-21	287	3	)	)	PUNCT
gsrj-21	287	4	.	.	PUNCT
gsrj-21	288	1	organoid	organoid	PROPN
gsrj-21	288	2	cultures	culture	NOUN
gsrj-21	288	3	derived	derive	VERB
gsrj-21	288	4	from	from	ADP
gsrj-21	288	5	patients	patient	NOUN
gsrj-21	288	6	with	with	ADP
gsrj-21	288	7	advanced	advanced	ADJ
gsrj-21	288	8	prostate	prostate	NOUN
gsrj-21	288	9	cancer	cancer	NOUN
gsrj-21	288	10	.	.	PUNCT
gsrj-21	289	1	cell	cell	NOUN
gsrj-21	289	2	,	,	PUNCT
gsrj-21	289	3	159(1	159(1	NUM
gsrj-21	289	4	)	)	PUNCT
gsrj-21	289	5	,	,	PUNCT
gsrj-21	289	6	176	176	NUM
gsrj-21	289	7	-	-	SYM
gsrj-21	289	8	187	187	NUM
gsrj-21	289	9	.	.	PUNCT
gsrj-21	290	1	https://doi.org/10.1016/j.cell.2014.08.016	https://doi.org/10.1016/j.cell.2014.08.016	NUM
gsrj-21	290	2	36	36	NUM
gsrj-21	290	3	.	.	PUNCT
gsrj-21	291	1	boj	boj	PROPN
gsrj-21	291	2	,	,	PUNCT
gsrj-21	291	3	s.	s.	PROPN
gsrj-21	291	4	f.	f.	PROPN
gsrj-21	291	5	,	,	PUNCT
gsrj-21	291	6	hwang	hwang	PROPN
gsrj-21	291	7	,	,	PUNCT
gsrj-21	291	8	c.	c.	PROPN
gsrj-21	291	9	,	,	PUNCT
gsrj-21	291	10	baker	baker	PROPN
gsrj-21	291	11	,	,	PUNCT
gsrj-21	291	12	l.	l.	PROPN
gsrj-21	291	13	a.	a.	PROPN
gsrj-21	291	14	,	,	PUNCT
gsrj-21	291	15	chio	chio	PROPN
gsrj-21	291	16	,	,	PUNCT
gsrj-21	291	17	i.	i.	PROPN
gsrj-21	291	18	i.	i.	PROPN
gsrj-21	291	19	c.	c.	PROPN
gsrj-21	291	20	,	,	PUNCT
gsrj-21	291	21	engle	engle	PROPN
gsrj-21	291	22	,	,	PUNCT
gsrj-21	291	23	d.	d.	PROPN
gsrj-21	291	24	d.	d.	PROPN
gsrj-21	291	25	,	,	PUNCT
gsrj-21	291	26	corbo	corbo	PROPN
gsrj-21	291	27	,	,	PUNCT
gsrj-21	291	28	v.	v.	ADV
gsrj-21	291	29	,	,	PUNCT
gsrj-21	291	30	et	et	PROPN
gsrj-21	291	31	al	al	PROPN
gsrj-21	291	32	.	.	PUNCT
gsrj-21	291	33	(	(	PUNCT
gsrj-21	291	34	2015	2015	NUM
gsrj-21	291	35	)	)	PUNCT
gsrj-21	291	36	.	.	PUNCT
gsrj-21	292	1	organoid	organoid	PROPN
gsrj-21	292	2	models	model	NOUN
gsrj-21	292	3	of	of	ADP
gsrj-21	292	4	human	human	ADJ
gsrj-21	292	5	and	and	CCONJ
gsrj-21	292	6	mouse	mouse	NOUN
gsrj-21	292	7	ductal	ductal	ADJ
gsrj-21	292	8	pancreatic	pancreatic	ADJ
gsrj-21	292	9	cancer	cancer	NOUN
gsrj-21	292	10	.	.	PUNCT
gsrj-21	293	1	cell	cell	NOUN
gsrj-21	293	2	,	,	PUNCT
gsrj-21	293	3	160(1	160(1	NUM
gsrj-21	293	4	-	-	SYM
gsrj-21	293	5	2	2	NUM
gsrj-21	293	6	)	)	PUNCT
gsrj-21	293	7	,	,	PUNCT
gsrj-21	293	8	324	324	NUM
gsrj-21	293	9	-	-	SYM
gsrj-21	293	10	338	338	NUM
gsrj-21	293	11	.	.	PUNCT
gsrj-21	294	1	https://doi.org/10.1016/j.cell.2014.12.021	https://doi.org/10.1016/j.cell.2014.12.021	NOUN
gsrj-21	294	2	57	57	NUM
gsrj-21	294	3	georgetown	georgetown	PROPN
gsrj-21	294	4	scientific	scientific	ADJ
gsrj-21	294	5	research	research	NOUN
gsrj-21	294	6	journal	journal	NOUN
gsrj-21	294	7	37	37	NUM
gsrj-21	294	8	.	.	PUNCT
gsrj-21	295	1	van	van	PROPN
gsrj-21	295	2	de	de	X
gsrj-21	295	3	wetering	wetering	PROPN
gsrj-21	295	4	,	,	PUNCT
gsrj-21	295	5	m.	m.	NOUN
gsrj-21	295	6	,	,	PUNCT
gsrj-21	295	7	francies	francie	NOUN
gsrj-21	295	8	,	,	PUNCT
gsrj-21	295	9	h.	h.	PROPN
gsrj-21	295	10	,	,	PUNCT
gsrj-21	295	11	francis	francis	PROPN
gsrj-21	295	12	,	,	PUNCT
gsrj-21	295	13	j.	j.	PROPN
gsrj-21	295	14	,	,	PUNCT
gsrj-21	295	15	bounova	bounova	PROPN
gsrj-21	295	16	,	,	PUNCT
gsrj-21	295	17	g.	g.	PROPN
gsrj-21	295	18	,	,	PUNCT
gsrj-21	295	19	iorio	iorio	PROPN
gsrj-21	295	20	,	,	PUNCT
gsrj-21	295	21	f.	f.	PROPN
gsrj-21	295	22	,	,	PUNCT
gsrj-21	295	23	pronk	pronk	PROPN
gsrj-21	295	24	,	,	PUNCT
gsrj-21	295	25	a.	a.	NOUN
gsrj-21	295	26	,	,	PUNCT
gsrj-21	295	27	et	et	PROPN
gsrj-21	295	28	al	al	PROPN
gsrj-21	295	29	.	.	PUNCT
gsrj-21	295	30	(	(	PUNCT
gsrj-21	295	31	2015	2015	NUM
gsrj-21	295	32	)	)	PUNCT
gsrj-21	295	33	.	.	PUNCT
gsrj-21	296	1	prospective	prospective	ADJ
gsrj-21	296	2	derivation	derivation	NOUN
gsrj-21	296	3	of	of	ADP
gsrj-21	296	4	a	a	DET
gsrj-21	296	5	living	live	VERB
gsrj-21	296	6	organoid	organoid	NOUN
gsrj-21	296	7	biobank	biobank	NOUN
gsrj-21	296	8	of	of	ADP
gsrj-21	296	9	colorectal	colorectal	ADJ
gsrj-21	296	10	cancer	cancer	NOUN
gsrj-21	296	11	patients	patient	NOUN
gsrj-21	296	12	.	.	PUNCT
gsrj-21	297	1	cell	cell	NOUN
gsrj-21	297	2	(	(	PUNCT
gsrj-21	297	3	cambridge	cambridge	PROPN
gsrj-21	297	4	)	)	PUNCT
gsrj-21	297	5	,	,	PUNCT
gsrj-21	297	6	161(4	161(4	NUM
gsrj-21	297	7	)	)	PUNCT
gsrj-21	297	8	,	,	PUNCT
gsrj-21	297	9	933	933	NUM
gsrj-21	297	10	-	-	SYM
gsrj-21	297	11	945	945	NUM
gsrj-21	297	12	.	.	PUNCT
gsrj-21	298	1	https://doi.org/10.1016/j.cell.2015.03.053	https://doi.org/10.1016/j.cell.2015.03.053	PROPN
gsrj-21	298	2	38	38	NUM
gsrj-21	298	3	.	.	PUNCT
gsrj-21	299	1	sachs	sachs	PROPN
gsrj-21	299	2	,	,	PUNCT
gsrj-21	299	3	n.	n.	NOUN
gsrj-21	299	4	,	,	PUNCT
gsrj-21	299	5	&	&	CCONJ
gsrj-21	299	6	clevers	clevers	PROPN
gsrj-21	299	7	,	,	PUNCT
gsrj-21	299	8	h.	h.	PROPN
gsrj-21	299	9	(	(	PUNCT
gsrj-21	299	10	2014	2014	NUM
gsrj-21	299	11	)	)	PUNCT
gsrj-21	299	12	.	.	PUNCT
gsrj-21	300	1	organoid	organoid	PROPN
gsrj-21	300	2	cultures	culture	NOUN
gsrj-21	300	3	for	for	ADP
gsrj-21	300	4	the	the	DET
gsrj-21	300	5	analysis	analysis	NOUN
gsrj-21	300	6	of	of	ADP
gsrj-21	300	7	cancer	cancer	NOUN
gsrj-21	300	8	phenotypes	phenotype	NOUN
gsrj-21	300	9	.	.	PUNCT
gsrj-21	301	1	current	current	ADJ
gsrj-21	301	2	opinion	opinion	NOUN
gsrj-21	301	3	in	in	ADP
gsrj-21	301	4	genetics	genetics	PROPN
gsrj-21	301	5	&	&	CCONJ
gsrj-21	301	6	development	development	PROPN
gsrj-21	301	7	,	,	PUNCT
gsrj-21	301	8	24	24	NUM
gsrj-21	301	9	,	,	PUNCT
gsrj-21	301	10	6873	6873	NUM
gsrj-21	301	11	.	.	PUNCT
gsrj-21	302	1	https://doi.org/10.1016/j.gde.2013.11.012	https://doi.org/10.1016/j.gde.2013.11.012	NOUN
gsrj-21	302	2	39	39	NUM
gsrj-21	302	3	.	.	PUNCT
gsrj-21	303	1	li	li	PROPN
gsrj-21	303	2	,	,	PUNCT
gsrj-21	303	3	x.	x.	PROPN
gsrj-21	303	4	,	,	PUNCT
gsrj-21	303	5	nadauld	nadauld	PROPN
gsrj-21	303	6	,	,	PUNCT
gsrj-21	303	7	l.	l.	PROPN
gsrj-21	303	8	,	,	PUNCT
gsrj-21	303	9	ootani	ootani	PROPN
gsrj-21	303	10	,	,	PUNCT
gsrj-21	303	11	a.	a.	NOUN
gsrj-21	303	12	,	,	PUNCT
gsrj-21	303	13	corney	corney	PROPN
gsrj-21	303	14	,	,	PUNCT
gsrj-21	303	15	d.	d.	PROPN
gsrj-21	303	16	c.	c.	PROPN
gsrj-21	303	17	,	,	PUNCT
gsrj-21	303	18	pai	pai	PROPN
gsrj-21	303	19	,	,	PUNCT
gsrj-21	303	20	r.	r.	PROPN
gsrj-21	303	21	k.	k.	PROPN
gsrj-21	303	22	,	,	PUNCT
gsrj-21	303	23	gevaert	gevaert	PROPN
gsrj-21	303	24	,	,	PUNCT
gsrj-21	303	25	o.	o.	PROPN
gsrj-21	303	26	,	,	PUNCT
gsrj-21	303	27	et	et	PROPN
gsrj-21	303	28	al	al	PROPN
gsrj-21	303	29	.	.	PUNCT
gsrj-21	303	30	(	(	PUNCT
gsrj-21	303	31	2014	2014	NUM
gsrj-21	303	32	)	)	PUNCT
gsrj-21	303	33	.	.	PUNCT
gsrj-21	304	1	oncogenic	oncogenic	ADJ
gsrj-21	304	2	transformation	transformation	NOUN
gsrj-21	304	3	of	of	ADP
gsrj-21	304	4	diverse	diverse	ADJ
gsrj-21	304	5	gastrointestinal	gastrointestinal	ADJ
gsrj-21	304	6	tissues	tissue	NOUN
gsrj-21	304	7	in	in	ADP
gsrj-21	304	8	primary	primary	ADJ
gsrj-21	304	9	organoid	organoid	PROPN
gsrj-21	304	10	culture	culture	NOUN
gsrj-21	304	11	.	.	PUNCT
gsrj-21	305	1	nature	nature	NOUN
gsrj-21	305	2	medicine	medicine	NOUN
gsrj-21	305	3	,	,	PUNCT
gsrj-21	305	4	20(7	20(7	NUM
gsrj-21	305	5	)	)	PUNCT
gsrj-21	305	6	,	,	PUNCT
gsrj-21	305	7	769	769	NUM
gsrj-21	305	8	-	-	SYM
gsrj-21	305	9	777	777	NUM
gsrj-21	305	10	.	.	PUNCT
gsrj-21	306	1	https://doi.org/10.1038/nm.3585	https://doi.org/10.1038/nm.3585	PROPN
gsrj-21	306	2	40	40	NUM
gsrj-21	306	3	.	.	PUNCT
gsrj-21	307	1	nadauld	nadauld	PROPN
gsrj-21	307	2	,	,	PUNCT
gsrj-21	307	3	l.	l.	PROPN
gsrj-21	307	4	d.	d.	PROPN
gsrj-21	307	5	,	,	PUNCT
gsrj-21	307	6	garcia	garcia	PROPN
gsrj-21	307	7	,	,	PUNCT
gsrj-21	307	8	s.	s.	PROPN
gsrj-21	307	9	,	,	PUNCT
gsrj-21	307	10	natsoulis	natsoulis	PROPN
gsrj-21	307	11	,	,	PUNCT
gsrj-21	307	12	g.	g.	PROPN
gsrj-21	307	13	,	,	PUNCT
gsrj-21	307	14	bell	bell	PROPN
gsrj-21	307	15	,	,	PUNCT
gsrj-21	307	16	j.	j.	PROPN
gsrj-21	307	17	m.	m.	PROPN
gsrj-21	307	18	,	,	PUNCT
gsrj-21	307	19	miotke	miotke	PROPN
gsrj-21	307	20	,	,	PUNCT
gsrj-21	307	21	l.	l.	PROPN
gsrj-21	307	22	,	,	PUNCT
gsrj-21	307	23	hopmans	hopmans	PROPN
gsrj-21	307	24	,	,	PUNCT
gsrj-21	307	25	e.	e.	PROPN
gsrj-21	307	26	s.	s.	PROPN
gsrj-21	307	27	,	,	PUNCT
gsrj-21	307	28	et	et	PROPN
gsrj-21	307	29	al	al	PROPN
gsrj-21	307	30	.	.	PUNCT
gsrj-21	308	1	(	(	PUNCT
gsrj-21	308	2	2014	2014	NUM
gsrj-21	308	3	)	)	PUNCT
gsrj-21	308	4	.	.	PUNCT
gsrj-21	309	1	metastatic	metastatic	ADJ
gsrj-21	309	2	tumor	tumor	NOUN
gsrj-21	309	3	evolution	evolution	NOUN
gsrj-21	309	4	and	and	CCONJ
gsrj-21	309	5	organoid	organoid	NOUN
gsrj-21	309	6	modeling	model	VERB
gsrj-21	309	7	implicate	implicate	VERB
gsrj-21	309	8	tgfbr2	tgfbr2	NOUN
gsrj-21	309	9	as	as	ADP
gsrj-21	309	10	a	a	DET
gsrj-21	309	11	cancer	cancer	NOUN
gsrj-21	309	12	driver	driver	NOUN
gsrj-21	309	13	in	in	ADP
gsrj-21	309	14	diffuse	diffuse	ADJ
gsrj-21	309	15	gastric	gastric	ADJ
gsrj-21	309	16	cancer	cancer	NOUN
gsrj-21	309	17	.	.	PUNCT
gsrj-21	310	1	genome	genome	NOUN
gsrj-21	310	2	biology	biology	NOUN
gsrj-21	310	3	,	,	PUNCT
gsrj-21	310	4	15(8	15(8	NOUN
gsrj-21	310	5	)	)	PUNCT
gsrj-21	310	6	,	,	PUNCT
gsrj-21	310	7	428	428	NUM
gsrj-21	310	8	.	.	PUNCT
gsrj-21	311	1	https://doi.org/10.1186/s13059-014-0428-9	https://doi.org/10.1186/s13059-014-0428-9	NUM
gsrj-21	311	2	41	41	NUM
gsrj-21	311	3	.	.	PUNCT
gsrj-21	312	1	tiriac	tiriac	PROPN
gsrj-21	312	2	,	,	PUNCT
gsrj-21	312	3	h.	h.	PROPN
gsrj-21	312	4	,	,	PUNCT
gsrj-21	312	5	bucobo	bucobo	PROPN
gsrj-21	312	6	,	,	PUNCT
gsrj-21	312	7	j.	j.	PROPN
gsrj-21	312	8	c.	c.	PROPN
gsrj-21	312	9	,	,	PUNCT
gsrj-21	312	10	tzimas	tzima	NOUN
gsrj-21	312	11	,	,	PUNCT
gsrj-21	312	12	d.	d.	PROPN
gsrj-21	312	13	,	,	PUNCT
gsrj-21	312	14	grewal	grewal	PROPN
gsrj-21	312	15	,	,	PUNCT
gsrj-21	312	16	s.	s.	PROPN
gsrj-21	312	17	,	,	PUNCT
gsrj-21	312	18	lacomb	lacomb	PROPN
gsrj-21	312	19	,	,	PUNCT
gsrj-21	312	20	j.	j.	PROPN
gsrj-21	312	21	,	,	PUNCT
gsrj-21	312	22	rowehl	rowehl	PROPN
gsrj-21	312	23	,	,	PUNCT
gsrj-21	312	24	l.	l.	PROPN
gsrj-21	312	25	,	,	PUNCT
gsrj-21	312	26	et	et	PROPN
gsrj-21	312	27	al	al	PROPN
gsrj-21	312	28	.	.	PUNCT
gsrj-21	312	29	(	(	PUNCT
gsrj-21	312	30	2018	2018	NUM
gsrj-21	312	31	)	)	PUNCT
gsrj-21	312	32	.	.	PUNCT
gsrj-21	313	1	successful	successful	ADJ
gsrj-21	313	2	creation	creation	NOUN
gsrj-21	313	3	of	of	ADP
gsrj-21	313	4	pancreatic	pancreatic	ADJ
gsrj-21	313	5	cancer	cancer	NOUN
gsrj-21	313	6	organoids	organoid	NOUN
gsrj-21	313	7	by	by	ADP
gsrj-21	313	8	means	mean	NOUN
gsrj-21	313	9	of	of	ADP
gsrj-21	313	10	eus	eus	PROPN
gsrj-21	313	11	-	-	PUNCT
gsrj-21	313	12	guided	guide	VERB
gsrj-21	313	13	fine	fine	ADJ
gsrj-21	313	14	-	-	PUNCT
gsrj-21	313	15	needle	needle	NOUN
gsrj-21	313	16	biopsy	biopsy	NOUN
gsrj-21	313	17	(	(	PUNCT
gsrj-21	313	18	eus	eus	PROPN
gsrj-21	313	19	-	-	NOUN
gsrj-21	313	20	fnb	fnb	NOUN
gsrj-21	313	21	)	)	PUNCT
gsrj-21	313	22	for	for	ADP
gsrj-21	313	23	personalized	personalized	ADJ
gsrj-21	313	24	cancer	cancer	NOUN
gsrj-21	313	25	treatment	treatment	NOUN
gsrj-21	313	26	.	.	PUNCT
gsrj-21	314	1	gastrointestinal	gastrointestinal	ADJ
gsrj-21	314	2	endoscopy	endoscopy	NOUN
gsrj-21	314	3	,	,	PUNCT
gsrj-21	314	4	87(6	87(6	NUM
gsrj-21	314	5	)	)	PUNCT
gsrj-21	314	6	,	,	PUNCT
gsrj-21	314	7	ab50	ab50	PROPN
gsrj-21	314	8	-	-	PUNCT
gsrj-21	314	9	ab51	ab51	PROPN
gsrj-21	314	10	.	.	PUNCT
gsrj-21	315	1	https://doi.org/10.1016/j.gie.2017.12.032	https://doi.org/10.1016/j.gie.2017.12.032	ADP
gsrj-21	315	2	42	42	NUM
gsrj-21	315	3	.	.	PUNCT
gsrj-21	316	1	öhlund	öhlund	PROPN
gsrj-21	316	2	,	,	PUNCT
gsrj-21	316	3	d.	d.	PROPN
gsrj-21	316	4	(	(	PUNCT
gsrj-21	316	5	2017	2017	NUM
gsrj-21	316	6	)	)	PUNCT
gsrj-21	316	7	.	.	PUNCT
gsrj-21	317	1	distinct	distinct	ADJ
gsrj-21	317	2	populations	population	NOUN
gsrj-21	317	3	of	of	ADP
gsrj-21	317	4	inflammatory	inflammatory	ADJ
gsrj-21	317	5	fibroblasts	fibroblast	NOUN
gsrj-21	317	6	and	and	CCONJ
gsrj-21	317	7	myofibroblasts	myofibroblast	NOUN
gsrj-21	317	8	in	in	ADP
gsrj-21	317	9	pancreatic	pancreatic	ADJ
gsrj-21	317	10	cancer	cancer	NOUN
gsrj-21	317	11	retrieved	retrieve	VERB
gsrj-21	317	12	from	from	ADP
gsrj-21	317	13	http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva132073	http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva132073	NOUN
gsrj-21	317	14	43	43	NUM
gsrj-21	317	15	.	.	PUNCT
gsrj-21	318	1	neal	neal	PROPN
gsrj-21	318	2	,	,	PUNCT
gsrj-21	318	3	j.	j.	PROPN
gsrj-21	318	4	t.	t.	PROPN
gsrj-21	318	5	,	,	PUNCT
gsrj-21	318	6	li	li	PROPN
gsrj-21	318	7	,	,	PUNCT
gsrj-21	318	8	x.	x.	PROPN
gsrj-21	318	9	,	,	PUNCT
gsrj-21	318	10	zhu	zhu	PROPN
gsrj-21	318	11	,	,	PUNCT
gsrj-21	318	12	j.	j.	PROPN
gsrj-21	318	13	,	,	PUNCT
gsrj-21	318	14	giangarra	giangarra	PROPN
gsrj-21	318	15	,	,	PUNCT
gsrj-21	318	16	v.	v.	PROPN
gsrj-21	318	17	,	,	PUNCT
gsrj-21	318	18	grzeskowiak	grzeskowiak	PROPN
gsrj-21	318	19	,	,	PUNCT
gsrj-21	318	20	c.	c.	PROPN
gsrj-21	318	21	l.	l.	PROPN
gsrj-21	318	22	,	,	PUNCT
gsrj-21	318	23	ju	ju	PROPN
gsrj-21	318	24	,	,	PUNCT
gsrj-21	318	25	j.	j.	PROPN
gsrj-21	318	26	,	,	PUNCT
gsrj-21	318	27	et	et	PROPN
gsrj-21	318	28	al	al	PROPN
gsrj-21	318	29	.	.	PUNCT
gsrj-21	318	30	(	(	PUNCT
gsrj-21	318	31	2018	2018	NUM
gsrj-21	318	32	)	)	PUNCT
gsrj-21	318	33	.	.	PUNCT
gsrj-21	319	1	organoid	organoid	VERB
gsrj-21	319	2	modeling	modeling	NOUN
gsrj-21	319	3	of	of	ADP
gsrj-21	319	4	the	the	DET
gsrj-21	319	5	tumor	tumor	NOUN
gsrj-21	319	6	immune	immune	ADJ
gsrj-21	319	7	microenvironment	microenvironment	NOUN
gsrj-21	319	8	mendeley	mendeley	NOUN
gsrj-21	319	9	.	.	PUNCT
gsrj-21	320	1	44	44	NUM
gsrj-21	320	2	.	.	PUNCT
gsrj-21	321	1	dijkstra	dijkstra	PROPN
gsrj-21	321	2	,	,	PUNCT
gsrj-21	321	3	k.	k.	PROPN
gsrj-21	321	4	k.	k.	PROPN
gsrj-21	321	5	,	,	PUNCT
gsrj-21	321	6	cattaneo	cattaneo	PROPN
gsrj-21	321	7	,	,	PUNCT
gsrj-21	321	8	c.	c.	PROPN
gsrj-21	321	9	m.	m.	PROPN
gsrj-21	321	10	,	,	PUNCT
gsrj-21	321	11	weeber	weeber	PROPN
gsrj-21	321	12	,	,	PUNCT
gsrj-21	321	13	f.	f.	PROPN
gsrj-21	321	14	,	,	PUNCT
gsrj-21	321	15	chalabi	chalabi	PROPN
gsrj-21	321	16	,	,	PUNCT
gsrj-21	321	17	m.	m.	NOUN
gsrj-21	321	18	,	,	PUNCT
gsrj-21	321	19	van	van	PROPN
gsrj-21	321	20	de	de	PROPN
gsrj-21	321	21	haar	haar	PROPN
gsrj-21	321	22	,	,	PUNCT
gsrj-21	321	23	j.	j.	PROPN
gsrj-21	321	24	,	,	PUNCT
gsrj-21	321	25	fanchi	fanchi	PROPN
gsrj-21	321	26	,	,	PUNCT
gsrj-21	321	27	l.	l.	PROPN
gsrj-21	321	28	f.	f.	PROPN
gsrj-21	321	29	,	,	PUNCT
gsrj-21	321	30	et	et	PROPN
gsrj-21	321	31	al	al	PROPN
gsrj-21	321	32	.	.	PUNCT
gsrj-21	322	1	(	(	PUNCT
gsrj-21	322	2	2018	2018	NUM
gsrj-21	322	3	)	)	PUNCT
gsrj-21	322	4	.	.	PUNCT
gsrj-21	323	1	generation	generation	NOUN
gsrj-21	323	2	of	of	ADP
gsrj-21	323	3	tumor	tumor	NOUN
gsrj-21	323	4	-	-	PUNCT
gsrj-21	323	5	reactive	reactive	NOUN
gsrj-21	323	6	t	t	NOUN
gsrj-21	323	7	cells	cell	NOUN
gsrj-21	323	8	by	by	ADP
gsrj-21	323	9	co	co	NOUN
gsrj-21	323	10	-	-	NOUN
gsrj-21	323	11	culture	culture	NOUN
gsrj-21	323	12	of	of	ADP
gsrj-21	323	13	peripheral	peripheral	ADJ
gsrj-21	323	14	blood	blood	NOUN
gsrj-21	323	15	lymphocytes	lymphocyte	NOUN
gsrj-21	323	16	and	and	CCONJ
gsrj-21	323	17	tumor	tumor	NOUN
gsrj-21	323	18	organoids	organoid	NOUN
gsrj-21	323	19	.	.	PUNCT
gsrj-21	324	1	cell	cell	NOUN
gsrj-21	324	2	,	,	PUNCT
gsrj-21	324	3	174(6	174(6	NUM
gsrj-21	324	4	)	)	PUNCT
gsrj-21	324	5	,	,	PUNCT
gsrj-21	324	6	1586	1586	NUM
gsrj-21	324	7	-	-	SYM
gsrj-21	324	8	1598.e12	1598.e12	NUM
gsrj-21	324	9	.	.	PUNCT
gsrj-21	325	1	https://doi.org/s0092-8674(18)30903-6	https://doi.org/s0092-8674(18)30903-6	PROPN
gsrj-21	325	2	45	45	NUM
gsrj-21	325	3	.	.	PUNCT
gsrj-21	326	1	biffi	biffi	PROPN
gsrj-21	326	2	,	,	PUNCT
gsrj-21	326	3	g.	g.	PROPN
gsrj-21	326	4	,	,	PUNCT
gsrj-21	326	5	oni	oni	PROPN
gsrj-21	326	6	,	,	PUNCT
gsrj-21	326	7	t.	t.	PROPN
gsrj-21	326	8	e.	e.	PROPN
gsrj-21	326	9	,	,	PUNCT
gsrj-21	326	10	spielman	spielman	PROPN
gsrj-21	326	11	,	,	PUNCT
gsrj-21	326	12	b.	b.	PROPN
gsrj-21	326	13	,	,	PUNCT
gsrj-21	326	14	hao	hao	PROPN
gsrj-21	326	15	,	,	PUNCT
gsrj-21	326	16	y.	y.	PROPN
gsrj-21	326	17	,	,	PUNCT
gsrj-21	326	18	elyada	elyada	PROPN
gsrj-21	326	19	,	,	PUNCT
gsrj-21	326	20	e.	e.	PROPN
gsrj-21	326	21	,	,	PUNCT
gsrj-21	326	22	park	park	NOUN
gsrj-21	326	23	,	,	PUNCT
gsrj-21	326	24	y.	y.	PROPN
gsrj-21	326	25	,	,	PUNCT
gsrj-21	326	26	et	et	PROPN
gsrj-21	326	27	al	al	PROPN
gsrj-21	326	28	.	.	PROPN
gsrj-21	327	1	(	(	PUNCT
gsrj-21	327	2	2019	2019	NUM
gsrj-21	327	3	)	)	PUNCT
gsrj-21	327	4	.	.	PUNCT
gsrj-21	328	1	il1	il1	X
gsrj-21	328	2	-	-	PUNCT
gsrj-21	328	3	induced	induce	VERB
gsrj-21	328	4	jak	jak	PROPN
gsrj-21	328	5	/	/	SYM
gsrj-21	328	6	stat	stat	PROPN
gsrj-21	328	7	signaling	signal	VERB
gsrj-21	328	8	is	be	AUX
gsrj-21	328	9	antagonized	antagonize	VERB
gsrj-21	328	10	by	by	ADP
gsrj-21	328	11	tgfβ	tgfβ	NOUN
gsrj-21	328	12	to	to	PART
gsrj-21	328	13	shape	shape	VERB
gsrj-21	328	14	caf	caf	NOUN
gsrj-21	328	15	heterogeneity	heterogeneity	NOUN
gsrj-21	328	16	in	in	ADP
gsrj-21	328	17	pancreatic	pancreatic	ADJ
gsrj-21	328	18	ductal	ductal	ADJ
gsrj-21	328	19	adenocarcinoma	adenocarcinoma	NOUN
gsrj-21	328	20	.	.	PUNCT
gsrj-21	329	1	cancer	cancer	NOUN
gsrj-21	329	2	discovery	discovery	NOUN
gsrj-21	329	3	,	,	PUNCT
gsrj-21	329	4	9(2	9(2	NUM
gsrj-21	329	5	)	)	PUNCT
gsrj-21	329	6	,	,	PUNCT
gsrj-21	329	7	282	282	NUM
gsrj-21	329	8	-	-	SYM
gsrj-21	329	9	301	301	NUM
gsrj-21	329	10	.	.	PUNCT
gsrj-21	330	1	46	46	NUM
gsrj-21	330	2	.	.	PUNCT
gsrj-21	331	1	kalchman	kalchman	PROPN
gsrj-21	331	2	,	,	PUNCT
gsrj-21	331	3	j.	j.	PROPN
gsrj-21	331	4	,	,	PUNCT
gsrj-21	331	5	kalchman	kalchman	PROPN
gsrj-21	331	6	,	,	PUNCT
gsrj-21	331	7	j.	j.	PROPN
gsrj-21	331	8	,	,	PUNCT
gsrj-21	331	9	fujioka	fujioka	PROPN
gsrj-21	331	10	,	,	PUNCT
gsrj-21	331	11	s.	s.	PROPN
gsrj-21	331	12	,	,	PUNCT
gsrj-21	331	13	fujioka	fujioka	PROPN
gsrj-21	331	14	,	,	PUNCT
gsrj-21	331	15	s.	s.	PROPN
gsrj-21	331	16	,	,	PUNCT
gsrj-21	331	17	chung	chung	PROPN
gsrj-21	331	18	,	,	PUNCT
gsrj-21	331	19	s.	s.	PROPN
gsrj-21	331	20	,	,	PUNCT
gsrj-21	331	21	chung	chung	PROPN
gsrj-21	331	22	,	,	PUNCT
gsrj-21	331	23	s.	s.	PROPN
gsrj-21	331	24	,	,	PUNCT
gsrj-21	331	25	et	et	PROPN
gsrj-21	331	26	al	al	PROPN
gsrj-21	331	27	.	.	PROPN
gsrj-21	332	1	(	(	PUNCT
gsrj-21	332	2	2013	2013	NUM
gsrj-21	332	3	)	)	PUNCT
gsrj-21	332	4	.	.	PUNCT
gsrj-21	333	1	a	a	DET
gsrj-21	333	2	threedimensional	threedimensional	ADJ
gsrj-21	333	3	microfluidic	microfluidic	ADJ
gsrj-21	333	4	tumor	tumor	NOUN
gsrj-21	333	5	cell	cell	NOUN
gsrj-21	333	6	migration	migration	NOUN
gsrj-21	333	7	assay	assay	VERB
gsrj-21	333	8	to	to	PART
gsrj-21	333	9	screen	screen	VERB
gsrj-21	333	10	the	the	DET
gsrj-21	333	11	effect	effect	NOUN
gsrj-21	333	12	of	of	ADP
gsrj-21	333	13	anti	anti	ADJ
gsrj-21	333	14	-	-	ADJ
gsrj-21	333	15	migratory	migratory	ADJ
gsrj-21	333	16	drugs	drug	NOUN
gsrj-21	333	17	and	and	CCONJ
gsrj-21	333	18	interstitial	interstitial	ADJ
gsrj-21	333	19	flow	flow	NOUN
gsrj-21	333	20	.	.	PUNCT
gsrj-21	334	1	microfluidics	microfluidic	NOUN
gsrj-21	334	2	and	and	CCONJ
gsrj-21	334	3	nanofluidics	nanofluidic	NOUN
gsrj-21	334	4	,	,	PUNCT
gsrj-21	334	5	14(6	14(6	NOUN
gsrj-21	334	6	)	)	PUNCT
gsrj-21	334	7	,	,	PUNCT
gsrj-21	334	8	969	969	NUM
gsrj-21	334	9	-	-	SYM
gsrj-21	334	10	981	981	NUM
gsrj-21	334	11	.	.	PUNCT
gsrj-21	335	1	https://doi.org/10.1007/s10404012-1104-6	https://doi.org/10.1007/s10404012-1104-6	PROPN
gsrj-21	335	2	47	47	NUM
gsrj-21	335	3	.	.	PUNCT
gsrj-21	336	1	bischel	bischel	PROPN
gsrj-21	336	2	,	,	PUNCT
gsrj-21	336	3	l.	l.	PROPN
gsrj-21	336	4	l.	l.	PROPN
gsrj-21	336	5	,	,	PUNCT
gsrj-21	336	6	beebe	beebe	PROPN
gsrj-21	336	7	,	,	PUNCT
gsrj-21	336	8	d.	d.	PROPN
gsrj-21	336	9	j.	j.	PROPN
gsrj-21	336	10	,	,	PUNCT
gsrj-21	336	11	&	&	CCONJ
gsrj-21	336	12	sung	sung	PROPN
gsrj-21	336	13	,	,	PUNCT
gsrj-21	336	14	k.	k.	PROPN
gsrj-21	336	15	e.	e.	PROPN
gsrj-21	336	16	(	(	PUNCT
gsrj-21	336	17	2015	2015	NUM
gsrj-21	336	18	)	)	PUNCT
gsrj-21	336	19	.	.	PUNCT
gsrj-21	337	1	microfluidic	microfluidic	ADJ
gsrj-21	337	2	model	model	NOUN
gsrj-21	337	3	of	of	ADP
gsrj-21	337	4	ductal	ductal	ADJ
gsrj-21	337	5	carcinoma	carcinoma	NOUN
gsrj-21	337	6	in	in	ADP
gsrj-21	337	7	situ	situ	NOUN
gsrj-21	337	8	with	with	ADP
gsrj-21	337	9	3d	3d	NUM
gsrj-21	337	10	,	,	PUNCT
gsrj-21	337	11	organotypic	organotypic	ADJ
gsrj-21	337	12	structure	structure	NOUN
gsrj-21	337	13	.	.	PUNCT
gsrj-21	338	1	bmc	bmc	ADJ
gsrj-21	338	2	cancer	cancer	NOUN
gsrj-21	338	3	,	,	PUNCT
gsrj-21	338	4	15	15	NUM
gsrj-21	338	5	,	,	PUNCT
gsrj-21	338	6	12	12	NUM
gsrj-21	338	7	.	.	PUNCT
gsrj-21	338	8	https://doi.org/10.1186/s12885-015-1007-5	https://doi.org/10.1186/s12885-015-1007-5	NUM
gsrj-21	338	9	48	48	NUM
gsrj-21	338	10	.	.	PUNCT
gsrj-21	339	1	zervantonakis	zervantonaki	NOUN
gsrj-21	339	2	,	,	PUNCT
gsrj-21	339	3	i.	i.	PROPN
gsrj-21	339	4	k.	k.	PROPN
gsrj-21	339	5	,	,	PUNCT
gsrj-21	339	6	hughes	hughes	NOUN
gsrj-21	339	7	-	-	PUNCT
gsrj-21	339	8	alford	alford	PROPN
gsrj-21	339	9	,	,	PUNCT
gsrj-21	339	10	s.	s.	PROPN
gsrj-21	339	11	k.	k.	PROPN
gsrj-21	339	12	,	,	PUNCT
gsrj-21	339	13	charest	charest	PROPN
gsrj-21	339	14	,	,	PUNCT
gsrj-21	339	15	j.	j.	PROPN
gsrj-21	339	16	l.	l.	PROPN
gsrj-21	339	17	,	,	PUNCT
gsrj-21	339	18	condeelis	condeelis	PROPN
gsrj-21	339	19	,	,	PUNCT
gsrj-21	339	20	j.	j.	PROPN
gsrj-21	339	21	s.	s.	PROPN
gsrj-21	339	22	,	,	PUNCT
gsrj-21	339	23	gertler	gertler	NOUN
gsrj-21	339	24	,	,	PUNCT
gsrj-21	339	25	f.	f.	PROPN
gsrj-21	339	26	b.	b.	PROPN
gsrj-21	339	27	,	,	PUNCT
gsrj-21	339	28	&	&	CCONJ
gsrj-21	339	29	kamm	kamm	PROPN
gsrj-21	339	30	,	,	PUNCT
gsrj-21	339	31	r.	r.	PROPN
gsrj-21	339	32	d.	d.	PROPN
gsrj-21	339	33	(	(	PUNCT
gsrj-21	339	34	2012	2012	NUM
gsrj-21	339	35	)	)	PUNCT
gsrj-21	339	36	.	.	PUNCT
gsrj-21	340	1	three	three	NUM
gsrj-21	340	2	-	-	PUNCT
gsrj-21	340	3	dimensional	dimensional	ADJ
gsrj-21	340	4	microfluidic	microfluidic	ADJ
gsrj-21	340	5	model	model	NOUN
gsrj-21	340	6	for	for	ADP
gsrj-21	340	7	tumor	tumor	NOUN
gsrj-21	340	8	cell	cell	NOUN
gsrj-21	340	9	intravasation	intravasation	NOUN
gsrj-21	340	10	and	and	CCONJ
gsrj-21	340	11	endothelial	endothelial	ADJ
gsrj-21	340	12	barrier	barrier	NOUN
gsrj-21	340	13	function	function	NOUN
gsrj-21	340	14	.	.	PUNCT
gsrj-21	341	1	proceedings	proceeding	NOUN
gsrj-21	341	2	of	of	ADP
gsrj-21	341	3	the	the	DET
gsrj-21	341	4	national	national	PROPN
gsrj-21	341	5	academy	academy	PROPN
gsrj-21	341	6	of	of	ADP
gsrj-21	341	7	sciences	sciences	PROPN
gsrj-21	341	8	of	of	ADP
gsrj-21	341	9	the	the	DET
gsrj-21	341	10	united	united	PROPN
gsrj-21	341	11	states	states	PROPN
gsrj-21	341	12	of	of	ADP
gsrj-21	341	13	america	america	PROPN
gsrj-21	341	14	,	,	PUNCT
gsrj-21	341	15	109(34	109(34	NUM
gsrj-21	341	16	)	)	PUNCT
gsrj-21	341	17	,	,	PUNCT
gsrj-21	341	18	13515	13515	NUM
gsrj-21	341	19	-	-	SYM
gsrj-21	341	20	13520	13520	NUM
gsrj-21	341	21	.	.	PUNCT
gsrj-21	342	1	https://doi.org/10.1073/pnas.1210182109	https://doi.org/10.1073/pnas.1210182109	PROPN
gsrj-21	342	2	49	49	NUM
gsrj-21	342	3	.	.	PUNCT
gsrj-21	343	1	bai	bai	PROPN
gsrj-21	343	2	,	,	PUNCT
gsrj-21	343	3	j.	j.	PROPN
gsrj-21	343	4	,	,	PUNCT
gsrj-21	343	5	adriani	adriani	PROPN
gsrj-21	343	6	,	,	PUNCT
gsrj-21	343	7	g.	g.	PROPN
gsrj-21	343	8	,	,	PUNCT
gsrj-21	343	9	dang	dang	PROPN
gsrj-21	343	10	,	,	PUNCT
gsrj-21	343	11	t.	t.	PROPN
gsrj-21	343	12	,	,	PUNCT
gsrj-21	343	13	tu	tu	PROPN
gsrj-21	343	14	,	,	PUNCT
gsrj-21	343	15	t.	t.	PROPN
gsrj-21	343	16	,	,	PUNCT
gsrj-21	343	17	penny	penny	PROPN
gsrj-21	343	18	,	,	PUNCT
gsrj-21	343	19	h.	h.	PROPN
gsrj-21	343	20	l.	l.	PROPN
gsrj-21	343	21	,	,	PUNCT
gsrj-21	343	22	wong	wong	PROPN
gsrj-21	343	23	,	,	PUNCT
gsrj-21	343	24	s.	s.	PROPN
gsrj-21	343	25	,	,	PUNCT
gsrj-21	343	26	et	et	PROPN
gsrj-21	343	27	al	al	PROPN
gsrj-21	343	28	.	.	PUNCT
gsrj-21	343	29	(	(	PUNCT
gsrj-21	343	30	2015	2015	NUM
gsrj-21	343	31	)	)	PUNCT
gsrj-21	343	32	.	.	PUNCT
gsrj-21	344	1	contact	contact	NOUN
gsrj-21	344	2	-	-	PUNCT
gsrj-21	344	3	dependent	dependent	ADJ
gsrj-21	344	4	carcinoma	carcinoma	NOUN
gsrj-21	344	5	aggregate	aggregate	ADJ
gsrj-21	344	6	dispersion	dispersion	NOUN
gsrj-21	344	7	by	by	ADP
gsrj-21	344	8	m2a	m2a	NOUN
gsrj-21	344	9	macrophages	macrophage	NOUN
gsrj-21	344	10	via	via	ADP
gsrj-21	344	11	icam-1	icam-1	NUM
gsrj-21	344	12	and	and	CCONJ
gsrj-21	344	13	β2	β2	PROPN
gsrj-21	344	14	integrin	integrin	NOUN
gsrj-21	344	15	interactions	interaction	NOUN
gsrj-21	344	16	.	.	PUNCT
gsrj-21	345	1	oncotarget	oncotarget	NOUN
gsrj-21	345	2	,	,	PUNCT
gsrj-21	345	3	6(28	6(28	NUM
gsrj-21	345	4	)	)	PUNCT
gsrj-21	345	5	,	,	PUNCT
gsrj-21	345	6	25295	25295	NUM
gsrj-21	345	7	-	-	SYM
gsrj-21	345	8	25307	25307	NUM
gsrj-21	345	9	.	.	PUNCT
gsrj-21	346	1	https://doi.org/10.18632/oncotarget.4716	https://doi.org/10.18632/oncotarget.4716	NOUN
gsrj-21	346	2	50	50	NUM
gsrj-21	346	3	.	.	PUNCT
gsrj-21	347	1	huang	huang	PROPN
gsrj-21	347	2	,	,	PUNCT
gsrj-21	347	3	c.	c.	PROPN
gsrj-21	347	4	p.	p.	PROPN
gsrj-21	347	5	,	,	PUNCT
gsrj-21	347	6	lu	lu	PROPN
gsrj-21	347	7	,	,	PUNCT
gsrj-21	347	8	j.	j.	PROPN
gsrj-21	347	9	,	,	PUNCT
gsrj-21	347	10	seon	seon	PROPN
gsrj-21	347	11	,	,	PUNCT
gsrj-21	347	12	h.	h.	PROPN
gsrj-21	347	13	,	,	PUNCT
gsrj-21	347	14	lee	lee	PROPN
gsrj-21	347	15	,	,	PUNCT
gsrj-21	347	16	a.	a.	PROPN
gsrj-21	347	17	p.	p.	PROPN
gsrj-21	347	18	,	,	PUNCT
gsrj-21	347	19	flanagan	flanagan	PROPN
gsrj-21	347	20	,	,	PUNCT
gsrj-21	347	21	l.	l.	PROPN
gsrj-21	347	22	a.	a.	PROPN
gsrj-21	347	23	,	,	PUNCT
gsrj-21	347	24	kim	kim	PROPN
gsrj-21	347	25	,	,	PUNCT
gsrj-21	347	26	h.	h.	PROPN
gsrj-21	347	27	,	,	PUNCT
gsrj-21	347	28	et	et	PROPN
gsrj-21	347	29	al	al	PROPN
gsrj-21	347	30	.	.	PUNCT
gsrj-21	347	31	(	(	PUNCT
gsrj-21	347	32	2009	2009	NUM
gsrj-21	347	33	)	)	PUNCT
gsrj-21	347	34	.	.	PUNCT
gsrj-21	348	1	engineering	engineer	VERB
gsrj-21	348	2	microscale	microscale	ADJ
gsrj-21	348	3	cellular	cellular	ADJ
gsrj-21	348	4	niches	niche	NOUN
gsrj-21	348	5	for	for	ADP
gsrj-21	348	6	threedimensional	threedimensional	ADJ
gsrj-21	348	7	multicellular	multicellular	ADJ
gsrj-21	348	8	co	co	NOUN
gsrj-21	348	9	-	-	NOUN
gsrj-21	348	10	cultures	culture	NOUN
gsrj-21	348	11	.	.	PUNCT
gsrj-21	349	1	lab	lab	NOUN
gsrj-21	349	2	on	on	ADP
gsrj-21	349	3	a	a	DET
gsrj-21	349	4	chip	chip	NOUN
gsrj-21	349	5	,	,	PUNCT
gsrj-21	349	6	9(12	9(12	NUM
gsrj-21	349	7	)	)	PUNCT
gsrj-21	349	8	,	,	PUNCT
gsrj-21	349	9	1740	1740	NUM
gsrj-21	349	10	-	-	SYM
gsrj-21	349	11	1748	1748	NUM
gsrj-21	349	12	.	.	PUNCT
gsrj-21	350	1	https://doi.org/10.1039/b818401a	https://doi.org/10.1039/b818401a	VERB
gsrj-21	350	2	51	51	NUM
gsrj-21	350	3	.	.	PUNCT
gsrj-21	351	1	li	li	PROPN
gsrj-21	351	2	,	,	PUNCT
gsrj-21	351	3	j.	j.	PROPN
gsrj-21	351	4	,	,	PUNCT
gsrj-21	351	5	jia	jia	PROPN
gsrj-21	351	6	,	,	PUNCT
gsrj-21	351	7	z.	z.	PROPN
gsrj-21	351	8	,	,	PUNCT
gsrj-21	351	9	kong	kong	PROPN
gsrj-21	351	10	,	,	PUNCT
gsrj-21	351	11	j.	j.	PROPN
gsrj-21	351	12	,	,	PUNCT
gsrj-21	351	13	zhang	zhang	PROPN
gsrj-21	351	14	,	,	PUNCT
gsrj-21	351	15	f.	f.	PROPN
gsrj-21	351	16	,	,	PUNCT
gsrj-21	351	17	fang	fang	PROPN
gsrj-21	351	18	,	,	PUNCT
gsrj-21	351	19	s.	s.	PROPN
gsrj-21	351	20	,	,	PUNCT
gsrj-21	351	21	li	li	PROPN
gsrj-21	351	22	,	,	PUNCT
gsrj-21	351	23	x.	x.	PROPN
gsrj-21	351	24	,	,	PUNCT
gsrj-21	351	25	et	et	PROPN
gsrj-21	351	26	al	al	PROPN
gsrj-21	351	27	.	.	PUNCT
gsrj-21	351	28	(	(	PUNCT
gsrj-21	351	29	2016	2016	NUM
gsrj-21	351	30	)	)	PUNCT
gsrj-21	351	31	.	.	PUNCT
gsrj-21	352	1	carcinoma	carcinoma	NOUN
gsrj-21	352	2	-	-	PUNCT
gsrj-21	352	3	associated	associate	VERB
gsrj-21	352	4	fibroblasts	fibroblast	NOUN
gsrj-21	352	5	lead	lead	VERB
gsrj-21	352	6	the	the	DET
gsrj-21	352	7	invasion	invasion	NOUN
gsrj-21	352	8	of	of	ADP
gsrj-21	352	9	salivary	salivary	ADJ
gsrj-21	352	10	gland	gland	NOUN
gsrj-21	352	11	adenoid	adenoid	NOUN
gsrj-21	352	12	cystic	cystic	ADJ
gsrj-21	352	13	carcinoma	carcinoma	NOUN
gsrj-21	352	14	cells	cell	NOUN
gsrj-21	352	15	by	by	ADP
gsrj-21	352	16	creating	create	VERB
gsrj-21	352	17	an	an	DET
gsrj-21	352	18	invasive	invasive	ADJ
gsrj-21	352	19	track	track	NOUN
gsrj-21	352	20	.	.	PUNCT
gsrj-21	353	1	plos	plos	PROPN
gsrj-21	353	2	one	one	NUM
gsrj-21	353	3	,	,	PUNCT
gsrj-21	353	4	11(3	11(3	NUM
gsrj-21	353	5	)	)	PUNCT
gsrj-21	353	6	,	,	PUNCT
gsrj-21	353	7	e0150247	e0150247	PROPN
gsrj-21	353	8	.	.	PROPN
gsrj-21	353	9	https://doi.org/10.1371/journal.pone.0150247	https://doi.org/10.1371/journal.pone.0150247	PROPN
gsrj-21	353	10	52	52	NUM
gsrj-21	353	11	.	.	PUNCT
gsrj-21	354	1	sung	sung	PROPN
gsrj-21	354	2	,	,	PUNCT
gsrj-21	354	3	k.	k.	PROPN
gsrj-21	354	4	e.	e.	PROPN
gsrj-21	354	5	,	,	PUNCT
gsrj-21	354	6	yang	yang	PROPN
gsrj-21	354	7	,	,	PUNCT
gsrj-21	354	8	n.	n.	NOUN
gsrj-21	354	9	,	,	PUNCT
gsrj-21	354	10	pehlke	pehlke	NOUN
gsrj-21	354	11	,	,	PUNCT
gsrj-21	354	12	c.	c.	NOUN
gsrj-21	354	13	,	,	PUNCT
gsrj-21	354	14	keely	keely	ADV
gsrj-21	354	15	,	,	PUNCT
gsrj-21	354	16	p.	p.	PROPN
gsrj-21	354	17	j.	j.	PROPN
gsrj-21	354	18	,	,	PUNCT
gsrj-21	354	19	eliceiri	eliceiri	PROPN
gsrj-21	354	20	,	,	PUNCT
gsrj-21	354	21	k.	k.	PROPN
gsrj-21	354	22	w.	w.	PROPN
gsrj-21	354	23	,	,	PUNCT
gsrj-21	354	24	friedl	friedl	ADJ
gsrj-21	354	25	,	,	PUNCT
gsrj-21	354	26	a.	a.	NOUN
gsrj-21	354	27	,	,	PUNCT
gsrj-21	354	28	et	et	PROPN
gsrj-21	354	29	al	al	PROPN
gsrj-21	354	30	.	.	PUNCT
gsrj-21	355	1	(	(	PUNCT
gsrj-21	355	2	2011	2011	NUM
gsrj-21	355	3	)	)	PUNCT
gsrj-21	355	4	.	.	PUNCT
gsrj-21	356	1	transition	transition	NOUN
gsrj-21	356	2	to	to	ADP
gsrj-21	356	3	invasion	invasion	NOUN
gsrj-21	356	4	in	in	ADP
gsrj-21	356	5	breast	breast	NOUN
gsrj-21	356	6	cancer	cancer	NOUN
gsrj-21	356	7	:	:	PUNCT
gsrj-21	356	8	a	a	DET
gsrj-21	356	9	microfluidic	microfluidic	NOUN
gsrj-21	356	10	in	in	ADP
gsrj-21	356	11	vitro	vitro	X
gsrj-21	356	12	model	model	NOUN
gsrj-21	356	13	enables	enable	VERB
gsrj-21	356	14	examination	examination	NOUN
gsrj-21	356	15	of	of	ADP
gsrj-21	356	16	spatial	spatial	ADJ
gsrj-21	356	17	and	and	CCONJ
gsrj-21	356	18	temporal	temporal	ADJ
gsrj-21	356	19	effects	effect	NOUN
gsrj-21	356	20	.	.	PUNCT
gsrj-21	357	1	integrative	integrative	ADJ
gsrj-21	357	2	biology	biology	NOUN
gsrj-21	357	3	:	:	PUNCT
gsrj-21	357	4	quantitative	quantitative	ADJ
gsrj-21	357	5	biosciences	bioscience	NOUN
gsrj-21	357	6	from	from	ADP
gsrj-21	357	7	nano	nano	PROPN
gsrj-21	357	8	to	to	ADP
gsrj-21	357	9	macro	macro	PROPN
gsrj-21	357	10	,	,	PUNCT
gsrj-21	357	11	3(4	3(4	NUM
gsrj-21	357	12	)	)	PUNCT
gsrj-21	357	13	,	,	PUNCT
gsrj-21	357	14	439	439	NUM
gsrj-21	357	15	-	-	SYM
gsrj-21	357	16	450	450	NUM
gsrj-21	357	17	.	.	PUNCT
gsrj-21	358	1	https://doi.org/10.1039/c0ib00063a	https://doi.org/10.1039/c0ib00063a	NOUN
gsrj-21	358	2	58	58	NUM
gsrj-21	358	3	georgetown	georgetown	PROPN
gsrj-21	358	4	scientific	scientific	PROPN
gsrj-21	358	5	research	research	PROPN
gsrj-21	358	6	journal	journal	PROPN
gsrj-21	358	7	53	53	NUM
gsrj-21	358	8	.	.	PUNCT
gsrj-21	359	1	wong	wong	PROPN
gsrj-21	359	2	,	,	PUNCT
gsrj-21	359	3	a.	a.	PROPN
gsrj-21	359	4	d.	d.	PROPN
gsrj-21	359	5	,	,	PUNCT
gsrj-21	359	6	&	&	CCONJ
gsrj-21	359	7	searson	searson	PROPN
gsrj-21	359	8	,	,	PUNCT
gsrj-21	359	9	p.	p.	PROPN
gsrj-21	359	10	c.	c.	PROPN
gsrj-21	359	11	(	(	PUNCT
gsrj-21	359	12	2014	2014	NUM
gsrj-21	359	13	)	)	PUNCT
gsrj-21	359	14	.	.	PUNCT
gsrj-21	360	1	live	live	ADJ
gsrj-21	360	2	-	-	PUNCT
gsrj-21	360	3	cell	cell	NOUN
gsrj-21	360	4	imaging	imaging	NOUN
gsrj-21	360	5	of	of	ADP
gsrj-21	360	6	invasion	invasion	NOUN
gsrj-21	360	7	and	and	CCONJ
gsrj-21	360	8	intravasation	intravasation	NOUN
gsrj-21	360	9	in	in	ADP
gsrj-21	360	10	an	an	DET
gsrj-21	360	11	artificial	artificial	ADJ
gsrj-21	360	12	microvessel	microvessel	NOUN
gsrj-21	360	13	platform	platform	NOUN
gsrj-21	360	14	.	.	PUNCT
gsrj-21	361	1	cancer	cancer	NOUN
gsrj-21	361	2	research	research	NOUN
gsrj-21	361	3	,	,	PUNCT
gsrj-21	361	4	74(17	74(17	NUM
gsrj-21	361	5	)	)	PUNCT
gsrj-21	361	6	,	,	PUNCT
gsrj-21	361	7	4937	4937	NUM
gsrj-21	361	8	-	-	SYM
gsrj-21	361	9	4945	4945	NUM
gsrj-21	361	10	.	.	PUNCT
gsrj-21	362	1	https://doi.org/10.1158/00085472.can-14-1042	https://doi.org/10.1158/00085472.can-14-1042	ADP
gsrj-21	362	2	54	54	NUM
gsrj-21	362	3	.	.	PUNCT
gsrj-21	363	1	parasido	parasido	PROPN
gsrj-21	363	2	,	,	PUNCT
gsrj-21	363	3	e.	e.	PROPN
gsrj-21	363	4	,	,	PUNCT
gsrj-21	363	5	avetian	avetian	PROPN
gsrj-21	363	6	,	,	PUNCT
gsrj-21	363	7	g.	g.	PROPN
gsrj-21	363	8	s.	s.	PROPN
gsrj-21	363	9	,	,	PUNCT
gsrj-21	363	10	naeem	naeem	PROPN
gsrj-21	363	11	,	,	PUNCT
gsrj-21	363	12	a.	a.	PROPN
gsrj-21	363	13	,	,	PUNCT
gsrj-21	363	14	graham	graham	PROPN
gsrj-21	363	15	,	,	PUNCT
gsrj-21	363	16	g.	g.	PROPN
gsrj-21	363	17	,	,	PUNCT
gsrj-21	363	18	pishvaian	pishvaian	NOUN
gsrj-21	363	19	,	,	PUNCT
gsrj-21	363	20	m.	m.	NOUN
gsrj-21	363	21	,	,	PUNCT
gsrj-21	363	22	glasgow	glasgow	PROPN
gsrj-21	363	23	,	,	PUNCT
gsrj-21	363	24	e.	e.	PROPN
gsrj-21	363	25	,	,	PUNCT
gsrj-21	363	26	et	et	PROPN
gsrj-21	363	27	al	al	PROPN
gsrj-21	363	28	.	.	PROPN
gsrj-21	363	29	(	(	PUNCT
gsrj-21	363	30	2019	2019	NUM
gsrj-21	363	31	)	)	PUNCT
gsrj-21	363	32	.	.	PUNCT
gsrj-21	364	1	the	the	DET
gsrj-21	364	2	sustained	sustained	ADJ
gsrj-21	364	3	induction	induction	NOUN
gsrj-21	364	4	of	of	ADP
gsrj-21	364	5	c	c	NOUN
gsrj-21	364	6	-	-	PUNCT
gsrj-21	364	7	myc	myc	NOUN
gsrj-21	364	8	drives	drive	VERB
gsrj-21	364	9	nabpaclitaxel	nabpaclitaxel	PROPN
gsrj-21	364	10	resistance	resistance	NOUN
gsrj-21	364	11	in	in	ADP
gsrj-21	364	12	primary	primary	ADJ
gsrj-21	364	13	pancreatic	pancreatic	ADJ
gsrj-21	364	14	ductal	ductal	ADJ
gsrj-21	364	15	carcinoma	carcinoma	NOUN
gsrj-21	364	16	cells	cell	NOUN
gsrj-21	364	17	.	.	PUNCT
gsrj-21	365	1	molecular	molecular	ADJ
gsrj-21	365	2	cancer	cancer	NOUN
gsrj-21	365	3	research	research	NOUN
gsrj-21	365	4	,	,	PUNCT
gsrj-21	365	5	17(9	17(9	NOUN
gsrj-21	365	6	)	)	PUNCT
gsrj-21	365	7	,	,	PUNCT
gsrj-21	365	8	1815	1815	NUM
gsrj-21	365	9	-	-	SYM
gsrj-21	365	10	1827	1827	NUM
gsrj-21	365	11	.	.	PUNCT
gsrj-21	366	1	https://doi.org/10.1158/15417786.mcr-19-0191	https://doi.org/10.1158/15417786.mcr-19-0191	NOUN
gsrj-21	366	2	55	55	NUM
gsrj-21	366	3	.	.	PUNCT
gsrj-21	367	1	behrens	behrens	PROPN
gsrj-21	367	2	,	,	PUNCT
gsrj-21	367	3	d.	d.	PROPN
gsrj-21	367	4	,	,	PUNCT
gsrj-21	367	5	walther	walther	NOUN
gsrj-21	367	6	,	,	PUNCT
gsrj-21	367	7	w.	w.	PROPN
gsrj-21	367	8	,	,	PUNCT
gsrj-21	367	9	&	&	CCONJ
gsrj-21	367	10	fichtner	fichtner	NOUN
gsrj-21	367	11	,	,	PUNCT
gsrj-21	367	12	i.	i.	PROPN
gsrj-21	367	13	(	(	PUNCT
gsrj-21	367	14	2017	2017	NUM
gsrj-21	367	15	)	)	PUNCT
gsrj-21	367	16	.	.	PUNCT
gsrj-21	368	1	pharmacology	pharmacology	NOUN
gsrj-21	368	2	&	&	CCONJ
gsrj-21	368	3	therapeutics	therapeutic	NOUN
gsrj-21	368	4	.	.	PUNCT
gsrj-21	369	1	pharmacology	pharmacology	NOUN
gsrj-21	369	2	&	&	CCONJ
gsrj-21	369	3	therapeutics	therapeutic	NOUN
gsrj-21	369	4	,	,	PUNCT
gsrj-21	369	5	173	173	NUM
gsrj-21	369	6	,	,	PUNCT
gsrj-21	369	7	146	146	NUM
gsrj-21	369	8	-	-	SYM
gsrj-21	369	9	158	158	NUM
gsrj-21	369	10	.	.	PUNCT
gsrj-21	369	11	retrieved	retrieve	VERB
gsrj-21	369	12	from	from	ADP
gsrj-21	369	13	http://www.sciencedirect.com/science/article/pii/s	http://www.sciencedirect.com/science/article/pii/s	PRON
gsrj-21	369	14	016372581730027x	016372581730027x	NOUN
gsrj-21	369	15	56	56	NUM
gsrj-21	369	16	.	.	PUNCT
gsrj-21	370	1	allen	allen	PROPN
gsrj-21	370	2	-	-	PUNCT
gsrj-21	370	3	petersen	petersen	PROPN
gsrj-21	370	4	,	,	PUNCT
gsrj-21	370	5	b.	b.	PROPN
gsrj-21	370	6	l.	l.	PROPN
gsrj-21	370	7	,	,	PUNCT
gsrj-21	370	8	risom	risom	NOUN
gsrj-21	370	9	,	,	PUNCT
gsrj-21	370	10	t.	t.	PROPN
gsrj-21	370	11	,	,	PUNCT
gsrj-21	370	12	feng	feng	PROPN
gsrj-21	370	13	,	,	PUNCT
gsrj-21	370	14	z.	z.	PROPN
gsrj-21	370	15	,	,	PUNCT
gsrj-21	370	16	wang	wang	PROPN
gsrj-21	370	17	,	,	PUNCT
gsrj-21	370	18	z.	z.	PROPN
gsrj-21	370	19	,	,	PUNCT
gsrj-21	370	20	jenny	jenny	PROPN
gsrj-21	370	21	,	,	PUNCT
gsrj-21	370	22	z.	z.	PROPN
gsrj-21	370	23	p.	p.	PROPN
gsrj-21	370	24	,	,	PUNCT
gsrj-21	370	25	thoma	thoma	PROPN
gsrj-21	370	26	,	,	PUNCT
gsrj-21	370	27	m.	m.	PROPN
gsrj-21	370	28	c.	c.	PROPN
gsrj-21	370	29	,	,	PUNCT
gsrj-21	370	30	et	et	PROPN
gsrj-21	370	31	al	al	PROPN
gsrj-21	370	32	.	.	PROPN
gsrj-21	370	33	(	(	PUNCT
gsrj-21	370	34	2019	2019	NUM
gsrj-21	370	35	)	)	PUNCT
gsrj-21	370	36	.	.	PUNCT
gsrj-21	371	1	activation	activation	NOUN
gsrj-21	371	2	of	of	ADP
gsrj-21	371	3	pp2a	pp2a	ADJ
gsrj-21	371	4	and	and	CCONJ
gsrj-21	371	5	inhibition	inhibition	NOUN
gsrj-21	371	6	of	of	ADP
gsrj-21	371	7	mtor	mtor	NOUN
gsrj-21	371	8	synergistically	synergistically	ADV
gsrj-21	371	9	reduce	reduce	VERB
gsrj-21	371	10	myc	myc	NOUN
gsrj-21	371	11	signaling	signal	VERB
gsrj-21	371	12	and	and	CCONJ
gsrj-21	371	13	decrease	decrease	VERB
gsrj-21	371	14	tumor	tumor	NOUN
gsrj-21	371	15	growth	growth	NOUN
gsrj-21	371	16	in	in	ADP
gsrj-21	371	17	pancreatic	pancreatic	ADJ
gsrj-21	371	18	ductal	ductal	ADJ
gsrj-21	371	19	adenocarcinoma	adenocarcinoma	NOUN
gsrj-21	371	20	.	.	PUNCT
gsrj-21	372	1	cancer	cancer	NOUN
gsrj-21	372	2	research	research	PROPN
gsrj-21	372	3	(	(	PUNCT
gsrj-21	372	4	chicago	chicago	PROPN
gsrj-21	372	5	,	,	PUNCT
gsrj-21	372	6	ill	ill	PROPN
gsrj-21	372	7	.	.	PUNCT
gsrj-21	372	8	)	)	PUNCT
gsrj-21	372	9	,	,	PUNCT
gsrj-21	372	10	79(1	79(1	NOUN
gsrj-21	372	11	)	)	PUNCT
gsrj-21	372	12	,	,	PUNCT
gsrj-21	372	13	209	209	NUM
gsrj-21	372	14	-	-	SYM
gsrj-21	372	15	219	219	NUM
gsrj-21	372	16	.	.	PUNCT
gsrj-21	373	1	https://doi.org/10.1158/00085472.can-18-0717	https://doi.org/10.1158/00085472.can-18-0717	PROPN
gsrj-21	373	2	57	57	NUM
gsrj-21	373	3	.	.	PUNCT
gsrj-21	374	1	ter	ter	PROPN
gsrj-21	374	2	brugge	brugge	PROPN
gsrj-21	374	3	,	,	PUNCT
gsrj-21	374	4	p.	p.	PROPN
gsrj-21	374	5	,	,	PUNCT
gsrj-21	374	6	kristel	kristel	PROPN
gsrj-21	374	7	,	,	PUNCT
gsrj-21	374	8	p.	p.	PROPN
gsrj-21	374	9	,	,	PUNCT
gsrj-21	374	10	van	van	PROPN
gsrj-21	374	11	der	der	PROPN
gsrj-21	374	12	burg	burg	PROPN
gsrj-21	374	13	,	,	PUNCT
gsrj-21	374	14	e.	e.	PROPN
gsrj-21	374	15	,	,	PUNCT
gsrj-21	374	16	boon	boon	PROPN
gsrj-21	374	17	,	,	PUNCT
gsrj-21	374	18	u.	u.	PROPN
gsrj-21	374	19	,	,	PUNCT
gsrj-21	374	20	de	de	PROPN
gsrj-21	374	21	maaker	maaker	NOUN
gsrj-21	374	22	,	,	PUNCT
gsrj-21	374	23	m.	m.	NOUN
gsrj-21	374	24	,	,	PUNCT
gsrj-21	374	25	lips	lip	NOUN
gsrj-21	374	26	,	,	PUNCT
gsrj-21	374	27	e.	e.	PROPN
gsrj-21	374	28	,	,	PUNCT
gsrj-21	374	29	et	et	PROPN
gsrj-21	374	30	al	al	PROPN
gsrj-21	374	31	.	.	PUNCT
gsrj-21	375	1	(	(	PUNCT
gsrj-21	375	2	2016	2016	NUM
gsrj-21	375	3	)	)	PUNCT
gsrj-21	375	4	.	.	PUNCT
gsrj-21	376	1	mechanisms	mechanism	NOUN
gsrj-21	376	2	of	of	ADP
gsrj-21	376	3	therapy	therapy	NOUN
gsrj-21	376	4	resistance	resistance	NOUN
gsrj-21	376	5	in	in	ADP
gsrj-21	376	6	patientderived	patientderive	VERB
gsrj-21	376	7	xenograft	xenograft	NOUN
gsrj-21	376	8	models	model	NOUN
gsrj-21	376	9	of	of	ADP
gsrj-21	376	10	brca1	brca1	PROPN
gsrj-21	376	11	-	-	ADJ
gsrj-21	376	12	deficient	deficient	ADJ
gsrj-21	376	13	breast	breast	NOUN
gsrj-21	376	14	cancer	cancer	NOUN
gsrj-21	376	15	.	.	PUNCT
gsrj-21	377	1	jnci	jnci	PROPN
gsrj-21	377	2	:	:	PUNCT
gsrj-21	377	3	journal	journal	NOUN
gsrj-21	377	4	of	of	ADP
gsrj-21	377	5	the	the	DET
gsrj-21	377	6	national	national	PROPN
gsrj-21	377	7	cancer	cancer	PROPN
gsrj-21	377	8	institute	institute	PROPN
gsrj-21	377	9	,	,	PUNCT
gsrj-21	377	10	108(11	108(11	NUM
gsrj-21	377	11	)	)	PUNCT
gsrj-21	377	12	https://doi.org/10.1093/jnci/djw148	https://doi.org/10.1093/jnci/djw148	NOUN
gsrj-21	377	13	58	58	NUM
gsrj-21	377	14	.	.	PUNCT
gsrj-21	378	1	tentler	tentler	PROPN
gsrj-21	378	2	,	,	PUNCT
gsrj-21	378	3	j.	j.	PROPN
gsrj-21	378	4	j.	j.	PROPN
gsrj-21	378	5	,	,	PUNCT
gsrj-21	378	6	tan	tan	PROPN
gsrj-21	378	7	,	,	PUNCT
gsrj-21	378	8	a.	a.	PROPN
gsrj-21	378	9	c.	c.	PROPN
gsrj-21	378	10	,	,	PUNCT
gsrj-21	378	11	weekes	weekes	PROPN
gsrj-21	378	12	,	,	PUNCT
gsrj-21	378	13	c.	c.	PROPN
gsrj-21	378	14	d.	d.	PROPN
gsrj-21	378	15	,	,	PUNCT
gsrj-21	378	16	jimeno	jimeno	PROPN
gsrj-21	378	17	,	,	PUNCT
gsrj-21	378	18	a.	a.	NOUN
gsrj-21	378	19	,	,	PUNCT
gsrj-21	378	20	leong	leong	PROPN
gsrj-21	378	21	,	,	PUNCT
gsrj-21	378	22	s.	s.	PROPN
gsrj-21	378	23	,	,	PUNCT
gsrj-21	378	24	pitts	pitt	NOUN
gsrj-21	378	25	,	,	PUNCT
gsrj-21	378	26	t.	t.	NOUN
gsrj-21	378	27	m.	m.	NOUN
gsrj-21	378	28	,	,	PUNCT
gsrj-21	378	29	et	et	PROPN
gsrj-21	378	30	al	al	PROPN
gsrj-21	378	31	.	.	PUNCT
gsrj-21	379	1	(	(	PUNCT
gsrj-21	379	2	2012	2012	NUM
gsrj-21	379	3	)	)	PUNCT
gsrj-21	379	4	.	.	PUNCT
gsrj-21	380	1	patientderived	patientderive	VERB
gsrj-21	380	2	tumour	tumour	PRON
gsrj-21	380	3	xenografts	xenograft	NOUN
gsrj-21	380	4	as	as	ADP
gsrj-21	380	5	models	model	NOUN
gsrj-21	380	6	for	for	ADP
gsrj-21	380	7	oncology	oncology	NOUN
gsrj-21	380	8	drug	drug	NOUN
gsrj-21	380	9	development	development	NOUN
gsrj-21	380	10	.	.	PUNCT
gsrj-21	381	1	nature	nature	NOUN
gsrj-21	381	2	reviews	review	NOUN
gsrj-21	381	3	.	.	PUNCT
gsrj-21	382	1	clinical	clinical	ADJ
gsrj-21	382	2	oncology	oncology	NOUN
gsrj-21	382	3	,	,	PUNCT
gsrj-21	382	4	9(6	9(6	NUM
gsrj-21	382	5	)	)	PUNCT
gsrj-21	382	6	,	,	PUNCT
gsrj-21	382	7	338	338	NUM
gsrj-21	382	8	-	-	SYM
gsrj-21	382	9	350	350	NUM
gsrj-21	382	10	.	.	PUNCT
gsrj-21	383	1	https://doi.org/10.1038/nrclinonc.2012.61	https://doi.org/10.1038/nrclinonc.2012.61	NOUN
gsrj-21	383	2	59	59	NUM
gsrj-21	383	3	.	.	PUNCT
gsrj-21	384	1	boone	boone	PROPN
gsrj-21	384	2	,	,	PUNCT
gsrj-21	384	3	j.	j.	PROPN
gsrj-21	384	4	d.	d.	PROPN
gsrj-21	384	5	,	,	PUNCT
gsrj-21	384	6	dobbin	dobbin	PROPN
gsrj-21	384	7	,	,	PUNCT
gsrj-21	384	8	z.	z.	PROPN
gsrj-21	384	9	c.	c.	PROPN
gsrj-21	384	10	,	,	PUNCT
gsrj-21	384	11	straughn	straughn	PROPN
gsrj-21	384	12	,	,	PUNCT
gsrj-21	384	13	j.	j.	PROPN
gsrj-21	384	14	m.	m.	PROPN
gsrj-21	384	15	,	,	PUNCT
gsrj-21	384	16	&	&	CCONJ
gsrj-21	384	17	buchsbaum	buchsbaum	PROPN
gsrj-21	384	18	,	,	PUNCT
gsrj-21	384	19	d.	d.	PROPN
gsrj-21	384	20	j.	j.	PROPN
gsrj-21	384	21	(	(	PUNCT
gsrj-21	384	22	2015	2015	NUM
gsrj-21	384	23	)	)	PUNCT
gsrj-21	384	24	.	.	PUNCT
gsrj-21	385	1	ovarian	ovarian	ADJ
gsrj-21	385	2	and	and	CCONJ
gsrj-21	385	3	cervical	cervical	ADJ
gsrj-21	385	4	cancer	cancer	NOUN
gsrj-21	385	5	patient	patient	NOUN
gsrj-21	385	6	derived	derive	VERB
gsrj-21	385	7	xenografts	xenograft	NOUN
gsrj-21	385	8	:	:	PUNCT
gsrj-21	385	9	the	the	DET
gsrj-21	385	10	past	past	NOUN
gsrj-21	385	11	,	,	PUNCT
gsrj-21	385	12	present	present	ADJ
gsrj-21	385	13	,	,	PUNCT
gsrj-21	385	14	and	and	CCONJ
gsrj-21	385	15	future	future	NOUN
gsrj-21	385	16	.	.	PUNCT
gsrj-21	386	1	gynecologic	gynecologic	ADJ
gsrj-21	386	2	oncology	oncology	NOUN
gsrj-21	386	3	,	,	PUNCT
gsrj-21	386	4	138(2	138(2	NUM
gsrj-21	386	5	)	)	PUNCT
gsrj-21	386	6	,	,	PUNCT
gsrj-21	386	7	486	486	NUM
gsrj-21	386	8	-	-	SYM
gsrj-21	386	9	491	491	NUM
gsrj-21	386	10	.	.	PUNCT
gsrj-21	387	1	https://doi.org/10.1016/j.ygyno.2015.05.022	https://doi.org/10.1016/j.ygyno.2015.05.022	PROPN
gsrj-21	387	2	60	60	NUM
gsrj-21	387	3	.	.	PUNCT
gsrj-21	387	4	bernardo	bernardo	PROPN
gsrj-21	387	5	,	,	PUNCT
gsrj-21	387	6	c.	c.	PROPN
gsrj-21	387	7	,	,	PUNCT
gsrj-21	387	8	costa	costa	PROPN
gsrj-21	387	9	,	,	PUNCT
gsrj-21	387	10	c.	c.	PROPN
gsrj-21	387	11	,	,	PUNCT
gsrj-21	387	12	sousa	sousa	PROPN
gsrj-21	387	13	,	,	PUNCT
gsrj-21	387	14	n.	n.	NOUN
gsrj-21	387	15	,	,	PUNCT
gsrj-21	387	16	amado	amado	ADJ
gsrj-21	387	17	,	,	PUNCT
gsrj-21	387	18	f.	f.	PROPN
gsrj-21	387	19	,	,	PUNCT
gsrj-21	387	20	&	&	CCONJ
gsrj-21	387	21	santos	santos	PROPN
gsrj-21	387	22	,	,	PUNCT
gsrj-21	387	23	l.	l.	PROPN
gsrj-21	387	24	(	(	PUNCT
gsrj-21	387	25	2015	2015	NUM
gsrj-21	387	26	)	)	PUNCT
gsrj-21	387	27	.	.	PUNCT
gsrj-21	388	1	patient	patient	NOUN
gsrj-21	388	2	-	-	PUNCT
gsrj-21	388	3	derived	derive	VERB
gsrj-21	388	4	bladder	bladder	NOUN
gsrj-21	388	5	cancer	cancer	NOUN
gsrj-21	388	6	xenografts	xenograft	NOUN
gsrj-21	388	7	:	:	PUNCT
gsrj-21	388	8	a	a	DET
gsrj-21	388	9	systematic	systematic	ADJ
gsrj-21	388	10	review	review	NOUN
gsrj-21	388	11	.	.	PUNCT
gsrj-21	389	1	translational	translational	ADJ
gsrj-21	389	2	research	research	NOUN
gsrj-21	389	3	:	:	PUNCT
gsrj-21	389	4	the	the	DET
gsrj-21	389	5	journal	journal	NOUN
gsrj-21	389	6	of	of	ADP
gsrj-21	389	7	laboratory	laboratory	NOUN
gsrj-21	389	8	and	and	CCONJ
gsrj-21	389	9	clinical	clinical	ADJ
gsrj-21	389	10	medicine	medicine	NOUN
gsrj-21	389	11	,	,	PUNCT
gsrj-21	389	12	166(4	166(4	NUM
gsrj-21	389	13	)	)	PUNCT
gsrj-21	389	14	,	,	PUNCT
gsrj-21	389	15	324	324	NUM
gsrj-21	389	16	-	-	SYM
gsrj-21	389	17	331	331	NUM
gsrj-21	389	18	.	.	PUNCT
gsrj-21	390	1	https://doi.org/10.1016/j.trsl.2015.02.001	https://doi.org/10.1016/j.trsl.2015.02.001	NOUN
gsrj-21	390	2	61	61	NUM
gsrj-21	390	3	.	.	PUNCT
gsrj-21	391	1	okumura	okumura	ADJ
gsrj-21	391	2	,	,	PUNCT
gsrj-21	391	3	m.	m.	NOUN
gsrj-21	391	4	,	,	PUNCT
gsrj-21	391	5	ichihara	ichihara	PROPN
gsrj-21	391	6	,	,	PUNCT
gsrj-21	391	7	h.	h.	PROPN
gsrj-21	391	8	,	,	PUNCT
gsrj-21	391	9	&	&	CCONJ
gsrj-21	391	10	matsumoto	matsumoto	PROPN
gsrj-21	391	11	,	,	PUNCT
gsrj-21	391	12	y.	y.	PROPN
gsrj-21	391	13	(	(	PUNCT
gsrj-21	391	14	2018	2018	NUM
gsrj-21	391	15	)	)	PUNCT
gsrj-21	391	16	.	.	PUNCT
gsrj-21	392	1	hybrid	hybrid	ADJ
gsrj-21	392	2	liposomes	liposome	NOUN
gsrj-21	392	3	showing	show	VERB
gsrj-21	392	4	enhanced	enhanced	ADJ
gsrj-21	392	5	accumulation	accumulation	NOUN
gsrj-21	392	6	in	in	ADP
gsrj-21	392	7	tumors	tumor	NOUN
gsrj-21	392	8	as	as	ADP
gsrj-21	392	9	theranostic	theranostic	ADJ
gsrj-21	392	10	agents	agent	NOUN
gsrj-21	392	11	in	in	ADP
gsrj-21	392	12	the	the	DET
gsrj-21	392	13	orthotopic	orthotopic	ADJ
gsrj-21	392	14	graft	graft	PROPN
gsrj-21	392	15	model	model	NOUN
gsrj-21	392	16	mouse	mouse	PROPN
gsrj-21	392	17	of	of	ADP
gsrj-21	392	18	colorectal	colorectal	ADJ
gsrj-21	392	19	cancer	cancer	NOUN
gsrj-21	392	20	.	.	PUNCT
gsrj-21	393	1	drug	drug	NOUN
gsrj-21	393	2	delivery	delivery	NOUN
gsrj-21	393	3	,	,	PUNCT
gsrj-21	393	4	25(1	25(1	NUM
gsrj-21	393	5	)	)	PUNCT
gsrj-21	393	6	,	,	PUNCT
gsrj-21	393	7	1192	1192	NUM
gsrj-21	393	8	-	-	SYM
gsrj-21	393	9	1199	1199	NUM
gsrj-21	393	10	.	.	PUNCT
gsrj-21	394	1	https://doi.org/10.1080/10717544.2018.1475517	https://doi.org/10.1080/10717544.2018.1475517	PROPN
gsrj-21	394	2	62	62	NUM
gsrj-21	394	3	.	.	PUNCT
gsrj-21	395	1	ware	ware	NOUN
gsrj-21	395	2	,	,	PUNCT
gsrj-21	395	3	m.	m.	PROPN
gsrj-21	395	4	j.	j.	PROPN
gsrj-21	395	5	,	,	PUNCT
gsrj-21	395	6	keshishian	keshishian	PROPN
gsrj-21	395	7	,	,	PUNCT
gsrj-21	395	8	v.	v.	PROPN
gsrj-21	395	9	,	,	PUNCT
gsrj-21	395	10	law	law	NOUN
gsrj-21	395	11	,	,	PUNCT
gsrj-21	395	12	j.	j.	PROPN
gsrj-21	395	13	j.	j.	PROPN
gsrj-21	395	14	,	,	PUNCT
gsrj-21	395	15	ho	ho	PROPN
gsrj-21	395	16	,	,	PUNCT
gsrj-21	395	17	j.	j.	PROPN
gsrj-21	395	18	c.	c.	PROPN
gsrj-21	395	19	,	,	PUNCT
gsrj-21	395	20	favela	favela	PROPN
gsrj-21	395	21	,	,	PUNCT
gsrj-21	395	22	c.	c.	PROPN
gsrj-21	395	23	a.	a.	PROPN
gsrj-21	395	24	,	,	PUNCT
gsrj-21	395	25	rees	rees	PROPN
gsrj-21	395	26	,	,	PUNCT
gsrj-21	395	27	p.	p.	PROPN
gsrj-21	395	28	,	,	PUNCT
gsrj-21	395	29	et	et	PROPN
gsrj-21	395	30	al	al	PROPN
gsrj-21	395	31	.	.	PUNCT
gsrj-21	396	1	(	(	PUNCT
gsrj-21	396	2	2016	2016	NUM
gsrj-21	396	3	)	)	PUNCT
gsrj-21	396	4	.	.	PUNCT
gsrj-21	397	1	generation	generation	NOUN
gsrj-21	397	2	of	of	ADP
gsrj-21	397	3	an	an	DET
gsrj-21	397	4	in	in	ADP
gsrj-21	397	5	vitro	vitro	X
gsrj-21	397	6	3d	3d	PROPN
gsrj-21	397	7	pdac	pdac	PROPN
gsrj-21	397	8	stroma	stroma	PROPN
gsrj-21	397	9	rich	rich	ADJ
gsrj-21	397	10	spheroid	spheroid	PROPN
gsrj-21	397	11	model	model	NOUN
gsrj-21	397	12	.	.	PUNCT
gsrj-21	398	1	biomaterials	biomaterial	NOUN
gsrj-21	398	2	,	,	PUNCT
gsrj-21	398	3	108	108	NUM
gsrj-21	398	4	,	,	PUNCT
gsrj-21	398	5	129	129	NUM
gsrj-21	398	6	-	-	SYM
gsrj-21	398	7	142	142	NUM
gsrj-21	398	8	.	.	PUNCT
gsrj-21	399	1	https://doi.org/10.1016/j.biomaterials.2016.08.041	https://doi.org/10.1016/j.biomaterials.2016.08.041	NUM
gsrj-21	399	2	63	63	NUM
gsrj-21	399	3	.	.	PUNCT
gsrj-21	400	1	lampreht	lampreht	PROPN
gsrj-21	400	2	tratar	tratar	PROPN
gsrj-21	400	3	,	,	PUNCT
gsrj-21	400	4	u.	u.	NOUN
gsrj-21	400	5	,	,	PUNCT
gsrj-21	400	6	horvat	horvat	PROPN
gsrj-21	400	7	,	,	PUNCT
gsrj-21	400	8	s.	s.	PROPN
gsrj-21	400	9	,	,	PUNCT
gsrj-21	400	10	&	&	CCONJ
gsrj-21	400	11	cemazar	cemazar	PROPN
gsrj-21	400	12	,	,	PUNCT
gsrj-21	400	13	m.	m.	NOUN
gsrj-21	400	14	(	(	PUNCT
gsrj-21	400	15	2018	2018	NUM
gsrj-21	400	16	)	)	PUNCT
gsrj-21	400	17	.	.	PUNCT
gsrj-21	401	1	transgenic	transgenic	NOUN
gsrj-21	401	2	mouse	mouse	NOUN
gsrj-21	401	3	models	model	NOUN
gsrj-21	401	4	in	in	ADP
gsrj-21	401	5	cancer	cancer	NOUN
gsrj-21	401	6	research	research	NOUN
gsrj-21	401	7	.	.	PUNCT
gsrj-21	402	1	frontiers	frontier	NOUN
gsrj-21	402	2	in	in	ADP
gsrj-21	402	3	oncology	oncology	NOUN
gsrj-21	402	4	,	,	PUNCT
gsrj-21	402	5	8	8	NUM
gsrj-21	402	6	https://doi.org/10.3389/fonc.2018.00268	https://doi.org/10.3389/fonc.2018.00268	PROPN
gsrj-21	402	7	64	64	NUM
gsrj-21	402	8	.	.	PUNCT
gsrj-21	402	9	ikink	ikink	PROPN
gsrj-21	402	10	,	,	PUNCT
gsrj-21	402	11	g.	g.	PROPN
gsrj-21	402	12	j.	j.	PROPN
gsrj-21	402	13	,	,	PUNCT
gsrj-21	402	14	boer	boer	PROPN
gsrj-21	402	15	,	,	PUNCT
gsrj-21	402	16	m.	m.	NOUN
gsrj-21	402	17	,	,	PUNCT
gsrj-21	402	18	bakker	bakker	PROPN
gsrj-21	402	19	,	,	PUNCT
gsrj-21	402	20	e.	e.	PROPN
gsrj-21	402	21	r.	r.	PROPN
gsrj-21	402	22	m.	m.	PROPN
gsrj-21	402	23	,	,	PUNCT
gsrj-21	402	24	vendelzwaagstra	vendelzwaagstra	PROPN
gsrj-21	402	25	,	,	PUNCT
gsrj-21	402	26	a.	a.	PROPN
gsrj-21	402	27	,	,	PUNCT
gsrj-21	402	28	klijn	klijn	PROPN
gsrj-21	402	29	,	,	PUNCT
gsrj-21	402	30	c.	c.	PROPN
gsrj-21	402	31	,	,	PUNCT
gsrj-21	402	32	ten	ten	NUM
gsrj-21	402	33	hoeve	hoeve	NOUN
gsrj-21	402	34	,	,	PUNCT
gsrj-21	402	35	j.	j.	PROPN
gsrj-21	402	36	,	,	PUNCT
gsrj-21	402	37	et	et	PROPN
gsrj-21	402	38	al	al	PROPN
gsrj-21	402	39	.	.	PUNCT
gsrj-21	403	1	(	(	PUNCT
gsrj-21	403	2	2018	2018	NUM
gsrj-21	403	3	)	)	PUNCT
gsrj-21	403	4	.	.	PUNCT
gsrj-21	404	1	insertional	insertional	ADJ
gsrj-21	404	2	mutagenesis	mutagenesis	NOUN
gsrj-21	404	3	in	in	ADP
gsrj-21	404	4	a	a	DET
gsrj-21	404	5	her2positive	her2positive	PROPN
gsrj-21	404	6	breast	breast	NOUN
gsrj-21	404	7	cancer	cancer	NOUN
gsrj-21	404	8	model	model	NOUN
gsrj-21	404	9	reveals	reveal	VERB
gsrj-21	404	10	eras	era	NOUN
gsrj-21	404	11	as	as	ADP
gsrj-21	404	12	a	a	DET
gsrj-21	404	13	driver	driver	NOUN
gsrj-21	404	14	of	of	ADP
gsrj-21	404	15	cancer	cancer	NOUN
gsrj-21	404	16	and	and	CCONJ
gsrj-21	404	17	therapy	therapy	NOUN
gsrj-21	404	18	resistance	resistance	NOUN
gsrj-21	404	19	.	.	PUNCT
gsrj-21	405	1	oncogene	oncogene	NOUN
gsrj-21	405	2	,	,	PUNCT
gsrj-21	405	3	37(12	37(12	NUM
gsrj-21	405	4	)	)	PUNCT
gsrj-21	405	5	,	,	PUNCT
gsrj-21	405	6	1594	1594	NUM
gsrj-21	405	7	-	-	SYM
gsrj-21	405	8	1609	1609	NUM
gsrj-21	405	9	.	.	PUNCT
gsrj-21	406	1	https://doi.org/10.1038/s41388-017-0031-0	https://doi.org/10.1038/s41388-017-0031-0	NUM
gsrj-21	406	2	65	65	NUM
gsrj-21	406	3	.	.	PUNCT
gsrj-21	407	1	wang	wang	PROPN
gsrj-21	407	2	,	,	PUNCT
gsrj-21	407	3	m.	m.	NOUN
gsrj-21	407	4	,	,	PUNCT
gsrj-21	407	5	yao	yao	PROPN
gsrj-21	407	6	,	,	PUNCT
gsrj-21	407	7	l.	l.	PROPN
gsrj-21	407	8	,	,	PUNCT
gsrj-21	407	9	cheng	cheng	PROPN
gsrj-21	407	10	,	,	PUNCT
gsrj-21	407	11	m.	m.	NOUN
gsrj-21	407	12	,	,	PUNCT
gsrj-21	407	13	cai	cai	PROPN
gsrj-21	407	14	,	,	PUNCT
gsrj-21	407	15	d.	d.	PROPN
gsrj-21	407	16	,	,	PUNCT
gsrj-21	407	17	martinek	martinek	ADJ
gsrj-21	407	18	,	,	PUNCT
gsrj-21	407	19	j.	j.	PROPN
gsrj-21	407	20	,	,	PUNCT
gsrj-21	407	21	pan	pan	PROPN
gsrj-21	407	22	,	,	PUNCT
gsrj-21	407	23	c.	c.	PROPN
gsrj-21	407	24	,	,	PUNCT
gsrj-21	407	25	et	et	PROPN
gsrj-21	407	26	al	al	PROPN
gsrj-21	407	27	.	.	PUNCT
gsrj-21	407	28	(	(	PUNCT
gsrj-21	407	29	2018	2018	NUM
gsrj-21	407	30	)	)	PUNCT
gsrj-21	407	31	.	.	PUNCT
gsrj-21	408	1	humanized	humanize	VERB
gsrj-21	408	2	mice	mouse	NOUN
gsrj-21	408	3	in	in	ADP
gsrj-21	408	4	studying	study	VERB
gsrj-21	408	5	efficacy	efficacy	NOUN
gsrj-21	408	6	and	and	CCONJ
gsrj-21	408	7	mechanisms	mechanism	NOUN
gsrj-21	408	8	of	of	ADP
gsrj-21	408	9	pd1	pd1	NOUN
gsrj-21	408	10	-	-	PUNCT
gsrj-21	408	11	targeted	target	VERB
gsrj-21	408	12	cancer	cancer	NOUN
gsrj-21	408	13	immunotherapy	immunotherapy	NOUN
gsrj-21	408	14	.	.	PUNCT
gsrj-21	409	1	the	the	DET
gsrj-21	409	2	faseb	faseb	PROPN
gsrj-21	409	3	journal	journal	PROPN
gsrj-21	409	4	,	,	PUNCT
gsrj-21	409	5	32(3	32(3	NUM
gsrj-21	409	6	)	)	PUNCT
gsrj-21	409	7	,	,	PUNCT
gsrj-21	409	8	1537	1537	NUM
gsrj-21	409	9	-	-	SYM
gsrj-21	409	10	1549	1549	NUM
gsrj-21	409	11	.	.	PUNCT
gsrj-21	409	12	https://doi.org/10.1096/fj.201700740r	https://doi.org/10.1096/fj.201700740r	PROPN
gsrj-21	410	1	66	66	NUM
gsrj-21	410	2	.	.	PUNCT
gsrj-21	411	1	chang	chang	PROPN
gsrj-21	411	2	,	,	PUNCT
gsrj-21	411	3	d.	d.	PROPN
gsrj-21	411	4	,	,	PUNCT
gsrj-21	411	5	moniz	moniz	PROPN
gsrj-21	411	6	,	,	PUNCT
gsrj-21	411	7	r.	r.	PROPN
gsrj-21	411	8	j.	j.	PROPN
gsrj-21	411	9	,	,	PUNCT
gsrj-21	411	10	xu	xu	PROPN
gsrj-21	411	11	,	,	PUNCT
gsrj-21	411	12	z.	z.	PROPN
gsrj-21	411	13	,	,	PUNCT
gsrj-21	411	14	sun	sun	PROPN
gsrj-21	411	15	,	,	PUNCT
gsrj-21	411	16	j.	j.	PROPN
gsrj-21	411	17	,	,	PUNCT
gsrj-21	411	18	signoretti	signoretti	NOUN
gsrj-21	411	19	,	,	PUNCT
gsrj-21	411	20	s.	s.	PROPN
gsrj-21	411	21	,	,	PUNCT
gsrj-21	411	22	zhu	zhu	PROPN
gsrj-21	411	23	,	,	PUNCT
gsrj-21	411	24	q.	q.	PROPN
gsrj-21	411	25	,	,	PUNCT
gsrj-21	411	26	et	et	PROPN
gsrj-21	411	27	al	al	PROPN
gsrj-21	411	28	.	.	PUNCT
gsrj-21	411	29	(	(	PUNCT
gsrj-21	411	30	2015	2015	NUM
gsrj-21	411	31	)	)	PUNCT
gsrj-21	411	32	.	.	PUNCT
gsrj-21	412	1	human	human	ADJ
gsrj-21	412	2	anticaix	anticaix	NOUN
gsrj-21	412	3	antibodies	antibodie	VERB
gsrj-21	412	4	mediate	mediate	VERB
gsrj-21	412	5	immune	immune	ADJ
gsrj-21	412	6	cell	cell	NOUN
gsrj-21	412	7	inhibition	inhibition	NOUN
gsrj-21	412	8	of	of	ADP
gsrj-21	412	9	renal	renal	ADJ
gsrj-21	412	10	cell	cell	NOUN
gsrj-21	412	11	carcinoma	carcinoma	NOUN
gsrj-21	412	12	in	in	ADP
gsrj-21	412	13	vitro	vitro	X
gsrj-21	412	14	and	and	CCONJ
gsrj-21	412	15	in	in	ADP
gsrj-21	412	16	a	a	DET
gsrj-21	412	17	humanized	humanize	VERB
gsrj-21	412	18	mouse	mouse	NOUN
gsrj-21	412	19	model	model	NOUN
gsrj-21	412	20	in	in	ADP
gsrj-21	412	21	vivo	vivo	NOUN
gsrj-21	412	22	.	.	PUNCT
gsrj-21	413	1	molecular	molecular	ADJ
gsrj-21	413	2	cancer	cancer	NOUN
gsrj-21	413	3	,	,	PUNCT
gsrj-21	413	4	14	14	NUM
gsrj-21	413	5	,	,	PUNCT
gsrj-21	413	6	119	119	NUM
gsrj-21	413	7	.	.	PUNCT
gsrj-21	414	1	https://doi.org/10.1186/s12943-015-0384-3	https://doi.org/10.1186/s12943-015-0384-3	NUM
gsrj-21	414	2	67	67	NUM
gsrj-21	414	3	.	.	PUNCT
gsrj-21	414	4	rahib	rahib	NOUN
gsrj-21	414	5	,	,	PUNCT
gsrj-21	414	6	l.	l.	PROPN
gsrj-21	414	7	,	,	PUNCT
gsrj-21	414	8	smith	smith	PROPN
gsrj-21	414	9	,	,	PUNCT
gsrj-21	414	10	b.	b.	PROPN
gsrj-21	414	11	d.	d.	PROPN
gsrj-21	414	12	,	,	PUNCT
gsrj-21	414	13	aizenberg	aizenberg	PROPN
gsrj-21	414	14	,	,	PUNCT
gsrj-21	414	15	r.	r.	PROPN
gsrj-21	414	16	,	,	PUNCT
gsrj-21	414	17	rosenzweig	rosenzweig	PROPN
gsrj-21	414	18	,	,	PUNCT
gsrj-21	414	19	a.	a.	PROPN
gsrj-21	414	20	b.	b.	PROPN
gsrj-21	414	21	,	,	PUNCT
gsrj-21	414	22	fleshman	fleshman	NOUN
gsrj-21	414	23	,	,	PUNCT
gsrj-21	414	24	j.	j.	PROPN
gsrj-21	414	25	m.	m.	PROPN
gsrj-21	414	26	,	,	PUNCT
gsrj-21	414	27	&	&	CCONJ
gsrj-21	414	28	matrisian	matrisian	PROPN
gsrj-21	414	29	,	,	PUNCT
gsrj-21	414	30	l.	l.	PROPN
gsrj-21	414	31	m.	m.	PROPN
gsrj-21	414	32	(	(	PUNCT
gsrj-21	414	33	2014	2014	NUM
gsrj-21	414	34	)	)	PUNCT
gsrj-21	414	35	.	.	PUNCT
gsrj-21	415	1	projecting	project	VERB
gsrj-21	415	2	cancer	cancer	NOUN
gsrj-21	415	3	incidence	incidence	NOUN
gsrj-21	415	4	and	and	CCONJ
gsrj-21	415	5	deaths	death	NOUN
gsrj-21	415	6	to	to	ADP
gsrj-21	415	7	2030	2030	NUM
gsrj-21	415	8	:	:	PUNCT
gsrj-21	415	9	the	the	DET
gsrj-21	415	10	unexpected	unexpected	ADJ
gsrj-21	415	11	burden	burden	NOUN
gsrj-21	415	12	of	of	ADP
gsrj-21	415	13	thyroid	thyroid	NOUN
gsrj-21	415	14	,	,	PUNCT
gsrj-21	415	15	liver	liver	NOUN
gsrj-21	415	16	,	,	PUNCT
gsrj-21	415	17	and	and	CCONJ
gsrj-21	415	18	pancreas	pancreas	NOUN
gsrj-21	415	19	cancers	cancer	NOUN
gsrj-21	415	20	in	in	ADP
gsrj-21	415	21	the	the	DET
gsrj-21	415	22	united	united	PROPN
gsrj-21	415	23	states	states	PROPN
gsrj-21	415	24	.	.	PUNCT
gsrj-21	416	1	cancer	cancer	NOUN
gsrj-21	416	2	research	research	NOUN
gsrj-21	416	3	,	,	PUNCT
gsrj-21	416	4	74(11	74(11	NUM
gsrj-21	416	5	)	)	PUNCT
gsrj-21	416	6	,	,	PUNCT
gsrj-21	416	7	2913	2913	NUM
gsrj-21	416	8	-	-	SYM
gsrj-21	416	9	2921	2921	NUM
gsrj-21	416	10	.	.	PUNCT
gsrj-21	417	1	68	68	NUM
gsrj-21	417	2	.	.	PUNCT
gsrj-21	418	1	laquente	laquente	PROPN
gsrj-21	418	2	,	,	PUNCT
gsrj-21	418	3	b.	b.	PROPN
gsrj-21	418	4	,	,	PUNCT
gsrj-21	418	5	calsina	calsina	PROPN
gsrj-21	418	6	-	-	PUNCT
gsrj-21	418	7	berna	berna	NOUN
gsrj-21	418	8	,	,	PUNCT
gsrj-21	418	9	a.	a.	PROPN
gsrj-21	418	10	,	,	PUNCT
gsrj-21	418	11	carmonabayonas	carmonabayona	NOUN
gsrj-21	418	12	,	,	PUNCT
gsrj-21	418	13	a.	a.	NOUN
gsrj-21	418	14	,	,	PUNCT
gsrj-21	418	15	jiménez	jiménez	PROPN
gsrj-21	418	16	-	-	PUNCT
gsrj-21	418	17	fonseca	fonseca	PROPN
gsrj-21	418	18	,	,	PUNCT
gsrj-21	418	19	p.	p.	NOUN
gsrj-21	418	20	,	,	PUNCT
gsrj-21	418	21	peiró	peiró	NOUN
gsrj-21	418	22	,	,	PUNCT
gsrj-21	418	23	i.	i.	PROPN
gsrj-21	418	24	,	,	PUNCT
gsrj-21	418	25	&	&	CCONJ
gsrj-21	418	26	carrato	carrato	PROPN
gsrj-21	418	27	,	,	PUNCT
gsrj-21	418	28	a.	a.	NOUN
gsrj-21	418	29	(	(	PUNCT
gsrj-21	418	30	2017	2017	NUM
gsrj-21	418	31	)	)	PUNCT
gsrj-21	418	32	.	.	PUNCT
gsrj-21	419	1	supportive	supportive	ADJ
gsrj-21	419	2	care	care	NOUN
gsrj-21	419	3	in	in	ADP
gsrj-21	419	4	pancreatic	pancreatic	ADJ
gsrj-21	419	5	ductal	ductal	ADJ
gsrj-21	419	6	adenocarcinoma	adenocarcinoma	NOUN
gsrj-21	419	7	.	.	PUNCT
gsrj-21	420	1	clinical	clinical	PROPN
gsrj-21	420	2	&	&	CCONJ
gsrj-21	420	3	translational	translational	ADJ
gsrj-21	420	4	59	59	NUM
gsrj-21	420	5	georgetown	georgetown	PROPN
gsrj-21	420	6	scientific	scientific	PROPN
gsrj-21	420	7	research	research	PROPN
gsrj-21	420	8	journal	journal	PROPN
gsrj-21	420	9	oncology	oncology	NOUN
gsrj-21	420	10	,	,	PUNCT
gsrj-21	420	11	19(11	19(11	NUM
gsrj-21	420	12	)	)	PUNCT
gsrj-21	420	13	,	,	PUNCT
gsrj-21	420	14	1293	1293	NUM
gsrj-21	420	15	-	-	SYM
gsrj-21	420	16	1302	1302	NUM
gsrj-21	420	17	.	.	PUNCT
gsrj-21	421	1	https://doi.org/10.1007/s12094-017-1682-6	https://doi.org/10.1007/s12094-017-1682-6	NUM
gsrj-21	421	2	69	69	NUM
gsrj-21	421	3	.	.	PUNCT
gsrj-21	422	1	blomstrand	blomstrand	PROPN
gsrj-21	422	2	,	,	PUNCT
gsrj-21	422	3	h.	h.	PROPN
gsrj-21	422	4	,	,	PUNCT
gsrj-21	422	5	scheibling	scheibling	NOUN
gsrj-21	422	6	,	,	PUNCT
gsrj-21	422	7	u.	u.	PROPN
gsrj-21	422	8	,	,	PUNCT
gsrj-21	422	9	bratthäll	bratthäll	PROPN
gsrj-21	422	10	,	,	PUNCT
gsrj-21	422	11	c.	c.	PROPN
gsrj-21	422	12	,	,	PUNCT
gsrj-21	422	13	green	green	NOUN
gsrj-21	422	14	,	,	PUNCT
gsrj-21	422	15	h.	h.	PROPN
gsrj-21	422	16	,	,	PUNCT
gsrj-21	422	17	&	&	CCONJ
gsrj-21	422	18	elander	elander	NOUN
gsrj-21	422	19	,	,	PUNCT
gsrj-21	422	20	n.	n.	NOUN
gsrj-21	422	21	o.	o.	PROPN
gsrj-21	422	22	(	(	PUNCT
gsrj-21	422	23	2019	2019	NUM
gsrj-21	422	24	)	)	PUNCT
gsrj-21	422	25	.	.	PUNCT
gsrj-21	423	1	real	real	ADJ
gsrj-21	423	2	world	world	NOUN
gsrj-21	423	3	evidence	evidence	NOUN
gsrj-21	423	4	on	on	ADP
gsrj-21	423	5	gemcitabine	gemcitabine	NOUN
gsrj-21	423	6	and	and	CCONJ
gsrj-21	423	7	nab	nab	NOUN
gsrj-21	423	8	-	-	PUNCT
gsrj-21	423	9	paclitaxel	paclitaxel	ADJ
gsrj-21	423	10	combination	combination	NOUN
gsrj-21	423	11	chemotherapy	chemotherapy	NOUN
gsrj-21	423	12	in	in	ADP
gsrj-21	423	13	advanced	advanced	ADJ
gsrj-21	423	14	pancreatic	pancreatic	ADJ
gsrj-21	423	15	cancer	cancer	NOUN
gsrj-21	423	16	.	.	PUNCT
gsrj-21	424	1	bmc	bmc	NOUN
gsrj-21	424	2	cancer	cancer	NOUN
gsrj-21	424	3	,	,	PUNCT
gsrj-21	424	4	19(1	19(1	NUM
gsrj-21	424	5	)	)	PUNCT
gsrj-21	424	6	,	,	PUNCT
gsrj-21	424	7	40	40	NUM
gsrj-21	424	8	.	.	PUNCT
gsrj-21	425	1	https://doi.org/10.1186/s12885-018-5244-2	https://doi.org/10.1186/s12885-018-5244-2	NUM
gsrj-21	425	2	70	70	NUM
gsrj-21	425	3	.	.	PUNCT
gsrj-21	426	1	siegel	siegel	PROPN
gsrj-21	426	2	,	,	PUNCT
gsrj-21	426	3	r.	r.	PROPN
gsrj-21	426	4	l.	l.	PROPN
gsrj-21	426	5	,	,	PUNCT
gsrj-21	426	6	miller	miller	PROPN
gsrj-21	426	7	,	,	PUNCT
gsrj-21	426	8	k.	k.	PROPN
gsrj-21	426	9	d.	d.	PROPN
gsrj-21	426	10	,	,	PUNCT
gsrj-21	426	11	&	&	CCONJ
gsrj-21	426	12	jemal	jemal	ADJ
gsrj-21	426	13	,	,	PUNCT
gsrj-21	426	14	a.	a.	NOUN
gsrj-21	426	15	(	(	PUNCT
gsrj-21	426	16	2020	2020	NUM
gsrj-21	426	17	)	)	PUNCT
gsrj-21	426	18	.	.	PUNCT
gsrj-21	427	1	cancer	cancer	NOUN
gsrj-21	427	2	statistics	statistic	NOUN
gsrj-21	427	3	,	,	PUNCT
gsrj-21	427	4	2020	2020	NUM
gsrj-21	427	5	.	.	PUNCT
gsrj-21	428	1	ca	ca	NOUN
gsrj-21	428	2	:	:	PUNCT
gsrj-21	428	3	a	a	DET
gsrj-21	428	4	cancer	cancer	NOUN
gsrj-21	428	5	journal	journal	NOUN
gsrj-21	428	6	for	for	ADP
gsrj-21	428	7	clinicians	clinician	NOUN
gsrj-21	428	8	,	,	PUNCT
gsrj-21	428	9	70(1	70(1	NOUN
gsrj-21	428	10	)	)	PUNCT
gsrj-21	428	11	,	,	PUNCT
gsrj-21	428	12	7	7	NUM
gsrj-21	428	13	-	-	SYM
gsrj-21	428	14	30	30	NUM
gsrj-21	428	15	.	.	PUNCT
gsrj-21	429	1	https://doi.org/10.3322/caac.21590	https://doi.org/10.3322/caac.21590	PROPN
gsrj-21	429	2	71	71	NUM
gsrj-21	429	3	.	.	PUNCT
gsrj-21	430	1	adamska	adamska	PROPN
gsrj-21	430	2	,	,	PUNCT
gsrj-21	430	3	a.	a.	NOUN
gsrj-21	430	4	,	,	PUNCT
gsrj-21	430	5	domenichini	domenichini	PROPN
gsrj-21	430	6	,	,	PUNCT
gsrj-21	430	7	a.	a.	NOUN
gsrj-21	430	8	,	,	PUNCT
gsrj-21	430	9	&	&	CCONJ
gsrj-21	430	10	falasca	falasca	PROPN
gsrj-21	430	11	,	,	PUNCT
gsrj-21	430	12	m.	m.	NOUN
gsrj-21	430	13	(	(	PUNCT
gsrj-21	430	14	2017	2017	NUM
gsrj-21	430	15	)	)	PUNCT
gsrj-21	430	16	.	.	PUNCT
gsrj-21	431	1	pancreatic	pancreatic	ADJ
gsrj-21	431	2	ductal	ductal	ADJ
gsrj-21	431	3	adenocarcinoma	adenocarcinoma	NOUN
gsrj-21	431	4	:	:	PUNCT
gsrj-21	431	5	current	current	ADJ
gsrj-21	431	6	and	and	CCONJ
gsrj-21	431	7	evolving	evolve	VERB
gsrj-21	431	8	therapies	therapy	NOUN
gsrj-21	431	9	.	.	PUNCT
gsrj-21	432	1	international	international	ADJ
gsrj-21	432	2	journal	journal	NOUN
gsrj-21	432	3	of	of	ADP
gsrj-21	432	4	molecular	molecular	ADJ
gsrj-21	432	5	sciences	science	NOUN
gsrj-21	432	6	,	,	PUNCT
gsrj-21	432	7	18(7	18(7	NUM
gsrj-21	432	8	)	)	PUNCT
gsrj-21	432	9	https://doi.org/10.3390/ijms18071338	https://doi.org/10.3390/ijms18071338	PROPN
gsrj-21	432	10	72	72	NUM
gsrj-21	432	11	.	.	PUNCT
gsrj-21	433	1	affram	affram	PROPN
gsrj-21	433	2	,	,	PUNCT
gsrj-21	433	3	k.	k.	PROPN
gsrj-21	433	4	,	,	PUNCT
gsrj-21	433	5	smith	smith	PROPN
gsrj-21	433	6	,	,	PUNCT
gsrj-21	433	7	t.	t.	PROPN
gsrj-21	433	8	,	,	PUNCT
gsrj-21	433	9	ofori	ofori	X
gsrj-21	433	10	,	,	PUNCT
gsrj-21	433	11	e.	e.	PROPN
gsrj-21	433	12	,	,	PUNCT
gsrj-21	433	13	krishnan	krishnan	PROPN
gsrj-21	433	14	,	,	PUNCT
gsrj-21	433	15	s.	s.	PROPN
gsrj-21	433	16	,	,	PUNCT
gsrj-21	433	17	underwood	underwood	PROPN
gsrj-21	433	18	,	,	PUNCT
gsrj-21	433	19	p.	p.	PROPN
gsrj-21	433	20	,	,	PUNCT
gsrj-21	433	21	trevino	trevino	PROPN
gsrj-21	433	22	,	,	PUNCT
gsrj-21	433	23	j.	j.	PROPN
gsrj-21	433	24	,	,	PUNCT
gsrj-21	433	25	et	et	PROPN
gsrj-21	433	26	al	al	PROPN
gsrj-21	433	27	.	.	PROPN
gsrj-21	433	28	(	(	PUNCT
gsrj-21	433	29	2020	2020	NUM
gsrj-21	433	30	)	)	PUNCT
gsrj-21	433	31	.	.	PUNCT
gsrj-21	434	1	cytotoxic	cytotoxic	ADJ
gsrj-21	434	2	effects	effect	NOUN
gsrj-21	434	3	of	of	ADP
gsrj-21	434	4	gemcitabine	gemcitabine	NOUN
gsrj-21	434	5	-	-	PUNCT
gsrj-21	434	6	loaded	load	VERB
gsrj-21	434	7	solid	solid	ADJ
gsrj-21	434	8	lipid	lipid	NOUN
gsrj-21	434	9	nanoparticles	nanoparticle	NOUN
gsrj-21	434	10	in	in	ADP
gsrj-21	434	11	pancreatic	pancreatic	ADJ
gsrj-21	434	12	cancer	cancer	NOUN
gsrj-21	434	13	cells.55	cells.55	NOUN
gsrj-21	434	14	,	,	PUNCT
gsrj-21	434	15	101374	101374	NUM
gsrj-21	434	16	.	.	PUNCT
gsrj-21	435	1	retrieved	retrieve	VERB
gsrj-21	435	2	from	from	ADP
gsrj-21	435	3	https://www.sciencedirect.com/science/journal/177	https://www.sciencedirect.com/science/journal/177	PROPN
gsrj-21	435	4	32247	32247	NUM
gsrj-21	435	5	73	73	NUM
gsrj-21	435	6	.	.	PUNCT
gsrj-21	436	1	kramer	kramer	PROPN
gsrj-21	436	2	,	,	PUNCT
gsrj-21	436	3	b.	b.	PROPN
gsrj-21	436	4	,	,	PUNCT
gsrj-21	436	5	haan	haan	PROPN
gsrj-21	436	6	,	,	PUNCT
gsrj-21	436	7	l.	l.	PROPN
gsrj-21	436	8	d.	d.	PROPN
gsrj-21	436	9	,	,	PUNCT
gsrj-21	436	10	vermeer	vermeer	PROPN
gsrj-21	436	11	,	,	PUNCT
gsrj-21	436	12	m.	m.	NOUN
gsrj-21	436	13	,	,	PUNCT
gsrj-21	436	14	olivier	olivier	NOUN
gsrj-21	436	15	,	,	PUNCT
gsrj-21	436	16	t.	t.	PROPN
gsrj-21	436	17	,	,	PUNCT
gsrj-21	436	18	hankemeier	hankemeier	NOUN
gsrj-21	436	19	,	,	PUNCT
gsrj-21	436	20	t.	t.	PROPN
gsrj-21	436	21	,	,	PUNCT
gsrj-21	436	22	vulto	vulto	NOUN
gsrj-21	436	23	,	,	PUNCT
gsrj-21	436	24	p.	p.	PROPN
gsrj-21	436	25	,	,	PUNCT
gsrj-21	436	26	et	et	PROPN
gsrj-21	436	27	al	al	PROPN
gsrj-21	436	28	.	.	PROPN
gsrj-21	436	29	(	(	PUNCT
gsrj-21	436	30	2019	2019	NUM
gsrj-21	436	31	)	)	PUNCT
gsrj-21	436	32	.	.	PUNCT
gsrj-21	437	1	interstitial	interstitial	ADJ
gsrj-21	437	2	flow	flow	NOUN
gsrj-21	437	3	recapitulates	recapitulate	VERB
gsrj-21	437	4	gemcitabine	gemcitabine	NOUN
gsrj-21	437	5	chemoresistance	chemoresistance	NOUN
gsrj-21	437	6	in	in	ADP
gsrj-21	437	7	a	a	DET
gsrj-21	437	8	3d	3d	NUM
gsrj-21	437	9	microfluidic	microfluidic	ADJ
gsrj-21	437	10	pancreatic	pancreatic	ADJ
gsrj-21	437	11	ductal	ductal	ADJ
gsrj-21	437	12	adenocarcinoma	adenocarcinoma	NOUN
gsrj-21	437	13	model	model	NOUN
gsrj-21	437	14	by	by	ADP
gsrj-21	437	15	induction	induction	NOUN
gsrj-21	437	16	of	of	ADP
gsrj-21	437	17	multidrug	multidrug	NOUN
gsrj-21	437	18	resistance	resistance	NOUN
gsrj-21	437	19	proteins	protein	NOUN
gsrj-21	437	20	.	.	PUNCT
gsrj-21	438	1	international	international	ADJ
gsrj-21	438	2	journal	journal	NOUN
gsrj-21	438	3	of	of	ADP
gsrj-21	438	4	molecular	molecular	ADJ
gsrj-21	438	5	sciences	science	NOUN
gsrj-21	438	6	,	,	PUNCT
gsrj-21	438	7	20(18	20(18	NUM
gsrj-21	438	8	)	)	PUNCT
gsrj-21	438	9	,	,	PUNCT
gsrj-21	438	10	4647	4647	NUM
gsrj-21	438	11	.	.	PUNCT
gsrj-21	439	1	https://doi.org/10.3390/ijms20184647	https://doi.org/10.3390/ijms20184647	ADJ
gsrj-21	439	2	74	74	NUM
gsrj-21	439	3	.	.	PUNCT
gsrj-21	440	1	chin	chin	PROPN
gsrj-21	440	2	,	,	PUNCT
gsrj-21	440	3	v.	v.	ADV
gsrj-21	440	4	,	,	PUNCT
gsrj-21	440	5	nagrial	nagrial	NOUN
gsrj-21	440	6	,	,	PUNCT
gsrj-21	440	7	a.	a.	NOUN
gsrj-21	440	8	,	,	PUNCT
gsrj-21	440	9	sjoquist	sjoquist	NOUN
gsrj-21	440	10	,	,	PUNCT
gsrj-21	440	11	k.	k.	PROPN
gsrj-21	440	12	,	,	PUNCT
gsrj-21	440	13	o'connor	o'connor	PROPN
gsrj-21	440	14	,	,	PUNCT
gsrj-21	440	15	c.	c.	PROPN
gsrj-21	440	16	a.	a.	PROPN
gsrj-21	440	17	,	,	PUNCT
gsrj-21	440	18	chantrill	chantrill	PROPN
gsrj-21	440	19	,	,	PUNCT
gsrj-21	440	20	l.	l.	PROPN
gsrj-21	440	21	,	,	PUNCT
gsrj-21	440	22	biankin	biankin	PROPN
gsrj-21	440	23	,	,	PUNCT
gsrj-21	440	24	a.	a.	PROPN
gsrj-21	440	25	v.	v.	PROPN
gsrj-21	440	26	,	,	PUNCT
gsrj-21	440	27	et	et	PROPN
gsrj-21	440	28	al	al	PROPN
gsrj-21	440	29	.	.	PUNCT
gsrj-21	440	30	(	(	PUNCT
gsrj-21	440	31	2018	2018	NUM
gsrj-21	440	32	)	)	PUNCT
gsrj-21	440	33	.	.	PUNCT
gsrj-21	441	1	chemotherapy	chemotherapy	NOUN
gsrj-21	441	2	and	and	CCONJ
gsrj-21	441	3	radiotherapy	radiotherapy	NOUN
gsrj-21	441	4	for	for	ADP
gsrj-21	441	5	advanced	advanced	ADJ
gsrj-21	441	6	pancreatic	pancreatic	ADJ
gsrj-21	441	7	cancer	cancer	NOUN
gsrj-21	441	8	.	.	PUNCT
gsrj-21	442	1	the	the	DET
gsrj-21	442	2	cochrane	cochrane	PROPN
gsrj-21	442	3	database	database	NOUN
gsrj-21	442	4	of	of	ADP
gsrj-21	442	5	systematic	systematic	ADJ
gsrj-21	442	6	reviews	review	NOUN
gsrj-21	442	7	,	,	PUNCT
gsrj-21	442	8	2018(3	2018(3	NUM
gsrj-21	442	9	)	)	PUNCT
gsrj-21	443	1	https://doi.orh/10.1002/14651858.cd011044.pub	https://doi.orh/10.1002/14651858.cd011044.pub	NOUN
gsrj-21	443	2	2	2	NUM
gsrj-21	443	3	75	75	NUM
gsrj-21	443	4	.	.	PUNCT
gsrj-21	444	1	shukla	shukla	NOUN
gsrj-21	444	2	,	,	PUNCT
gsrj-21	444	3	s.	s.	PROPN
gsrj-21	444	4	k.	k.	PROPN
gsrj-21	444	5	,	,	PUNCT
gsrj-21	444	6	purohit	purohit	PROPN
gsrj-21	444	7	,	,	PUNCT
gsrj-21	444	8	v.	v.	ADV
gsrj-21	444	9	,	,	PUNCT
gsrj-21	444	10	mehla	mehla	PROPN
gsrj-21	444	11	,	,	PUNCT
gsrj-21	444	12	k.	k.	PROPN
gsrj-21	444	13	,	,	PUNCT
gsrj-21	444	14	gunda	gunda	PROPN
gsrj-21	444	15	,	,	PUNCT
gsrj-21	444	16	v.	v.	PROPN
gsrj-21	444	17	,	,	PUNCT
gsrj-21	444	18	chaika	chaika	NOUN
gsrj-21	444	19	,	,	PUNCT
gsrj-21	444	20	n.	n.	PROPN
gsrj-21	444	21	v.	v.	PROPN
gsrj-21	444	22	,	,	PUNCT
gsrj-21	444	23	vernucci	vernucci	PROPN
gsrj-21	444	24	,	,	PUNCT
gsrj-21	444	25	e.	e.	PROPN
gsrj-21	444	26	,	,	PUNCT
gsrj-21	444	27	et	et	PROPN
gsrj-21	444	28	al	al	PROPN
gsrj-21	444	29	.	.	PUNCT
gsrj-21	444	30	(	(	PUNCT
gsrj-21	444	31	2017	2017	NUM
gsrj-21	444	32	)	)	PUNCT
gsrj-21	444	33	.	.	PUNCT
gsrj-21	445	1	muc1	muc1	PROPN
gsrj-21	445	2	and	and	CCONJ
gsrj-21	445	3	hif-1alpha	hif-1alpha	NOUN
gsrj-21	445	4	signaling	signal	VERB
gsrj-21	445	5	crosstalk	crosstalk	NOUN
gsrj-21	445	6	induces	induce	VERB
gsrj-21	445	7	anabolic	anabolic	NOUN
gsrj-21	445	8	glucose	glucose	NOUN
gsrj-21	445	9	metabolism	metabolism	NOUN
gsrj-21	445	10	to	to	PART
gsrj-21	445	11	impart	impart	VERB
gsrj-21	445	12	gemcitabine	gemcitabine	NOUN
gsrj-21	445	13	resistance	resistance	NOUN
gsrj-21	445	14	to	to	ADP
gsrj-21	445	15	pancreatic	pancreatic	ADJ
gsrj-21	445	16	cancer	cancer	NOUN
gsrj-21	445	17	.	.	PUNCT
gsrj-21	446	1	cancer	cancer	NOUN
gsrj-21	446	2	cell	cell	NOUN
gsrj-21	446	3	,	,	PUNCT
gsrj-21	446	4	32(1	32(1	NUM
gsrj-21	446	5	)	)	PUNCT
gsrj-21	446	6	,	,	PUNCT
gsrj-21	446	7	71	71	NUM
gsrj-21	446	8	-	-	SYM
gsrj-21	446	9	87.e7	87.e7	NUM
gsrj-21	446	10	.	.	PUNCT
gsrj-21	447	1	https://doi.org/10.1016/j.ccell.2017.06.004	https://doi.org/10.1016/j.ccell.2017.06.004	PROPN
gsrj-21	447	2	76	76	NUM
gsrj-21	447	3	.	.	PUNCT
gsrj-21	448	1	krulikas	krulikas	PROPN
gsrj-21	448	2	,	,	PUNCT
gsrj-21	448	3	l.	l.	PROPN
gsrj-21	448	4	j.	j.	PROPN
gsrj-21	448	5	,	,	PUNCT
gsrj-21	448	6	mcdonald	mcdonald	PROPN
gsrj-21	448	7	,	,	PUNCT
gsrj-21	448	8	i.	i.	PROPN
gsrj-21	448	9	m.	m.	PROPN
gsrj-21	448	10	,	,	PUNCT
gsrj-21	448	11	lee	lee	PROPN
gsrj-21	448	12	,	,	PUNCT
gsrj-21	448	13	b.	b.	PROPN
gsrj-21	448	14	,	,	PUNCT
gsrj-21	448	15	okumu	okumu	PROPN
gsrj-21	448	16	,	,	PUNCT
gsrj-21	448	17	d.	d.	PROPN
gsrj-21	448	18	o.	o.	PROPN
gsrj-21	448	19	,	,	PUNCT
gsrj-21	448	20	east	east	PROPN
gsrj-21	448	21	,	,	PUNCT
gsrj-21	448	22	m.	m.	PROPN
gsrj-21	448	23	p.	p.	PROPN
gsrj-21	448	24	,	,	PUNCT
gsrj-21	448	25	gilbert	gilbert	PROPN
gsrj-21	448	26	,	,	PUNCT
gsrj-21	448	27	t.	t.	PROPN
gsrj-21	448	28	s.	s.	PROPN
gsrj-21	448	29	k.	k.	PROPN
gsrj-21	448	30	,	,	PUNCT
gsrj-21	448	31	et	et	PROPN
gsrj-21	448	32	al	al	PROPN
gsrj-21	448	33	.	.	PUNCT
gsrj-21	449	1	(	(	PUNCT
gsrj-21	449	2	2018	2018	NUM
gsrj-21	449	3	)	)	PUNCT
gsrj-21	449	4	.	.	PUNCT
gsrj-21	450	1	application	application	NOUN
gsrj-21	450	2	of	of	ADP
gsrj-21	450	3	integrated	integrate	VERB
gsrj-21	450	4	drug	drug	NOUN
gsrj-21	450	5	screening	screening	NOUN
gsrj-21	450	6	/	/	SYM
gsrj-21	450	7	kinome	kinome	VERB
gsrj-21	450	8	analysis	analysis	NOUN
gsrj-21	450	9	to	to	PART
gsrj-21	450	10	identify	identify	VERB
gsrj-21	450	11	inhibitors	inhibitor	NOUN
gsrj-21	450	12	of	of	ADP
gsrj-21	450	13	gemcitabineresistant	gemcitabineresistant	ADJ
gsrj-21	450	14	pancreatic	pancreatic	ADJ
gsrj-21	450	15	cancer	cancer	NOUN
gsrj-21	450	16	cell	cell	NOUN
gsrj-21	450	17	growth	growth	NOUN
gsrj-21	450	18	.	.	PUNCT
gsrj-21	451	1	slas	slas	PROPN
gsrj-21	451	2	discovery	discovery	PROPN
gsrj-21	451	3	,	,	PUNCT
gsrj-21	451	4	23(8	23(8	NOUN
gsrj-21	451	5	)	)	PUNCT
gsrj-21	451	6	,	,	PUNCT
gsrj-21	451	7	850	850	NUM
gsrj-21	451	8	-	-	SYM
gsrj-21	451	9	861	861	NUM
gsrj-21	451	10	.	.	PUNCT
gsrj-21	452	1	https://doi.org/10.1177/2472555218773045	https://doi.org/10.1177/2472555218773045	ADJ
gsrj-21	452	2	77	77	NUM
gsrj-21	452	3	.	.	PUNCT
gsrj-21	453	1	amrutkar	amrutkar	NOUN
gsrj-21	453	2	,	,	PUNCT
gsrj-21	453	3	m.	m.	NOUN
gsrj-21	453	4	,	,	PUNCT
gsrj-21	453	5	aasrum	aasrum	NOUN
gsrj-21	453	6	,	,	PUNCT
gsrj-21	453	7	m.	m.	NOUN
gsrj-21	453	8	,	,	PUNCT
gsrj-21	453	9	verbeke	verbeke	ADJ
gsrj-21	453	10	,	,	PUNCT
gsrj-21	453	11	c.	c.	PROPN
gsrj-21	453	12	s.	s.	PROPN
gsrj-21	453	13	,	,	PUNCT
gsrj-21	453	14	&	&	CCONJ
gsrj-21	453	15	gladhaug	gladhaug	PROPN
gsrj-21	453	16	,	,	PUNCT
gsrj-21	453	17	i.	i.	PROPN
gsrj-21	453	18	p.	p.	PROPN
gsrj-21	453	19	(	(	PUNCT
gsrj-21	453	20	2019	2019	NUM
gsrj-21	453	21	)	)	PUNCT
gsrj-21	453	22	.	.	PUNCT
gsrj-21	454	1	secretion	secretion	NOUN
gsrj-21	454	2	of	of	ADP
gsrj-21	454	3	fibronectin	fibronectin	NOUN
gsrj-21	454	4	by	by	ADP
gsrj-21	454	5	human	human	ADJ
gsrj-21	454	6	pancreatic	pancreatic	ADJ
gsrj-21	454	7	stellate	stellate	ADJ
gsrj-21	454	8	cells	cell	NOUN
gsrj-21	454	9	promotes	promote	VERB
gsrj-21	454	10	chemoresistance	chemoresistance	NOUN
gsrj-21	454	11	to	to	PART
gsrj-21	454	12	gemcitabine	gemcitabine	VERB
gsrj-21	454	13	in	in	ADP
gsrj-21	454	14	pancreatic	pancreatic	ADJ
gsrj-21	454	15	cancer	cancer	NOUN
gsrj-21	454	16	cells	cell	NOUN
gsrj-21	454	17	.	.	PUNCT
gsrj-21	455	1	bmc	bmc	ADJ
gsrj-21	455	2	cancer	cancer	NOUN
gsrj-21	455	3	,	,	PUNCT
gsrj-21	455	4	19(1	19(1	NUM
gsrj-21	455	5	)	)	PUNCT
gsrj-21	455	6	,	,	PUNCT
gsrj-21	455	7	596	596	NUM
gsrj-21	455	8	.	.	PUNCT
gsrj-21	456	1	https://doi.org/10.1186/s12885-019-5803-1	https://doi.org/10.1186/s12885-019-5803-1	NUM
gsrj-21	457	1	78	78	NUM
gsrj-21	457	2	.	.	PUNCT
gsrj-21	458	1	amrutkar	amrutkar	NOUN
gsrj-21	458	2	,	,	PUNCT
gsrj-21	458	3	m.	m.	NOUN
gsrj-21	458	4	,	,	PUNCT
gsrj-21	458	5	vethe	vethe	NOUN
gsrj-21	458	6	,	,	PUNCT
gsrj-21	458	7	n.	n.	PROPN
gsrj-21	458	8	t.	t.	PROPN
gsrj-21	458	9	,	,	PUNCT
gsrj-21	458	10	verbeke	verbeke	ADJ
gsrj-21	458	11	,	,	PUNCT
gsrj-21	458	12	c.	c.	PROPN
gsrj-21	458	13	s.	s.	PROPN
gsrj-21	458	14	,	,	PUNCT
gsrj-21	458	15	aasrum	aasrum	PROPN
gsrj-21	458	16	,	,	PUNCT
gsrj-21	458	17	m.	m.	NOUN
gsrj-21	458	18	,	,	PUNCT
gsrj-21	458	19	finstadsveen	finstadsveen	PROPN
gsrj-21	458	20	,	,	PUNCT
gsrj-21	458	21	a.	a.	PROPN
gsrj-21	458	22	v.	v.	PROPN
gsrj-21	458	23	,	,	PUNCT
gsrj-21	458	24	sántha	sántha	NOUN
gsrj-21	458	25	,	,	PUNCT
gsrj-21	458	26	p.	p.	PROPN
gsrj-21	458	27	,	,	PUNCT
gsrj-21	458	28	et	et	PROPN
gsrj-21	458	29	al	al	PROPN
gsrj-21	458	30	.	.	PROPN
gsrj-21	459	1	(	(	PUNCT
gsrj-21	459	2	2020	2020	NUM
gsrj-21	459	3	)	)	PUNCT
gsrj-21	459	4	.	.	PUNCT
gsrj-21	460	1	differential	differential	ADJ
gsrj-21	460	2	gemcitabine	gemcitabine	NOUN
gsrj-21	460	3	sensitivity	sensitivity	NOUN
gsrj-21	460	4	in	in	ADP
gsrj-21	460	5	primary	primary	ADJ
gsrj-21	460	6	human	human	ADJ
gsrj-21	460	7	pancreatic	pancreatic	ADJ
gsrj-21	460	8	cancer	cancer	NOUN
gsrj-21	460	9	cells	cell	NOUN
gsrj-21	460	10	and	and	CCONJ
gsrj-21	460	11	paired	pair	VERB
gsrj-21	460	12	stellate	stellate	ADJ
gsrj-21	460	13	cells	cell	NOUN
gsrj-21	460	14	is	be	AUX
gsrj-21	460	15	driven	drive	VERB
gsrj-21	460	16	by	by	ADP
gsrj-21	460	17	heterogenous	heterogenous	ADJ
gsrj-21	460	18	drug	drug	NOUN
gsrj-21	460	19	uptake	uptake	NOUN
gsrj-21	460	20	and	and	CCONJ
gsrj-21	460	21	processing	processing	NOUN
gsrj-21	460	22	.	.	PUNCT
gsrj-21	461	1	cancers	cancer	NOUN
gsrj-21	461	2	,	,	PUNCT
gsrj-21	461	3	12(12	12(12	NUM
gsrj-21	461	4	)	)	PUNCT
gsrj-21	461	5	https://doi.org/10.3390/cancers12123628	https://doi.org/10.3390/cancers12123628	NOUN
gsrj-21	461	6	79	79	NUM
gsrj-21	461	7	.	.	PUNCT
gsrj-21	462	1	dalin	dalin	PROPN
gsrj-21	462	2	,	,	PUNCT
gsrj-21	462	3	s.	s.	PROPN
gsrj-21	462	4	,	,	PUNCT
gsrj-21	462	5	sullivan	sullivan	PROPN
gsrj-21	462	6	,	,	PUNCT
gsrj-21	462	7	m.	m.	PROPN
gsrj-21	462	8	r.	r.	PROPN
gsrj-21	462	9	,	,	PUNCT
gsrj-21	462	10	lau	lau	PROPN
gsrj-21	462	11	,	,	PUNCT
gsrj-21	462	12	a.	a.	NOUN
gsrj-21	462	13	n.	n.	PROPN
gsrj-21	462	14	,	,	PUNCT
gsrj-21	462	15	graumanboss	graumanboss	PROPN
gsrj-21	462	16	,	,	PUNCT
gsrj-21	462	17	b.	b.	PROPN
gsrj-21	462	18	,	,	PUNCT
gsrj-21	462	19	mueller	mueller	PROPN
gsrj-21	462	20	,	,	PUNCT
gsrj-21	462	21	h.	h.	PROPN
gsrj-21	462	22	s.	s.	PROPN
gsrj-21	462	23	,	,	PUNCT
gsrj-21	462	24	kreidl	kreidl	PROPN
gsrj-21	462	25	,	,	PUNCT
gsrj-21	462	26	e.	e.	PROPN
gsrj-21	462	27	,	,	PUNCT
gsrj-21	462	28	et	et	PROPN
gsrj-21	462	29	al	al	PROPN
gsrj-21	462	30	.	.	PROPN
gsrj-21	462	31	(	(	PUNCT
gsrj-21	462	32	2019	2019	NUM
gsrj-21	462	33	)	)	PUNCT
gsrj-21	462	34	.	.	PUNCT
gsrj-21	463	1	deoxycytidine	deoxycytidine	PROPN
gsrj-21	463	2	release	release	NOUN
gsrj-21	463	3	from	from	ADP
gsrj-21	463	4	pancreatic	pancreatic	ADJ
gsrj-21	463	5	stellate	stellate	ADJ
gsrj-21	463	6	cells	cell	NOUN
gsrj-21	463	7	promotes	promote	VERB
gsrj-21	463	8	gemcitabine	gemcitabine	NOUN
gsrj-21	463	9	resistance	resistance	NOUN
gsrj-21	463	10	.	.	PUNCT
gsrj-21	464	1	cancer	cancer	NOUN
gsrj-21	464	2	research	research	NOUN
gsrj-21	464	3	,	,	PUNCT
gsrj-21	464	4	79(22	79(22	PROPN
gsrj-21	464	5	)	)	PUNCT
gsrj-21	464	6	,	,	PUNCT
gsrj-21	464	7	5723	5723	NUM
gsrj-21	464	8	-	-	SYM
gsrj-21	464	9	5733	5733	NUM
gsrj-21	464	10	.	.	PUNCT
gsrj-21	465	1	https://doi.org/10.1158/00085472.can-19-0960	https://doi.org/10.1158/00085472.can-19-0960	PROPN
gsrj-21	465	2	80	80	NUM
gsrj-21	465	3	.	.	PUNCT
gsrj-21	466	1	hwang	hwang	PROPN
gsrj-21	466	2	,	,	PUNCT
gsrj-21	466	3	h.	h.	PROPN
gsrj-21	466	4	j.	j.	PROPN
gsrj-21	466	5	,	,	PUNCT
gsrj-21	466	6	oh	oh	INTJ
gsrj-21	466	7	,	,	PUNCT
gsrj-21	466	8	m.	m.	NOUN
gsrj-21	466	9	,	,	PUNCT
gsrj-21	466	10	lee	lee	PROPN
gsrj-21	466	11	,	,	PUNCT
gsrj-21	466	12	d.	d.	PROPN
gsrj-21	466	13	w.	w.	PROPN
gsrj-21	466	14	,	,	PUNCT
gsrj-21	466	15	&	&	CCONJ
gsrj-21	466	16	kuh	kuh	PROPN
gsrj-21	466	17	,	,	PUNCT
gsrj-21	466	18	h.	h.	PROPN
gsrj-21	466	19	(	(	PUNCT
gsrj-21	466	20	2019	2019	NUM
gsrj-21	466	21	)	)	PUNCT
gsrj-21	466	22	.	.	PUNCT
gsrj-21	467	1	multiplex	multiplex	PROPN
gsrj-21	467	2	quantitative	quantitative	ADJ
gsrj-21	467	3	analysis	analysis	NOUN
gsrj-21	467	4	of	of	ADP
gsrj-21	467	5	stromamediated	stromamediate	VERB
gsrj-21	467	6	cancer	cancer	NOUN
gsrj-21	467	7	cell	cell	NOUN
gsrj-21	467	8	invasion	invasion	NOUN
gsrj-21	467	9	,	,	PUNCT
gsrj-21	467	10	matrix	matrix	NOUN
gsrj-21	467	11	remodeling	remodeling	NOUN
gsrj-21	467	12	,	,	PUNCT
gsrj-21	467	13	and	and	CCONJ
gsrj-21	467	14	drug	drug	NOUN
gsrj-21	467	15	response	response	NOUN
gsrj-21	467	16	in	in	ADP
gsrj-21	467	17	a	a	DET
gsrj-21	467	18	3d	3d	NUM
gsrj-21	467	19	co	co	ADJ
gsrj-21	467	20	-	-	NOUN
gsrj-21	467	21	culture	culture	ADJ
gsrj-21	467	22	model	model	NOUN
gsrj-21	467	23	of	of	ADP
gsrj-21	467	24	pancreatic	pancreatic	ADJ
gsrj-21	467	25	tumor	tumor	NOUN
gsrj-21	467	26	spheroids	spheroid	NOUN
gsrj-21	467	27	and	and	CCONJ
gsrj-21	467	28	stellate	stellate	ADJ
gsrj-21	467	29	cells	cell	NOUN
gsrj-21	467	30	.	.	PUNCT
gsrj-21	468	1	journal	journal	NOUN
gsrj-21	468	2	of	of	ADP
gsrj-21	468	3	experimental	experimental	PROPN
gsrj-21	468	4	&	&	CCONJ
gsrj-21	468	5	clinical	clinical	ADJ
gsrj-21	468	6	cancer	cancer	NOUN
gsrj-21	468	7	research	research	NOUN
gsrj-21	468	8	:	:	PUNCT
gsrj-21	468	9	cr	cr	PROPN
gsrj-21	468	10	,	,	PUNCT
gsrj-21	468	11	38(1	38(1	PROPN
gsrj-21	468	12	)	)	PUNCT
gsrj-21	468	13	,	,	PUNCT
gsrj-21	468	14	258	258	NUM
gsrj-21	468	15	.	.	PUNCT
gsrj-21	469	1	https://doi.org/10.1186/s13046019-1225-9	https://doi.org/10.1186/s13046019-1225-9	PROPN
gsrj-21	469	2	81	81	NUM
gsrj-21	469	3	.	.	PUNCT
gsrj-21	470	1	ormanns	ormanns	PROPN
gsrj-21	470	2	,	,	PUNCT
gsrj-21	470	3	s.	s.	PROPN
gsrj-21	470	4	,	,	PUNCT
gsrj-21	470	5	haas	haas	PROPN
gsrj-21	470	6	,	,	PUNCT
gsrj-21	470	7	m.	m.	NOUN
gsrj-21	470	8	,	,	PUNCT
gsrj-21	470	9	baechmann	baechmann	PROPN
gsrj-21	470	10	,	,	PUNCT
gsrj-21	470	11	s.	s.	PROPN
gsrj-21	470	12	,	,	PUNCT
gsrj-21	470	13	altendorf	altendorf	PROPN
gsrj-21	470	14	-	-	PUNCT
gsrj-21	470	15	hofmann	hofmann	PROPN
gsrj-21	470	16	,	,	PUNCT
gsrj-21	470	17	a.	a.	PROPN
gsrj-21	470	18	,	,	PUNCT
gsrj-21	470	19	remold	remold	VERB
gsrj-21	470	20	,	,	PUNCT
gsrj-21	470	21	a.	a.	NOUN
gsrj-21	470	22	,	,	PUNCT
gsrj-21	470	23	quietzsch	quietzsch	NOUN
gsrj-21	470	24	,	,	PUNCT
gsrj-21	470	25	d.	d.	PROPN
gsrj-21	470	26	,	,	PUNCT
gsrj-21	470	27	et	et	PROPN
gsrj-21	470	28	al	al	PROPN
gsrj-21	470	29	.	.	PUNCT
gsrj-21	471	1	(	(	PUNCT
gsrj-21	471	2	2016	2016	NUM
gsrj-21	471	3	)	)	PUNCT
gsrj-21	471	4	.	.	PUNCT
gsrj-21	472	1	impact	impact	NOUN
gsrj-21	472	2	of	of	ADP
gsrj-21	472	3	sparc	sparc	NOUN
gsrj-21	472	4	expression	expression	NOUN
gsrj-21	472	5	on	on	ADP
gsrj-21	472	6	outcome	outcome	NOUN
gsrj-21	472	7	in	in	ADP
gsrj-21	472	8	patients	patient	NOUN
gsrj-21	472	9	with	with	ADP
gsrj-21	472	10	advanced	advanced	ADJ
gsrj-21	472	11	pancreatic	pancreatic	ADJ
gsrj-21	472	12	cancer	cancer	NOUN
gsrj-21	472	13	not	not	PART
gsrj-21	472	14	receiving	receive	VERB
gsrj-21	472	15	nab	nab	NOUN
gsrj-21	472	16	-	-	PUNCT
gsrj-21	472	17	paclitaxel	paclitaxel	ADJ
gsrj-21	472	18	:	:	PUNCT
gsrj-21	472	19	a	a	DET
gsrj-21	472	20	pooled	pool	VERB
gsrj-21	472	21	analysis	analysis	NOUN
gsrj-21	472	22	from	from	ADP
gsrj-21	472	23	prospective	prospective	ADJ
gsrj-21	472	24	clinical	clinical	ADJ
gsrj-21	472	25	and	and	CCONJ
gsrj-21	472	26	translational	translational	ADJ
gsrj-21	472	27	trials	trial	NOUN
gsrj-21	472	28	.	.	PUNCT
gsrj-21	473	1	british	british	ADJ
gsrj-21	473	2	journal	journal	PROPN
gsrj-21	473	3	of	of	ADP
gsrj-21	473	4	cancer	cancer	NOUN
gsrj-21	473	5	,	,	PUNCT
gsrj-21	473	6	115(12	115(12	NUM
gsrj-21	473	7	)	)	PUNCT
gsrj-21	473	8	,	,	PUNCT
gsrj-21	473	9	15201529	15201529	NUM
gsrj-21	473	10	.	.	PUNCT
gsrj-21	474	1	https://doi.org/10.1038/bjc.2016.355	https://doi.org/10.1038/bjc.2016.355	PROPN
gsrj-21	474	2	82	82	NUM
gsrj-21	474	3	.	.	PUNCT
gsrj-21	475	1	xiao	xiao	PROPN
gsrj-21	475	2	,	,	PUNCT
gsrj-21	475	3	y.	y.	PROPN
gsrj-21	475	4	,	,	PUNCT
gsrj-21	475	5	zhang	zhang	PROPN
gsrj-21	475	6	,	,	PUNCT
gsrj-21	475	7	h.	h.	PROPN
gsrj-21	475	8	,	,	PUNCT
gsrj-21	475	9	ma	ma	PROPN
gsrj-21	475	10	,	,	PUNCT
gsrj-21	475	11	q.	q.	PROPN
gsrj-21	475	12	,	,	PUNCT
gsrj-21	475	13	huang	huang	PROPN
gsrj-21	475	14	,	,	PUNCT
gsrj-21	475	15	r.	r.	PROPN
gsrj-21	475	16	,	,	PUNCT
gsrj-21	475	17	lu	lu	PROPN
gsrj-21	475	18	,	,	PUNCT
gsrj-21	475	19	j.	j.	PROPN
gsrj-21	475	20	,	,	PUNCT
gsrj-21	475	21	liang	liang	PROPN
gsrj-21	475	22	,	,	PUNCT
gsrj-21	475	23	x.	x.	PROPN
gsrj-21	475	24	,	,	PUNCT
gsrj-21	475	25	et	et	PROPN
gsrj-21	475	26	al	al	PROPN
gsrj-21	475	27	.	.	PROPN
gsrj-21	475	28	(	(	PUNCT
gsrj-21	475	29	2019	2019	NUM
gsrj-21	475	30	)	)	PUNCT
gsrj-21	475	31	.	.	PUNCT
gsrj-21	476	1	yap1	yap1	NOUN
gsrj-21	476	2	-	-	PUNCT
gsrj-21	476	3	mediated	mediate	VERB
gsrj-21	476	4	pancreatic	pancreatic	ADJ
gsrj-21	476	5	stellate	stellate	ADJ
gsrj-21	476	6	cell	cell	NOUN
gsrj-21	476	7	activation	activation	NOUN
gsrj-21	476	8	inhibits	inhibit	VERB
gsrj-21	476	9	pancreatic	pancreatic	ADJ
gsrj-21	476	10	cancer	cancer	NOUN
gsrj-21	476	11	cell	cell	NOUN
gsrj-21	476	12	proliferation	proliferation	NOUN
gsrj-21	476	13	.	.	PUNCT
gsrj-21	477	1	cancer	cancer	NOUN
gsrj-21	477	2	letters	letter	NOUN
gsrj-21	477	3	,	,	PUNCT
gsrj-21	477	4	462	462	NUM
gsrj-21	477	5	,	,	PUNCT
gsrj-21	477	6	51	51	NUM
gsrj-21	477	7	-	-	SYM
gsrj-21	477	8	60	60	NUM
gsrj-21	477	9	.	.	PUNCT
gsrj-21	478	1	https://doi.org/10.1016/j.canlet.2019.07.015	https://doi.org/10.1016/j.canlet.2019.07.015	NOUN
gsrj-21	478	2	60	60	NUM
gsrj-21	478	3	georgetown	georgetown	PROPN
gsrj-21	478	4	scientific	scientific	ADJ
gsrj-21	478	5	research	research	NOUN
gsrj-21	478	6	journal	journal	NOUN
gsrj-21	478	7	83	83	NUM
gsrj-21	478	8	.	.	PUNCT
gsrj-21	479	1	kettunen	kettunen	PROPN
gsrj-21	479	2	,	,	PUNCT
gsrj-21	479	3	k.	k.	PROPN
gsrj-21	479	4	,	,	PUNCT
gsrj-21	479	5	boström	boström	ADV
gsrj-21	479	6	,	,	PUNCT
gsrj-21	479	7	p.	p.	PROPN
gsrj-21	479	8	j.	j.	PROPN
gsrj-21	479	9	,	,	PUNCT
gsrj-21	479	10	lamminen	lamminen	PROPN
gsrj-21	479	11	,	,	PUNCT
gsrj-21	479	12	t.	t.	PROPN
gsrj-21	479	13	,	,	PUNCT
gsrj-21	479	14	heinosalo	heinosalo	PROPN
gsrj-21	479	15	,	,	PUNCT
gsrj-21	479	16	t.	t.	PROPN
gsrj-21	479	17	,	,	PUNCT
gsrj-21	479	18	west	west	PROPN
gsrj-21	479	19	,	,	PUNCT
gsrj-21	479	20	g.	g.	PROPN
gsrj-21	479	21	,	,	PUNCT
gsrj-21	479	22	saarinen	saarinen	PROPN
gsrj-21	479	23	,	,	PUNCT
gsrj-21	479	24	i.	i.	PROPN
gsrj-21	479	25	,	,	PUNCT
gsrj-21	479	26	et	et	PROPN
gsrj-21	479	27	al	al	PROPN
gsrj-21	479	28	.	.	PROPN
gsrj-21	479	29	(	(	PUNCT
gsrj-21	479	30	2019	2019	NUM
gsrj-21	479	31	)	)	PUNCT
gsrj-21	479	32	.	.	PUNCT
gsrj-21	480	1	personalized	personalize	VERB
gsrj-21	480	2	drug	drug	NOUN
gsrj-21	480	3	sensitivity	sensitivity	NOUN
gsrj-21	480	4	screening	screen	VERB
gsrj-21	480	5	for	for	ADP
gsrj-21	480	6	bladder	bladder	NOUN
gsrj-21	480	7	cancer	cancer	NOUN
gsrj-21	480	8	using	use	VERB
gsrj-21	480	9	conditionally	conditionally	ADV
gsrj-21	480	10	reprogrammed	reprogramme	VERB
gsrj-21	480	11	patientderived	patientderive	VERB
gsrj-21	480	12	cells	cell	NOUN
gsrj-21	480	13	.	.	PUNCT
gsrj-21	481	1	european	european	ADJ
gsrj-21	481	2	urology	urology	NOUN
gsrj-21	481	3	,	,	PUNCT
gsrj-21	481	4	76(4	76(4	NUM
gsrj-21	481	5	)	)	PUNCT
gsrj-21	481	6	,	,	PUNCT
gsrj-21	481	7	430	430	NUM
gsrj-21	481	8	-	-	SYM
gsrj-21	481	9	434	434	NUM
gsrj-21	481	10	.	.	PUNCT
gsrj-21	482	1	https://doi.org/10.1016/j.eururo.2019.06.016	https://doi.org/10.1016/j.eururo.2019.06.016	NOUN
gsrj-21	482	2	84	84	NUM
gsrj-21	482	3	.	.	PUNCT
gsrj-21	483	1	svirshchevskaya	svirshchevskaya	PROPN
gsrj-21	483	2	,	,	PUNCT
gsrj-21	483	3	e.	e.	PROPN
gsrj-21	483	4	,	,	PUNCT
gsrj-21	483	5	doronina	doronina	PROPN
gsrj-21	483	6	,	,	PUNCT
gsrj-21	483	7	e.	e.	PROPN
gsrj-21	483	8	,	,	PUNCT
gsrj-21	483	9	grechikhina	grechikhina	PROPN
gsrj-21	483	10	,	,	PUNCT
gsrj-21	483	11	m.	m.	NOUN
gsrj-21	483	12	,	,	PUNCT
gsrj-21	483	13	matushevskaya	matushevskaya	PROPN
gsrj-21	483	14	,	,	PUNCT
gsrj-21	483	15	e.	e.	PROPN
gsrj-21	483	16	,	,	PUNCT
gsrj-21	483	17	kotsareva	kotsareva	PROPN
gsrj-21	483	18	,	,	PUNCT
gsrj-21	483	19	o.	o.	PROPN
gsrj-21	483	20	,	,	PUNCT
gsrj-21	483	21	fattakhova	fattakhova	PROPN
gsrj-21	483	22	,	,	PUNCT
gsrj-21	483	23	g.	g.	PROPN
gsrj-21	483	24	,	,	PUNCT
gsrj-21	483	25	et	et	PROPN
gsrj-21	483	26	al	al	PROPN
gsrj-21	483	27	.	.	PROPN
gsrj-21	483	28	(	(	PUNCT
gsrj-21	483	29	2019	2019	NUM
gsrj-21	483	30	)	)	PUNCT
gsrj-21	483	31	.	.	PUNCT
gsrj-21	484	1	characteristics	characteristic	NOUN
gsrj-21	484	2	of	of	ADP
gsrj-21	484	3	multicellular	multicellular	ADJ
gsrj-21	484	4	tumor	tumor	NOUN
gsrj-21	484	5	spheroids	spheroid	NOUN
gsrj-21	484	6	formed	form	VERB
gsrj-21	484	7	by	by	ADP
gsrj-21	484	8	pancreatic	pancreatic	ADJ
gsrj-21	484	9	cells	cell	NOUN
gsrj-21	484	10	expressing	express	VERB
gsrj-21	484	11	different	different	ADJ
gsrj-21	484	12	adhesion	adhesion	NOUN
gsrj-21	484	13	molecules	molecule	NOUN
gsrj-21	484	14	.	.	PUNCT
gsrj-21	485	1	life	life	NOUN
gsrj-21	485	2	sciences	science	NOUN
gsrj-21	485	3	(	(	PUNCT
gsrj-21	485	4	1973	1973	NUM
gsrj-21	485	5	)	)	PUNCT
gsrj-21	485	6	,	,	PUNCT
gsrj-21	485	7	219	219	NUM
gsrj-21	485	8	,	,	PUNCT
gsrj-21	485	9	343	343	NUM
gsrj-21	485	10	-	-	SYM
gsrj-21	485	11	352	352	NUM
gsrj-21	485	12	.	.	PUNCT
gsrj-21	486	1	https://doi.org/10.1016/j.lfs.2019.01.034	https://doi.org/10.1016/j.lfs.2019.01.034	VERB
gsrj-21	486	2	85	85	NUM
gsrj-21	486	3	.	.	PUNCT
gsrj-21	487	1	frappart	frappart	NOUN
gsrj-21	487	2	,	,	PUNCT
gsrj-21	487	3	p.	p.	NOUN
gsrj-21	487	4	,	,	PUNCT
gsrj-21	487	5	&	&	CCONJ
gsrj-21	487	6	hofmann	hofmann	PROPN
gsrj-21	487	7	,	,	PUNCT
gsrj-21	487	8	t.	t.	PROPN
gsrj-21	487	9	g.	g.	PROPN
gsrj-21	487	10	(	(	PUNCT
gsrj-21	487	11	2020	2020	NUM
gsrj-21	487	12	)	)	PUNCT
gsrj-21	487	13	.	.	PUNCT
gsrj-21	488	1	pancreatic	pancreatic	ADJ
gsrj-21	488	2	ductal	ductal	ADJ
gsrj-21	488	3	adenocarcinoma	adenocarcinoma	NOUN
gsrj-21	488	4	(	(	PUNCT
gsrj-21	488	5	pdac	pdac	NOUN
gsrj-21	488	6	)	)	PUNCT
gsrj-21	488	7	organoids	organoid	NOUN
gsrj-21	488	8	:	:	PUNCT
gsrj-21	488	9	the	the	DET
gsrj-21	488	10	shining	shine	VERB
gsrj-21	488	11	light	light	NOUN
gsrj-21	488	12	at	at	ADP
gsrj-21	488	13	the	the	DET
gsrj-21	488	14	end	end	NOUN
gsrj-21	488	15	of	of	ADP
gsrj-21	488	16	the	the	DET
gsrj-21	488	17	tunnel	tunnel	NOUN
gsrj-21	488	18	for	for	ADP
gsrj-21	488	19	drug	drug	NOUN
gsrj-21	488	20	response	response	NOUN
gsrj-21	488	21	prediction	prediction	NOUN
gsrj-21	488	22	and	and	CCONJ
gsrj-21	488	23	personalized	personalized	ADJ
gsrj-21	488	24	medicine	medicine	NOUN
gsrj-21	488	25	.	.	PUNCT
gsrj-21	489	1	cancers	cancer	NOUN
gsrj-21	489	2	,	,	PUNCT
gsrj-21	489	3	12(10	12(10	NUM
gsrj-21	489	4	)	)	PUNCT
gsrj-21	489	5	https://doi.org/10.3390/cancers12102750	https://doi.org/10.3390/cancers12102750	NOUN
gsrj-21	489	6	86	86	NUM
gsrj-21	489	7	.	.	PUNCT
gsrj-21	490	1	lee	lee	PROPN
gsrj-21	490	2	,	,	PUNCT
gsrj-21	490	3	j.	j.	PROPN
gsrj-21	490	4	,	,	PUNCT
gsrj-21	490	5	kim	kim	PROPN
gsrj-21	490	6	,	,	PUNCT
gsrj-21	490	7	s.	s.	PROPN
gsrj-21	490	8	,	,	PUNCT
gsrj-21	490	9	khawar	khawar	PROPN
gsrj-21	490	10	,	,	PUNCT
gsrj-21	490	11	i.	i.	PROPN
gsrj-21	490	12	a.	a.	PROPN
gsrj-21	490	13	,	,	PUNCT
gsrj-21	490	14	jeong	jeong	PROPN
gsrj-21	490	15	,	,	PUNCT
gsrj-21	490	16	s.	s.	PROPN
gsrj-21	490	17	,	,	PUNCT
gsrj-21	490	18	chung	chung	PROPN
gsrj-21	490	19	,	,	PUNCT
gsrj-21	490	20	s.	s.	PROPN
gsrj-21	490	21	,	,	PUNCT
gsrj-21	490	22	&	&	CCONJ
gsrj-21	490	23	kuh	kuh	PROPN
gsrj-21	490	24	,	,	PUNCT
gsrj-21	490	25	h.	h.	PROPN
gsrj-21	490	26	(	(	PUNCT
gsrj-21	490	27	2018	2018	NUM
gsrj-21	490	28	)	)	PUNCT
gsrj-21	490	29	.	.	PUNCT
gsrj-21	491	1	microfluidic	microfluidic	ADJ
gsrj-21	491	2	co	co	NOUN
gsrj-21	491	3	-	-	NOUN
gsrj-21	491	4	culture	culture	NOUN
gsrj-21	491	5	of	of	ADP
gsrj-21	491	6	pancreatic	pancreatic	ADJ
gsrj-21	491	7	tumor	tumor	NOUN
gsrj-21	491	8	spheroids	spheroid	NOUN
gsrj-21	491	9	with	with	ADP
gsrj-21	491	10	stellate	stellate	ADJ
gsrj-21	491	11	cells	cell	NOUN
gsrj-21	491	12	as	as	ADP
gsrj-21	491	13	a	a	DET
gsrj-21	491	14	novel	novel	ADJ
gsrj-21	491	15	3d	3d	NUM
gsrj-21	491	16	model	model	NOUN
gsrj-21	491	17	for	for	ADP
gsrj-21	491	18	investigation	investigation	NOUN
gsrj-21	491	19	of	of	ADP
gsrj-21	491	20	stromamediated	stromamediate	VERB
gsrj-21	491	21	cell	cell	NOUN
gsrj-21	491	22	motility	motility	NOUN
gsrj-21	491	23	and	and	CCONJ
gsrj-21	491	24	drug	drug	NOUN
gsrj-21	491	25	resistance	resistance	NOUN
gsrj-21	491	26	.	.	PUNCT
gsrj-21	492	1	journal	journal	PROPN
gsrj-21	492	2	of	of	ADP
gsrj-21	492	3	experimental	experimental	PROPN
gsrj-21	492	4	&	&	CCONJ
gsrj-21	492	5	clinical	clinical	ADJ
gsrj-21	492	6	cancer	cancer	NOUN
gsrj-21	492	7	research	research	NOUN
gsrj-21	492	8	:	:	PUNCT
gsrj-21	492	9	cr	cr	X
gsrj-21	492	10	,	,	PUNCT
gsrj-21	492	11	37	37	NUM
gsrj-21	492	12	https://doi.org/10.1186/s13046-017-0654-6	https://doi.org/10.1186/s13046-017-0654-6	NUM
gsrj-21	492	13	87	87	NUM
gsrj-21	492	14	.	.	PUNCT
gsrj-21	493	1	tiriac	tiriac	PROPN
gsrj-21	493	2	,	,	PUNCT
gsrj-21	493	3	h.	h.	PROPN
gsrj-21	493	4	,	,	PUNCT
gsrj-21	493	5	belleau	belleau	PROPN
gsrj-21	493	6	,	,	PUNCT
gsrj-21	493	7	p.	p.	PROPN
gsrj-21	493	8	,	,	PUNCT
gsrj-21	493	9	engle	engle	PROPN
gsrj-21	493	10	,	,	PUNCT
gsrj-21	493	11	d.	d.	PROPN
gsrj-21	493	12	d.	d.	PROPN
gsrj-21	493	13	,	,	PUNCT
gsrj-21	493	14	plenker	plenker	PROPN
gsrj-21	493	15	,	,	PUNCT
gsrj-21	493	16	d.	d.	PROPN
gsrj-21	493	17	,	,	PUNCT
gsrj-21	493	18	deschênes	deschêne	NOUN
gsrj-21	493	19	,	,	PUNCT
gsrj-21	493	20	a.	a.	PROPN
gsrj-21	493	21	,	,	PUNCT
gsrj-21	493	22	somerville	somerville	PROPN
gsrj-21	493	23	,	,	PUNCT
gsrj-21	493	24	t.	t.	PROPN
gsrj-21	493	25	d.	d.	PROPN
gsrj-21	493	26	d.	d.	PROPN
gsrj-21	493	27	,	,	PUNCT
gsrj-21	493	28	et	et	PROPN
gsrj-21	493	29	al	al	PROPN
gsrj-21	493	30	.	.	PUNCT
gsrj-21	493	31	(	(	PUNCT
gsrj-21	493	32	2018	2018	NUM
gsrj-21	493	33	)	)	PUNCT
gsrj-21	493	34	.	.	PUNCT
gsrj-21	494	1	organoid	organoid	PROPN
gsrj-21	494	2	profiling	profiling	NOUN
gsrj-21	494	3	identifies	identify	VERB
gsrj-21	494	4	common	common	ADJ
gsrj-21	494	5	responders	responder	NOUN
gsrj-21	494	6	to	to	PART
gsrj-21	494	7	chemotherapy	chemotherapy	VERB
gsrj-21	494	8	in	in	ADP
gsrj-21	494	9	pancreatic	pancreatic	ADJ
gsrj-21	494	10	cancer	cancer	NOUN
gsrj-21	494	11	.	.	PUNCT
gsrj-21	495	1	cancer	cancer	NOUN
gsrj-21	495	2	discovery	discovery	PROPN
gsrj-21	495	3	,	,	PUNCT
gsrj-21	495	4	8(9	8(9	NUM
gsrj-21	495	5	)	)	PUNCT
gsrj-21	495	6	,	,	PUNCT
gsrj-21	495	7	1112	1112	NUM
gsrj-21	495	8	-	-	SYM
gsrj-21	495	9	1129	1129	NUM
gsrj-21	495	10	.	.	PUNCT
gsrj-21	496	1	https://doi.org/10.1158/2159-8290.cd-18-0349	https://doi.org/10.1158/2159-8290.cd-18-0349	PROPN
gsrj-21	496	2	88	88	NUM
gsrj-21	496	3	.	.	PUNCT
gsrj-21	497	1	wang	wang	PROPN
gsrj-21	497	2	,	,	PUNCT
gsrj-21	497	3	b.	b.	PROPN
gsrj-21	497	4	,	,	PUNCT
gsrj-21	497	5	shen	shen	PROPN
gsrj-21	497	6	,	,	PUNCT
gsrj-21	497	7	c.	c.	PROPN
gsrj-21	497	8	,	,	PUNCT
gsrj-21	497	9	li	li	PROPN
gsrj-21	497	10	,	,	PUNCT
gsrj-21	497	11	y.	y.	PROPN
gsrj-21	497	12	,	,	PUNCT
gsrj-21	497	13	zhang	zhang	PROPN
gsrj-21	497	14	,	,	PUNCT
gsrj-21	497	15	t.	t.	PROPN
gsrj-21	497	16	,	,	PUNCT
gsrj-21	497	17	huang	huang	PROPN
gsrj-21	497	18	,	,	PUNCT
gsrj-21	497	19	h.	h.	PROPN
gsrj-21	497	20	,	,	PUNCT
gsrj-21	497	21	ren	ren	PROPN
gsrj-21	497	22	,	,	PUNCT
gsrj-21	497	23	j.	j.	PROPN
gsrj-21	497	24	,	,	PUNCT
gsrj-21	497	25	et	et	PROPN
gsrj-21	497	26	al	al	PROPN
gsrj-21	497	27	.	.	PROPN
gsrj-21	497	28	(	(	PUNCT
gsrj-21	497	29	2019	2019	NUM
gsrj-21	497	30	)	)	PUNCT
gsrj-21	497	31	.	.	PUNCT
gsrj-21	498	1	oridonin	oridonin	PROPN
gsrj-21	498	2	overcomes	overcome	VERB
gsrj-21	498	3	the	the	DET
gsrj-21	498	4	gemcitabine	gemcitabine	NOUN
gsrj-21	498	5	resistant	resistant	ADJ
gsrj-21	498	6	panc-1	panc-1	NOUN
gsrj-21	498	7	/	/	SYM
gsrj-21	498	8	gem	gem	NOUN
gsrj-21	498	9	cells	cell	NOUN
gsrj-21	498	10	by	by	ADP
gsrj-21	498	11	regulating	regulate	VERB
gsrj-21	498	12	gst	gst	PROPN
gsrj-21	498	13	pi	pi	NOUN
gsrj-21	498	14	and	and	CCONJ
gsrj-21	498	15	lrp/1	lrp/1	PROPN
gsrj-21	498	16	erk	erk	PROPN
gsrj-21	498	17	/	/	SYM
gsrj-21	498	18	jnk	jnk	PROPN
gsrj-21	498	19	signalling	signal	VERB
gsrj-21	498	20	.	.	PUNCT
gsrj-21	499	1	oncotargets	oncotarget	NOUN
gsrj-21	499	2	and	and	CCONJ
gsrj-21	499	3	therapy	therapy	NOUN
gsrj-21	499	4	,	,	PUNCT
gsrj-21	499	5	12	12	NUM
gsrj-21	499	6	,	,	PUNCT
gsrj-21	499	7	57515765	57515765	NUM
gsrj-21	499	8	.	.	PUNCT
gsrj-21	499	9	https://doi.org/10.2147/ott.s208924	https://doi.org/10.2147/ott.s208924	X
gsrj-21	499	10	89	89	NUM
gsrj-21	499	11	.	.	PUNCT
gsrj-21	500	1	wei	wei	PROPN
gsrj-21	500	2	,	,	PUNCT
gsrj-21	500	3	l.	l.	PROPN
gsrj-21	500	4	,	,	PUNCT
gsrj-21	500	5	ye	ye	PROPN
gsrj-21	500	6	,	,	PUNCT
gsrj-21	500	7	h.	h.	PROPN
gsrj-21	500	8	,	,	PUNCT
gsrj-21	500	9	li	li	PROPN
gsrj-21	500	10	,	,	PUNCT
gsrj-21	500	11	g.	g.	PROPN
gsrj-21	500	12	,	,	PUNCT
gsrj-21	500	13	lu	lu	PROPN
gsrj-21	500	14	,	,	PUNCT
gsrj-21	500	15	y.	y.	PROPN
gsrj-21	500	16	,	,	PUNCT
gsrj-21	500	17	zhou	zhou	PROPN
gsrj-21	500	18	,	,	PUNCT
gsrj-21	500	19	q.	q.	PROPN
gsrj-21	500	20	,	,	PUNCT
gsrj-21	500	21	zheng	zheng	PROPN
gsrj-21	500	22	,	,	PUNCT
gsrj-21	500	23	s.	s.	PROPN
gsrj-21	500	24	,	,	PUNCT
gsrj-21	500	25	et	et	PROPN
gsrj-21	500	26	al	al	PROPN
gsrj-21	500	27	.	.	PUNCT
gsrj-21	500	28	(	(	PUNCT
gsrj-21	500	29	2018	2018	NUM
gsrj-21	500	30	)	)	PUNCT
gsrj-21	500	31	.	.	PUNCT
gsrj-21	501	1	cancer	cancer	NOUN
gsrj-21	501	2	-	-	PUNCT
gsrj-21	501	3	associated	associate	VERB
gsrj-21	501	4	fibroblasts	fibroblast	NOUN
gsrj-21	501	5	promote	promote	VERB
gsrj-21	501	6	progression	progression	NOUN
gsrj-21	501	7	and	and	CCONJ
gsrj-21	501	8	gemcitabine	gemcitabine	NOUN
gsrj-21	501	9	resistance	resistance	NOUN
gsrj-21	501	10	via	via	ADP
gsrj-21	501	11	the	the	DET
gsrj-21	501	12	sdf1	sdf1	PROPN
gsrj-21	501	13	/	/	SYM
gsrj-21	501	14	satb-1	satb-1	NUM
gsrj-21	501	15	pathway	pathway	NOUN
gsrj-21	501	16	in	in	ADP
gsrj-21	501	17	pancreatic	pancreatic	ADJ
gsrj-21	501	18	cancer	cancer	NOUN
gsrj-21	501	19	springer	springer	NOUN
gsrj-21	501	20	science	science	NOUN
gsrj-21	501	21	and	and	CCONJ
gsrj-21	501	22	business	business	NOUN
gsrj-21	501	23	media	medium	NOUN
gsrj-21	501	24	llc	llc	PROPN
gsrj-21	501	25	.	.	PUNCT
gsrj-21	502	1	https://doi.org/10.1038/s41419-018-1104-x	https://doi.org/10.1038/s41419-018-1104-x	PROPN
gsrj-21	502	2	90	90	NUM
gsrj-21	502	3	.	.	PUNCT
gsrj-21	503	1	guo	guo	PROPN
gsrj-21	503	2	,	,	PUNCT
gsrj-21	503	3	l.	l.	PROPN
gsrj-21	503	4	,	,	PUNCT
gsrj-21	503	5	zheng	zheng	PROPN
gsrj-21	503	6	,	,	PUNCT
gsrj-21	503	7	j.	j.	PROPN
gsrj-21	503	8	,	,	PUNCT
gsrj-21	503	9	yu	yu	PROPN
gsrj-21	503	10	,	,	PUNCT
gsrj-21	503	11	t.	t.	PROPN
gsrj-21	503	12	,	,	PUNCT
gsrj-21	503	13	liu	liu	PROPN
gsrj-21	503	14	,	,	PUNCT
gsrj-21	503	15	y.	y.	PROPN
gsrj-21	503	16	,	,	PUNCT
gsrj-21	503	17	&	&	CCONJ
gsrj-21	503	18	duo	duo	NOUN
gsrj-21	503	19	,	,	PUNCT
gsrj-21	503	20	l.	l.	PROPN
gsrj-21	503	21	(	(	PUNCT
gsrj-21	503	22	2017	2017	NUM
gsrj-21	503	23	)	)	PUNCT
gsrj-21	503	24	.	.	PUNCT
gsrj-21	504	1	elevated	elevated	ADJ
gsrj-21	504	2	expression	expression	NOUN
gsrj-21	504	3	of	of	ADP
gsrj-21	504	4	satb1	satb1	PROPN
gsrj-21	504	5	is	be	AUX
gsrj-21	504	6	involved	involve	VERB
gsrj-21	504	7	in	in	ADP
gsrj-21	504	8	pancreatic	pancreatic	ADJ
gsrj-21	504	9	tumorigenesis	tumorigenesis	NOUN
gsrj-21	504	10	and	and	CCONJ
gsrj-21	504	11	is	be	AUX
gsrj-21	504	12	associated	associate	VERB
gsrj-21	504	13	with	with	ADP
gsrj-21	504	14	poor	poor	ADJ
gsrj-21	504	15	patient	patient	ADJ
gsrj-21	504	16	survival	survival	NOUN
gsrj-21	504	17	.	.	PUNCT
gsrj-21	505	1	molecular	molecular	ADJ
gsrj-21	505	2	medicine	medicine	NOUN
gsrj-21	505	3	reports	report	NOUN
gsrj-21	505	4	,	,	PUNCT
gsrj-21	505	5	16(6	16(6	NUM
gsrj-21	505	6	)	)	PUNCT
gsrj-21	505	7	,	,	PUNCT
gsrj-21	505	8	8842	8842	NUM
gsrj-21	505	9	-	-	SYM
gsrj-21	505	10	8848	8848	NUM
gsrj-21	505	11	.	.	PUNCT
gsrj-21	506	1	https://doi.org/10.3892/mmr.2017.7683	https://doi.org/10.3892/mmr.2017.7683	PROPN
gsrj-21	506	2	91	91	NUM
gsrj-21	506	3	.	.	PUNCT
gsrj-21	507	1	chen	chen	PROPN
gsrj-21	507	2	,	,	PUNCT
gsrj-21	507	3	z.	z.	PROPN
gsrj-21	507	4	,	,	PUNCT
gsrj-21	507	5	li	li	PROPN
gsrj-21	507	6	,	,	PUNCT
gsrj-21	507	7	z.	z.	PROPN
gsrj-21	507	8	,	,	PUNCT
gsrj-21	507	9	li	li	PROPN
gsrj-21	507	10	,	,	PUNCT
gsrj-21	507	11	w.	w.	PROPN
gsrj-21	507	12	,	,	PUNCT
gsrj-21	507	13	zong	zong	PROPN
gsrj-21	507	14	,	,	PUNCT
gsrj-21	507	15	y.	y.	PROPN
gsrj-21	507	16	,	,	PUNCT
gsrj-21	507	17	zhu	zhu	PROPN
gsrj-21	507	18	,	,	PUNCT
gsrj-21	507	19	y.	y.	PROPN
gsrj-21	507	20	,	,	PUNCT
gsrj-21	507	21	miao	miao	NOUN
gsrj-21	507	22	,	,	PUNCT
gsrj-21	507	23	y.	y.	PROPN
gsrj-21	507	24	,	,	PUNCT
gsrj-21	507	25	et	et	PROPN
gsrj-21	507	26	al	al	PROPN
gsrj-21	507	27	.	.	PUNCT
gsrj-21	507	28	(	(	PUNCT
gsrj-21	507	29	2015	2015	NUM
gsrj-21	507	30	)	)	PUNCT
gsrj-21	507	31	.	.	PUNCT
gsrj-21	508	1	satb1	satb1	PROPN
gsrj-21	508	2	promotes	promote	VERB
gsrj-21	508	3	pancreatic	pancreatic	ADJ
gsrj-21	508	4	cancer	cancer	NOUN
gsrj-21	508	5	growth	growth	NOUN
gsrj-21	508	6	and	and	CCONJ
gsrj-21	508	7	invasion	invasion	NOUN
gsrj-21	508	8	depending	depend	VERB
gsrj-21	508	9	on	on	ADP
gsrj-21	508	10	myc	myc	NOUN
gsrj-21	508	11	activation	activation	NOUN
gsrj-21	508	12	springer	springer	NOUN
gsrj-21	508	13	science	science	NOUN
gsrj-21	508	14	and	and	CCONJ
gsrj-21	508	15	business	business	NOUN
gsrj-21	508	16	media	medium	NOUN
gsrj-21	508	17	llc	llc	PROPN
gsrj-21	508	18	.	.	PUNCT
gsrj-21	509	1	https://doi.org/10.1007/s10620-015-3759-9	https://doi.org/10.1007/s10620-015-3759-9	NUM
gsrj-21	509	2	92	92	NUM
gsrj-21	509	3	.	.	PUNCT
gsrj-21	510	1	dandawate	dandawate	PROPN
gsrj-21	510	2	,	,	PUNCT
gsrj-21	510	3	p.	p.	PROPN
gsrj-21	510	4	,	,	PUNCT
gsrj-21	510	5	kaushik	kaushik	PROPN
gsrj-21	510	6	,	,	PUNCT
gsrj-21	510	7	g.	g.	PROPN
gsrj-21	510	8	,	,	PUNCT
gsrj-21	510	9	ghosh	ghosh	PROPN
gsrj-21	510	10	,	,	PUNCT
gsrj-21	510	11	c.	c.	PROPN
gsrj-21	510	12	,	,	PUNCT
gsrj-21	510	13	standing	standing	NOUN
gsrj-21	510	14	,	,	PUNCT
gsrj-21	510	15	d.	d.	PROPN
gsrj-21	510	16	,	,	PUNCT
gsrj-21	510	17	ali	ali	PROPN
gsrj-21	510	18	sayed	sayed	PROPN
gsrj-21	510	19	,	,	PUNCT
gsrj-21	510	20	a.	a.	NOUN
gsrj-21	510	21	a.	a.	PROPN
gsrj-21	510	22	,	,	PUNCT
gsrj-21	510	23	choudhury	choudhury	PROPN
gsrj-21	510	24	,	,	PUNCT
gsrj-21	510	25	s.	s.	PROPN
gsrj-21	510	26	,	,	PUNCT
gsrj-21	510	27	et	et	PROPN
gsrj-21	510	28	al	al	PROPN
gsrj-21	510	29	.	.	PROPN
gsrj-21	511	1	(	(	PUNCT
gsrj-21	511	2	2020	2020	NUM
gsrj-21	511	3	)	)	PUNCT
gsrj-21	511	4	.	.	PUNCT
gsrj-21	512	1	diphenylbutylpiperidine	diphenylbutylpiperidine	PROPN
gsrj-21	512	2	antipsychotic	antipsychotic	ADJ
gsrj-21	512	3	drugs	drug	NOUN
gsrj-21	512	4	inhibit	inhibit	VERB
gsrj-21	512	5	prolactin	prolactin	ADJ
gsrj-21	512	6	receptor	receptor	NOUN
gsrj-21	512	7	signaling	signal	VERB
gsrj-21	512	8	to	to	PART
gsrj-21	512	9	reduce	reduce	VERB
gsrj-21	512	10	growth	growth	NOUN
gsrj-21	512	11	of	of	ADP
gsrj-21	512	12	pancreatic	pancreatic	ADJ
gsrj-21	512	13	ductal	ductal	ADJ
gsrj-21	512	14	adenocarcinoma	adenocarcinoma	NOUN
gsrj-21	512	15	in	in	ADP
gsrj-21	512	16	mice	mouse	NOUN
gsrj-21	512	17	.	.	PUNCT
gsrj-21	513	1	gastroenterology	gastroenterology	NOUN
gsrj-21	513	2	,	,	PUNCT
gsrj-21	513	3	158(5	158(5	NUM
gsrj-21	513	4	)	)	PUNCT
gsrj-21	513	5	,	,	PUNCT
gsrj-21	513	6	1433	1433	NUM
gsrj-21	513	7	-	-	SYM
gsrj-21	513	8	1449.e27	1449.e27	NUM
gsrj-21	513	9	.	.	PUNCT
gsrj-21	514	1	https://doi.org/10.1053/j.gastro.2019.11.279	https://doi.org/10.1053/j.gastro.2019.11.279	NOUN
gsrj-21	514	2	93	93	NUM
gsrj-21	514	3	.	.	PUNCT
gsrj-21	515	1	daher	daher	PROPN
gsrj-21	515	2	,	,	PUNCT
gsrj-21	515	3	b.	b.	PROPN
gsrj-21	515	4	,	,	PUNCT
gsrj-21	515	5	parks	park	NOUN
gsrj-21	515	6	,	,	PUNCT
gsrj-21	515	7	s.	s.	PROPN
gsrj-21	515	8	k.	k.	PROPN
gsrj-21	515	9	,	,	PUNCT
gsrj-21	515	10	durivault	durivault	PROPN
gsrj-21	515	11	,	,	PUNCT
gsrj-21	515	12	j.	j.	PROPN
gsrj-21	515	13	,	,	PUNCT
gsrj-21	515	14	cormerais	cormerais	PROPN
gsrj-21	515	15	,	,	PUNCT
gsrj-21	515	16	y.	y.	PROPN
gsrj-21	515	17	,	,	PUNCT
gsrj-21	515	18	baidarjad	baidarjad	NOUN
gsrj-21	515	19	,	,	PUNCT
gsrj-21	515	20	h.	h.	PROPN
gsrj-21	515	21	,	,	PUNCT
gsrj-21	515	22	tambutte	tambutte	PROPN
gsrj-21	515	23	,	,	PUNCT
gsrj-21	515	24	e.	e.	PROPN
gsrj-21	515	25	,	,	PUNCT
gsrj-21	515	26	et	et	PROPN
gsrj-21	515	27	al	al	PROPN
gsrj-21	515	28	.	.	PROPN
gsrj-21	515	29	(	(	PUNCT
gsrj-21	515	30	2019	2019	NUM
gsrj-21	515	31	)	)	PUNCT
gsrj-21	515	32	.	.	PUNCT
gsrj-21	516	1	genetic	genetic	ADJ
gsrj-21	516	2	ablation	ablation	NOUN
gsrj-21	516	3	of	of	ADP
gsrj-21	516	4	the	the	DET
gsrj-21	516	5	cystine	cystine	NOUN
gsrj-21	516	6	transporter	transporter	NOUN
gsrj-21	516	7	xct	xct	ADJ
gsrj-21	516	8	in	in	ADP
gsrj-21	516	9	pdac	pdac	NOUN
gsrj-21	516	10	cells	cell	NOUN
gsrj-21	516	11	inhibits	inhibit	VERB
gsrj-21	516	12	mtorc1	mtorc1	NOUN
gsrj-21	516	13	,	,	PUNCT
gsrj-21	516	14	growth	growth	NOUN
gsrj-21	516	15	,	,	PUNCT
gsrj-21	516	16	survival	survival	NOUN
gsrj-21	516	17	,	,	PUNCT
gsrj-21	516	18	and	and	CCONJ
gsrj-21	516	19	tumor	tumor	NOUN
gsrj-21	516	20	formation	formation	NOUN
gsrj-21	516	21	via	via	ADP
gsrj-21	516	22	nutrient	nutrient	NOUN
gsrj-21	516	23	and	and	CCONJ
gsrj-21	516	24	oxidative	oxidative	ADJ
gsrj-21	516	25	stresses	stress	NOUN
gsrj-21	516	26	.	.	PUNCT
gsrj-21	517	1	cancer	cancer	NOUN
gsrj-21	517	2	research	research	NOUN
gsrj-21	517	3	,	,	PUNCT
gsrj-21	517	4	79(15	79(15	PROPN
gsrj-21	517	5	)	)	PUNCT
gsrj-21	517	6	,	,	PUNCT
gsrj-21	517	7	3877	3877	NUM
gsrj-21	517	8	-	-	SYM
gsrj-21	517	9	3890	3890	NUM
gsrj-21	517	10	.	.	PUNCT
gsrj-21	518	1	https://doi.org/10.1158/0008-5472.can-18-3855	https://doi.org/10.1158/0008-5472.can-18-3855	PROPN
gsrj-21	518	2	94	94	NUM
gsrj-21	518	3	.	.	PUNCT
gsrj-21	519	1	mattie	mattie	PROPN
gsrj-21	519	2	,	,	PUNCT
gsrj-21	519	3	m.	m.	NOUN
gsrj-21	519	4	,	,	PUNCT
gsrj-21	519	5	christensen	christensen	PROPN
gsrj-21	519	6	,	,	PUNCT
gsrj-21	519	7	a.	a.	PROPN
gsrj-21	519	8	,	,	PUNCT
gsrj-21	519	9	chang	chang	PROPN
gsrj-21	519	10	,	,	PUNCT
gsrj-21	519	11	m.	m.	PROPN
gsrj-21	519	12	s.	s.	PROPN
gsrj-21	519	13	,	,	PUNCT
gsrj-21	519	14	yeh	yeh	PROPN
gsrj-21	519	15	,	,	PUNCT
gsrj-21	519	16	w.	w.	PROPN
gsrj-21	519	17	,	,	PUNCT
gsrj-21	519	18	said	say	VERB
gsrj-21	519	19	,	,	PUNCT
gsrj-21	519	20	s.	s.	PROPN
gsrj-21	519	21	,	,	PUNCT
gsrj-21	519	22	shostak	shostak	PROPN
gsrj-21	519	23	,	,	PUNCT
gsrj-21	519	24	y.	y.	PROPN
gsrj-21	519	25	,	,	PUNCT
gsrj-21	519	26	et	et	PROPN
gsrj-21	519	27	al	al	PROPN
gsrj-21	519	28	.	.	PROPN
gsrj-21	520	1	(	(	PUNCT
gsrj-21	520	2	2013	2013	NUM
gsrj-21	520	3	)	)	PUNCT
gsrj-21	520	4	.	.	PUNCT
gsrj-21	521	1	molecular	molecular	ADJ
gsrj-21	521	2	characterization	characterization	NOUN
gsrj-21	521	3	of	of	ADP
gsrj-21	521	4	patient	patient	NOUN
gsrj-21	521	5	-	-	PUNCT
gsrj-21	521	6	derived	derive	VERB
gsrj-21	521	7	human	human	ADJ
gsrj-21	521	8	pancreatic	pancreatic	ADJ
gsrj-21	521	9	tumor	tumor	NOUN
gsrj-21	521	10	xenograft	xenograft	NOUN
gsrj-21	521	11	models	model	NOUN
gsrj-21	521	12	for	for	ADP
gsrj-21	521	13	preclinical	preclinical	ADJ
gsrj-21	521	14	and	and	CCONJ
gsrj-21	521	15	translational	translational	ADJ
gsrj-21	521	16	development	development	NOUN
gsrj-21	521	17	of	of	ADP
gsrj-21	521	18	cancer	cancer	NOUN
gsrj-21	521	19	therapeutics	therapeutic	NOUN
gsrj-21	521	20	.	.	PUNCT
gsrj-21	522	1	neoplasia	neoplasia	NOUN
gsrj-21	522	2	(	(	PUNCT
gsrj-21	522	3	new	new	PROPN
gsrj-21	522	4	york	york	PROPN
gsrj-21	522	5	,	,	PUNCT
gsrj-21	522	6	n.y	n.y	PROPN
gsrj-21	522	7	.	.	PROPN
gsrj-21	522	8	)	)	PUNCT
gsrj-21	522	9	,	,	PUNCT
gsrj-21	522	10	15(10	15(10	NUM
gsrj-21	522	11	)	)	PUNCT
gsrj-21	522	12	,	,	PUNCT
gsrj-21	522	13	1138	1138	NUM
gsrj-21	522	14	-	-	SYM
gsrj-21	522	15	1150	1150	NUM
gsrj-21	522	16	.	.	PUNCT
gsrj-21	523	1	https://doi.org/10.1593/neo.13922	https://doi.org/10.1593/neo.13922	PROPN
gsrj-21	523	2	95	95	NUM
gsrj-21	523	3	.	.	PUNCT
gsrj-21	523	4	tang	tang	PROPN
gsrj-21	523	5	,	,	PUNCT
gsrj-21	523	6	b.	b.	PROPN
gsrj-21	523	7	,	,	PUNCT
gsrj-21	523	8	yang	yang	PROPN
gsrj-21	523	9	,	,	PUNCT
gsrj-21	523	10	y.	y.	PROPN
gsrj-21	523	11	,	,	PUNCT
gsrj-21	523	12	kang	kang	PROPN
gsrj-21	523	13	,	,	PUNCT
gsrj-21	523	14	m.	m.	NOUN
gsrj-21	523	15	,	,	PUNCT
gsrj-21	523	16	wang	wang	PROPN
gsrj-21	523	17	,	,	PUNCT
gsrj-21	523	18	y.	y.	PROPN
gsrj-21	523	19	,	,	PUNCT
gsrj-21	523	20	wang	wang	PROPN
gsrj-21	523	21	,	,	PUNCT
gsrj-21	523	22	y.	y.	PROPN
gsrj-21	523	23	,	,	PUNCT
gsrj-21	523	24	bi	bi	NOUN
gsrj-21	523	25	,	,	PUNCT
gsrj-21	523	26	y.	y.	PROPN
gsrj-21	523	27	,	,	PUNCT
gsrj-21	523	28	et	et	PROPN
gsrj-21	523	29	al	al	PROPN
gsrj-21	523	30	.	.	PROPN
gsrj-21	523	31	(	(	PUNCT
gsrj-21	523	32	2020	2020	NUM
gsrj-21	523	33	)	)	PUNCT
gsrj-21	523	34	.	.	PUNCT
gsrj-21	524	1	m6a	m6a	PROPN
gsrj-21	524	2	demethylase	demethylase	PROPN
gsrj-21	524	3	alkbh5	alkbh5	PROPN
gsrj-21	524	4	inhibits	inhibit	VERB
gsrj-21	524	5	pancreatic	pancreatic	ADJ
gsrj-21	524	6	cancer	cancer	NOUN
gsrj-21	524	7	tumorigenesis	tumorigenesis	NOUN
gsrj-21	524	8	by	by	ADP
gsrj-21	524	9	decreasing	decrease	VERB
gsrj-21	524	10	wif-1	wif-1	ADP
gsrj-21	524	11	rna	rna	NOUN
gsrj-21	524	12	methylation	methylation	NOUN
gsrj-21	524	13	and	and	CCONJ
gsrj-21	524	14	mediating	mediate	VERB
gsrj-21	524	15	wnt	wnt	NOUN
gsrj-21	524	16	signaling	signal	VERB
gsrj-21	524	17	.	.	PUNCT
gsrj-21	525	1	molecular	molecular	ADJ
gsrj-21	525	2	cancer	cancer	NOUN
gsrj-21	525	3	,	,	PUNCT
gsrj-21	525	4	19(1	19(1	NUM
gsrj-21	525	5	)	)	PUNCT
gsrj-21	525	6	,	,	PUNCT
gsrj-21	525	7	3	3	X
gsrj-21	525	8	.	.	X
gsrj-21	525	9	https://doi.org10.1186	https://doi.org10.1186	PROPN
gsrj-21	525	10	/	/	SYM
gsrj-21	525	11	s12943	s12943	NOUN
gsrj-21	525	12	-	-	PUNCT
gsrj-21	525	13	019	019	NUM
gsrj-21	525	14	-	-	PUNCT
gsrj-21	525	15	1128	1128	NUM
gsrj-21	525	16	-	-	SYM
gsrj-21	525	17	6	6	NUM
gsrj-21	525	18	96	96	NUM
gsrj-21	525	19	.	.	PUNCT
gsrj-21	526	1	wei	wei	PROPN
gsrj-21	526	2	,	,	PUNCT
gsrj-21	526	3	x.	x.	PROPN
gsrj-21	526	4	,	,	PUNCT
gsrj-21	526	5	yang	yang	PROPN
gsrj-21	526	6	,	,	PUNCT
gsrj-21	526	7	j.	j.	PROPN
gsrj-21	526	8	,	,	PUNCT
gsrj-21	526	9	adair	adair	PROPN
gsrj-21	526	10	,	,	PUNCT
gsrj-21	526	11	s.	s.	PROPN
gsrj-21	526	12	j.	j.	PROPN
gsrj-21	526	13	,	,	PUNCT
gsrj-21	526	14	ozturk	ozturk	PROPN
gsrj-21	526	15	,	,	PUNCT
gsrj-21	526	16	h.	h.	PROPN
gsrj-21	526	17	,	,	PUNCT
gsrj-21	526	18	kuscu	kuscu	PROPN
gsrj-21	526	19	,	,	PUNCT
gsrj-21	526	20	c.	c.	PROPN
gsrj-21	526	21	,	,	PUNCT
gsrj-21	526	22	lee	lee	PROPN
gsrj-21	526	23	,	,	PUNCT
gsrj-21	526	24	k.	k.	PROPN
gsrj-21	526	25	y.	y.	PROPN
gsrj-21	526	26	,	,	PUNCT
gsrj-21	526	27	et	et	PROPN
gsrj-21	526	28	al	al	PROPN
gsrj-21	526	29	.	.	PROPN
gsrj-21	526	30	(	(	PUNCT
gsrj-21	526	31	2020	2020	NUM
gsrj-21	526	32	)	)	PUNCT
gsrj-21	526	33	.	.	PUNCT
gsrj-21	527	1	targeted	target	VERB
gsrj-21	527	2	crispr	crispr	ADJ
gsrj-21	527	3	screening	screening	NOUN
gsrj-21	527	4	identifies	identify	VERB
gsrj-21	527	5	prmt5	prmt5	ADJ
gsrj-21	527	6	as	as	ADP
gsrj-21	527	7	synthetic	synthetic	ADJ
gsrj-21	527	8	lethality	lethality	NOUN
gsrj-21	527	9	combinatorial	combinatorial	ADJ
gsrj-21	527	10	target	target	NOUN
gsrj-21	527	11	with	with	ADP
gsrj-21	527	12	gemcitabine	gemcitabine	NOUN
gsrj-21	527	13	in	in	ADP
gsrj-21	527	14	pancreatic	pancreatic	ADJ
gsrj-21	527	15	cancer	cancer	NOUN
gsrj-21	527	16	cells	cell	NOUN
gsrj-21	527	17	.	.	PUNCT
gsrj-21	528	1	proceedings	proceeding	NOUN
gsrj-21	528	2	of	of	ADP
gsrj-21	528	3	the	the	DET
gsrj-21	528	4	national	national	PROPN
gsrj-21	528	5	academy	academy	PROPN
gsrj-21	528	6	of	of	ADP
gsrj-21	528	7	sciences	sciences	PROPN
gsrj-21	528	8	of	of	ADP
gsrj-21	528	9	the	the	DET
gsrj-21	528	10	united	united	PROPN
gsrj-21	528	11	states	states	PROPN
gsrj-21	528	12	of	of	ADP
gsrj-21	528	13	america	america	PROPN
gsrj-21	528	14	,	,	PUNCT
gsrj-21	528	15	117(45	117(45	NUM
gsrj-21	528	16	)	)	PUNCT
gsrj-21	528	17	,	,	PUNCT
gsrj-21	528	18	28068	28068	NUM
gsrj-21	528	19	-	-	SYM
gsrj-21	528	20	28079	28079	NUM
gsrj-21	528	21	.	.	PUNCT
gsrj-21	529	1	https://doi.org/10.1073/pnas.2009899117	https://doi.org/10.1073/pnas.2009899117	PROPN
gsrj-21	529	2	97	97	NUM
gsrj-21	529	3	.	.	PUNCT
gsrj-21	529	4	lee	lee	PROPN
gsrj-21	529	5	,	,	PUNCT
gsrj-21	529	6	j.	j.	PROPN
gsrj-21	529	7	w.	w.	PROPN
gsrj-21	529	8	,	,	PUNCT
gsrj-21	529	9	komar	komar	PROPN
gsrj-21	529	10	,	,	PUNCT
gsrj-21	529	11	c.	c.	PROPN
gsrj-21	529	12	a.	a.	PROPN
gsrj-21	529	13	,	,	PUNCT
gsrj-21	529	14	bengsch	bengsch	PROPN
gsrj-21	529	15	,	,	PUNCT
gsrj-21	529	16	f.	f.	PROPN
gsrj-21	529	17	,	,	PUNCT
gsrj-21	529	18	graham	graham	PROPN
gsrj-21	529	19	,	,	PUNCT
gsrj-21	529	20	k.	k.	PROPN
gsrj-21	529	21	,	,	PUNCT
gsrj-21	529	22	&	&	CCONJ
gsrj-21	529	23	beatty	beatty	PROPN
gsrj-21	529	24	,	,	PUNCT
gsrj-21	529	25	g.	g.	PROPN
gsrj-21	529	26	l.	l.	PROPN
gsrj-21	529	27	(	(	PUNCT
gsrj-21	529	28	2016	2016	NUM
gsrj-21	529	29	)	)	PUNCT
gsrj-21	529	30	.	.	PUNCT
gsrj-21	530	1	genetically	genetically	ADV
gsrj-21	530	2	engineered	engineer	VERB
gsrj-21	530	3	mouse	mouse	NOUN
gsrj-21	530	4	models	model	NOUN
gsrj-21	530	5	of	of	ADP
gsrj-21	530	6	pancreatic	pancreatic	ADJ
gsrj-21	530	7	cancer	cancer	NOUN
gsrj-21	530	8	:	:	PUNCT
gsrj-21	530	9	the	the	DET
gsrj-21	530	10	kpc	kpc	PROPN
gsrj-21	530	11	model	model	NOUN
gsrj-21	530	12	(	(	PUNCT
gsrj-21	530	13	lsl	lsl	PROPN
gsrj-21	530	14	-	-	ADJ
gsrj-21	530	15	krasg12d/+;lsl61	krasg12d/+;lsl61	ADJ
gsrj-21	530	16	georgetown	georgetown	PROPN
gsrj-21	530	17	scientific	scientific	PROPN
gsrj-21	530	18	research	research	PROPN
gsrj-21	530	19	journal	journal	PROPN
gsrj-21	530	20	trp53r172h/+;pdx-1	trp53r172h/+;pdx-1	PROPN
gsrj-21	530	21	-	-	PUNCT
gsrj-21	530	22	cre	cre	PROPN
gsrj-21	530	23	)	)	PUNCT
gsrj-21	530	24	,	,	PUNCT
gsrj-21	530	25	its	its	PRON
gsrj-21	530	26	variants	variant	NOUN
gsrj-21	530	27	and	and	CCONJ
gsrj-21	530	28	their	their	PRON
gsrj-21	530	29	application	application	NOUN
gsrj-21	530	30	in	in	ADP
gsrj-21	530	31	immuno	immuno	ADJ
gsrj-21	530	32	-	-	PUNCT
gsrj-21	530	33	oncology	oncology	NOUN
gsrj-21	530	34	drug	drug	NOUN
gsrj-21	530	35	discovery	discovery	NOUN
gsrj-21	530	36	.	.	PUNCT
gsrj-21	531	1	current	current	ADJ
gsrj-21	531	2	protocols	protocol	NOUN
gsrj-21	531	3	in	in	ADP
gsrj-21	531	4	pharmacology	pharmacology	NOUN
gsrj-21	531	5	/	/	SYM
gsrj-21	531	6	editorial	editorial	NOUN
gsrj-21	531	7	board	board	NOUN
gsrj-21	531	8	,	,	PUNCT
gsrj-21	531	9	s.j	s.j	PROPN
gsrj-21	531	10	.	.	PROPN
gsrj-21	531	11	enna	enna	PROPN
gsrj-21	531	12	(	(	PUNCT
gsrj-21	531	13	editor	editor	NOUN
gsrj-21	531	14	-	-	PUNCT
gsrj-21	531	15	in	in	ADP
gsrj-21	531	16	-	-	PUNCT
gsrj-21	531	17	chief	chief	NOUN
gsrj-21	531	18	)	)	PUNCT
gsrj-21	531	19	...	...	PUNCT
gsrj-21	532	1	[	[	X
gsrj-21	532	2	et	et	X
gsrj-21	532	3	al	al	PROPN
gsrj-21	532	4	.	.	PROPN
gsrj-21	532	5	]	]	X
gsrj-21	532	6	,	,	PUNCT
gsrj-21	532	7	73	73	NUM
gsrj-21	532	8	,	,	PUNCT
gsrj-21	532	9	14.39.114.39.20	14.39.114.39.20	NUM
gsrj-21	532	10	.	.	PUNCT
gsrj-21	533	1	https://doi.org/10.1002/cpph.2	https://doi.org/10.1002/cpph.2	PROPN
gsrj-21	533	2	98	98	NUM
gsrj-21	533	3	.	.	PUNCT
gsrj-21	533	4	westphalen	westphalen	PROPN
gsrj-21	533	5	,	,	PUNCT
gsrj-21	533	6	c.	c.	PROPN
gsrj-21	533	7	b.	b.	PROPN
gsrj-21	533	8	,	,	PUNCT
gsrj-21	533	9	&	&	CCONJ
gsrj-21	533	10	olive	olive	PROPN
gsrj-21	533	11	,	,	PUNCT
gsrj-21	533	12	k.	k.	PROPN
gsrj-21	534	1	p.	p.	PROPN
gsrj-21	534	2	(	(	PUNCT
gsrj-21	534	3	2012	2012	NUM
gsrj-21	534	4	)	)	PUNCT
gsrj-21	534	5	.	.	PUNCT
gsrj-21	535	1	genetically	genetically	ADV
gsrj-21	535	2	engineered	engineer	VERB
gsrj-21	535	3	mouse	mouse	NOUN
gsrj-21	535	4	models	model	NOUN
gsrj-21	535	5	of	of	ADP
gsrj-21	535	6	pancreatic	pancreatic	ADJ
gsrj-21	535	7	cancer	cancer	NOUN
gsrj-21	535	8	.	.	PUNCT
gsrj-21	536	1	cancer	cancer	NOUN
gsrj-21	536	2	journal	journal	PROPN
gsrj-21	536	3	(	(	PUNCT
gsrj-21	536	4	sudbury	sudbury	PROPN
gsrj-21	536	5	,	,	PUNCT
gsrj-21	536	6	mass	mass	PROPN
gsrj-21	536	7	.	.	PUNCT
gsrj-21	536	8	)	)	PUNCT
gsrj-21	536	9	,	,	PUNCT
gsrj-21	536	10	18(6	18(6	NOUN
gsrj-21	536	11	)	)	PUNCT
gsrj-21	536	12	,	,	PUNCT
gsrj-21	536	13	502510	502510	NUM
gsrj-21	536	14	.	.	PUNCT
gsrj-21	537	1	https://doi.org/10.1097/ppo.0b013e31827ab4c4	https://doi.org/10.1097/ppo.0b013e31827ab4c4	PROPN
gsrj-21	537	2	99	99	NUM
gsrj-21	537	3	.	.	PUNCT
gsrj-21	537	4	olive	olive	PROPN
gsrj-21	537	5	,	,	PUNCT
gsrj-21	537	6	k.	k.	PROPN
gsrj-21	538	1	p.	p.	PROPN
gsrj-21	538	2	,	,	PUNCT
gsrj-21	538	3	&	&	CCONJ
gsrj-21	538	4	tuveson	tuveson	PROPN
gsrj-21	538	5	,	,	PUNCT
gsrj-21	538	6	d.	d.	PROPN
gsrj-21	538	7	a.	a.	PROPN
gsrj-21	538	8	(	(	PUNCT
gsrj-21	538	9	2006	2006	NUM
gsrj-21	538	10	)	)	PUNCT
gsrj-21	538	11	.	.	PUNCT
gsrj-21	539	1	the	the	DET
gsrj-21	539	2	use	use	NOUN
gsrj-21	539	3	of	of	ADP
gsrj-21	539	4	targeted	target	VERB
gsrj-21	539	5	mouse	mouse	NOUN
gsrj-21	539	6	models	model	NOUN
gsrj-21	539	7	for	for	ADP
gsrj-21	539	8	preclinical	preclinical	ADJ
gsrj-21	539	9	testing	testing	NOUN
gsrj-21	539	10	of	of	ADP
gsrj-21	539	11	novel	novel	ADJ
gsrj-21	539	12	cancer	cancer	NOUN
gsrj-21	539	13	therapeutics	therapeutic	NOUN
gsrj-21	539	14	.	.	PUNCT
gsrj-21	540	1	clinical	clinical	ADJ
gsrj-21	540	2	cancer	cancer	NOUN
gsrj-21	540	3	research	research	NOUN
gsrj-21	540	4	,	,	PUNCT
gsrj-21	540	5	12(18	12(18	NUM
gsrj-21	540	6	)	)	PUNCT
gsrj-21	540	7	,	,	PUNCT
gsrj-21	540	8	5277	5277	NUM
gsrj-21	540	9	-	-	SYM
gsrj-21	540	10	5287	5287	NUM
gsrj-21	540	11	.	.	PUNCT
gsrj-21	541	1	100	100	NUM
gsrj-21	541	2	.	.	PUNCT
gsrj-21	542	1	tadros	tadro	NOUN
gsrj-21	542	2	,	,	PUNCT
gsrj-21	542	3	s.	s.	PROPN
gsrj-21	542	4	,	,	PUNCT
gsrj-21	542	5	shukla	shukla	NOUN
gsrj-21	542	6	,	,	PUNCT
gsrj-21	542	7	s.	s.	PROPN
gsrj-21	542	8	k.	k.	PROPN
gsrj-21	542	9	,	,	PUNCT
gsrj-21	542	10	king	king	PROPN
gsrj-21	542	11	,	,	PUNCT
gsrj-21	542	12	r.	r.	PROPN
gsrj-21	542	13	j.	j.	PROPN
gsrj-21	542	14	,	,	PUNCT
gsrj-21	542	15	gunda	gunda	PROPN
gsrj-21	542	16	,	,	PUNCT
gsrj-21	542	17	v.	v.	PROPN
gsrj-21	542	18	,	,	PUNCT
gsrj-21	542	19	vernucci	vernucci	PROPN
gsrj-21	542	20	,	,	PUNCT
gsrj-21	542	21	e.	e.	PROPN
gsrj-21	542	22	,	,	PUNCT
gsrj-21	542	23	abrego	abrego	PROPN
gsrj-21	542	24	,	,	PUNCT
gsrj-21	542	25	j.	j.	PROPN
gsrj-21	542	26	,	,	PUNCT
gsrj-21	542	27	et	et	PROPN
gsrj-21	542	28	al	al	PROPN
gsrj-21	542	29	.	.	PUNCT
gsrj-21	542	30	(	(	PUNCT
gsrj-21	542	31	2017	2017	NUM
gsrj-21	542	32	)	)	PUNCT
gsrj-21	542	33	.	.	PUNCT
gsrj-21	543	1	de	de	PROPN
gsrj-21	543	2	novo	novo	PROPN
gsrj-21	543	3	lipid	lipid	NOUN
gsrj-21	543	4	synthesis	synthesis	NOUN
gsrj-21	543	5	facilitates	facilitate	VERB
gsrj-21	543	6	gemcitabine	gemcitabine	VERB
gsrj-21	543	7	resistance	resistance	NOUN
gsrj-21	543	8	through	through	ADP
gsrj-21	543	9	endoplasmic	endoplasmic	ADJ
gsrj-21	543	10	reticulum	reticulum	NOUN
gsrj-21	543	11	stress	stress	NOUN
gsrj-21	543	12	in	in	ADP
gsrj-21	543	13	pancreatic	pancreatic	ADJ
gsrj-21	543	14	cancer	cancer	NOUN
gsrj-21	543	15	.	.	PUNCT
gsrj-21	544	1	cancer	cancer	NOUN
gsrj-21	544	2	research	research	NOUN
gsrj-21	544	3	,	,	PUNCT
gsrj-21	544	4	77(20	77(20	NUM
gsrj-21	544	5	)	)	PUNCT
gsrj-21	544	6	,	,	PUNCT
gsrj-21	544	7	5503	5503	NUM
gsrj-21	544	8	-	-	SYM
gsrj-21	544	9	5517	5517	NUM
gsrj-21	544	10	.	.	PUNCT
gsrj-21	545	1	https://doi.org/10.1158/0008-5472.can-16-3062	https://doi.org/10.1158/0008-5472.can-16-3062	ADP
gsrj-21	545	2	101	101	NUM
gsrj-21	545	3	.	.	PUNCT
gsrj-21	546	1	buchholz	buchholz	PROPN
gsrj-21	546	2	,	,	PUNCT
gsrj-21	546	3	s.	s.	PROPN
gsrj-21	546	4	m.	m.	PROPN
gsrj-21	546	5	,	,	PUNCT
gsrj-21	546	6	goetze	goetze	PROPN
gsrj-21	546	7	,	,	PUNCT
gsrj-21	546	8	r.	r.	PROPN
gsrj-21	546	9	g.	g.	PROPN
gsrj-21	546	10	,	,	PUNCT
gsrj-21	546	11	singh	singh	PROPN
gsrj-21	546	12	,	,	PUNCT
gsrj-21	546	13	s.	s.	PROPN
gsrj-21	546	14	k.	k.	PROPN
gsrj-21	546	15	,	,	PUNCT
gsrj-21	546	16	ammer	ammer	ADJ
gsrj-21	546	17	-	-	PUNCT
gsrj-21	546	18	herrmenau	herrmenau	PROPN
gsrj-21	546	19	,	,	PUNCT
gsrj-21	546	20	c.	c.	PROPN
gsrj-21	546	21	,	,	PUNCT
gsrj-21	546	22	richards	richards	PROPN
gsrj-21	546	23	,	,	PUNCT
gsrj-21	546	24	f.	f.	PROPN
gsrj-21	546	25	m.	m.	PROPN
gsrj-21	546	26	,	,	PUNCT
gsrj-21	546	27	jodrell	jodrell	PROPN
gsrj-21	546	28	,	,	PUNCT
gsrj-21	546	29	d.	d.	PROPN
gsrj-21	546	30	i.	i.	PROPN
gsrj-21	546	31	,	,	PUNCT
gsrj-21	546	32	et	et	PROPN
gsrj-21	546	33	al	al	PROPN
gsrj-21	546	34	.	.	PROPN
gsrj-21	546	35	(	(	PUNCT
gsrj-21	546	36	2020	2020	NUM
gsrj-21	546	37	)	)	PUNCT
gsrj-21	546	38	.	.	PUNCT
gsrj-21	547	1	depletion	depletion	NOUN
gsrj-21	547	2	of	of	ADP
gsrj-21	547	3	macrophages	macrophage	NOUN
gsrj-21	547	4	improves	improve	VERB
gsrj-21	547	5	therapeutic	therapeutic	ADJ
gsrj-21	547	6	response	response	NOUN
gsrj-21	547	7	to	to	PART
gsrj-21	547	8	gemcitabine	gemcitabine	VERB
gsrj-21	547	9	in	in	ADP
gsrj-21	547	10	murine	murine	ADJ
gsrj-21	547	11	pancreas	pancreas	NOUN
gsrj-21	547	12	cancer	cancer	NOUN
gsrj-21	547	13	.	.	PUNCT
gsrj-21	548	1	cancers	cancer	NOUN
gsrj-21	548	2	,	,	PUNCT
gsrj-21	548	3	12(7	12(7	NUM
gsrj-21	548	4	)	)	PUNCT
gsrj-21	548	5	https://doi.org/10.3390/cancers12071978	https://doi.org/10.3390/cancers12071978	PROPN
gsrj-21	548	6	102	102	NUM
gsrj-21	548	7	.	.	PUNCT
gsrj-21	549	1	aiello	aiello	PROPN
gsrj-21	549	2	,	,	PUNCT
gsrj-21	549	3	n.	n.	PROPN
gsrj-21	549	4	m.	m.	NOUN
gsrj-21	549	5	,	,	PUNCT
gsrj-21	549	6	bajor	bajor	NOUN
gsrj-21	549	7	,	,	PUNCT
gsrj-21	549	8	d.	d.	PROPN
gsrj-21	549	9	l.	l.	PROPN
gsrj-21	549	10	,	,	PUNCT
gsrj-21	549	11	norgard	norgard	PROPN
gsrj-21	549	12	,	,	PUNCT
gsrj-21	549	13	r.	r.	PROPN
gsrj-21	549	14	j.	j.	PROPN
gsrj-21	549	15	,	,	PUNCT
gsrj-21	549	16	sahmoud	sahmoud	PROPN
gsrj-21	549	17	,	,	PUNCT
gsrj-21	549	18	a.	a.	NOUN
gsrj-21	549	19	,	,	PUNCT
gsrj-21	549	20	bhagwat	bhagwat	NOUN
gsrj-21	549	21	,	,	PUNCT
gsrj-21	549	22	n.	n.	PROPN
gsrj-21	549	23	,	,	PUNCT
gsrj-21	549	24	pham	pham	PROPN
gsrj-21	549	25	,	,	PUNCT
gsrj-21	549	26	m.	m.	NOUN
gsrj-21	549	27	n.	n.	PROPN
gsrj-21	549	28	,	,	PUNCT
gsrj-21	549	29	et	et	PROPN
gsrj-21	549	30	al	al	PROPN
gsrj-21	549	31	.	.	PUNCT
gsrj-21	549	32	(	(	PUNCT
gsrj-21	549	33	2016	2016	NUM
gsrj-21	549	34	)	)	PUNCT
gsrj-21	549	35	.	.	PUNCT
gsrj-21	550	1	metastatic	metastatic	ADJ
gsrj-21	550	2	progression	progression	NOUN
gsrj-21	550	3	is	be	AUX
gsrj-21	550	4	associated	associate	VERB
gsrj-21	550	5	with	with	ADP
gsrj-21	550	6	dynamic	dynamic	ADJ
gsrj-21	550	7	changes	change	NOUN
gsrj-21	550	8	in	in	ADP
gsrj-21	550	9	the	the	DET
gsrj-21	550	10	local	local	ADJ
gsrj-21	550	11	microenvironment	microenvironment	NOUN
gsrj-21	550	12	.	.	PUNCT
gsrj-21	551	1	nature	nature	NOUN
gsrj-21	551	2	communications	communication	NOUN
gsrj-21	551	3	,	,	PUNCT
gsrj-21	551	4	7	7	NUM
gsrj-21	551	5	,	,	PUNCT
gsrj-21	551	6	12819	12819	NUM
gsrj-21	551	7	.	.	PUNCT
gsrj-21	552	1	https://doi.org/10.1038/ncomms12819	https://doi.org/10.1038/ncomms12819	PROPN
gsrj-21	552	2	103	103	NUM
gsrj-21	552	3	.	.	PUNCT
gsrj-21	552	4	principe	principe	PROPN
gsrj-21	552	5	,	,	PUNCT
gsrj-21	552	6	d.	d.	PROPN
gsrj-21	552	7	r.	r.	PROPN
gsrj-21	552	8	,	,	PUNCT
gsrj-21	552	9	narbutis	narbutis	PROPN
gsrj-21	552	10	,	,	PUNCT
gsrj-21	552	11	m.	m.	NOUN
gsrj-21	552	12	,	,	PUNCT
gsrj-21	552	13	kumar	kumar	PROPN
gsrj-21	552	14	,	,	PUNCT
gsrj-21	552	15	s.	s.	PROPN
gsrj-21	552	16	,	,	PUNCT
gsrj-21	552	17	park	park	NOUN
gsrj-21	552	18	,	,	PUNCT
gsrj-21	552	19	a.	a.	NOUN
gsrj-21	552	20	,	,	PUNCT
gsrj-21	552	21	viswakarma	viswakarma	NOUN
gsrj-21	552	22	,	,	PUNCT
gsrj-21	552	23	n.	n.	NOUN
gsrj-21	552	24	,	,	PUNCT
gsrj-21	552	25	dorman	dorman	PROPN
gsrj-21	552	26	,	,	PUNCT
gsrj-21	552	27	m.	m.	PROPN
gsrj-21	552	28	j.	j.	PROPN
gsrj-21	552	29	,	,	PUNCT
gsrj-21	552	30	et	et	PROPN
gsrj-21	552	31	al	al	PROPN
gsrj-21	552	32	.	.	PROPN
gsrj-21	552	33	(	(	PUNCT
gsrj-21	552	34	2020	2020	NUM
gsrj-21	552	35	)	)	PUNCT
gsrj-21	552	36	.	.	PUNCT
gsrj-21	553	1	long	long	ADJ
gsrj-21	553	2	-	-	PUNCT
gsrj-21	553	3	term	term	NOUN
gsrj-21	553	4	gemcitabine	gemcitabine	NOUN
gsrj-21	553	5	treatment	treatment	NOUN
gsrj-21	553	6	reshapes	reshape	VERB
gsrj-21	553	7	the	the	DET
gsrj-21	553	8	pancreatic	pancreatic	ADJ
gsrj-21	553	9	tumor	tumor	NOUN
gsrj-21	553	10	microenvironment	microenvironment	NOUN
gsrj-21	553	11	and	and	CCONJ
gsrj-21	553	12	sensitizes	sensitize	VERB
gsrj-21	553	13	murine	murine	ADJ
gsrj-21	553	14	carcinoma	carcinoma	NOUN
gsrj-21	553	15	to	to	PART
gsrj-21	553	16	combination	combination	VERB
gsrj-21	553	17	immunotherapy	immunotherapy	NOUN
gsrj-21	553	18	.	.	PUNCT
gsrj-21	554	1	cancer	cancer	NOUN
gsrj-21	554	2	research	research	NOUN
gsrj-21	554	3	,	,	PUNCT
gsrj-21	554	4	80(15	80(15	PROPN
gsrj-21	554	5	)	)	PUNCT
gsrj-21	554	6	,	,	PUNCT
gsrj-21	554	7	3101	3101	NUM
gsrj-21	554	8	-	-	SYM
gsrj-21	554	9	3115	3115	NUM
gsrj-21	554	10	.	.	PUNCT
gsrj-21	555	1	https://doi.org/10.1158/0008-5472.can-19-2959	https://doi.org/10.1158/0008-5472.can-19-2959	ADP
gsrj-21	555	2	104	104	NUM
gsrj-21	555	3	.	.	PUNCT
gsrj-21	556	1	halbrook	halbrook	NOUN
gsrj-21	556	2	,	,	PUNCT
gsrj-21	556	3	c.	c.	PROPN
gsrj-21	556	4	j.	j.	PROPN
gsrj-21	556	5	,	,	PUNCT
gsrj-21	556	6	pontious	pontious	NOUN
gsrj-21	556	7	,	,	PUNCT
gsrj-21	556	8	c.	c.	NOUN
gsrj-21	556	9	,	,	PUNCT
gsrj-21	556	10	kovalenko	kovalenko	PROPN
gsrj-21	556	11	,	,	PUNCT
gsrj-21	556	12	i.	i.	NOUN
gsrj-21	556	13	,	,	PUNCT
gsrj-21	556	14	lapienyte	lapienyte	PROPN
gsrj-21	556	15	,	,	PUNCT
gsrj-21	556	16	l.	l.	PROPN
gsrj-21	556	17	,	,	PUNCT
gsrj-21	556	18	dreyer	dreyer	PROPN
gsrj-21	556	19	,	,	PUNCT
gsrj-21	556	20	s.	s.	PROPN
gsrj-21	556	21	,	,	PUNCT
gsrj-21	556	22	lee	lee	PROPN
gsrj-21	556	23	,	,	PUNCT
gsrj-21	556	24	h.	h.	PROPN
gsrj-21	556	25	,	,	PUNCT
gsrj-21	556	26	et	et	PROPN
gsrj-21	556	27	al	al	PROPN
gsrj-21	556	28	.	.	PROPN
gsrj-21	557	1	(	(	PUNCT
gsrj-21	557	2	2019	2019	NUM
gsrj-21	557	3	)	)	PUNCT
gsrj-21	557	4	.	.	PUNCT
gsrj-21	558	1	macrophage	macrophage	ADJ
gsrj-21	558	2	-	-	PUNCT
gsrj-21	558	3	released	release	VERB
gsrj-21	558	4	pyrimidines	pyrimidine	NOUN
gsrj-21	558	5	inhibit	inhibit	VERB
gsrj-21	558	6	gemcitabine	gemcitabine	NOUN
gsrj-21	558	7	therapy	therapy	NOUN
gsrj-21	558	8	in	in	ADP
gsrj-21	558	9	pancreatic	pancreatic	ADJ
gsrj-21	558	10	cancer	cancer	NOUN
gsrj-21	558	11	.	.	PUNCT
gsrj-21	559	1	cell	cell	NOUN
gsrj-21	559	2	metabolism	metabolism	NOUN
gsrj-21	559	3	,	,	PUNCT
gsrj-21	559	4	29(6	29(6	NUM
gsrj-21	559	5	)	)	PUNCT
gsrj-21	559	6	,	,	PUNCT
gsrj-21	559	7	1390	1390	NUM
gsrj-21	559	8	-	-	SYM
gsrj-21	559	9	1399.e6	1399.e6	NUM
gsrj-21	559	10	.	.	PUNCT
gsrj-21	560	1	https://doi.org/10.1016/j.cmet.2019.02.001	https://doi.org/10.1016/j.cmet.2019.02.001	PROPN
gsrj-21	560	2	105	105	NUM
gsrj-21	560	3	.	.	PUNCT
gsrj-21	561	1	özdemir	özdemir	PROPN
gsrj-21	561	2	,	,	PUNCT
gsrj-21	561	3	b.	b.	PROPN
gsrj-21	561	4	c.	c.	PROPN
gsrj-21	561	5	,	,	PUNCT
gsrj-21	561	6	pentcheva	pentcheva	PROPN
gsrj-21	561	7	-	-	PUNCT
gsrj-21	561	8	hoang	hoang	PROPN
gsrj-21	561	9	,	,	PUNCT
gsrj-21	561	10	t.	t.	PROPN
gsrj-21	561	11	,	,	PUNCT
gsrj-21	561	12	carstens	carstens	PROPN
gsrj-21	561	13	,	,	PUNCT
gsrj-21	561	14	j.	j.	PROPN
gsrj-21	561	15	l.	l.	PROPN
gsrj-21	561	16	,	,	PUNCT
gsrj-21	561	17	zheng	zheng	PROPN
gsrj-21	561	18	,	,	PUNCT
gsrj-21	561	19	x.	x.	PROPN
gsrj-21	561	20	,	,	PUNCT
gsrj-21	561	21	wu	wu	PROPN
gsrj-21	561	22	,	,	PUNCT
gsrj-21	561	23	c.	c.	PROPN
gsrj-21	561	24	,	,	PUNCT
gsrj-21	561	25	simpson	simpson	PROPN
gsrj-21	561	26	,	,	PUNCT
gsrj-21	561	27	t.	t.	PROPN
gsrj-21	561	28	,	,	PUNCT
gsrj-21	561	29	et	et	PROPN
gsrj-21	561	30	al	al	PROPN
gsrj-21	561	31	.	.	PUNCT
gsrj-21	562	1	(	(	PUNCT
gsrj-21	562	2	2014	2014	NUM
gsrj-21	562	3	)	)	PUNCT
gsrj-21	562	4	.	.	PUNCT
gsrj-21	563	1	depletion	depletion	NOUN
gsrj-21	563	2	of	of	ADP
gsrj-21	563	3	carcinoma	carcinoma	NOUN
gsrj-21	563	4	-	-	PUNCT
gsrj-21	563	5	associated	associate	VERB
gsrj-21	563	6	fibroblasts	fibroblast	NOUN
gsrj-21	563	7	and	and	CCONJ
gsrj-21	563	8	fibrosis	fibrosis	NOUN
gsrj-21	563	9	induces	induce	VERB
gsrj-21	563	10	immunosuppression	immunosuppression	NOUN
gsrj-21	563	11	and	and	CCONJ
gsrj-21	563	12	accelerates	accelerate	VERB
gsrj-21	563	13	pancreas	pancreas	ADJ
gsrj-21	563	14	cancer	cancer	NOUN
gsrj-21	563	15	with	with	ADP
gsrj-21	563	16	diminished	diminished	ADJ
gsrj-21	563	17	survival	survival	NOUN
gsrj-21	563	18	.	.	PUNCT
gsrj-21	564	1	cancer	cancer	NOUN
gsrj-21	564	2	cell	cell	NOUN
gsrj-21	564	3	,	,	PUNCT
gsrj-21	564	4	25(6	25(6	NOUN
gsrj-21	564	5	)	)	PUNCT
gsrj-21	564	6	,	,	PUNCT
gsrj-21	564	7	719	719	NUM
gsrj-21	564	8	-	-	SYM
gsrj-21	564	9	734	734	NUM
gsrj-21	564	10	.	.	PUNCT
gsrj-21	565	1	https://doi.org/10.1016/j.ccr.2014.04.005	https://doi.org/10.1016/j.ccr.2014.04.005	PROPN
gsrj-21	565	2	106	106	NUM
gsrj-21	565	3	.	.	PUNCT
gsrj-21	566	1	zhu	zhu	PROPN
gsrj-21	566	2	,	,	PUNCT
gsrj-21	566	3	x.	x.	PROPN
gsrj-21	566	4	,	,	PUNCT
gsrj-21	566	5	shen	shen	PROPN
gsrj-21	566	6	,	,	PUNCT
gsrj-21	566	7	x.	x.	PROPN
gsrj-21	566	8	,	,	PUNCT
gsrj-21	566	9	qu	qu	PROPN
gsrj-21	566	10	,	,	PUNCT
gsrj-21	566	11	j.	j.	PROPN
gsrj-21	566	12	,	,	PUNCT
gsrj-21	566	13	straubinger	straubinger	PROPN
gsrj-21	566	14	,	,	PUNCT
gsrj-21	566	15	r.	r.	PROPN
gsrj-21	566	16	m.	m.	PROPN
gsrj-21	566	17	,	,	PUNCT
gsrj-21	566	18	&	&	CCONJ
gsrj-21	566	19	jusko	jusko	PROPN
gsrj-21	566	20	,	,	PUNCT
gsrj-21	566	21	w.	w.	PROPN
gsrj-21	566	22	j.	j.	PROPN
gsrj-21	566	23	(	(	PUNCT
gsrj-21	566	24	2018	2018	NUM
gsrj-21	566	25	)	)	PUNCT
gsrj-21	566	26	.	.	PUNCT
gsrj-21	567	1	proteomic	proteomic	ADJ
gsrj-21	567	2	analysis	analysis	NOUN
gsrj-21	567	3	of	of	ADP
gsrj-21	567	4	combined	combined	ADJ
gsrj-21	567	5	gemcitabine	gemcitabine	NOUN
gsrj-21	567	6	and	and	CCONJ
gsrj-21	567	7	birinapant	birinapant	ADJ
gsrj-21	567	8	in	in	ADP
gsrj-21	567	9	pancreatic	pancreatic	ADJ
gsrj-21	567	10	cancer	cancer	NOUN
gsrj-21	567	11	cells	cell	NOUN
gsrj-21	567	12	.	.	PUNCT
gsrj-21	568	1	frontiers	frontier	NOUN
gsrj-21	568	2	in	in	ADP
gsrj-21	568	3	pharmacology	pharmacology	NOUN
gsrj-21	568	4	,	,	PUNCT
gsrj-21	568	5	9	9	NUM
gsrj-21	568	6	,	,	PUNCT
gsrj-21	568	7	84	84	NUM
gsrj-21	568	8	.	.	PUNCT
gsrj-21	569	1	https://doi.org/10.3389/fphar.2018.00084	https://doi.org/10.3389/fphar.2018.00084	PROPN
gsrj-21	569	2	107	107	NUM
gsrj-21	569	3	.	.	PUNCT
gsrj-21	570	1	chen	chen	PROPN
gsrj-21	570	2	,	,	PUNCT
gsrj-21	570	3	y.	y.	PROPN
gsrj-21	570	4	,	,	PUNCT
gsrj-21	570	5	liu	liu	PROPN
gsrj-21	570	6	,	,	PUNCT
gsrj-21	570	7	j.	j.	PROPN
gsrj-21	570	8	,	,	PUNCT
gsrj-21	570	9	lin	lin	PROPN
gsrj-21	570	10	,	,	PUNCT
gsrj-21	570	11	s.	s.	PROPN
gsrj-21	570	12	,	,	PUNCT
gsrj-21	570	13	li	li	PROPN
gsrj-21	570	14	,	,	PUNCT
gsrj-21	570	15	j.	j.	PROPN
gsrj-21	570	16	,	,	PUNCT
gsrj-21	570	17	huang	huang	PROPN
gsrj-21	570	18	,	,	PUNCT
gsrj-21	570	19	s.	s.	PROPN
gsrj-21	570	20	,	,	PUNCT
gsrj-21	570	21	chen	chen	PROPN
gsrj-21	570	22	,	,	PUNCT
gsrj-21	570	23	j.	j.	PROPN
gsrj-21	570	24	,	,	PUNCT
gsrj-21	570	25	et	et	PROPN
gsrj-21	570	26	al	al	PROPN
gsrj-21	570	27	.	.	PUNCT
gsrj-21	570	28	(	(	PUNCT
gsrj-21	570	29	2011	2011	NUM
gsrj-21	570	30	)	)	PUNCT
gsrj-21	570	31	.	.	PUNCT
gsrj-21	571	1	proteomic	proteomic	ADJ
gsrj-21	571	2	analysis	analysis	NOUN
gsrj-21	571	3	of	of	ADP
gsrj-21	571	4	gemcitabineinduced	gemcitabineinduce	VERB
gsrj-21	571	5	drug	drug	NOUN
gsrj-21	571	6	resistance	resistance	NOUN
gsrj-21	571	7	in	in	ADP
gsrj-21	571	8	pancreatic	pancreatic	ADJ
gsrj-21	571	9	cancer	cancer	NOUN
gsrj-21	571	10	cells	cell	NOUN
gsrj-21	571	11	.	.	PUNCT
gsrj-21	572	1	molecular	molecular	ADJ
gsrj-21	572	2	biosystems	biosystem	NOUN
gsrj-21	572	3	,	,	PUNCT
gsrj-21	572	4	7(11	7(11	NUM
gsrj-21	572	5	)	)	PUNCT
gsrj-21	572	6	,	,	PUNCT
gsrj-21	572	7	3065	3065	NUM
gsrj-21	572	8	-	-	SYM
gsrj-21	572	9	3074	3074	NUM
gsrj-21	572	10	.	.	PUNCT
gsrj-21	573	1	https://doi.org/10.1039/c1mb05125c	https://doi.org/10.1039/c1mb05125c	PROPN
gsrj-21	573	2	108	108	NUM
gsrj-21	573	3	.	.	PUNCT
gsrj-21	574	1	law	law	NOUN
gsrj-21	574	2	,	,	PUNCT
gsrj-21	574	3	h.	h.	PROPN
gsrj-21	574	4	c.	c.	PROPN
gsrj-21	574	5	-	-	PUNCT
gsrj-21	574	6	.	.	PROPN
gsrj-21	574	7	,	,	PUNCT
gsrj-21	574	8	lagundžin	lagundžin	PROPN
gsrj-21	574	9	,	,	PUNCT
gsrj-21	574	10	d.	d.	PROPN
gsrj-21	574	11	,	,	PUNCT
gsrj-21	574	12	clement	clement	PROPN
gsrj-21	574	13	,	,	PUNCT
gsrj-21	574	14	e.	e.	PROPN
gsrj-21	574	15	j.	j.	PROPN
gsrj-21	574	16	,	,	PUNCT
gsrj-21	574	17	qiao	qiao	PROPN
gsrj-21	574	18	,	,	PUNCT
gsrj-21	574	19	f.	f.	PROPN
gsrj-21	574	20	,	,	PUNCT
gsrj-21	574	21	wagner	wagner	PROPN
gsrj-21	574	22	,	,	PUNCT
gsrj-21	574	23	z.	z.	PROPN
gsrj-21	574	24	s.	s.	PROPN
gsrj-21	574	25	,	,	PUNCT
gsrj-21	574	26	krieger	krieger	PROPN
gsrj-21	574	27	,	,	PUNCT
gsrj-21	574	28	k.	k.	PROPN
gsrj-21	574	29	l.	l.	PROPN
gsrj-21	574	30	,	,	PUNCT
gsrj-21	574	31	et	et	PROPN
gsrj-21	574	32	al	al	PROPN
gsrj-21	574	33	.	.	PROPN
gsrj-21	574	34	(	(	PUNCT
gsrj-21	574	35	2020	2020	NUM
gsrj-21	574	36	)	)	PUNCT
gsrj-21	574	37	.	.	PUNCT
gsrj-21	575	1	the	the	DET
gsrj-21	575	2	proteomic	proteomic	ADJ
gsrj-21	575	3	landscape	landscape	NOUN
gsrj-21	575	4	of	of	ADP
gsrj-21	575	5	pancreatic	pancreatic	ADJ
gsrj-21	575	6	ductal	ductal	ADJ
gsrj-21	575	7	adenocarcinoma	adenocarcinoma	NOUN
gsrj-21	575	8	liver	liver	NOUN
gsrj-21	575	9	metastases	metastasis	NOUN
gsrj-21	575	10	identifies	identify	VERB
gsrj-21	575	11	molecular	molecular	ADJ
gsrj-21	575	12	subtypes	subtype	NOUN
gsrj-21	575	13	and	and	CCONJ
gsrj-21	575	14	associations	association	NOUN
gsrj-21	575	15	with	with	ADP
gsrj-21	575	16	clinical	clinical	ADJ
gsrj-21	575	17	response	response	NOUN
gsrj-21	575	18	.	.	PUNCT
gsrj-21	576	1	clinical	clinical	ADJ
gsrj-21	576	2	cancer	cancer	NOUN
gsrj-21	576	3	research	research	NOUN
gsrj-21	576	4	:	:	PUNCT
gsrj-21	576	5	an	an	DET
gsrj-21	576	6	official	official	ADJ
gsrj-21	576	7	journal	journal	NOUN
gsrj-21	576	8	of	of	ADP
gsrj-21	576	9	the	the	DET
gsrj-21	576	10	american	american	PROPN
gsrj-21	576	11	association	association	PROPN
gsrj-21	576	12	for	for	ADP
gsrj-21	576	13	cancer	cancer	NOUN
gsrj-21	576	14	research	research	NOUN
gsrj-21	576	15	,	,	PUNCT
gsrj-21	576	16	26(5	26(5	NUM
gsrj-21	576	17	)	)	PUNCT
gsrj-21	576	18	,	,	PUNCT
gsrj-21	576	19	1065	1065	NUM
gsrj-21	576	20	-	-	SYM
gsrj-21	576	21	1076	1076	NUM
gsrj-21	576	22	.	.	PUNCT
gsrj-21	577	1	https://doi.org/10.1158/1078-0432.ccr-19-1496	https://doi.org/10.1158/1078-0432.ccr-19-1496	NUM
gsrj-21	577	2	109	109	NUM
gsrj-21	577	3	.	.	PUNCT
gsrj-21	577	4	yamamoto	yamamoto	PROPN
gsrj-21	577	5	,	,	PUNCT
gsrj-21	577	6	k.	k.	PROPN
gsrj-21	577	7	n.	n.	PROPN
gsrj-21	577	8	,	,	PUNCT
gsrj-21	577	9	nakamura	nakamura	PROPN
gsrj-21	577	10	,	,	PUNCT
gsrj-21	577	11	a.	a.	PROPN
gsrj-21	577	12	,	,	PUNCT
gsrj-21	577	13	liu	liu	PROPN
gsrj-21	577	14	,	,	PUNCT
gsrj-21	577	15	l.	l.	PROPN
gsrj-21	577	16	l.	l.	PROPN
gsrj-21	577	17	,	,	PUNCT
gsrj-21	577	18	stein	stein	PROPN
gsrj-21	577	19	,	,	PUNCT
gsrj-21	577	20	s.	s.	PROPN
gsrj-21	577	21	,	,	PUNCT
gsrj-21	577	22	tramontano	tramontano	PROPN
gsrj-21	577	23	,	,	PUNCT
gsrj-21	577	24	a.	a.	PROPN
gsrj-21	577	25	c.	c.	PROPN
gsrj-21	577	26	,	,	PUNCT
gsrj-21	577	27	kartoun	kartoun	PROPN
gsrj-21	577	28	,	,	PUNCT
gsrj-21	577	29	u.	u.	PROPN
gsrj-21	577	30	,	,	PUNCT
gsrj-21	577	31	et	et	PROPN
gsrj-21	577	32	al	al	PROPN
gsrj-21	577	33	.	.	PROPN
gsrj-21	577	34	(	(	PUNCT
gsrj-21	577	35	2019	2019	NUM
gsrj-21	577	36	)	)	PUNCT
gsrj-21	577	37	.	.	PUNCT
gsrj-21	578	1	computational	computational	ADJ
gsrj-21	578	2	modeling	modeling	NOUN
gsrj-21	578	3	of	of	ADP
gsrj-21	578	4	pancreatic	pancreatic	ADJ
gsrj-21	578	5	cancer	cancer	NOUN
gsrj-21	578	6	patients	patient	NOUN
gsrj-21	578	7	receiving	receive	VERB
gsrj-21	578	8	folfirinox	folfirinox	NOUN
gsrj-21	578	9	and	and	CCONJ
gsrj-21	578	10	gemcitabine	gemcitabine	NOUN
gsrj-21	578	11	-	-	PUNCT
gsrj-21	578	12	based	base	VERB
gsrj-21	578	13	therapies	therapy	NOUN
gsrj-21	578	14	identifies	identify	VERB
gsrj-21	578	15	optimum	optimum	ADJ
gsrj-21	578	16	intervention	intervention	NOUN
gsrj-21	578	17	strategies	strategy	NOUN
gsrj-21	578	18	.	.	PUNCT
gsrj-21	579	1	plos	plos	PROPN
gsrj-21	579	2	one	one	NUM
gsrj-21	579	3	,	,	PUNCT
gsrj-21	579	4	14(4	14(4	NUM
gsrj-21	579	5	)	)	PUNCT
gsrj-21	579	6	,	,	PUNCT
gsrj-21	579	7	e0215409	e0215409	NOUN
gsrj-21	579	8	.	.	PUNCT
gsrj-21	580	1	https://doi.org/10.1371/journal.pone.0215409	https://doi.org/10.1371/journal.pone.0215409	PROPN
gsrj-21	580	2	110	110	NUM
gsrj-21	580	3	.	.	PUNCT
gsrj-21	581	1	dominguez	dominguez	PROPN
gsrj-21	581	2	,	,	PUNCT
gsrj-21	581	3	c.	c.	PROPN
gsrj-21	581	4	x.	x.	PROPN
gsrj-21	581	5	,	,	PUNCT
gsrj-21	581	6	müller	müller	PROPN
gsrj-21	581	7	,	,	PUNCT
gsrj-21	581	8	s.	s.	PROPN
gsrj-21	581	9	,	,	PUNCT
gsrj-21	581	10	keerthivasan	keerthivasan	PROPN
gsrj-21	581	11	,	,	PUNCT
gsrj-21	581	12	s.	s.	PROPN
gsrj-21	581	13	,	,	PUNCT
gsrj-21	581	14	koeppen	koeppen	PROPN
gsrj-21	581	15	,	,	PUNCT
gsrj-21	581	16	h.	h.	PROPN
gsrj-21	581	17	,	,	PUNCT
gsrj-21	581	18	hung	hung	PROPN
gsrj-21	581	19	,	,	PUNCT
gsrj-21	581	20	j.	j.	PROPN
gsrj-21	581	21	,	,	PUNCT
gsrj-21	581	22	gierke	gierke	PROPN
gsrj-21	581	23	,	,	PUNCT
gsrj-21	581	24	s.	s.	PROPN
gsrj-21	581	25	,	,	PUNCT
gsrj-21	581	26	et	et	PROPN
gsrj-21	581	27	al	al	PROPN
gsrj-21	581	28	.	.	PROPN
gsrj-21	582	1	(	(	PUNCT
gsrj-21	582	2	2020	2020	NUM
gsrj-21	582	3	)	)	PUNCT
gsrj-21	582	4	.	.	PUNCT
gsrj-21	583	1	single	single	ADJ
gsrj-21	583	2	-	-	PUNCT
gsrj-21	583	3	cell	cell	NOUN
gsrj-21	583	4	rna	rna	NOUN
gsrj-21	583	5	sequencing	sequencing	NOUN
gsrj-21	583	6	reveals	reveal	VERB
gsrj-21	583	7	stromal	stromal	ADJ
gsrj-21	583	8	evolution	evolution	NOUN
gsrj-21	583	9	into	into	ADP
gsrj-21	583	10	lrrc15	lrrc15	NOUN
gsrj-21	583	11	+	+	NUM
gsrj-21	583	12	myofibroblasts	myofibroblast	NOUN
gsrj-21	583	13	as	as	ADP
gsrj-21	583	14	a	a	DET
gsrj-21	583	15	determinant	determinant	NOUN
gsrj-21	583	16	of	of	ADP
gsrj-21	583	17	patient	patient	ADJ
gsrj-21	583	18	response	response	NOUN
gsrj-21	583	19	to	to	ADP
gsrj-21	583	20	cancer	cancer	NOUN
gsrj-21	583	21	immunotherapy	immunotherapy	NOUN
gsrj-21	583	22	.	.	PUNCT
gsrj-21	584	1	cancer	cancer	NOUN
gsrj-21	584	2	discovery	discovery	NOUN
gsrj-21	584	3	,	,	PUNCT
gsrj-21	584	4	10(2	10(2	NUM
gsrj-21	584	5	)	)	PUNCT
gsrj-21	584	6	,	,	PUNCT
gsrj-21	584	7	232	232	NUM
gsrj-21	584	8	-	-	SYM
gsrj-21	584	9	253	253	NUM
gsrj-21	584	10	.	.	PUNCT
gsrj-21	584	11	https://doi.org/10.1158/2159-8290.cd-19-0644	https://doi.org/10.1158/2159-8290.cd-19-0644	PROPN
gsrj-21	584	12	111	111	NUM
gsrj-21	584	13	.	.	PUNCT
gsrj-21	585	1	hassel	hassel	PROPN
gsrj-21	585	2	,	,	PUNCT
gsrj-21	585	3	b.	b.	PROPN
gsrj-21	585	4	a.	a.	PROPN
gsrj-21	585	5	,	,	PUNCT
gsrj-21	585	6	guyal	guyal	NOUN
gsrj-21	585	7	,	,	PUNCT
gsrj-21	585	8	g.	g.	PROPN
gsrj-21	585	9	,	,	PUNCT
gsrj-21	585	10	lee	lee	PROPN
gsrj-21	585	11	,	,	PUNCT
gsrj-21	585	12	e.	e.	PROPN
gsrj-21	585	13	,	,	PUNCT
gsrj-21	585	14	sontheimerphelps	sontheimerphelp	VERB
gsrj-21	585	15	,	,	PUNCT
gsrj-21	585	16	a.	a.	NOUN
gsrj-21	585	17	,	,	PUNCT
gsrj-21	585	18	levy	levy	NOUN
gsrj-21	585	19	,	,	PUNCT
gsrj-21	585	20	o.	o.	PROPN
gsrj-21	585	21	,	,	PUNCT
gsrj-21	585	22	chen	chen	PROPN
gsrj-21	585	23	,	,	PUNCT
gsrj-21	585	24	c.	c.	PROPN
gsrj-21	585	25	s.	s.	PROPN
gsrj-21	585	26	,	,	PUNCT
gsrj-21	585	27	&	&	CCONJ
gsrj-21	585	28	ingber	ingber	PROPN
gsrj-21	585	29	,	,	PUNCT
gsrj-21	585	30	d.	d.	PROPN
gsrj-21	585	31	e.	e.	PROPN
gsrj-21	585	32	(	(	PUNCT
gsrj-21	585	33	2017	2017	NUM
gsrj-21	585	34	)	)	PUNCT
gsrj-21	585	35	.	.	PUNCT
gsrj-21	586	1	human	human	ADJ
gsrj-21	586	2	organ	organ	NOUN
gsrj-21	586	3	chip	chip	NOUN
gsrj-21	586	4	models	model	NOUN
gsrj-21	586	5	recapitulate	recapitulate	VERB
gsrj-21	586	6	orthotopic	orthotopic	ADJ
gsrj-21	586	7	lung	lung	NOUN
gsrj-21	586	8	cancer	cancer	NOUN
gsrj-21	586	9	growth	growth	NOUN
gsrj-21	586	10	,	,	PUNCT
gsrj-21	586	11	therapeutic	therapeutic	ADJ
gsrj-21	586	12	responses	response	NOUN
gsrj-21	586	13	,	,	PUNCT
gsrj-21	586	14	and	and	CCONJ
gsrj-21	586	15	tumor	tumor	NOUN
gsrj-21	586	16	dormancy	dormancy	NOUN
gsrj-21	586	17	in	in	ADP
gsrj-21	586	18	vitro	vitro	X
gsrj-21	586	19	,	,	PUNCT
gsrj-21	586	20	cell	cell	NOUN
gsrj-21	586	21	reports	report	NOUN
gsrj-21	586	22	,	,	PUNCT
gsrj-21	586	23	21(2	21(2	NUM
gsrj-21	586	24	)	)	PUNCT
gsrj-21	586	25	,	,	PUNCT
gsrj-21	586	26	508	508	NUM
gsrj-21	586	27	-	-	SYM
gsrj-21	586	28	516	516	NUM
gsrj-21	586	29	.	.	PUNCT
gsrj-21	587	1	https://doi.org/10.1016/j.celrep.2017.09.043	https://doi.org/10.1016/j.celrep.2017.09.043	NOUN
gsrj-21	587	2	62	62	NUM
gsrj-21	587	3	73	73	NUM
gsrj-21	587	4	danya	danya	PROPN
gsrj-21	587	5	adams	adams	PROPN
gsrj-21	587	6	�	�	PROPN
gsrj-21	587	7	table	table	NOUN
gsrj-21	587	8	of	of	ADP
gsrj-21	587	9	contents	content	NOUN
gsrj-21	587	10	letter	letter	NOUN
gsrj-21	587	11	from	from	ADP
gsrj-21	587	12	the	the	DET
gsrj-21	587	13	editors	editor	NOUN
gsrj-21	587	14	an	an	DET
gsrj-21	587	15	investigation	investigation	NOUN
gsrj-21	587	16	into	into	ADP
gsrj-21	587	17	the	the	DET
gsrj-21	587	18	mathematics	mathematic	NOUN
gsrj-21	587	19	of	of	ADP
gsrj-21	587	20	decryptiontechniques	decryptiontechnique	NOUN
gsrj-21	587	21	in	in	ADP
gsrj-21	587	22	rsa	rsa	NOUN
gsrj-21	587	23	encryption	encryption	NOUN
gsrj-21	587	24	,	,	PUNCT
gsrj-21	587	25	with	with	ADP
gsrj-21	587	26	an	an	DET
gsrj-21	587	27	implementation	implementation	NOUN
gsrj-21	587	28	in	in	ADP
gsrj-21	587	29	python	python	PROPN
gsrj-21	587	30	gpr40	gpr40	PROPN
gsrj-21	587	31	and	and	CCONJ
gsrj-21	587	32	postsynaptic	postsynaptic	ADJ
gsrj-21	587	33	nmda	nmda	ADJ
gsrj-21	587	34	receptors	receptor	NOUN
gsrj-21	587	35	:	:	PUNCT
gsrj-21	587	36	a	a	DET
gsrj-21	587	37	pair	pair	NOUN
gsrj-21	587	38	against	against	ADP
gsrj-21	587	39	epilepsy	epilepsy	NOUN
gsrj-21	587	40	the	the	DET
gsrj-21	587	41	burn	burn	NOUN
gsrj-21	587	42	behind	behind	ADP
gsrj-21	587	43	the	the	DET
gsrj-21	587	44	bullet	bullet	NOUN
gsrj-21	587	45	:	:	PUNCT
gsrj-21	587	46	understanding	understand	VERB
gsrj-21	587	47	black	black	ADJ
gsrj-21	587	48	mothers	mother	NOUN
gsrj-21	587	49	’	'	PUNCT
gsrj-21	587	50	experiences	experience	NOUN
gsrj-21	587	51	after	after	ADP
gsrj-21	587	52	losing	lose	VERB
gsrj-21	587	53	a	a	DET
gsrj-21	587	54	child	child	NOUN
gsrj-21	587	55	to	to	PART
gsrj-21	587	56	gun	gun	NOUN
gsrj-21	587	57	violence	violence	NOUN
gsrj-21	587	58	in	in	ADP
gsrj-21	587	59	washington	washington	PROPN
gsrj-21	587	60	,	,	PUNCT
gsrj-21	587	61	dc	dc	PROPN
gsrj-21	587	62	-	-	PUNCT
gsrj-21	587	63	baltimore	baltimore	PROPN
gsrj-21	587	64	city	city	PROPN
gsrj-21	587	65	metropolitan	metropolitan	PROPN
gsrj-21	587	66	region	region	NOUN
gsrj-21	587	67	cancer	cancer	NOUN
gsrj-21	587	68	models	model	NOUN
gsrj-21	587	69	to	to	PART
gsrj-21	587	70	defeat	defeat	VERB
gsrj-21	587	71	therapy	therapy	NOUN
gsrj-21	587	72	resistance	resistance	NOUN
gsrj-21	587	73	in	in	ADP
gsrj-21	587	74	pancreatic	pancreatic	ADJ
gsrj-21	587	75	ductal	ductal	ADJ
gsrj-21	587	76	adenocarcinoma	adenocarcinoma	NOUN
gsrj-21	587	77	about	about	ADP
gsrj-21	587	78	the	the	DET
gsrj-21	587	79	authors	author	NOUN
gsrj-21	587	80	meet	meet	VERB
gsrj-21	587	81	the	the	DET
gsrj-21	587	82	staff	staff	NOUN
gsrj-21	587	83	acknowledgements	acknowledgement	NOUN